annual report saw good sales momentum across pharmaceuticals vaccines consumer healthcare pipeline progresswe global scienceled healthcare company three worldleading businesses research deliver innovative medicines vaccines consumer healthcare products front cover case study gsk innovation underpins three businesses using next generation technology return rd investment accelerate develop new approaches disease development new products management control addition improve patients lives research development active pipeline innovative gain insights network products across six core areas respiratory collaborations biotechs hiv infectious diseases vaccines companies academic institutions immunoinflammation oncology enables efficient trial design rare diseases greater use software analytics new technology helping increase productivity maximise arthur works upper providence rd lab cautionary statement regarding forwardlooking statements groups reports filed furnished us securities exchange commission sec including document written information released oral statements made public future behalf group may contain forwardlooking statements forwardlooking statements give groups current expectations forecasts future events investor identify statements fact relate strictly historical current facts use words anticipate estimate expect intend project plan believe words terms similar meaning connection discussion future operating financial performance particular include statements relating future actions prospective products product approvals future performance results current anticipated products sales efforts expenses outcome contingencies legal proceedings financial results accordance legal regulatory obligations including uk listing rules disclosure transparency rules financial conduct authority group undertakes obligation update forwardlooking statements whether result new information future events otherwise reader however consult additional disclosures group may make documents publishes andor files sec readers wherever located take note disclosures accordingly assurance given particular expectation met shareholders investors cautioned place undue reliance forwardlooking statements forwardlooking statements subject assumptions inherent risks uncertainties many relate factors beyond groups control precise estimate group cautions investors number important factors including document could cause actual results differ materially expressed implied forwardlooking statement factors include limited discussed principal risks uncertainties pages annual report forwardlooking statements made behalf group speak date made based upon knowledge information available directors date annual report expectations targets regarding future performance also read together assumptions related outlook inside back cover document number adjusted measures used report performance business measures defined reconciliation core results total results set gsk annual report strategic report governance remuneration financial statements investor information strategic report performance summary us chairmans statement ceos statement bn bn integrated approach market operate group turnover new pharmaceutical business model aer cer vaccine salesb clear strategy growth proforma cera aer cera measure success manage risks pharmaceuticals bn bn vaccines consumer healthcare total operating profit core operating profit responsible business aer cerac aer cer group financial review proforma cera governance remuneration chairman 's governance statement p p board corporate executive team leadership effectiveness total earnings per share core earnings per share nominations committee report aer cerac aer cera accountability audit risk committee report relations shareholders bn bn corporate responsibility committee report net cash inflow free cash flowa operating activities remuneration report chairmans annual statement annual report remuneration bn remuneration policy summary remuneration policy report dividends declared assets data expected end financial statements directors statement responsibilities delivering sustainable performance independent auditors ' report financial statements notes financial statements st access rd financial statements glaxosmithkline plc prepared uk gaap medicine index pharmaceutical sector investor information since launch dow jones sustainability index quarterly trend five year record product development pipeline product competition intellectual property principal risks uncertainties share capital share price dividends financial calendar footnotes annual general meeting aer growth rates represent growth actual exchange rates use number adjusted nonifrs tax information shareholders measures report performance business described including core results shareholder services contacts free cash flow cer proforma growth rates measures used management us law regulation planning reporting purposes may directly comparable similarly described measures used companies core results exclude number items presented management group companies believes core results allow key trends factors driving performance easily glossary terms clearly identified shareholders nonifrs measures may considered addition substitute superior information presented accordance ifrs reconciliation total results core results set b new products defined pharmaceuticals relvarbreo ellipta incruse ellipta anoro ellipta arnuity ellipta eperzantanzeum nucala tivicay triumeq vaccines menveo bexsero shingrix yet approved c primarily reflecting impact billion profit disposal oncology business gsk annual report us three worldleading businesses gsk mission improve pharmaceuticals vaccines consumer healthcare quality human life businesses generated combined turnover billion enabling people business benefits global commercial infrastructure feel better integrated supply networks innovative rd live longer number employees number markets manufacturing sites rd innovation underpins businesses invested billion rd across three businesses external partnerships collaborations enable us develop access knowledge increase understanding new areas science focus research across six core areas using next generation technology develop new approaches disease management control respiratory diseases hivinfectious diseases vaccines immunoinflammation oncology rare diseases efficient global operating model focused optimising operations restructuring investment modernisation improve profitability efficiency bn footnote use number adjusted nonifrs measures report performance business described incremental annual total operating profit core operating profit including core results free cash flow cer savings delivered margin margin proforma growth rates nonifrs measures may including billion considered addition substitute superior information presented accordance ifrs currency benefit gsk annual report strategic report governance remuneration financial statements investor information pharmaceuticals vaccines consumer healthcare pharmaceuticals business vaccines business consumer healthcare business discovers develops broadest portfolio company develops markets products commercialises medicines vaccines people wellness oral health nutrition treat range acute chronic ages babies adolescents skin health categories diseases broad portfolio adults older people seven global power brands otrivin innovative established deliver two million vaccine panadol parodontax poligrip medicines respiratory hiv doses per day people living sensodyne theraflu voltaren global leaders countries include trusted focus research across bestselling brands world respiratory hiv infectious read pages diseases immunoinflammation read pages oncology rare diseases read pages top three categories sales top three categories sales sales category respiratory infanrixpediarix wellness hiv hepatitis oral health established products meningitis nutrition skin health bn bn bn turnover turnover turnover group turnover group turnover group turnover bn bn packs medicines vaccines delivered consumer healthcare products produced produced gsk annual report chairmans statement pleased report gsk made board unanimous decision good progress appoint emma walmsley previously head operating performance significantly gsks consumer healthcare business improved three businesses new ceo emma strong continued progress late early leadership skills clear track record stage rd pipeline every important area delivery performance board believe year solid achievement emma bring new thinking group operates todays healthcare performance environment whilst time management continues make strong harnessing momentum evident progress driving sales cost current performance benefits integration novartis gsk made businesses vaccines consumer want thank sir andrew progress healthcare businesses dedicated service gsk transformed transaction commitment leadership gsk built operating performance true global leaders respective balanced set businesses fine markets well positioned strategically prospects delivered significant significantly improved improving financially rewards shareholders substantial continued cash returns also led efforts pharmaceuticals new product sales address pressing concerns progress rd shown good momentum industry faces ranging reforming particularly hiv respiratory new pipeline products make around quarter commercial model increasing transparency trial results ensuring medicines total pharmaceutical sales important priced fairly made accessible given pricing pressure faced generally patients worldwide much pharmaceutical companies potential missed within gsk wish well introduction generic competition advair read future endeavours many years groups biggest single source profits us board changes year continue refresh board governance report see groups improved operational welcomed two new nonexecutive performance also contributed markedly corporate governance report sets directors dr jesse goodman increased cash generation operational corporate governance practices includes dr vivienne cox jesse professor reports board committees cash flow also benefited strongly medicine georgetown university devaluation sterling following remuneration see brexit vote june although value leader public health vivienne brings many years experience complex global remuneration report sets nonsterling liabilities debt funding manufacturing organisations meanwhile remuneration arrangements executive contingent consideration also stacey cartwright stepped nonexecutive directors includes new increased board end december thanks go remuneration policy ordinary dividends p per share stacey nearly six years dedicated diversity statement see declared level service board company expects maintain boards diversity policy including gender enter critical period pipeline payment accordance sets measurable objectives activity reflected board statements made level nominations committee monitors reports creation new board science progress towards achievement distribution still exceeds free cash flow committee chaired dr goodman generated business despite viability statement see material improvement cash generated addition dr patrick vallance president rd joined board later year moncef viability statement sets assessment referred given slaoui step board prospects group next last year three year dividend years company moncef three years commitment made board scientist global repute considering appropriate dividend remarkable presence gsk particularly policy beyond vaccines business wish course year well future ceo succession closing would like thank gsks key area focus board employees partners hard manage ceo work dedication business succession sir andrew steps outstanding people made years company successful year tenth year ceo board conducted thorough global search successor included internal external candidates philip hampton chairman gsk annual report strategic report governance remuneration financial statements ceos statement investor information group executed strongly investment rd organisation delivering sales growth across three continues deliver significant innovation businesses remaining disciplined example saw european costs progressing pipeline approval strimvelis first kind innovative products gene therapy children rare condition adascid remarkable trading performance technology potential platform group sales rose actual rates number gene therapies cer proforma billion despite uncertainty volatility next two years exciting time experienced globally total earnings rd organisation key research per share p actual data assets due end gsk performed strongly rates cer primarily reflecting good sales comparisons billion profit delivering performance responsibly disposal marketed gsk strong commitment operating growth across three oncology assets core earnings per share responsibly playing part meeting pa cer increase businesses excellent new societys biggest healthcare top end guidance year challenges product momentum saw growth across three took industryleading pipeline progress groups businesses steps stopping payments healthcare particular contribution new professionals speak medicines pharmaceuticals vaccine products prescribers offered essential sales portfolio doubled vaccines lowest price organisations billion pharmaceuticals supporting refugees acute need new products accounted sales also introduced new approach filing hiv products tivicay triumeq continued enforcing patents ip based standout products sales country 's economic maturity working billion new respiratory partners help world better prepare products relvarbreo anoro incruse future epidemics ebola zika arnuity nucala also grew strongly pleased efforts meningitis vaccines bexsero operate valuesbased company menveo expect momentum recognised came first group products continue access medicine index consumer healthcare business fifth consecutive time performed strongly sales outlook actual rates cer proforma progress highlights billion driven power brands investments made group sensodyne voltaren panadol last several years build scale well growth flonase sustainability well develop new switched prescription products expect group make overthecounter continued progress strong rd innovation pipeline enter new period leadership filed four assets regulators company believe gsk well positioned approved potential deliver longterm performance drive growth business shareholders including shingrix candidate vaccine finally last annual report shingles oncedaily closed retire would like thank triple therapy copd addition employees partners shareholders also started number phase iii trials support time ceo assets hiv respiratory anaemia gsk special company touches peoples lives across world enormously privileged lead footnote sir andrew witty use number adjusted nonifrs measures chief executive officer report performance business described including core results free cash flow cer proforma growth rates nonifrs measures may considered addition substitute superior information presented accordance ifrs ggsskk aannnnuuaall rreeppoorrtt integrated approach understanding operating environment clear strategy measure performance manage risks deliver longterm value shareholders society market operate business model operate growing marketplace strategy rd underpins three businesses prioritise investments designed respond challenges opportunities see potential develop innovative products sector unmet medical needs demographic rd pharmaceuticals change changing political vaccines landscape consumer healthcare increasing payer emphasis cost value access commercialisation manufacturing distribution increased expectations businesses technological scientific advances read read ggsskk aannnnuuaall rreeppoorrtt ssttrraatteeggiicc rreeppoorrtt ggoovveerrnnaannccee aanndd rreemmuunneerraattiioonn ffiinnaanncciiaall ssttaatteemmeennttss iinnvveessttoorr iinnffoorrmmaattiioonn clear strategy growth measure success manage risks strategic priorities provide framework assess performance manage number current create longterm value shareholders set financial nonfinancial emerging risks principal risks society measures many form mapped primary strategic basis executive remuneration priority likely impact turnover growth intellectual property grow growth earnings per share commercialisation grow balanced business product portfolio centred three global businesses new pharmaceuticals vaccines product quality deliver product performance research practices supply continuity crisis management deliver products value offer improved treatment patients consumers healthcare providers operating profit margin financial control reporting simplify free cash flow information protection dividends declared simplify way operate reduce net debt complexity increase efficiency free resources reinvest business return shareholders wherever see attractive returns access medicine index patient safety responsible business dow jones sustainability index antibribery corruption environment health safety responsible business sustainability deliver success important results achieve read read read gsk annual report operate growing marketplace strategy designed respond challenges opportunities face market operate bn worlds population people worlds population aged billiona live urban areas f global population access mobile phonef global middle class reside asiapacific f global youth resides developing countriesf future state global megatrends shaping government kpmg gsk annual report strategic report governance remuneration financial statements investor information business model clear strategy growth measure success manage risks global global pharmaceutical sales developed economies demand billion month rolling healthcare provision continues remain healthcare market basis september high although dynamics becoming continued grow billion equivalent period complex trends higher life september north america expectancy contributing towards backdrop remained largest pharmaceuticals increasing proportion elderly people market share global sales along improvements medical challenging global europe represented asia pacific technology putting pressure economic environment including japan emerging healthcare budgets markets b changing global political landscape global vaccine sales totalled billion shifting attitudes globalisation expected grow free trade wage stagnation many annually c concerns inequality causing significant volatility uncertainty consumer healthcare markets western markets gsk operates account approximately billion projected grow characterised political annually next five yearsd uncertainty exemplified vote leave eu uk societal trends supported market growth result us presidential election also contributing challenges political uncertainty europe expected healthcare sector particularly price continue national elections affordability france germany demographic change us also uncertainty world population continues grow new administration shape according united nations healthcare particularly respect predicted reach billion repealing replacing affordable proportion elderly people growing care act prescription drug pricing number people age regulation coupled questions expected reach billion impact new administrations e time developing economic tax trade policies countries experiencing growth middle classes expected uk remains unclear brexit worlds population affect countrys trading relationships middle classf corporate taxation policy movement people regulatory affairs emerging markets longterm economic growth increasing expectations healthcare provision changing diets lifestyles increasing demand healthcare products especially treat chronic conditions including respiratory cardiovascular disease demand expected grow significantly faster markets coming years mature economies footnotes w orld population ageing highlights united nations b ims data latest available time publishing c nternal data evaluatepharma world preview nternal forecasts based nicholas hall euromonitor e w orld population ageing highlights united nations f f uture state global megatrends shaping government kpmg gsk annual report market operate continued strategy create increasing payer emphasis cost technological scientific advances value access key advances understanding balanced business demographic changes contributing human biology genomics leading product portfolio increased demand healthcare fundamental changes research turn putting pressure government diseases pharmaceutical industrys positions us well budgets payers led ability develop treatments specifically continued focus public debate tackle innovative treatment changes industrys approach drug approaches increased substantially marketplace pricing across key markets recent years alongside scientific advances digital technology data us ultimately unsuccessful analytics enabling researchers explore proposition vote called interpret larger volumes biological medicine price controls california data genomics disease biology first several drug pricing ballot ever providing initiatives expected us opportunities increase speed also increasing use healthcare efficiency drug discovery technology assessments consider development novel therapies could value money well medical efficacy transform diseases managed governmentappointed bodies like uks national institute health care increasing expectations companies excellence australias pharmaceutical beyond sectorspecific context benefits advisory committee value cost affordability important society increasing changing demand healthcare emerging expectations companies particularly markets rises governments continuing large global companies stakeholders reform healthcare systems support employees consumers policy access china government continues makers influencers expect companies work realise goals set behave integrity fairness operate healthy china plan significant transparently connected local measures taken year reduce communities play part pharmaceutical prices national addressing global challenges health price negotiations epidemics climate change responding year uns highlevel panel requires strong partnership access medicines report reiterated connectivity public private rights countries issue compulsory sector organisations licences access cheaper supplies generic drugs expect political public scrutiny pricing continue gsk annual report strategic report governance remuneration financial statements investor information business model clear strategy growth measure success manage risks strategic response three worldleading gsk well positioned take advantage demographicled demand new innovative products three worldleading businesses pharmaceuticals vaccines businesses consumer healthcare global presence markets example underpinned emerging markets significant demographic changes societal trends innovative rd increasing demand healthcare pharmaceuticals business sells volume nearest competitor emerging markets sell vaccines region represents onethird consumer healthcare business strategy create three balanced businesses helps mitigate risk access growth opportunities around world navigate changes portfolio challenges face todays operating environment global company global company understand benefits free trade globalisation also importance companies like significant local presence communities significant operate large global footprint make important contribution local presence markets operate example tax pay jobs create engaging government directly industry trade bodies abpi bia important way inform policy impact sector example uk eu life sciences steering group gsk working closely peers uk government address needs industry eu exit negotiations overall continue believe brexit cause material impact financial position long term may cause disruption shortterm global strategy focus pricing products level provides attractive volume expansion opportunities means able access patients consumers around world sustainable understand payer patient concerns affordability healthcare pricing leading efforts develop sustainable solutions equitable pricing strategy medicines vaccines based country disease area product type patients ability pay us launched six newest products priced similar medicines aim replace also pioneering efforts show impact medicines realworld clinical practice settings researchbased company rely protection patents regulatory data exclusivity rights ensure reasonable return investment however recognise need flexible approach patent protection expanded current approach filing enforcing patents opting file patent protection leastdeveloped lowincome countries granting licences generic manufacturers supply versions medicines lower middle income countries g countries leading responsible responsible business fundamental gsk understand society requires businesses behave integrity operate important financial results business approach deliver lead industry efforts access medicines clinical trial data transparency fight antimicrobial resistance evolving commercial model ensure patients interests come first longer pay healthcare professionals speak behalf gsk annual report rd underpins three businesses prioritise investments see potential develop innovative products unmet medical needs market business model operate resources create value strong rd across three world people culture innovation leading businesses almost employees bring expertise values everything rd pharmaceuticals financial capital earnings cash flow access capital markets allow us invest business vaccines collaborations partnerships rd partnerships consumer collaborations academic healthcare institutions biotechs ngos companies bring important insights innovation suppliers suppliers provide essential services materials reinvestment gsk annual report strategic report governance remuneration financial statements investor information clear strategy growth measure success manage risks create value value create efficient global operating model shareholders aim deliver sustainable earnings growth total core eps growth eps growtha dividends p primarily reflecting comparison bn profit disposal marketed oncology assets dividend manufacturing patients consumers increased access quality products enable people doses vaccines feel better live longer produced commercialisation society distribution bn healthier communities tax charge economic contribution jobs taxation donated local communities product donations time cash employees countries environment feel valued part global rollout employees family members countries access groundbreaking preventive healthcare programme reinvestment footnote use number adjusted nonifrs measures report performance business described including core results free cash flow cer proforma growth rates nonifrs measures may considered addition substitute superior information presented accordance ifrs gsk annual report strategic priorities provide framework create longterm value shareholders society market business model clear strategy growth operate strategic priorities progress global sales billion p grow aer cer proforma cer total earnings per share new pharmaceutical vaccine aer cer product sales billion aer cer grow balanced business p product portfolio centred consumer healthcare sales core earnings per share three global businesses billion aer cer aer cera proforma cer strong contributions power brands new pharmaceutical vaccine product sales four filings regulators including deliver shingrix candidate vaccine closed triple filings regulators eu approval strimvelis deliver products value first gene therapy rare disease offer improved treatment patients adascid consumers healthcare providers consumer healthcare innovation sales products launched last three years improved core operating leverage simplify across three businesses total operating profit margin incremental annual cost savings billion delivered including simplify way operate reduce billion currency benefit complexity increase efficiency free core operating profit margin continued roll new global resources reinvest business systems standardisation percentage points return shareholders wherever processes proforma cera see attractive returns expanded graduated approach responsible business st patents ip widen access medicines access medicine index committed supply essential responsible business vaccines lowest price civil rd deliver success important society organisations refugees results achieve ema approval chlorhexedine sector dow jones sustainability index antiseptic gel newborn umbilical cord infections developing countries footnote use number adjusted nonifrs measures report performance business described including core results free cash flow cer proforma growth rates nonifrs measures may considered addition substitute superior information presented accordance ifrs gsk annual report strategic report governance remuneration financial statements investor information clear strategy growth measure success manage risks key challenges key priorities continued pricing pressure deliver guidance us europe drive sales market growth respiratory volatility slowing emerging hiv meningitis vaccines power brands market economies progress four regulatory filings made launch successfully approved manage impact possible generic competition advair us continued prioritisation deliver key data assets pipeline appropriate end manage prioritisation deployment resources capital allocation increasing global demand continue improve efficiency capacity vaccines complex supply chain new existing products manufacturing process leading supply pressures integration reporting continue roll new global systems systems processes standardisation processes following novartis transaction continue focus improving cash conversion management working capital continue optimise capital expenditure responding stakeholder ensure sustainable funding biopreparedness concerns affordability organisation enhance preparedness access future epidemics continue strengthen embed flexible approach ip patent protection valuesbased culture gsk annual report assess performance set financial nonfinancial metrics many form basis executive remuneration market business model clear strategy growth measure operate success growth cer group turnover reported proforma bn bn bn bn growth cer reported proforma reported proforma pharmaceuticals vaccines consumer healthcare new pharmaceutical vaccine product performanceb r growth cer bn growth cer operating profit margin r total core reported proforma total bn cored bn growth earnings per share total core cer total p cored p gsk annual report strategic report governance remuneration financial statements investor information measure manage risks success free cash flowd r growth e bn e na e dividends declared dividends bn c net debt bn access medicine index ranking dow jones sustainability index ranking st rd first since pharmaceutical industry index began th percentile th percentile th percentile see information see information key r remuneration executives linked key indicators marked see footnotes excluding divestments completed b new products defined pharmaceuticals relvarbreo ellipta anoro ellipta incruse ellipta arnutiy ellipta eperzantanzeum nucala tivicay triumeq vaccines menveo bexsero shingrix yet approved c includes special dividend use number adjusted nonifrs measures report performance business described including core results free cash flow cer proforma growth rates nonifrs measures may considered addition substitute superior information presented accordance ifrs e free cash flow excluding payments legal costs restructuring tax oncology disposal purchase hiv clinical assets treated intangible asset purchases gsk annual report manage current emerging risks may impact strategic priorities rigorous consistent risk management processes market business model clear strategy growth measure success operate principal risks regularly reviewed principal risk description assessment macro gsk exposure environment post mitigation corporate executive team assess whether reflective patient safety macro environment remained stable patient safety regulation standards remaining consistent significant risks facing organisation failure appropriately collect review follow report adverse events improved safety data management patient communications product labelling improvements based evolving internal external potential sources act relevant findings timely manner incorporated throughout organisation leaving gsk exposure level unchanged factors table opposite lists principal risks managed across intellectual property macro risk unchanged due significant changes affect ability secure maintain group also includes enforce patents failure appropriately secure maintain enforce intellectual property rights definition risk assessment gsk exposure level stable based maturity risk management processes general change risk year ability enforce defend patents appropriate macro level gsks mitigating activities product quality macro risk higher increasing regulatory scrutiny data integrity supply continuity drug shortages accompanied new guidance revised legislation failure comply current good manufacturing practices cgmp inadequate controls governance quality supply chain covering supplier standards despite challenging macro environment gsk exposure level unchanged reflecting effective responses manufacturing distribution products external regulatory reviews greater focus data integrity improved governance financial controls reporting macro environment remained stable due material change financial reporting requirements failure comply current tax law incurring significant losses due treasury unchanged gsk exposure level reflective significant systems operating model changes activities failure report accurate financial information compliance accounting implemented throughout organisation well continued risk thirdparty relationships standards applicable legislation failure maintain adequate governance oversight expect system model changes reduce risk future risk impact thirdparty relationships changes mitigated strong risk management governance well continued progress global third party oversight programme antibribery corruption macro environment remained stable regulatory environment global attitude towards antibribery corruption remaining within expectations failure gsk employees consultants third parties comply antibribery corruption abac principles standards well gsk exposure level lower risk management practices gained strength embedded applicable legislation deeper across organisation abac programme builds group 's values standards enabled us manage risk effectively commercialisation macro risk level increased due greater industry pricing pressures increased regulatory scrutiny respect sales promotional activities failure execute business strategies effectively manage competitive opportunities threats accordance letter spirit legal gsk exposure level unchanged implement industryleading changes operating model industry groups requirements particular compensation model sales representatives relationships healthcare professionals research practices macro risk level elevated due increased regulatory scrutiny good clinical practices failure adequately conduct ethical sound preclinical clinical research gsk exposure level unchanged based mature internal control processes enhanced governance addition failure engage scientific activities consistent letter programme designed promote best practice across business units spirit law industry groups requirements environment health safety sustainability macro risk level higher due greater focus increased regulatory activity environmental issues arrows key failure manage environment health safety sustainability ehss risks gsk exposure level unchanged due controls governance well established capable increased risk line objectives policies relevant laws regulations allowing increased focus regulatory activity change risk information protection macro risk increased threat become sophisticated targeted higher volume incidents risk gsk business activities information becomes disclosed decreased risk authorised see information systems fail available corrupted gsk exposure level unchanged see effects substantial progress made upgrading level protection cyber attacks safeguarding critical sensitive data supply continuity crisis management macro factors regulatory focus contract manufacturers outside us eu increased data integrity expectations increasing supply risk failure deliver continuous supply compliant finished product inability respond extensive information gsk risks effectively crisis incident timely manner recover sustain gsk exposure level stable based significant improvements delivered ongoing supply including risk impact mitigating activities critical operations risk previously called crisis continuity management remediation programmes increased monitoring supervision third parties see pages see viability statement gsk annual report strategic report governance remuneration financial statements investor information manage risks principal risk description assessment macro gsk exposure environment post mitigation patient safety macro environment remained stable patient safety regulation standards remaining consistent failure appropriately collect review follow report adverse events improved safety data management patient communications product labelling improvements potential sources act relevant findings timely manner incorporated throughout organisation leaving gsk exposure level unchanged intellectual property macro risk unchanged due significant changes affect ability secure maintain enforce patents failure appropriately secure maintain enforce intellectual property rights gsk exposure level stable based maturity risk management processes general ability enforce defend patents appropriate product quality macro risk higher increasing regulatory scrutiny data integrity supply continuity drug shortages accompanied new guidance revised legislation failure comply current good manufacturing practices cgmp inadequate controls governance quality supply chain covering supplier standards despite challenging macro environment gsk exposure level unchanged reflecting effective responses manufacturing distribution products external regulatory reviews greater focus data integrity improved governance financial controls reporting macro environment remained stable due material change financial reporting requirements failure comply current tax law incurring significant losses due treasury unchanged gsk exposure level reflective significant systems operating model changes activities failure report accurate financial information compliance accounting implemented throughout organisation well continued risk thirdparty relationships standards applicable legislation failure maintain adequate governance oversight expect system model changes reduce risk future risk impact thirdparty relationships changes mitigated strong risk management governance well continued progress global third party oversight programme antibribery corruption macro environment remained stable regulatory environment global attitude towards antibribery corruption remaining within expectations failure gsk employees consultants third parties comply antibribery corruption abac principles standards well gsk exposure level lower risk management practices gained strength embedded applicable legislation deeper across organisation abac programme builds group 's values standards enabled us manage risk effectively commercialisation macro risk level increased due greater industry pricing pressures increased regulatory scrutiny respect sales promotional activities failure execute business strategies effectively manage competitive opportunities threats accordance letter spirit legal gsk exposure level unchanged implement industryleading changes operating model industry groups requirements particular compensation model sales representatives relationships healthcare professionals research practices macro risk level elevated due increased regulatory scrutiny good clinical practices failure adequately conduct ethical sound preclinical clinical research gsk exposure level unchanged based mature internal control processes enhanced governance addition failure engage scientific activities consistent letter programme designed promote best practice across business units spirit law industry groups requirements environment health safety sustainability macro risk level higher due greater focus increased regulatory activity environmental issues failure manage environment health safety sustainability ehss risks gsk exposure level unchanged due controls governance well established capable line objectives policies relevant laws regulations allowing increased focus regulatory activity information protection macro risk increased threat become sophisticated targeted higher volume incidents risk gsk business activities information becomes disclosed authorised see information systems fail available corrupted gsk exposure level unchanged see effects substantial progress made upgrading level protection cyber attacks safeguarding critical sensitive data supply continuity crisis management macro factors regulatory focus contract manufacturers outside us eu increased data integrity expectations increasing supply risk failure deliver continuous supply compliant finished product inability respond effectively crisis incident timely manner recover sustain gsk exposure level stable based significant improvements delivered ongoing supply critical operations risk previously called crisis continuity management remediation programmes increased monitoring supervision third parties ggsskk aannnnuuaall rreeppoorrtt leader respiratory gsk forefront research area years pharmaceuticals pharmaceuticals business discovers develops commercialises medicines treat broad range worlds common acute chronic diseases ggsskk aannnnuuaall rreeppoorrtt ssttrraatteeggiicc rreeppoorrtt ggoovveerrnnaannccee aanndd rreemmuunneerraattiioonn ffiinnaanncciiaall ssttaatteemmeennttss iinnvveessttoorr iinnffoorrmmaattiioonn grow deliver simplify responsible business bn pharmaceutical three filings operating profit margin launched reported sales regulators last six new products aer cera closed triple percentage points us priced similar proforma cer benlysta subcutaneous higher aim sales new products sirukumab percentage points higher replace cer proforma basis pharmaceutical sales footnote use number adjusted nonifrs measures report performance business described including core results free cash flow cer proforma growth rates nonifrs measures may considered addition substitute superior information presented accordance ifrs gsk annual report pharmaceuticals overview hiv improve healthcare global hiv business managed pharmaceuticals business viiv healthcare company preventing disease portfolio innovative established owned gsk pfizer medicines across broad range therapy treating illness shionogi shareholders areas including respiratory hiv seeking longlasting global leaders well viiv healthcare growing rapidly immunoinflammation antiinfectives accounts pharmaceutical solutions chronic urology rare diseases around sales led strong demand quarter pharmaceutical sales come tivicay dolutegravir innovative integrase acute conditions products launched past four years strand transfer inhibitor triumeq including rare diseases singlepill treatment combining dolutegravir respiratory abacavir lamivudine industrys broadest range inhaled respiratory products respiratory specialty products portfolio largest contributor specialty products portfolio includes pharmaceutical sales expectation medicines benlysta treatment nine products account lupus disease tanzeumeperzan approximately respiratory sales type diabetes compared four classic established products past four years launched classic established products new generation respiratory products include postpatent medicines including nucala mepolizumab areas antiinfectives allergy ellipta portfolio neurosciences dermatology respiratory urology many medicines continue topselling brand therapy area products important part emerging markets business sell volume nearest competitor leader respiratory leader respiratory gsk forefront research area years today patients clinical ensure patients get full benefits studies investigating chronic obstructive one inhalation treatments pulmonary disease copd almost research shows patients taking countries believe insights medicine experienced improved lung research alongside early phase scientific function higher quality life fewer discovery help us meet patient needs exacerbations compared leading well future twicedaily treatment new generation inhaled respiratory looking beyond inhaled medicines medicines clear evidence benefits tackling areas highest unmet research range including need respiratory diseases anoro ellipta worlds leading longacting launched nucala first muscarinic antagonistlongacting betaagonist injectable biologic treatment severe copd value giving physicians eosinophilic asthma study results showed unprecedented choice provide right patients using nucala risk treatment right patient experiencing asthma attack requiring emergency hospital care half year filed regulatory approval receiving current standard closed triple therapy us care europe approved first copd treatment combine three vital oncedaily treatments single inhaler gsk annual report strategic report governance remuneration financial statements investor information grow performance summary europe pharmaceutical reported sales reported pharmaceutical sales declined proforma respiratory million actual rates sales declined reflecting sales respiratory cer adjusting disposal ongoing transition new respiratory products returned oncology business novartis portfolio generic competition proforma turnover cer seretide partly offset growth growth new respiratory products performance reflected return growth recorded sales million established respiratory business grew products million sales new respiratory products launched last four years including ellipta international sales million based products breo anoro arnuity proforma sales emerging incruse well biologic nucala markets impacted decline doubled million hiv sales china business primarily result increased million ongoing reshaping programme broader us driven primarily healthcare reforms including price strong performances triumeq reductions tivicay sales million worldwide hiv sales increased million million us sales new pharmaceutical products europe international million account growth primarily driven strong total pharmaceutical sales performance triumeq tivicay us pharmaceutical sales continued implement new million declined reported basis commercial model stopped payments growth rates cer proforma respiratory sales grew hcps speak behalf january nonifrs measure described sales new respiratory products continued drive recruit hcps unless otherwise stated million exceeding decline internal medical experts addition advair continued roll digital tools medical education efforts following medical product information sessions gsk experts countries hcps agreed interaction helped make informed decision benefiting patient care around rated experience superior similar interactions pharmaceutical companies working hard early stage research find cure hivaids formed unique partnership accelerate search hiv cure million men women children partnership recruiting top talent around world live hiv leading around world redefining researchbased pharmaceutical healthcare traditional way conducting research company legacy success hivaids one approaches developing treatments hiv investigated known shock kill seeks reveal hidden virus gsk strong pipeline new medicines persists people hiv infection hiv scientists continue work towards despite successful drug therapy goal one day finding cure augment patients immune system hivaids epidemic clear last traces virus continue invest hiv cure center infected cells qura therapeutics unique jointownership collaboration created university north carolina uncchapel hill single focus finding cure hivaids gsk annual report pharmaceuticals continued deliver pharmaceuticals rd organisation hiv pipeline contains number drives discovery development several promising medicines regimens areas research including respiratory hiv innovative formulations mode action achieved infectious diseases immunoinflammation delivery methods announced positive accelerated filing oncology rare diseases results two phase iii studies evaluating twodrug regimen combining dolutegravir first oncedaily closed triple progress rilpivirine edurant janssen medicine continued see progress across therapy copd received breaking mould conventional stages rd pipeline respiratory approval europe filed oncedaily closed triple therapy threedrug treatments therapy could reduce streamline hiv medication first gene therapy medicine copd regulatory approval future europe us bringing forward obtained positive data original us filing date months three hiv programmes support new single tablet also announced positive results phase iii new attachment inhibitor pioneering copd salford lung study another twodrug regimen combining twodrug hiv regimen study showed compared dolutegravir lamivudine receiving usual standard care copd cabotegravir oncemonthly injectable patients using relvarbreo ellipta achieved therapy combined longacting superior reduction exacerbations rilpivirine could also make hiv treatment everyday clinical practice setting simpler easier adhere addition announced start phase iii study also strengthened prospects evaluate longacting cabotegravir next wave respiratory medicines injection every two months prevention inlicensing novel antiilr men sex men risk hiv antibody severe asthma new data infection also completed acquisitions supporting progression potential bms hiv pipeline discovery oral treatment danirixin phase iib teams programmes clinical development potential use fully integrated viiv healthcares treating patients copd rd organisation timeline development stages pharmaceutical product industry average drug preclinical clinical trials licensing approval discovery testing phase phase ii phase iii candidates medicine available patients medicine candidates candidates candidates candidates years years years years years years source abpi gsk annual report strategic report governance remuneration financial statements investor information continued strengthen emerging also received positive phase ii data immunoinflammation portfolio firstinclass antibacterial gepotidacin regulatory filings europe us treating gonorrhoea us food subcutaneous formulation benlysta drug administration fda granted treatment systemic lupus disease fasttrack status basis serious assets data expected currently available iv formulation unmet need new medicines area end sirukumab investigational il treatment oncology assets clinical rheumatoid arthritis development seen encouraging codeveloping janssen approved developments core areas immuno treatments selfadministered oncology cell therapy epigenetics home making convenient year fda granted treatment option patients breakthrough therapy status affinity also gained approval enhanced tcell therapy targets strimvelis first corrective gene therapy antigen nyeso synovial cancer children suffering rare developing adaptimmune disease adascid adenosine deaminase terminated development severe combined immunodeficiency iosmapimod copd following analysis see case study phase ii results halted development started several phase ii studies hiv maturation inhibitor including one evaluate antigmcsf favour maturation inhibitors antigranulocyte macrophage colony pipeline may better profile stimulating factor monoclonal antibody milestones inflammatory hand osteoarthritis coming two years significant assessing oral rip kinase inhibitor pharmaceutical pipeline marking rheumatoid arthritis psoriasis patients start another intense period rd activity company expect important data assets areas including hiv respiratory immunoinflammation oncology approval gsks first gene therapy opens new chapter treatment rare diseases application groundbreaking technology resulted worlds first corrective gene therapy children european commissions approval working together took experimental strimvelis onetime treatment adascid medicine procedure developed rigorous adenosine deaminase severe combined manufacturing quality control systems immunodeficiency first authorisation ensure could evaluated corrective stem cell gene therapy children regulators major milestone commitment survival rate three years developing innovative transformative medicines treatment observed children adascid caused faulty gene pivotal study every child receiving inherited parents affects around strimvelis contributed marketing newborns europe year child authorisation data package alive today born adascid healthy patients referred treatment receive fullyfunctioning immune system gene therapy ospedale san raffaele consequence unable fight everyday hope strimvelis first infections treatment involves correcting number innovative gene therapy often fatal disorder using patients medicines bring patients cells next years development strimvelis follows two programmes using collaboration gsk original italian platform metachromatic leukodystropy developers san raffaele telethon institute wiskottaldrich syndrome gene therapy milan italy clinical trials gsk annual report pharmaceuticals continued deliver continued pharmaceuticals rd approach treatment advances medicines focus investment areas development teams multidisciplinary believe attractive specialists ensure progress opportunities considered patient investigational medicine later stage need market opportunity scientific development filing regulators understanding concentrate ongoing evidence generation mechanisms might slow strategic issues overall budget reverse course diseases present management overseen rd opportunities achieve remission cure management team robust governance early research efforts centre around boards manage investment technical discovery performance units scientific commercial decisions nimble units budgets throughout molecules lifecycle range partners includes project accountability different academic institutions publicprivate collaboration external partners traditional hierarchical rd model partnerships pharmaceutical important part approach help us maintain flexibility create biotechnology companies partner agility enable us focus organisations around world including promising early opportunities academic institutions publicprivate partnerships pharmaceutical biotechnology companies collaborating francis crick institute gsk joins forces worldleading biomedical research centre landmark collaboration gsk development novel approaches francis crick institute aims achieve problems pooling knowledge new breakthroughs understanding resources hope collaboration treating diseases ultimately improve success rate discovering new medicines open innovation collaboration combines pharmaceutical rd expertise spirit open innovation research cricks deep knowledge disease biology findings collaboration shared externally via joint publication mutual aim explore new avenues peerreviewed journals enable medical research drug discovery across important discoveries applied across range diseases collaboration takes research community maximising linklabs approach working teams potential progress scientific understanding scientists organisation working accelerate development sidebyside integrated teams treatments patients cricks worldleading centre biomedical research heart london gsks francis crick institute charity funded global rd hub stevenage gsk medical research council cancer crick believe fluid interchange skills research uk wellcome trust university ideas benefits sides introducing college london imperial college london new ways working stimulating kings college london gsk annual report strategic report governance remuneration financial statements investor information simplify continued reshape enterprise resource planning erp pharmaceuticals business reduce system enabling better sharing data complexity supply chain improve planning capabilities end supply chain maintaining commitment quality system live transformation programme pharmaceuticals manufacturing sites cost savings generated delivered significant pharmaceutical business contributed committed quality delivery billion annual savings committed meeting highest reductions manufacturing including billion currency benefit standards stringent quality control costs streamlined group end operating quality assurance processes external supply network profit margin pharmaceuticals medicines vaccines manufactured percentage points higher according current good manufacturing cer basis percentage practice cgmp regulations points higher proforma cer basis internal quality management system pharmaceutical manufacturing completed threeyear sites regulatory inspections transformation programme move six findings resolving endtoend supply chain july received warning letter delivered improvements customer service us food drug administration fda quality productivity combined relating inspection carried simplification portfolio months earlier gsks worthing uk delivered significant reduction primary manufacturing site responded manufacturing costs streamlined promptly fda address points external supply network raised advised programme part commitment creating work well advanced worldclass supply chain agreed fiveyear global logistics contract international freight company contract key enabler reduce site costs year responsible leading fight antimicrobial resistance business demonstrated continuing commitment tackling antimicrobial resistance signing landmark industry roadmap resistance antibiotics becoming major advanced asset public health crisis people antibiotics pipeline gepotidacin dying every year drug resistant infections developed collaboration roadmap commits us participating us governments biomedical pharmaceutical companies advanced research development authority achieving four significant targets barda gepotidacin include reducing environmental impact moving towards phase iii studies antibiotics production ensuring following positive phase ii results used patients need global health threat antimicrobial roadmap builds january commitment resistance requires multistakeholder davos declaration combat antibiotic response seen industry resistance collaboration beyond last years roadmap active discovering work barda also partner developing antibiotics years governments companies today pharmaceuticals focus developing progress research development new new antibiotics active pipeline antibiotics new medicines addition vaccines business member innovative medicines researches develops new vaccines prevent initiatives newdrugsbadbugs bacterial infections saving lives reducing longterm partner dependence antibiotics defence threat reduction agency ggsskk aannnnuuaall rreeppoorrtt following impressive clinical trial results filed candidate shingles vaccine regulators us canada europe vaccines broadest vaccines portfolio company vaccines people ages babies adolescents adults older people ggsskk aannnnuuaall rreeppoorrtt ssttrraatteeggiicc rreeppoorrtt ggoovveerrnnaannccee aanndd rreemmuunneerraattiioonn ffiinnaanncciiaall ssttaatteemmeennttss iinnvveessttoorr iinnffoorrmmaattiioonn grow deliver simplify responsible business bn vaccines sales filed operating profit margin working aer cera candidate shingles partners help world proforma cer vaccine shingrix percentage points higher better prepared growth across candidate global health epidemics us europe vaccines pipeline percentage points higher international markets range diseases cer proforma basis footnote use number adjusted nonifrs measures report performance business described including core results free cash flow cer proforma growth rates nonifrs measures may considered addition substitute superior information presented accordance ifrs gsk annual report vaccines vaccines business portfolio behind commercial portfolio vaccines business paediatric adolescent adult older robust research pipeline reflects people travel vaccines offer expertise virology bacterial one largest protection different diseases infection across different technological world delivering include bexsero meningitis b platforms vaccine menveo meningitis c w scientists dedicated discovering two million doses flu hepatitis synflorix pneumococcal developing vaccines across three vaccines per day disease rotarix rotavirus gastroenteritis global rd centres us europe vaccines diphtheria tetanus well internal research people whooping cough namely infanrixpediarix rd partnerships boostrix external scientists leading academic countries public health institutions demand vaccines continues increase worlds population grows help people benefit changes meet demand must vaccine protection use tiered deliver reliable high quality vaccines pricing approach based nations push boundaries science gross national income per head technology develop innovative vaccines ability pay also one largest contributors gavi vaccine alliance publicprivate partnership aims improve access vaccines developing countries candidate shingles vaccine filed following impressive clinical trial results filed candidate shingles vaccine shingrix regulators us canada europe seeking approval shingrix first time high efficacy candidate vaccine use preventing shingles demonstrated candidate vaccine common potentially serious condition older people whose weakened immune complications people shingles systems often leave susceptible sufferers develop painful itchy rash disease possibility therefore also getting postherpetic neuralgia phn technology based may open intense pain last least three effective treatments conditions months affecting older adults one three people expect results clinical likely shingles lifetime studies shingrix people individuals compromised immune high risk shingles due weakening systems cancer patients undergoing immune systems patients chemotherapy especially susceptible revaccinated candidate vaccine previously received existing vaccine study published found shingrix efficacy people maintained four years earlier research showed efficacy gsk annual report strategic report governance remuneration financial statements investor information grow performance summary sales international markets grew vaccines sales grew actual rates proforma growth primarily cer proforma cer driven synflorix due market expansion vaccines sales grew million performance asia certain african countries reported basis driven sales new products menveo sales also contributed growth including meningitis vaccines bexsero driven significant tender award proforma billion menveo contributed million argentina vaccine sales increased strong performance also strong demand fluarix brazil due strong demand bexsero meningitis flulaval sales million menjugate boostrix flu vaccines us sales grew proforma bexsero menveo boostrix seeing market share growth infanrix pediarix benefited competitor supply issues market europe sales grew proforma driven primarily bexsero sales uk governments immunisation programme growth rates cer private market channels several nonifrs measure described countries boostrix sales europe unless otherwise stated benefited higher demand competitor supply issues uk infants benefit meningitis b vaccine number cases meningitis b reported uk fell significantly babies vaccinated bexsero meningococcal vaccine uk became first country world invasive meningococcal b disease introduce national infant immunisation leading cause meningitis programme meningitis b late industrialised world develops rapidly children vaccinated two typically among previously healthy children four months receiving booster adolescents one ten oneyearold contract disease die suffering major physical ten months programme neurological disability limb launched public health england phe hearing loss figures showed percent effectiveness bexsero meningitis b bexsero meningococcal b vaccine licensed europe past two years numbers doses bexsero produced grown two million cumulative total ten million gsk annual report vaccines continued deliver vaccines rd work focuses following positive scientific opinion discovering developing vaccines european regulators infant help protect people broad range malaria vaccine mosquirix world health broad pipeline diseases conditions across age organization start pilot implementation includes vaccines targeting groups pipeline candidate vaccine three subsaharan africa vaccines early mid late stage countries partners shingles meningitis respiratory development range diseases nonprofit organisation path donate syncytial virus group b doses mosquirix pilots received regulatory approval streptococcus new expand indication flulaval bid assist zika virus vaccine concept copd us cover infants six months age evaluating new vaccine technology known rather three years obtained sam selfamplifying mrna approval europe label update national institutes health believe boostrix boostrix polio human technology may potentially induce safety data support use pregnant protective immunity zika women also launched hiberix investment governance vaccine us priorities meeting patient needs filed regulatory approval addressing global health challenges north america europe vaccines yet exist candidate vaccine prevention significant improvements could made shingles complications see case vaccine rd investment study plan file million million use japan number promising earlier rd complemented existing assets pipeline example global hubs siena italy wavre candidate vaccines phase ii belgium opening third centre meningococcal abcwy respiratory rockville maryland close major syncytial virus rsv group b streptococcus us public health stakeholders three exacerbations chronic obstructive global centres area pulmonary disease copd expertise vaccine discovery specific assets development also benefiting scientific exchange three worldclass teams vaccines research development cycle industry average identify produce preclinical phase phase ii proof phase iii file registration antigens antigens testing concept postmarketing surveillance research including immunology preclinical development clinical development including postmarketing surveillance transfer process manufacturing years years years year gsk annual report strategic report governance remuneration financial statements investor information simplify continued simplify committed quality operating model strengthen discovery development new manufacturing network reduce vaccines complex process vaccines continued supply costs manufactured highest quality simplify operating model standards according current good year completed majority manufacturing practice cgmp regulations realised significant savings novartis vaccines business integration regulatory inspections cost savings generated vaccines minor findings business contributed delivery cases worked regulators billion annual savings group address observations end including billion currency benefit savings combined strong sales growth delivered improved operating leverage profit margin percentage points higher percentage points higher proforma cer basis investing supply chain vaccine manufacturing sites countries international presence enables us manufacture vaccines greater capacity efficiency flexibility aim keep critical production steps inhouse wherever possible year invested new production facilities marburg site germany enable us produce active components bexsero vaccine inhouse adds new mumps production line combined measles mumps rubella varicella vaccine responsible preparing public health emergencies business gsk committed helping whenever public health crises occur ebola broke west africa guidance independent experts would accelerated development candidate dedicated permanent rd pilot ebola vaccine following outbreak production facilities capacity zika employed novel technology respond rapidly future global health platforms start vaccine discovery programme emergencies us national institutes bpo would operate noprofit health noloss basis funding however responding lifethreatening governments nongovernmental disease surfaces enough vaccine research organisations discovery lengthy process typically taking also strongly support coalition years epidemic preparedness innovations cepi best chance save lives global community focus vaccines development prepare advance solution protecting infectious reason proposing create disease outbreaks stand ready partner dedicated permanent biopreparedness cepi advance epidemic organisation bpo global vaccines rd preparedness centre rockville planned facility would design develop manufacture new vaccines potential public health threats targeted pathogens selected prioritised ggsskk aannnnuuaall rreeppoorrtt consumer healthcare consumer healthcare business develops markets products wellness oral health nutrition skin health portfolio includes worlds trusted bestselling brands sensodyne voltaren panadol ggsskk aannnnuuaall rreeppoorrtt ssttrraatteeggiicc rreeppoorrtt ggoovveerrnnaannccee aanndd rreemmuunneerraattiioonn ffiinnaanncciiaall ssttaatteemmeennttss iinnvveessttoorr iinnffoorrmmaattiioonn migraine headache excedrin helping people us manage symptoms grow deliver simplify responsible business bn sales increased sales operating profit margin panadol power brand aer cera product innovations helping raise awareness proforma cer launched past percentage points higher dengue fever growth broadly three years balanced across percentage points higher us europe cer proforma basis international markets footnote use number adjusted nonifrs measures report performance business described including core results free cash flow cer proforma growth rates nonifrs measures may considered addition substitute superior information presented accordance ifrs gsk annual report consumer healthcare consumer healthcare business nutrition consumer healthcare split almost equally overthe nutrition business includes horlicks counter otc medicines fast moving long established wheat milk malted business world consumer goods fmcg across four barley drink leading overthecounter categories wellness oral health nutrition skin health skin health consumer healthcare top three sales globally wellness medicated skin health treats products company global leader wellness conditions cold sores dry largest category number one sensitive skin abreva zovirax countries retail sales leading brands hold leading positions global positions respiratory cold flu worlds largest markets nasal decongestants allergy smoking power brands cessation pain management prioritise seven global power brands two top four brands panadol otrivin panadol parodontax poligrip voltaren sensodyne theraflu voltaren oral health regional core brands including flonase top three company globally horlicks tums brands including sales toothpaste number physiogel benefit broad geographic one specialist oral health globally footprint combined focus scientific countries leading positions expertise consumer insight sensitivity acid erosion denture care gum health sensodyne became first billion consumer healthcare represents consumer healthcare joint venture brand making thirdlargest product novartis together gsk consumer sales whole gsk portfolio healthcare listed businesses india nigeria managing migraine symptoms excedrin brought home painful reality migraines recent virtual reality campaign excedrin one top overthecounter brands four worked vr experts create sales us launched visual effects experience attacks virtual reality vr campaign correct including blurred vision flashes object misunderstandings migraines campaign auras room spinning partial blindness included multichannel campaign made enormous impact media activity expert celebrity panel social media million views discussion high profile new york event almost engagements launched march product sales rose shares film comments retweets campaign shown double digit growth year excedrin created campaign customer insight research showed sufferers felt misunderstood documentarystyle film featured migraine simulator developed help four migraine sufferers gsk annual report strategic report governance remuneration financial statements investor information grow performance summary europe sales grew million consumer healthcare sales grew proforma good momentum across actual rates cer germany scandinavia italy partly strong growth proforma basis million offset impact challenging economic oral health wellness conditions commonwealth category basis growth independent states voltaren grew power brands helped wellness oral health doubledigits result continued skin health partly offset consumer healthcare success hour variant nutrition declined increase reported oral health sensodyne gum health brand level sensodyne panadol portfolio also recorded strong growth sales proforma otrivin performed strongly sales international markets sales grew billion sensodyne reached billion proforma million growth first time sales innovation within impacted sale nigerian last three years represented sales beverages business september particular contribution flonase effective cessation switched otc q trade venezuela end notable launches included demonetisation implemented india sensodyne true white excedrin november also impacted indian geltabs us business sales middle east latin growth broadly balanced across america china grew particularly three global geographies us sales strongly result better pricing grew million proforma new product introductions driven primarily sensodyne delivering doubledigit growth following launch growth rates cer true white combined strong nonifrs measure described momentum pronamel within wellness unless otherwise stated flonase otc grew strongly first half following line extensions new overthecounter launch extends flonase brand continue see success switching products prescriptiononly overthecounter fda approved flonase sensimist new product acts multiple inflammatory allergy relief seasonal perennial substances additional features allergies builds success moving suitable children young two products prescriptiononly years old scent alcoholfree overthecounter otc usa causing little drip product launched february applied time allergy season making bringing sensimist flonase product available otc meeting allergy relief umbrella aim build consumer demand greater control flonases market success personal healthcare product formerly available prescription veramyst managing switch otc drew regulatory insights pharmaceuticals business helped us navigate highly regulated pharmaceutical environment gsk annual report consumer healthcare continued deliver success consumer healthcare continue see success moving business built ability understand products prescriptiononly customer needs meet effective thecounter approval launch success delivering products strong research pipeline flonase sensimist allergy relief consumerdriven scienceled refocused investment us see case study innovation ensure achieve high return innovation enabled us understanding consumers everyday delivered newtomarket product healthcare needs views product generate bestever sales launches sales preferences integral part new recent launches generated innovations launched product development process digital past three years highest technology becomes central lives level ever exploring ways internally rd investment consumer discussion external entrepreneurs healthcare million inventors harnessing digital million prioritise investment capability improve consumer health power core brands continued invest stateoftheart strategic focus fewer bigger digital real life innovation opening innovations examples included new us shopper sensory labs sales generated sensodyne true white excedrin geltabs see case study innovations launched past new eno ajwain herb flavour variant three years strengthened commitment india otrivin oxy launched rd india building headcount record six months conception people significant increase versus legacy organisations increased focus innovation area already paying seven marketfirst innovations launched region course year two six rd hubs based emerging markets region represents third business science consumer insight new innovation labs us increased ability understand deliver unmet consumer needs following success uk innovation labs shopper science facility enables launched three labs based us work retail partners new us consumer healthcare hq warren best way present products store enable us integrate customer insights together labs enabling us discover stages product development fresh insights develop tailormade original inception idea items products meet needs positioning store shelf include consumers retailers helps us rd suite combining flexible work meet ambition becoming first choice spaces rapid prototyping capabilities shoppers customers allowing us move swiftly concept manufacture whether tablets liquids powders creams consumer sensory capabilities assess people use products includes simulated environments products often found example bathroom doctors consulting room shop pharmacy gsk annual report strategic report governance remuneration financial statements investor information simplify completed majority unified branding rolled integration enabling us increase integrated sites emphasis core innovation artwork changes delivered continued deliver stronger growth brands streamlining efforts also involved simplify streamline incremental annual cost savings markets moving standardised helped increase operating profit consumer healthcare business platforms course year margin percentage points track deliver increased operating percentage points higher synergy targets profit margin cer basis percentage points higher cer proforma basis committed quality remain track deliver annual cost consumer healthcare products savings anticipated deliver target manufactured highest quality operating margin least standards according current good manufacturing practice cgmp regulations consolidation activities year regulatory inspections resulted reduction costs satisfactory outcomes overheads established common distribution routes shared enterprise resource planning platforms enabling access data across organisation informed decision making responsible helping communities better identify prevent treat dengue fever business gskled health campaign encouraged better understanding manage disease mosquitoborne dengue fever causes around included train trainer sessions million infections deaths refresh physicians pharmacists year endemic knowledge virus recruitment countries particularly across south east voluntary dengue warriors asia western pacific regions spread word prevention treatment distribution dengue paracetamol panadol help treat proficiency kits healthcare professionals symptoms dengue fever gsk consumer healthcare launched assisted wide media coverage allied dengue campaign campaigns impact dramatic malaysia indonesia malaysia three years rising philippines brought together gsk mortality rates campaign contributed panadol power brand doctors pharmacy towards number deaths falling chains governments nongovernment organisations campaign also helped increase campaign helped educate regional consumer healthcare product seven million people disease sales philippines alone net sales increased q versus period ggsskk aannnnuuaall rreeppoorrtt responsible business responsible business central strategy deliver success important results achieve ggsskk aannnnuuaall rreeppoorrtt ssttrraatteeggiicc rreeppoorrtt ggoovveerrnnaannccee aanndd rreemmuunneerraattiioonn ffiinnaanncciiaall ssttaatteemmeennttss iinnvveessttoorr iinnffoorrmmaattiioonn expanded graduated approach filing enforcing patents intellectual property widen access medicines poorest countries health behaviour people planet countries partnership mandatory annual partnership cut operational save children reached training code prevention programme carbon emissions scope additional million conduct completed rolled since children employees globally offering total value chain treatments immunisations complementary unprecedented access emissions risen interventions workers preventive healthcare extend access almost employees medicines family members working address countries footnote remaining represents employees complete training required timeframe subject disciplinary action see employees still within completion timeframe eg new starters gsk annual report responsible business commercially creating value society responsible business priorities developing innovative healthcare gsks responsible business priorities sit successful operating products directly benefit patients within context macroeconomic responsibly improve consumers equitable pricing strategy social trends affect companies allows prices reflect countrys wider society trends present peoples health benefit ability pay global footprint enables opportunities challenges global greater access medicines vaccines healthcare companies like gsk see society well create consumer healthcare products report progress across four areas value shareholders delivering profitable sustainable health behaviour people business performance generate value planet identified priorities returns shareholders areas understanding issues reinvest business important business wider society benefits healthy stakeholders people essential building strong sustainable communities longerterm commitments across four areas reflect global health needs make significant direct indirect align gsks strategic priorities economic contributions countries values detail progress communities operate commitments responsible tax employment people business supplement available charitable support wwwgskcomresponsibility graduated approach intellectual property expanded approach filing enforcing patents reflect countrys economic maturity announced would adapt agreement enables dolutegravir current approach filing enforcing patents made available adults generic ensure balance need manufacturers royalty fees tiered protect intellectual property depending national gross domestic countrys economic maturity product following approval regulators means people living hiv means longer file patents developing world covered medicines leastdeveloped countries licence agreement lowincome countries lower middle income countries apply patents also outlined intent commit think appropriate also offer licences future portfolio cancer treatments allow supplies generic versions patent pooling work medicines countries g medicines patent pool explore countries ten years help address increasing burden cancer developing countries line approach viiv healthcare expanded licence agreement medicines patent pool adult formulation hiv drug dolutegravir include vast majority lower middle income countries gsk annual report strategic report governance remuneration financial statements investor information measuring wellestablished longterm also cites companywide ownership responsible commitments sit across access key strength together progress four areas health behaviour commitment research development people planet also low middle income countries measure performance access highpriority medical needs medicine index dow jones beginning also performed sustainability index well first ever access vaccines access medicine index index leading three categories gsk topped access consideration medicine index fifth consecutive time dow jones sustainability index means led every edition came third sector biannual index since launch dow jones sustainability index index access medicine index funded analyses economic environmental bill melinda gates foundation social performance worlds leading uk dutch governments measures companies overall percentile ranking top pharmaceutical companies efforts increased th th improve access healthcare developing meaning scored within top countries led peers three sector indexs seven categories research led industry code business development pricing manufacturing conduct climate strategy environmental distribution product donations reporting health outcome contributions index describes gsk strong performance corporate accessoriented company recognises governance marketing practices risk clear strategy increasing access crisis management tax corporate medicines aligned citizenship corporate strategy progress responsible business commitments assessment shows three commitments complete progressing well five track one work details performance see responsible business supplement wwwgskcomresponsibility health behaviour progress progress innovation unmet medical needs completed ethical conduct progressing well better access medicines vaccines progressing well promoting values sales progressing well marketing practices building products better meet needs progressing well strengthening healthcare infrastructure progressing well transparency clinical trial data completed fighting malaria progressing well rigorous patient consumer safety progressing well eliminating controlling neglected progressing well minimising animal testing track tropical diseases ensuring ethical interactions progressing well eradicating polio progressing well promoting human rights track access antiretroviral treatment hiv progressing well working third parties track reducing child mortality progressing well people planet progress progress developing people inspiring progressing well aiming carbon neutral work needed healthy workplaces reducing water impact progressing well promoting inclusion diversity track reducing waste track community volunteering completed create change gsk annual report responsible business continued approach gel help prevent umbilical health tackling greatest cord infections newborns received global health challenges innovating positive scientific opinion european meet unmet needs making medicines medicines agency ema three million committed vaccines accessible babies die year infection often developing innovative strengthening healthcare systems newlycut umbilical cord attracts products extending innovating unmet needs bacteria particular issue developing countries approved local regulators access healthcare aim develop innovative products make gel available notforprofit diseases disproportionately affect people matter price share manufacturing knowledge worlds poorest people widely made live need greatest mosquirix vaccine targets significant ability pay committed working health threat malaria phase iii trials governments multinational organisations vaccine received positive opinion ngos enhance preparedness ema shown potential future outbreaks vaccine could considerable public diseases ebola zika health impact used combination supporting coalition epidemic malaria control measures preparedness innovation cepi see case study proposing world health organization create permanent biopreparedness confirmed full funding organisation bpo rockville committed enable pilot implementation maryland vaccines site mosquirix three settings subsaharan africa due begin early protecting refugees essential vaccines supplying essential vaccines lowest price civil society organisations use acute humanitarian situations along homes livelihoods great humanitarian need governments communities refugees often lose easy unable assist access healthcare leaving potentially developing reliable predictable vulnerable vaccinepreventable disease supply csos stepped time continue work response gsk committed supply partners strengthen longterm essential vaccines internationally recognised capacity local health systems support civil society organisations csos refugees host communities mdecins sans frontires save photo nour wahidsave children children lowest prices use pledge comes tens thousands acute humanitarian situations governments refugees continue flee conflict syria unable assist south sudan elsewhere builds decades effort gsk working first vaccine covered commitment partners increase synflorix pneumococcal vaccine access vaccines charities protects children diseases responding emergencies pneumonia working partners gavi vaccine alliance provide synflorix deeply discounted price charities fund deliver immunisation programmes refugees displaced people future explore extending offer essential vaccines commitment designed help maintain stable vaccination programmes times gsk annual report strategic report governance remuneration financial statements investor information also share expertise resources also understand payer patient intellectual property external concerns affordability developed researchers open innovation lab markets leading efforts tres cantos spain built portfolio develop sustainable solutions example research projects looking diseases usa last six gsk pharmaceutical since invested million developing world since products launched similar countries trained frontline visiting scientists results prices medicines aim health workers reached million people lab led papers supersede integrated three scientific publications africa us patient assistance programmes noncommunicable diseases open lab one gsk patient assistance program currently focusing cardiovascular designed simplify improve disease oncology chronic respiratory programme experience eligible disease chronic kidney disease uninsured patients patients diabetes first project looks severe medicare part prescription drug plan asthma across east africa led ugandas europe continue engage makerere university payers eu markets balance affordable extending affordability availability cost healthcare systems funding committed widening access solutions also support ongoing charitable giving totalled medicines vaccines equitable innovation medicines achieved million million pricing strategy based country reimbursement ellipta portfolio disease area product type patients eu markets finding local solutions ability pay issues affordability challenged introduction new innovation since capped prices patented medicines vaccines strengthening healthcare systems leastdeveloped countries ldcs reinvest profits prices eu france sales pharmaceuticals consumer germany italy spain uk long healthcare products ldcs strengthen manufacturing costs covered healthcare infrastructure nations since working amref health offer lowest vaccine prices africa care international save organisations gavi vaccine product inkind children invested million cash alliance supports countries countries reached million people management low gross national income trained frontline health workers time pulse delivered million doses synflorix vaccine pneumoccal pioneering partnership disease million doses save children reached million rotarix vaccine rotavirus children livesaving interventions gastroenteritis bringing total number million since one million middleincome countries many children screened malnutrition still live poverty equitable pricing underfives approach enables people access immunised children products egypt offer portfolio vaccinated measles polio prices meet needs levels treated income including price reduction diarrhoea malaria pneumonia seretide inhaler devices targeted middle lower income groups gsk annual report responsible business continued approach working third parties behaviour aim valuesbased culture expect suppliers share high training people standards ethical standards increased expect encouraging reporting use preferred suppliers bringing values underpin concerns embedding values global everything way measure employee performance purchase order spend continued ensuring rigorous safety patient consumer safety rollout global thirdparty oversight programme reached total standards manufacture medicines vaccines countries across latin america according current good manufacturing interact healthcare south east asia programme aims practice regulations internal quality drive improvements supply chain professionals management system distributor network ensure regulatory inspections third parties engage support manufacturing sites values received observations minor also completed third observationsa eleven inspections party audits health safety ethics gsk values conducted us food environment labour rights also drug administration fda five conducted audits focused resulted form issued specifically quality processes sites citing deficiencies current good identify areas improvement manufacturing practices cgmp none engage respective third parties observations direct impact develop improvement plans track product supply sites completion overall aim enhancing corrective action plans mitigate performance supply chain may observations submitted also suspend terminate work fda cases thirdparty significant issues identified transparency clinical trial data training people gsk first company sign updated code conduct alltrials campaigns every clinical accompanying annual training give trial registered results reported people deeper understanding leading industry clinical apply values everyday activities study transparency past decade publicly posted b employees expect employees act line clinical study reports complementary workers completed values result summaries mandatory training code code conduct training enables learner researchers submit proposals understand manage risks request access details around associated business activities clinical trials includes antibribery corruption wwwclinicalstudydatarequestcom website risk maintain zero tolerance independent panel reviews proposals approach people working scientific merit ensure patient high risk roles completed additional privacy confidentiality protected indepth antibribery corruption training proposals approved help understand manage research teams granted access particular challenges may face anonymised patientlevel data daily work also begun providing plain reporting investigating concerns language summaries clinical studies centrally track misconduct allegations online clinical study register concerns multiple speak channels investigations team received reports reduction since footnotes time still awaiting reports inspections b remaining represents employees complete training required time subject disciplinary action well still within completion timeframe eg new starters gsk annual report strategic report governance remuneration financial statements investor information disciplinary action safety ensuring employees disciplined take action employees fail act communicated consistently breakdown types policy violation line policies year revised thirdparty contracts monitor employees disciplined policy existing suppliers screen new ones violations including approach tax employees failing complete mandatory understand responsibility pay training code conduct antibribery appropriate amount tax fully corruption within required support efforts ensure companies timeframe total disciplined transparent manage employees received documented warning tax affairs verbal warnings dismissed pay significant amount tax uk agreed leave company voluntarily global corporate functions related significant manufacturing rd attendance marketing payroll promotional activities attendance payroll included facilities located countries training completion code conduct disciplinary actions related employee around world substantial good manufacturing falsification absence punctuality misstating hours business employment presence distribution documents worked past years paid practices travel expense local work regulations environment health human rights billion corporation tax globally violations safety gsk signatory un global billion nearly compact sets key principles global total paid uk read business human rights committed upholding universal engage artificial tax declaration human rights arrangements without business international labour organisations core commercial substance labour standards time responsibility focus areas shareholders financially efficient operations biggest potential impact deliver sustainable tax rate human rights manage human rights details approach tax risks supply chain reinforcing tax disclosures found requirements labour rights health putting patients interests first continue lead industry modernising way market sell medicines since january stopped paying sales teams compensated since january healthcare professionals hcps speak pharmaceutical medical sales prescribers medicines representatives longer compensated vaccines instead strengthened individual sales targets instead online resources supplement information rewarded technical skills scientific provided salesforce knowledge quality service broader business performance also significantly expanded global team inhouse medical experts provide new approach well received information medicines vaccines following medical product information hcps ways convenient sessions gsk experts around medical experts dedicated countries exclusively supporting hcps hcps agreed interaction helped also engage make informed decision benefiting part roles patient care around rated experience superior similar interactions pay hcps activities pharmaceutical companies clinical market research help us develop also seen improvement customer medicines vaccines meet patients needs trust transparent transactions survey us hcps gsk ranked first disclose payments made hcps customer trust fourth year markets row customer value across europe including russia ukraine third time australia japan us also changed way gsk gsk annual report responsible business continued approach put particular emphasis leadership people need talented motivated workforce development trained around deliver strategy achieve people support promotion strive attract best people first second line leader roles continued aim create safe create environment empowers evolve global leadership development inclusive environment inspires people strategy focuses programmes found managers everyone reach talent leadership performance complete show significant engagement improvement effectiveness based full potential feedback teams talent leadership talent leadership programmes also trained leaders coaches focus developing employees strategic use coaching levels skills need advance recognised worldclass careers international coach federations prism award welcomed graduates postgraduates onto future leaders performance engagement esprit programmes including global performance system centres emerging markets gsk voted set clear expectations top graduate employer research emphasises results people development times top achieve way achieve graduate employers th line values successive year ranked th overall listening people essential employee engagement responding even year responded insights global employee survey employees completed members cet hosted five listening sessions senior leaders conducted discussions topics raised including evaluate performance future leaders programme building next generation leaders future leaders programme delivering programme rated highly participants fresh ideas talent needed continue driving recent survey alumni success across key markets future leaders programme found respondents felt rotations provides graduates breadth potential helped develop relevant skills career pathways rd finance experience career gsk marketing procurement option move functions benefits business also clear several job rotations number geographical spread intake means homegrown leaders job rotations make rooted markets including emerging programme feedback mentoring countries new recruits coaching constituting formal representing nationalities training remainder balance enables countries graduates develop specific eight nations skills effective individual role business getting broad grasp company learning gsks graduates joined future leaders distinctive global leadership approach programme gsk annual report strategic report governance remuneration financial statements investor information women management monitor progress also employee volunteering introduced pulse surveys evaluate gsk employees impact engagement efforts countries contributed million svpvp regular intervals annual survey worth skilled services nonprofit director partners countries promoting inclusion diversity manager diverse perspectives experiences pulse volunteer partnership total global workforce strengthen worked assignments aligned worldwide healthcare challenges business help us meet needs un sustainable development goals employees gender number patients consumers health wellbeing percentage women management male female total healthcare company think hard rose women board best support represented corporate executive management team cet board health patients consumers total compares average among also employees global energy resilience training programmes ftse boards according cranfield management senior managers defined innovative ambitious partnership companies act strategic report directors board report prevention programme pp report regulations includes persons responsible planning directing controlling women began created strong foundations activities company strategically significant part accelerating difference programme company board including directors helps female leaders progress pp offer almost undertakings included consolidated accounts employees family members senior roles programme countries unprecedented access recognised best practice cranfield preventive healthcare services universitys female ftse board immunisations cancer screening report little extra cost extended global organisation want services india russia leaders represent varied markets commonwealth independent states gsk employees countries serve five nationalities currently keeping us track achieve goal spent six months nonprofit represented cet board global coverage organisations share skills part efforts promote protecting people environment everyone feels included want prevent incidents established lesbian gay occur however global business bisexual transgender lgbt council operating markets council chaired president injuries occur pharmaceuticals rd endorsed cet reportable injury aims engage educate employees illness rate per hours lgbt issues achieved worked according pharmaceutical score human rights campaign safety group psg data comparable foundations corporate equality index leading companies sector rates workplaces lgbt equality sadly one fatality sales us representative died result road making gsk accessible place traffic incident india try prevent work people disabilities priority road incidents driver safety us working global programmes india indonesia vietnam disability council develop online people taking part accessibility portal allows employees find information support adjustments working environments committed removing barriers increasing understanding ensuring disabilities opportunities gsk annual report responsible business continued approach supply chain represents largest planet aim reduce environmental impacts part value chain footprint across value chain extending followed use products access products minimising operations logistics end aim reduce carbon footprint water use life disposal make remaining environmental impacts operational waste largest value chain impact focus across value chain carbon helping suppliers make environmental extending access operational emissions scope improvements example suppliers totalled million tonnes co e covering billion spend direct products broadly previous year raw materials disclose information represents decrease ecodesk online platform monitor baseline reduced promote environmental improvements emissions continued focus supply chain addition energy efficiency renewable energy suppliers use online sustainability investment sustainable buildings collaboration platform gsk supplier exchange share best practice revised calculation method scope emissions current certain products disproportionate ghg protocol methodology effect value chain emissions includes impact purchased services particularly ventolin propellantbased capital investments fuel energy related inhalers emit greenhouse gases activities logistics upstream supply use continue research chain business travel commuting solutions issue including changing based latest methodology way manufacture reduce increased baseline figure amount propellant used maintaining million tonnes co e million efficacy patients tonnes co e overall carbon footprint scope increased million tonnes co e million tonnes co e due novartis integration represents increase overall footprint versus baseline excluding novartis footprint remained flat despite volume medicines vaccines consumer footnote healthcare products shipped recently available scope data factories increased approximately publish data online period late carbon emissions plus intensity ratios per regulations tonnes coea b scope emissions scope emissions data available scope emissions may intensity ratios scope emissionssales revenue tonnes coem scope fte tonnes coefte carbon emissions calculated according greenhouse gas protocol corporate accounting reporting standard revised edition b data includes former novartis sites emissions headcount gsk annual report strategic report governance remuneration financial statements investor information water innovative project rajasthan arid new water stewardship policy region india replenishing water reinforces commitment reduce source village sawaipura gsks water impact across value chain around quarter amount water continue look ways use water three horlicks factories located across sites successfully efficiently reduce consumption india use operations together achieved zero waste landfill used million water across alternative development initiatives indian purposing materials would otherwise go waste using wastetoenergy operations reduction ngo also supporting communities services less around horlicks supply chain improve water management agricultural yields amount use one aspect overall water impact across value waste chain includes factors local aim reduce operational waste water scarcity quality health social compared regulatory reputational risks operations produced thousand tonnes waste less focus efforts small number previous year highimpact gsk sites waterscarce baseline majority recycled regions agricultural supply chain incinerated recover energy horlicks products makes sent landfill around sites biggest portion total value chain achieved zero waste landfill water footprint repurposing materials would otherwise go waste using wastetoenergy services gsk recognised cdp leaders climate change water gsk included prestigious cdp list climate water efforts reduce carbon emissions included reducing emissions acknowledged inclusion manufacture inhalers launching cdp climate list cdp assessed companies complete cycle scheme first globally across ten industry sectors kind work pharmacists patients one companies applicants recover recycle inhalers steps seven healthcare companies alisted helped us reduce operational emissions since high rating reflects significant steps taken help meet goal becoming also one carbon neutral continuing grow applicants companies business meet healthcare needs healthcare company included people water list success reflects achievements reducing water usage since commitment water stewardship gsk annual report group financial review section cfos statement approach tax viability statement reporting framework noncontrolling interests viiv healthcare segmental review total results core results proforma growth rate reconciliations cash generation conversion financial position resources critical accounting policies treasury policies gsk annual report strategic report governance remuneration financial statements group financial review investor information continued make progress items adjusted total delivering strategy well core results consistent year financial goals set significant financial architecture three include remeasurement charges related businesses contributed delivery liabilities future contingent broadlybased revenue growth consideration significantly continued focus execution consideration due shionogi related integration restructuring programmes former interest dolutegravir accelerated delivery targeted value future put options well benefits allowing us improve margins major restructuring charges operating leverage still making continued make ifrs requires us provide contingent substantial investments behind new consideration liabilities related previous progress delivering products supply chain improvements business acquisitions basis well progressing rd pipeline strategy estimated present value potential also maintained focus future payments estimates could well financial goals financial efficiency allocation broad range outcomes effect capital allowing us deliver core eps ifrs accounting treatment gsk set growtha ahead sales growth recognises fair value liabilities financial architecture top end financial guidance well balance sheet charges significant improvement cash measurement reflected immediately generation dividend pence operating income gsk make per share cash payments future discharge liabilities liabilities financial architecture established acquisition financial architecture designed viability statement subsequent remeasurement charges support consistent execution viability statement sets income statement payments strategy enhance returns assessment prospects group charged future earnings next three years presented deliver shareholders focused delivering sustainable sales growth sales growth across company improving operating three businesses delivered leverage profitability enhancing growth line medium financial efficiency objective term growth expectations laid driving growth eps ahead sales capital markets day performance converting pharmaceuticals sales earnings cash actual rates cer proforma used invest business returned cer growth new products shareholders wherever see offsetting decline seretideadvair attractive returns sales addition strong growth hiv respiratory portfolio returned growth clear set priorities ensures actual rates cer consistency capital allocated across different businesses vaccines sales actual rates within gsk relative returns cer proforma cer driven business benchmarked relevant external strong execution across business comparatives using cash flow return particularly around flu meningitis investment cfroi based framework franchises bexsero particular metrics specific capital investments consumer healthcare delivered strong also benchmarked similar way performance first full year joint reporting framework venture sales actual rates addition total reported results cer proforma cer prepared ifrs annual report growth seven power brands makes reference number core offset tough comparators performance measures used headwinds international markets management planning reporting operating leverage purposes nonifrs measures total operating margin adjusted number items management sales compared believe useful separate movement primarily reflecting key trends driving performance combination higher remeasurement business clearly identified charges consumer healthcare put footnote shareholders core results may however option viiv healthcare contingent use number adjusted nonifrs measures vary significantly total results consideration liability report performance business adjustments may material described including core results free benefit profit disposal case cash flow cer proforma growth rates oncology business year nonifrs measures may considered addition substitute superior information presented accordance ifrs gsk annual report group financial review continued gsk financial architecture driving improved returns shareholders sales growth operating leverage eps returns shareholders financial efficiency free cash flow cash flow growth core operating margin improved impact decline total eps guidance driven increased leverage three partly offset benefit improved expect continued progress businesses proforma core margina operating performance reduced three businesses expected continue basis points total points restructuring charges year benefit recent new product launches coming currency points investments made core eps pa actual operational improvements driven exchange rates constant expectation core eps growth combination leverage stronger exchange rates dependent number factors including growth top line billion particular uncertainties relating including million currency benefits contingent consideration timing extent potential generic additional integration restructuring end gsk liabilities competition advair us benefits well continued tight cost contingent consideration payments control allowed us deliver margin billion billion related event generic version advair improvements continuing make estimated present value future payments introduced us market important investments three businesses shionogi viiv healthcare payments group expects core eps growth shionogi calculated quarter cera based expected accelerating delivery targeted based highteens percentage decline us advair sales benefits integration restructuring revenues relevant products principally programme key objective dolutegravir discounted fair value pleased progress made year event midyear introduction total future payments reflecting current sustained focus across group substitutable generic competitor advair expectations total future sales executing programme end us group expects fullyear products details provided delivered annual benefits us advair sales around billion cer note contingent consideration liabilities billion excluding million us core eps flat slight currency benefits almost full target free cash flow decline percentage terms cera programme year earlier originally net cash inflow operating activities able give guidance total planned confident delivering billion free cash flow results reliably forecast certain remaining million bring group billiona significantly material elements total results total benefits delivered billion improved small outflow saw future fair value movements annual savings constant currency basis driven improved contingent consideration put options operating performance including continued financial efficiency tight control capital expenditure returns shareholders continue focus improving restructuring expenditure well maintained ordinary dividend financial efficiency overall funding benefit currency tail winds continue p per share level paid costs protecting credit profile make progress towards objective line commitment particular shortterm target credit rebuilding cash generating capacity made shareholders time closed ratings net finance costs slightly group post completion novartis transaction early mainly due currency restructuring integration programme maintain dividend completed earnings per share integration reshaping group net debt total eps p p despite shortterm pressures free cash net debt end decline primarily reflected comparison flow restructuring costs would create billion billion higher net debt billion profit sale end currency significant fuller review financial results set marketed oncology assets novartis factor adverse translation effects driving pages also impact charges billion increase remaining arising increases valuations increase billion reflected impact liabilities contingent consideration dividends paid year put options associated increases billion including special dividend sterling value groups hiv billion declared partly consumer healthcare businesses offset disposal proceeds approximately simon dingemans billion free cash flow billion chief financial officer gsk annual report strategic report governance remuneration financial statements investor information approach tax understand responsibility pay seek maintain open positive appropriate amount tax fully relationships governments tax understand support efforts ensure companies authorities worldwide welcome responsibility pay transparent tax affairs constructive debate taxation policy managed tax important element appropriate amount tax continued significant economic contribution bring focus tax reform financially countries operate including oecds base erosion engage artificial tax arrangements efficient delivering profit shifting beps project without business commercial european commission initiatives sustainable tax rate substance seek avoid tax increased use fiscal state aid use tax havens transactions investigations oecd beps reports would fully disclose tax authority clarify important principle tax time responsibility paid profits throughout shareholders financially supply chain profit making efficient deliver sustainable tax activity takes place rate part approach look gsk supports approach particular align investment strategies implementation oecds countries already recommendations country country substantial economic activity reporting including exchange government policies promote tax regimes data tax authorities key attractive business success data validated investment transparent intent existing information held taxpayers available relevant tax payers support ability ensure multinational uk patent box groups pay right amount tax group corporate tax charge scope timeline us million million tax reform remain uncertain present profits million gsk would supportive steps million representing effective simplify us tax code provide tax rate clear roadmap make us tax system increase total tax rate primarily efficient competitive reflected higher nondeductible remeasurement charges related put tax implications brexit option liabilities lower credits dependent outcome negotiations reassessment prior years tax charges uk eu therefore made cash tax payments currently unknown however continue million year million work closely abpi bia analyse implications industry addition taxes pay order highlight key focus areas profits pay duties levies transactional government part brexit employment taxes negotiations direct tax implications ongoing alignment group expected limited gsk structure reflect mix operations indirect tax implications may geographies helped us maintain significant including potential customs efficient effective tax rate core tax duty costs additional transaction rate administrative costs associated core tax rate expected managing import export obligations range given movement goods groups momentum changing earnings uk eu mix challenging uncertain approach tax set detail tax environment due factors within public policy positions section described moderate upward website details pressure rate expected corporate tax charges year set next years tax risk managed set policies procedures seek ensure consistency compliance tax legislation audit risk committee footnote board responsible use number adjusted nonifrs measures report performance business approving tax policies risk described including core results free management cash flow cer proforma growth rates nonifrs measures may considered addition substitute superior information presented accordance ifrs gsk annual report group financial review continued viability statement accordance provision c revision following hypothetical downside scenarios evaluated code gsk assessed prospects company scenario business performance risks include key longer period months required going concern performance risks including lower sales new products provision directors confirm reasonable possible impact generic alternative seretideadvair us expectation gsk continue operate meets liabilities greater adverse impact generic competition gsk fall due next three years directors assessment products well possible supply manufacturing challenges made reference gsks current position prospects strategy boards risk appetite gsks scenario external macroeconomic risks scenario reflects principal risks managed detailed pages incremental risks business driven outside factors strategic report intense competition increased pricing pressure us europe well potential impact material negative board reviews internal controls risk management changes macroeconomic healthcare environment policies approves governance structure code conduct also appraises approves major financing investment scenario principal risks scenario includes severe licensing decisions evaluates monitors performance assessment potential loss impact principal risks prospects gsk whole focus largely improving set pages related patient safety product longterm financial performance simplifying operating quality supply chain continuity well antibribery corruption model growing diversified global business delivering could fundamentally threaten operations risks products value managed mitigating activities described pages board reviews gsks strategy makes significant capital investment decisions long term time horizon based scenario put option exercise scenario evaluates multiyear assessment return capital performance additional funding requirements assuming earliest potential business units market opportunity pharmaceutical exercise outstanding put options held partners vaccines consumer sectors approach aligned gsks hiv consumer businesses model achieving balanced growth investing high quality three year review also makes certain assumptions innovative products patients consumers healthcare normal level capital recycling likely occur considers whether providers however since many internal external parameters additional financing facilities required respective level become increasingly unpredictable longer time horizons gsk funding flexibility headroom focuses detailed bottomup plan three year cycle plan results stress testing show certain combinations reviewed least annually directors approve business hypothetical scenarios could increase funding demands forecasts showing expected financial impact directors believe gsk require mitigating changes groups funding strategy three year assessment period viability statement however light liquidity available group based appropriate aligns companys well established analysis directors reasonable expectation even business planning processes balance long term nature severe stress tests company able investments pharmaceutical vaccines consumer sectors continue operation meet liabilities fall due assessment period analysis near term three year period assessment business performance realistically visible plan stress tested series robust operational principal risk downside scenarios part boards review risk downside scenarios consider gsks cash flows sustainability dividends funding strategy insurance provision recovery well key financial ratios period metrics subject sensitivity analyses involve flexing number main assumptions underlying forecasts individually combination along mitigating actions could realistically taken avoid reduce impact occurrence underlying risk gsk annual report strategic report governance remuneration financial statements investor information reporting framework presentation group results pharmaceuticals segment turnover operating profit group financial review discusses operating financial year ended december adjusted exclude two performance group cash flows financial position months sales former gsk oncology business january resources compare results year primarily february results preceding year reconciliations reported growth rates proforma total results growth rates nonifrs measures set total reported results represent groups overall performance contingent consideration however results contain material unusual non gsk recognised significant liability contingent consideration operational items may obscure key trends factors million december fair value discounted basis determining groups operational performance result million represented estimated present value also report core results nonifrs measure future amounts payable shionogi relating viiv healthcare core results discounted payments shionogi calculated core results exclude following items total results based sales performance life relevant products amortisation impairment intangible assets excluding principally dolutegravir described effect computer software goodwill major restructuring costs ifrs accounting treatment gsk recognises fair value including costs following material acquisitions legal charges liabilities balance sheet remeasurement charges reflected net insurance recoveries expenses settlement immediately operating income charges adjusted litigation government investigations transactionrelated total results present core results gsk make cash accounting adjustments significant acquisitions payments future discharge liability items including disposals associates products businesses recorded profit loss account future earnings operating income royalty income together changes segment reporting tax effects items completion novartis transaction march items excluded core results either changed balance group gsk changed impact significant exclusion improves segment reporting reflect effect january comparabilities consistency reporting majority gsk reported results four segments pharmaceuticals peer companies definition core results aligns includes hiv pharmaceuticals rd vaccines consumer groups results better majority peer companies healthcare addition number minor product reclassifications report earnings segments made comparative information restated accordingly core results reporting utilised one bases internal performance reporting alongside total results cash flow generation free cash flow number metrics core results presented free cash flow nonifrs measure net cash discussed group financial review believe core inflow operating activities less capital expenditure interest results representative performance groups dividends paid noncontrolling interests plus proceeds operations allow key trends factors driving sale property plant equipment dividends received performance easily clearly identified shareholders joint ventures associated undertakings equity investments reasons results four segments used management planning reporting purposes pharmaceuticals pharmaceuticals rd vaccines consumer discussions presentations investment analysts rating healthcare reported measured basis agencies free cash flow growth calculated reported basis reconciliation net cash inflow operations free cash flow reconciliations total core results including detailed presented breakdowns key noncore items set provided shareholders ensure full visibility transparency adjusted free cash flow assess groups performance adjusted free cash flow nonifrs measure excludes payments made settle legal disputes payments could also use number adjusted nonifrs measures fluctuate significantly reporting periods removing report performance business measures allows trends free cash flow easily identified used management planning reporting purposes shareholders reconciliation net cash inflow operations discussions presentations investment analysts rating adjusted free cash flow presented agencies may directly comparable similarly described measures used companies nonifrs measures may working capital conversion cycle considered addition substitute superior working capital conversion cycle calculated number information presented accordance ifrs days sales outstanding plus days inventory outstanding less days purchases outstanding proforma growth rates novartis transaction completed march gsks cer growth reported results include results former novartis vaccines order illustrate underlying performance practice consumer healthcare businesses exclude results discuss results terms constant exchange rate cer growth former gsk oncology business march represents growth calculated exchange rates used vaccines consumer healthcare segments proforma growth determine results overseas companies sterling remained rates calculated comparing reported turnover core operating unchanged used previous year cer represents profits year ended december turnover growth constant exchange rates aer represents growth operating profit year ended december adjusted actual exchange rates include two months sales former novartis vaccines growth rates included report cer unless otherwise consumer healthcare products respectively stated gsk annual report group financial review continued noncontrolling interests viiv healthcare trading profit allocations exit rights viiv healthcare subsidiary group pfizer may request ipo viiv healthcare time operating results turnover operating profit profit tax either gsk consent ipo offering included within group income statement portion completed within nine months pfizer could require gsk acquire earnings allocated noncontrolling interests owned shareholding original agreements gsk shareholders line respective equity unconditional right long made subsequent distribution shareholdings pfizer shionogi shareholders withhold consent exercise shareholders including gsk also entitled preferential dividends pfizer put options result accordance ifrs gsk determined performance certain products recognise liability put option balance sheet shareholder contributed relative performance q gsk notified pfizer irrevocably given products changes time proportion overall earnings right accordingly recognised liability put option viiv healthcare allocated shareholder change groups balance sheet initial value million particular increasing sales tivicay triumeq consistent revised treatment end q favourable impact proportion preferential dividends gsk also recognised liabilities future preferential dividends allocated gsk gsk entitled approximately anticipated become payable pfizer shionogi core earnings viiv healthcare groups balance sheet take account cash payments made shionogi viiv closing balances liabilities related pfizers shareholding healthcare recorded earnings remeasurements follows liabilities preferential dividends allocated pfizer shionogi included within operating income acquisitionrelated arrangements pfizer put option part agreement reached acquire shionogis interest pfizer preferential dividend former shionogiviiv healthcare joint venture viiv healthcare agreed pay additional consideration shionogi original agreements shionogi could also requested contingent performance products developed gsk acquire shareholding viiv healthcare six month joint venture principally dolutegravir liability windows commencing gsk contingent consideration estimated recognised unconditional right long made subsequent distribution groups balance sheet date acquisition subsequent shareholders withhold consent exercise remeasurements reflected within operating income shionogi put option result gsk recognise liability cash payments made shionogi viiv healthcare put option balance sheet q gsk notified quarter reduce balance sheet liability contingent shionogi irrevocably given right accordingly consideration result recorded income recognised liability put option groups balance statement total cash payments made shionogi sheet initial value million q shionogi respect contingent consideration amounted million irrevocably agreed waive put option result gsk payments calculated based sales performance derecognised liability put option groups balance relevant products previous quarter reflected sheet directly equity value liability million cash flow statement partly operating cash flows partly derecognised purchases businesses within investing activities tax relief gsk also call option shionogis shareholding viiv payments reflected groups noncore total tax healthcare original agreements exercisable charge part payment relating original estimate six month windows commencing gsk fair value contingent consideration acquisition irrevocably agreed waive first two exercise windows shionogiviiv healthcare joint venture million last six month window remains call option reported within investing activities cash flow statement fair value value accounting purposes part payment relating increase liability since acquisition reported within operating cash flows movements contingent consideration payable shionogi follows contingent consideration beginning year additions remeasurement income statement cash payments operating cash flows cash payments purchases businesses movements contingent consideration end year additions represented recognition preferential dividends payable shionogi gsk annual report strategic report governance remuneration financial statements investor information group turnover turnover bn group turnover year increased actual rates cer million pharmaceuticals vaccines bn consumer healthcare growth three businesses still reflecting impact novartis transaction completed march proforma basis group turnover pharmaceuticals vaccines consumer healthcare sales new pharmaceutical vaccine products million sterling increase aer growth cer growth million group turnover geographic region growth growth cer group turnover us europe restated growth growth cer international pharmaceuticals vaccines group turnover outside us europe represented consumer healthcare total group turnover segment turnover sales new pharmaceutical vaccine products corporate unallocated turnover growth growth cer group turnover respiratory relvarbreo ellipta anoro ellipta arnuity ellipta incruse ellipta nucala cvmu eperzantanzeum hiv tivicay triumeq pharmaceuticals bexsero menveo vaccines identified series new pharmaceutical vaccine products expected deliver least billion revenues per annum cer basis products plus current clinical pipeline asset shingrix set group defined new pharmaceutical vaccine products sales new pharmaceutical vaccine products expected reach billion revenues per annum cer basis two years earlier sales new pharmaceutical vaccine products million represented approximately pharmaceuticals vaccines turnover gsk annual report group financial review continued pharmaceuticals turnover bn pharmaceuticals pharmaceuticals turnover million actual rates cer adjusting disposal oncology business novartis proforma hiv sales grew group turnover respiratory portfolio returned growth sales continuing transition globally newer products respiratory sales grew us international declined europe sales new pharmaceutical products million sterling aer growth cer growth increase million offset sterling decline seretideadvair sales million sales established products declined declines regions particularly international reflecting loss exclusivity valtrex canada pharmaceuticals turnover impact market reforms continued reshaping business china impact biennial price revisions japan restated growth growth overall impact pricing net sales pharmaceuticals cer around respiratory us pharmaceuticals turnover million declined cardiovascular metabolic reported basis grew proforma basis urology proforma performance reflected growth respiratory immunoinflammation portfolio partly offset impact generic competition pharmaceuticals avodart million lovaza established products million relenza sales also million hiv following reallocation government funding sales new respiratory products totalled million growth products exceeded decline advair advair sales fell million representing volume decline negative impact price ventolin sales million benefiting competitor supply constraints early year flovent sales declined million reflecting pricing pressures ics market benlysta sales increased million ongoing demand growth europe pharmaceuticals turnover declined million reported basis proforma basis respiratory sales declined million reflecting ongoing transition new respiratory portfolio generic competition seretide declined volume decline negative impact price million partly offset growth new respiratory products recorded sales million established products sales million international pharmaceuticals sales million reported basis proforma basis sales emerging markets declined reported proforma basis impacted decline china business primarily result ongoing reshaping programme broader healthcare reforms including price reductions also recent divestments international region limitation trading venezuela japan pharmaceutical sales reported basis proforma million impacted biennial price revisions older products well supply interruptions avodart early year respiratory sales japan grew strong growth new respiratory products million offsetting decline adoair sales gsk annual report strategic report governance remuneration financial statements investor information respiratory established products respiratory sales increased million reflecting established products turnover fell million valtrex continuing transition respiratory portfolio newer sales million driven decline canada products growth new respiratory products recorded million following loss exclusivity zeffix sales combined sales million including relvarbreo ellipta sales million lovaza sales us fell million offset decline seretideadvair million flixotideflovent sales decreased million ventolin hiv sales grew million hiv sales increased million us us respiratory sales increased million europe international growth three volume growth negative impact price growth regions driven triumeq tivicay new respiratory products offset decline triumeq tivicay sales million million advair volume decline negative impact price respectively epzicomkivexa sales declined million new ellipta products recorded combined sales million selzentry sales declined million also including breo ellipta sales million nucala continued declines mature portfolio mainly driven generic treatment severe asthma reporting sales million competition combivir million lexiva established respiratory assets included ventolin sales million million flovent declined million ventolin sales benefited competitor supply constraints early year flovent continued impacted ongoing pricing pressures ics market european respiratory sales million seretide sales million volume decline negative impact price reflecting continued competition generics transition respiratory portfolio newer products new respiratory products recorded combined sales million including relvar ellipta sales million respiratory sales international region increased million emerging markets japan emerging markets sales seretide million ventolin grew million japan growth new respiratory products offset adoair decline cardiovascular metabolic urology sales category million avodart franchise million primarily due decline us following launch generic competition q sales eperzantanzeum million primarily us prolia divested end therefore sales recorded compared million immunoinflammation immunoinflammation sales grew million sales benlysta million sales us million pharmaceuticals sales therapy areas decreased million dermatology sales declined million adversely affected supply constraints augmentin sales flat million sales products rare diseases flat million included sales volibris million gsk annual report group financial review continued vaccines turnover bn vaccines sales grew actual rates cer proforma million growth benefited strong performance bexsero across regions higher demand fluarixflulaval us international tender award group turnover menveo international growth driven synflorix due market expansion international tender award europe boostrix sales benefited higher demand europe international growth partly offset infanrixpediarix due aer growth cer growth supply constraints international well unfavourable cdc stockpile movements number products across portfolio us sales grew proforma basis million growth driven market share growth bexsero menveo boostrix improved supply higher demand restated growth growth fluarixflulaval competitor supply issues benefited cer infanrixpediarix growth partly offset adverse stockpile rotarix movements menveo unfavourable comparison synflorix benefit cdc stockpile movements infanrixpediarix fluarix flulaval boostrix rotarix bexsero europe sales grew proforma basis menveo million growth driven primarily bexsero sales boostrix private market channels several countries including spain infanrix pediarix italy uk following inclusion nhs immunisation hepatitis programme boostrix sales benefited higher demand priorix priorix tetra varilrix competitor supply issues sales increased germany driven cervarix improved supply hepatitis vaccines higher demand encepur rabipur sales growth also helped tender award synflorix poland infanrixpediarix sales adversely impacted mainly germany france italy competitors return market year growth also partly offset unfavourable comparison menveo sales uk benefited catchup tender win international sales grew proforma basis million growth driven primarily synflorix due market expansion nigeria higher demand africa private market demand asia growth menveo sales driven tender award argentina rotarix sales benefited higher demand brazil japan growth region driven brazil due strong demand bexsero menjugate boostrix fluarixflulaval sales grew due higher uptake australia growth region partly offset lower sales infanrixpediarix due supply constraints lower hepatitis vaccines sales due wholesaler destocking china following introduction new private market distribution regulations gsk annual report strategic report governance remuneration financial statements investor information consumer healthcare turnover bn consumer healthcare business represents consumer healthcare joint venture novartis together gsk consumer healthcare listed businesses india nigeria excluded joint venture results include group turnover trading performance nigeria beverages business q following sale september sales grew actual rates cer million aer growth cer growth benefiting significantly inclusion sales former novartis products first time first two months period proforma growth price contributed volume strong performances delivered power brands within oral health wellness categories across regions sales innovation within last three years represented restated growth growth approximately sales particular contribution cer flonase switched otc q notable wellness launches included sensodyne true white excedrin oral health geltabs us nutrition us sales grew proforma million sensodyne skin health delivered doubledigit growth benefiting launch repair protect launch true white first quarter together distribution gains pronamel newly launched pronamel strong bright variant flonase otc delivered restated growth growth cer high singledigit growth strong performance first half us driven new formats impacted second half increasing private label competition excedrin grew doubledigits europe driven geltab launch new digital campaigns international tums also delivered doubledigit growth benefiting supply improvements partly offset decline aquafresh sales due increased competitive pressures realignment investment behind power brands sales europe grew million proforma basis driven primarily performances within wellness oral health categories voltaren continued deliver doubledigit growth driven largely hour variant strong performances across key markets oral health sales grew mid singledigits strong growth sensodyne gum health portfolio partly offset flat performance aquafresh due increased competitive pressures market level sales grew well italy scandinavia uk germany partly offset decline sales cis due impact consumer spending weaker economic environment international sales million grew proforma growth growth delivered many priority markets primarily power brands across oral health wellness categories partly offset impact sale nigeria beverages business end q well affect restructuring activity venezuela end growth international region also affected combined impact indian business demonetisation implemented november general slowing health food drink category impacted performance nutrition category horlicks particular elsewhere strong growth delivered middle east latin america china growth middle east driven strong momentum across power brands particularly otrivin panadol sensodyne doubledigit performances delivered brazil argentina result better pricing new product launches within oral health china delivered high singledigit sales growth contributions across portfolio sensodyne voltaren particular benefiting ecommerce retail distribution expansion gsk annual report group financial review continued total results turnover bn cost sales cost sales percentage turnover bn percentage points sterling terms percentage points cer terms compared reflected improved product mix particularly impact higher hiv sales pharmaceuticals also vaccines consumer healthcare lower restructuring costs well increased contribution integration restructuring savings three businesses aer growth cer growth benefits partly offset continued adverse pricing pressure pharmaceuticals primarily respiratory well continued investments supply chain total operating profit bn selling general administration sga costs turnover percentage points lower bn percentage points lower cer basis primarily reflected lower restructuring costs well benefits pharmaceuticals restructuring programme integration benefits vaccines consumer healthcare partly offset investment promotional product support particularly new aer growth cer growth launches respiratory hiv vaccines consumer healthcare research development rd expenditure million turnover higher lower cer basis reflected benefit cost reduction programmes pharmaceuticals total results group set consumer healthcare vaccines rd lower restructuring costs partly offset increased investment particularly growth pharmaceuticals reflecting investments number new programmes costs acquired bms hiv programme turnover turnover cer turnover operating incomeexpense cost sales net operating expense million million selling general income primarily reflected accounting charges related administration remeasurement contingent consideration liability related research former shionogiviiv healthcare joint venture along development remeasurement value attributable consumer healthcare royalty income joint venture put option liabilities first recognised q operating income pfizer shionogi put options preferential dividends expense viiv healthcare remeasurements driven operating profit unwinding discount applied future liabilities well net finance costs updated trading forecasts changes exchange rate profit disposal assumptions used updating periodend rates interest associates increased estimated total sterling values gsks consumer share tax healthcare viiv healthcare businesses profits associates charges partly offset milestone income joint ventures million relation disposal ofatumumab completed profit taxation gains number divestments made taxation year including remaining shares held group aspen profit taxation pharmacare net operating income million year included profit disposal oncology business profit attributable novartis million shareholders earnings per share p earnings per ads us gsk annual report strategic report governance remuneration financial statements investor information total results continued operating profit profit taxation total operating profit million compared taking account net finance costs share profit million benefited net disposal associates profit taxation million compared gains recorded following disposal oncology business million part novartis transaction taxation operating profit benefited improved operating leverage driven sales growth favourable mix across three businesses together lower levels restructuring costs uk current year charge compared however accounting rest world current year charge charges related remeasurement contingent consideration charge respect prior periods liability related former shionogiviiv healthcare joint venture total current taxation along remeasurement value attributable consumer total deferred taxation healthcare joint venture put option liabilities first recognised q pfizer shionogi put options preferential taxation total profits dividends viiv healthcare tax charge million total profit represented effective contingent consideration cash payments made shionogi tax rate reflected nondeductibility companies reduce balance sheet liability certain items included within transactionrelated adjustments hence recorded income statement total contingent particularly remeasurements put options related viiv consideration cash payments amounted million healthcare consumer healthcare joint venture million included cash payments made viiv noncontrolling interests healthcare shionogi relation contingent consideration allocation earnings noncontrolling interests amounted liability including preferential dividends amounted million million including noncontrolling million million milestone payment interest allocations consumer healthcare profits million million made novartis relation vaccines million allocation viiv healthcare losses acquisition million million including impact changes net finance costs proportions preferential dividends due shareholder based relative performance different products year finance income allocation also reflected impact contribution interest income groups entities noncontrolling interests primarily fair value movements result net losses entities arising exchange earnings per share total earnings per share p compared p finance expense decrease primarily reflected benefit interest expense disposal oncology business novartis closed unwinding discounts liabilities march together impact charges arising remeasurements fair value movements increases valuations liabilities contingent finance expense consideration put options associated increases sterling value groups hiv consumer healthcare businesses partly offset improved performance reduced share tax profits associates joint ventures restructuring costs share profits associates joint ventures million dividends million board declared four interim dividends resulting total dividend year pence line dividend declared see note financial statements dividends gsk annual report group financial review continued total results continued core results reconciliation december intangible intangible total asset asset major legal transaction divestments core results amortisation impairment restructuring charges related results turnover cost sales gross profit selling general administration research development royalty income operating incomeexpense operating profit net finance costs share tax profits associates joint ventures profit taxation taxation tax rate profit taxation profit attributable noncontrolling interests profit attributable shareholders earnings per share p p p p p p p p weighted average number shares millions core results reconciliation december intangible intangible total asset asset major legal transaction divestments core results amortisation impairment restructuring charges related results turnover cost sales gross profit selling general administration research development royalty income operating income operating profit net finance costs profit disposal associates share tax profits associates joint ventures profit taxation taxation tax rate profit taxation lossprofit attributable noncontrolling interests profit attributable shareholders earnings per share p p p p p p p p weighted average number shares millions gsk annual report strategic report governance remuneration financial statements investor information total results continued items adjusted total results present core results transactionrelated adjustments total results adjusted number items order present transactionrelated adjustments resulted net charge core results explained items discussed million million primarily reflected accounting charges remeasurement liability unwinding discounting effects value attributable intangible asset amortisation impairment consumer healthcare joint venture put option held novartis intangible asset amortisation million compared remeasurement unwinding discounting effects million intangible asset impairments million contingent consideration relating acquisition former million included impairments rd commercial shionogiviiv healthcare joint venture value attributable assets charges noncash items put options preferential dividends payable pfizer major restructuring integration shionogi major restructuring integration charges million incurred million reflecting phasing planned restructuring projects following completion chargecredit consumer healthcare joint venture put option novartis transaction well reduced charges pharmaceuticals restructuring projects programme enters contingent consideration former shionogiviiv later stages cash payments made million healthcare joint venture including shionogi million including settlement certain charges accrued preferential dividends previous quarters viiv healthcare put options pfizer preferential dividends charges combined restructuring integration programme adjustments date billion cash charges billion cash total transactionrelated charges payments date billion anticipated total cash charges combined programme expected billion aggregate impact unwinding discount future noncash charges billion programme potential liabilities million million including delivered incremental cost savings billion including million consumer healthcare joint venture put option currency benefit billion delivered approximately million contingent consideration former shionogi billion annual savings including currency benefit viiv healthcare joint venture million viiv healthcare programme remains track deliver originally targeted total put options preference dividends remaining charge annual savings billion constant currency basis million driven primarily changes exchange rate estimated million additional cash charges assumptions well updates trading forecasts expected along residual noncash charges gsk shionogi made several amendments legal charges shareholders agreement viiv healthcare regarding legal charges million million included shionogi put option gsk call option estimated liability benefit settlement existing matters well provisions shionogis put option initially recognised gsks balance ongoing litigation cash payments million compared sheet end q derecognised december million directly equity stood million explanation accounting noncontrolling interests viiv healthcare set divestments items divestments items included equity investment disposals including disposal remaining aspen pharmacare investment dividends impairments milestone income ofatumumab number asset disposals certain adjusting items divestments items included profit disposal oncology business novartis gsk annual report group financial review continued core results turnover bn research development growth bn turnover turnover cer research development rd expenditure million turnover higher aer growth cer growth higher cer basis reflecting increased investment particularly total pharmaceuticals increased cer operations pharmaceuticals rd broadly split discovery activities completion phase iia trials core operating profit bn development work phase iib onwards supported specific common infrastructure shared services bn appropriate phase iv costs administrative expenses reported sga included table growth cer discovery aer growth cer growth development facilities central support functions total pharmaceuticals vaccines rd use core results nonifrs measure among consumer healthcare rd metrics including total results cash flow generation research development manage performance group nonifrs measures significant factor driving total pharmaceuticals rd may considered addition substitute growth progression viiv healthcare hiv portfolio superior information presented accordance ifrs including programmes acquired bms earlier year definition core results set increase discovery also driven progression early cost sales stage oncology portfolio early investment bioelectronics growth development growth primarily due start new phase iii programmes including hiv respiratory anaemia partly offset turnover turnover cer benefit rd cost reduction programmes increase cost sales facilities central support functions costs partly reflected investment new data warehousing analytics transform cost sales percentage turnover way data harnessed across rd together reallocation percentage points sterling terms percentage points central support costs cer terms compared proforma basis cost sales percentage decreased percentage points compared royalty income percentage points cer terms royalty income million million primarily reflected improved product mix particularly impact higher reflecting increased royalty income gardasil sales well hiv sales pharmaceuticals also vaccines consumer benefit catchup adjustment prioryear estimates healthcare well increased contribution integration restructuring savings three businesses partly offset core operating profit continued adverse pricing pressure pharmaceuticals primarily core operating profit million actual rates respiratory well continued investments supply chain higher cer terms turnover increase core operating margin percentage points selling general administration higher percentage points higher cer growth basis proforma basis core operating profit higher turnover turnover cer cer terms compared turnover growth core selling general administration operating margin percentage points higher percentage points higher cer terms proforma sga costs turnover percentage points lower basis reflecting improved operating leverage driven sales growth percentage points lower cer basis favourable mix across three businesses well proforma basis sga percentage sales reduced delivery restructuring integration benefits tight control percentage points percentage points cer primarily ongoing costs partly offset continued price pressure particularly reflected tight control ongoing costs well benefits respiratory supply chain rd investments pharmaceuticals restructuring programme integration benefits vaccines consumer healthcare partly offset investment promotional product support particularly new launches respiratory hiv vaccines consumer healthcare gsk annual report strategic report governance remuneration financial statements investor information core results continued contingent consideration cash payments made shionogi net finance costs companies reduce balance sheet liability hence recorded income statement total contingent finance income consideration cash payments amounted million interest income million included cash payments made viiv fair value movements healthcare shionogi relation contingent consideration liability including preferential dividends amounted million million milestone payment finance expense million made novartis interest expense core operating profit business unwinding discounts liabilities remeasurements fair value movements restated growth finance expense margin margin cer pharmaceuticals net core finance expense million compared pharmaceuticals rd million reflecting translation effect exchange pharmaceuticals rate movements reported sterling costs foreign currency vaccines denominated interestbearing instruments consumer share tax profitslosses joint ventures healthcare share profits associates joint ventures million million loss corporate core profit taxation unallocated costs core operating profit growth pharmaceuticals turnover turnover cer pharmaceuticals operating profit million higher core profit tax cer terms turnover increase operating taxation margin percentage points higher tax core profit amounted million represented percentage points higher cer basis proforma basis effective core tax rate increase operating margin increased percentage points cer effective rate primarily reflected groups changing earnings mix basis reflecting favourable product mix primarily driven see taxation details growth hiv sales cost reduction benefit pharmaceuticals restructuring programme partly offset increased noncontrolling interests investment new product support increased investment rd allocation earnings noncontrolling interests amounted number new programmes continued impact lower prices million million including noncontrolling particularly respiratory broader transition interest allocations consumer healthcare profits million respiratory portfolio million allocation viiv healthcare profits increased million million including vaccines impact changes proportions preferential dividends due vaccines operating profit million higher shareholder based relative performance different cer terms turnover increase operating products year allocation also reflected impact profit margin percentage points higher contribution groups entities non percentage points higher cer basis controlling interests primarily result net losses proforma basis operating margin improved percentage entities arising exchange points points cer terms primarily driven improved product mix enhanced operating leverage strong sales core earnings per share growth together restructuring integration benefits cost core eps p actual rates sales sga rd higher royalty income partly cer terms compared cer increase operating profit offset sga investments support business growth number primarily reflecting increased tax rate compared inventory adjustments additional supply chain investments greater contribution growth businesses significant noncontrolling interests consumer healthcare consumer healthcare operating profit million higher cer terms turnover increase operating margin percentage points higher percentage points higher cer basis proforma basis consumer healthcare operating margin percentage points higher cer basis due improvements gross margin reflecting mix benefits power brand strategy better pricing well strong contribution integration synergies benefiting sga rd percentage sales gsk annual report group financial review continued proforma growth rate reconciliations following table sets reconciliations reported cer growth rates proforma cer growth rates stated items turnover adjustment include adjustment include adjustment exclude january february january february january february turnover turnover former turnover former reported former novartis novartis consumer gsk oncology proforma growth rate vaccines products healthcare products products growth rate turnover cer cer cer cer cer group turnover us europe international pharmaceuticals us pharmaceuticals europe pharmaceuticals international pharmaceuticals emerging markets pharmaceuticals japan pharmaceuticals vaccines us vaccines europe vaccines international vaccines menveo vaccines consumer healthcare us consumer healthcare europe consumer healthcare international consumer healthcare wellness oral health nutrition skin health following table sets reconciliations reported cer growth rates proforma cer growth rates stated core expense headings core operating profit adjustment include adjustment include adjustment exclude january february january february january february turnover former turnover former turnover former reported novartis vaccines novartis consumer gsk oncology proforma core expenses growth rate products healthcare products products growth rate operating profit cer cer cer cer cer cost sales selling general administration research development royalty income core operating profit pharmaceuticals operating profit pharmaceuticals operating profit excluding rd pharmaceuticals rd vaccines operating profit consumer healthcare operating profit gsk annual report strategic report governance remuneration financial statements investor information cash generation conversion summary consolidated cash flow statement set reconciliation net cash inflow operating activities free cash flow adjusted free cash flow reconciliation net cash inflow operating activities net cash inflow operating activities closest equivalent ifrs measure free cash flow shown net cash outflowinflow investing activities net cash outflow financing activities decreaseincrease cash bank overdrafts net cash inflow operating activities purchase property plant equipment cash bank overdrafts beginning year purchase intangible assets decreaseincrease cash bank overdrafts proceeds sale property plant equipment exchange adjustments interest paid cash bank overdrafts end year interest received cash bank overdrafts end year dividends associates joint ventures comprise distributions noncontrolling interests cash cash equivalents free cash flow overdrafts legal payments adjusted free cash flow adjusted net cash inflow operating activities future cash flow net cash inflow operating activities year long term expect future cash generated million million increase primarily operations sufficient fund operating debt servicing reflected improved operating performance across segments costs normal levels capital expenditure obligations positive currency benefit excluding legal settlements existing licensing agreements expenditure arising restructuring million million adjusted net cash inflow programmes routine outflows including tax pension operating activities million million contributions dividends subject principal risks addition payments restructuring integration costs uncertainties discussed pages may time million million tax payment time additional demands finance acquisitions million million sale oncology including potentially acquiring increased ownership portions business funded divestment viiv healthcare consumer healthcare businesses proceeds minority shareholders hold put options share repurchases total cash payments made viiv healthcare shionogi access multiple sources liquidity short longterm relation contingent consideration liability including preferential capital markets financial institutions addition cash flow dividends year million million operations needs million million recognised cash investment appraisal flows operating activities million million formal process assessing potential investment recognised within investing cash flows proposals order ensure decisions aligned overall free cash flow strategy process includes assessment cash flow free cash flow amount cash generated business return individual investment cfroi well net present meeting obligations interest tax dividends paid value npv internal rate return irr timeline noncontrolling interests capital expenditure property project long term also consider impact eps plant equipment intangible assets credit profile relevant discount rate used perform financial analyses decided internally allow determination extent investments free cash inflowoutflow cover cost capital specific investments discount rate adjusted free cash flow may adjusted take account country risk weightings free cash flow million year million working capital outflow excluding legal payments adjusted free cash flow working capital programme continued make progress million million also making improvements collection receivables restructuring integration payments additional tax payment inventory management sale oncology business purchase hiv clinical assets million treated intangible asset working capital percentage turnover purchases excluding items funded divestment proceeds adjusted free cash flow would working capital conversion cycle days million million reported working capital conversion cycle days capital expenditure financial investment distorted temporary favourable impact days arising cash payments tangible intangible fixed assets amounted novartis transaction excluding impact conversion cycle million million disposals realised around days resulting reduction days million million cash payments acquire equity compared predominantly due beneficial investments million million made sales impact exchange reduced receivables days improved equity investments realised million million collections reduced inventory days gsk annual report group financial review continued financial position resources property plant equipment business sciencebased technologyintensive highly assets regulated governmental authorities allocate significant noncurrent assets financial resources renewal maintenance property plant equipment minimise risks interruption production property plant equipment ensure compliance regulatory standards number goodwill processes use hazardous materials intangible assets investments associates joint ventures total cost property plant equipment december million net book value million investments land buildings represented million plant deferred tax assets equipment million assets construction million noncurrent assets invested million new property plant total noncurrent assets equipment mainly related large number projects renewal improvement expansion facilities various current assets worldwide sites property mainly held freehold new investment inventories financed liquid resources december current tax recoverable contractual commitments future capital expenditure trade receivables million operating lease commitments million believe derivative financial instruments facilities adequate current needs liquid investments observe stringent procedures use specialist skills cash cash equivalents manage environmental risks activities environmental issues assets held sale sometimes dating operations modified discontinued total current assets reported planet note financial statements legal proceedings total assets goodwill liabilities goodwill increased year million current liabilities december million increase primarily shortterm borrowings reflected impact exchange movements contingent consideration liability intangible assets trade payables intangible assets include cost intangibles acquired derivative financial instruments third parties computer software net book value current tax payable intangible assets december million shortterm provisions million increase reflected impact exchange movements development costs capitalised total current liabilities year million partly offset amortisation impairment noncurrent liabilities existing intangibles million million respectively longterm borrowings investments associates joint ventures deferred tax liabilities held investments associates joint ventures carrying pensions postemployment benefits value december million million provisions market value december million contingent consideration liability million largest investments innoviva inc book value december million noncurrent liabilities million market value december total noncurrent liabilities million see note financial statements investments total liabilities associates joint ventures net assets equity share capital share premium account retained earnings reserves shareholders equity noncontrolling interests total equity gsk annual report strategic report governance remuneration financial statements investor information financial position resources continued investments noncurrent liabilities held investments carrying value december noncurrent liabilities million december million million decrease million included million carrying value year primarily due sale million related present value estimated amount payable groups remaining stake aspen pharmacare holdings limited us event full exercise novartis right require us book value december million acquire shareholding consumer healthcare joint significant investments held december venture details provided note key accounting theravance biopharma inc book value judgements estimates december million million contingent consideration liabilities investments included equity stakes companies contingent consideration liabilities amounted million research collaborations provide access biotechnology december million million developments potential interest interests companies million represented estimated present value arise business divestments amounts payable shionogi relating viiv healthcare derivative financial instruments assets million million represented estimated present current derivative financial instruments held fair value value contingent consideration payable novartis related million million majority amount vaccines acquisition liability due shionogi included related foreign exchange contracts designated million respect preferential dividends million designated accounting hedges recognised directly equity year liability preferential dividends due pfizer december million inventories explanation accounting treatment interests viiv inventory million increased million healthcare set increase primarily reflected impact exchange movements net debt trade receivables trade receivables million increased million primarily reflecting exchange movements cash cash equivalents liquid investments derivative financial instruments liabilities borrowings repayable within one year held current derivative financial instruments fair value borrowings repayable one year million million primarily related foreign net debt exchange contracts designated designated accounting hedges december net debt billion compared trade payables billion december comprising gross debt trade payables amounting million increased billion cash liquid investments billion million reflecting pfizer put option related increase net debt primarily reflected billion adverse viiv healthcare recognised year increase accruals exchange impact translation nonsterling denominated customer returns rebates impact exchange debt exchange financing items dividends paid movements shareholders billion including special dividend billion partly offset free cash flow billion provisions asset disposals billion carried deferred tax provisions shortterm noncurrent provisions million december december cash liquid investments held million million million follows related legal disputes million million related major restructuring programme provision made legal disputes indemnified disposal bank balances deposits liabilities employee related liabilities costs us treasury treasury repo restructuring programme extent balance sheet money market funds date legal constructive obligation existed could liquidity funds reliably estimated government securities pensions postemployment benefits account pension postemployment arrangements accordance ias deficits net surpluses cash liquid investments billion billion allowing deferred taxation million held centrally december million pension arrangements million million unfunded postemployment liabilities increases deficits predominantly driven lower discount rates used discount value liabilities together increase uk inflation rate assumptions stronger us dollar year end partly offset special funding contributions uk schemes significant uk asset gains gsk annual report group financial review continued financial position resources continued maturity profile gross debt maturity profile gross debt equivalent gbp bonds eur bonds usd bonds commercial paper bank borrowings leases analysis cash gross debt effects hedging total equity follows december total equity decreased million december million primarily reflected recognition transactionrelated adjustments million impact dividends paid increase cash liquid investments pension deficit million partly offset profit gross debt fixed year favourable exchange translation impact weaker floating sterling rates noninterest bearing summary movements equity set net debt movements net debt total equity beginning year total comprehensive income year dividends shareholders net debt beginning year ordinary shares issued decreaseincrease cash bank overdrafts gain transfer net assets increase liquid investments consumer healthcare jv net increase inrepayment shortterm loans consumer healthcare jv put option exchange movements loss transfer equity investment movements investment associate net debt end year changes noncontrolling interests recognition liabilities noncontrolling interests derecognition liabilities noncontrolling interests shares acquired esop trusts sharebased incentive plans tax sharebased incentive plans distributions noncontrolling interests total equity end year gsk annual report strategic report governance remuneration financial statements investor information financial position resources continued share purchases entered number research collaborations develop employee share ownership plan esop trusts new compounds pharmaceutical companies terms acquired million shares glaxosmithkline plc arrangements include upfront fees equity investments million shares held trusts satisfy future exercises loans commitments fund specified levels research options awards group share option award addition often agree make payments future schemes proportion shares held trusts milestones achieved respect awards rules scheme require us satisfy agreements relate compounds early exercises market purchases rather issue new stages development potential obligation make milestone shares shares held trusts matched options payments continue number years compounds move awards granted successfully development process generally closer december esop trusts held million product marketing approval greater probability million gsk shares future exercise share options success amounts shown within intangible assets share awards carrying value million represent maximum would paid milestones million deducted reserves market achieved include billion relates externalised value shares million million projects discovery portfolio number new commitments made licensing agreements offset shares repurchased december amendments existing agreements held million shares treasury shares million shares cost million million reached agreement trustees uk deducted retained earnings pension schemes make additional contributions including eliminate pension deficit identified december ordinary shares purchased period january actuarial funding valuation table includes commitment march company expect make excludes normal ongoing annual funding requirement ordinary share repurchases remainder uk approximately million information pension commitments contingent liabilities obligations see note financial statements pensions financial commitments summarised note financial postemployment benefits statements commitments contingent liabilities contingent liabilities obligations respect short longterm debt set following table sets contingent liabilities comprising note financial statements contingent liabilities discounted bills performance guarantees letters credit note financial statements net debt items arising normal course business amounts provided pensions postretirement benefits expected expire set note financial statements pensions postemployment benefits amounts provided restructuring total yr yrs yrs yrs programmes legal environmental disputes set note financial statements provisions guarantees contingent liabilities contractual obligations commitments total following table sets contractual obligations commitments december fall due payment normal course business provided various total yr yrs yrs yrs indemnification guarantees respect business disposals legal disputes subsequently arisen provision loans made outflow resources considered probable interest loans reliable estimate made likely outcome dispute included note financial statements finance lease obligations provisions finance lease charges operating lease provide outcome tax legal disputes outflow resources considered probable reliable estimate commitments outflow may made december intangible assets disputes provision made possible property plant equipment make reliable estimate potential outflow funds might investments required settle disputes possibility purchase commitments outflow remote pensions ultimate liability matters may vary significantly commitments amounts provided dependent upon outcome litigation total proceedings negotiations relevant tax authorities commitments respect loans future interest payable loans discussed principal risks uncertainties pages disclosed taking account effect derivatives notes financial statements taxation legal proceedings gsk annual report group financial review continued critical accounting policies consolidated financial statements prepared accordance reconciliation gross turnover net turnover us ifrs adopted use european union also pharmaceuticals business including puerto rico follows ifrs issued iasb following accounting policies approved board described note financial restated restated statements accounting principles policies margin margin margin required make estimates assumptions affect gross turnover amounts assets liabilities revenue expenses reported financial statements actual amounts results could differ market driven estimates segments critical accounting policies relate following areas government mandated turnover state programs taxation note cash discounts legal disputes notes customer returns prior year adjustments goodwill intangible asset impairments notes items total deductions business combinations note net turnover pensions postemployment benefits note information judgements estimates made areas market driven segments consist primarily managed care given note financial statements key accounting medicare plans gsk negotiates contract pricing judgements estimates honoured via rebates chargebacks mandated segments consist primarily medicaid federal government programmes turnover receive government mandated pricing via rebates respect turnover accounting policy largest business chargebacks us pharmaceuticals us market complex arrangements rebates discounts allowances following increased deductions market driven segments briefly describes nature arrangements existence gross turnover net turnover reconciliation primarily reflected us pharmaceuticals business higher rebates chargebacks respiratory products advair particular advair accounted arrangements certain indirect customers whereby us pharmaceuticals turnover approximately total customer able buy products wholesalers reduced deduction rebates returns respiratory portfolio prices chargeback represents difference whole accounted approximately total deduction invoice price wholesaler indirect customers year advair continued suffer pricing pressure contractual discounted price accruals estimating chargebacks business sought transition respiratory portfolio newer calculated based terms agreement historical products experience product growth rates balance sheet accruals rebates discounts allowances customer rebates offered key managed care group returns us pharmaceuticals vaccines businesses purchasing organisations gpo direct indirect managed combined basis december customers arrangements require customer achieve total accrual amounted million million certain performance targets relating value product purchased formulary status predetermined market shares monthly process operated monitor inventory levels relative competitors accrual customer rebates wholesalers abnormal movements process uses estimated based specific terms agreement gross sales volumes prescription volumes based third party historical experience product growth rates data sources information received key wholesalers us medicaid programme stateadministered programme aim maintain inventories consistent level year providing assistance certain poor vulnerable patients year based pattern consumption medicaid drug rebate program established basis us pharmaceuticals vaccines inventory levels reduce state federal expenditure prescription drugs wholesalers distribution channels december patient protection affordable care act became law estimated amount approximately five weeks turnover participate providing rebates states accruals medicaid calculation uses third party information accuracy rebates calculated based specific terms relevant totally verified believed sufficiently reliable regulations patient protection affordable care act purpose cash discounts offered customers encourage prompt payment accrued time invoicing adjusted subsequently reflect actual experience record accrual estimated sales returns applying historical experience customer returns amounts invoiced together market related information stock levels wholesalers anticipated price increases competitor activity gsk annual report strategic report governance remuneration financial statements investor information critical accounting policies continued legal disputes like many pharmaceutical companies faced various respect accounting policy legal disputes complex product liability antitrust patent litigation well following briefly describes process determine investigations operations conducted various governmental level provision necessary regulatory agencies throughout year general counsel group head groups legal function senior accordance requirements ias provisions vice president head global litigation group contingent liabilities contingent assets provide responsible litigation government investigations routinely anticipated settlement costs outflow resources brief chief executive officer chief financial officer considered probable reliable estimate may made board directors significant litigation pending likely outcome dispute legal expenses arising group governmental investigations group claims group may become involved significant legal proceedings respect possible meetings appropriate detail status significant litigation make reliable estimate expected financial effect government investigations review matters number could result ultimate resolution proceedings claims notified us information potential claims yet notified cases appropriate disclosure cases would included assessment validity claims progress made settling claims annual report provision would made recent settlement levels potential reimbursement insurers position could change time therefore meetings also include assessment whether assurance losses result outcome legal sufficient information available us able make reliable proceedings exceed material amount amount estimate potential outcomes disputes often external provisions reported groups financial statements counsel assisting us various litigation matters investigations also assist briefing board senior management following discussions matters possible make reliable estimate amount provision may required level provision legal disputes reviewed adjusted appropriate matters discussed note financial statements legal proceedings treasury policies report sterling pay dividends sterling cash flows capital management role treasury monitor manage groups external financial strategy implemented groups financial internal funding requirements financial risks support architecture supports gsks strategic priorities regularly strategic objectives gsk operates global basis primarily reviewed board manage capital structure subsidiary companies manage capital ensure group appropriate mix debt equity subsidiaries able operate going concerns gsks longterm credit rating standard poors optimise returns shareholders appropriate balance stable outlook moodys investor services moodys debt equity treasury activities governed policies negative outlook shortterm credit ratings approved annually board directors recently p standard poors moodys respectively july treasury management group tmg meeting chaired chief financial officer takes place monthly liquidity risk management basis review treasury activities members receive management policy borrow centrally order meet anticipated funding information relating activities requirements cash flow forecasts funding requirements monitored tmg monthly basis strategy diversify treasury operations liquidity sources using range facilities maintain broad objective treasury activity minimise posttax net access financial markets cost financial operations reduce volatility order benefit earnings cash flows use variety financial instruments day sweep cash number global subsidiaries finance operations derivative financial instruments manage central treasury accounts liquidity management purposes market risks operations derivatives principally interest rate risk management comprising interest rate swaps foreign exchange forward contracts objective minimise effective net interest cost swaps used swap borrowings liquid assets balance mix debt fixed floating interest rates time currencies required group purposes manage exposure policy interest rate risk management limits amount financial risks changes foreign exchange rates floating interest payments prescribed percentage operating interest rates profit hold issue derivatives speculative purposes gsks treasury policies specifically prohibit activity transactions financial instruments undertaken manage risks arising underlying business activities gsk annual report group financial review continued treasury policies continued foreign exchange risk management borrowings denominated swapped foreign currencies foreign currency transaction exposures arising external trade match investments overseas group assets may treated flows normally hedged foreign currency transaction hedge relevant assets forward contracts major exposures arising internal trade flows selectively hedged currencies also used reduce exposure groups objective minimise exposure overseas operating investment overseas group assets tmg reviews subsidiaries transaction risk matching local currency income ratio borrowings assets major currencies monthly local currency costs possible gsks internal trading counterparty risk management transactions matched centrally manage intercompany set global counterparty limits banking payment terms reduce foreign currency risk foreign currency investment counterparties based longterm credit ratings cash flows hedged selectively management moodys standard poors treasurys usage limits treasury tmg include hedges foreign monitored daily corporate compliance officer cco exchange risk arising acquisitions disposals assets operates independently treasury breach limits would possible manage cash surpluses borrowing reported cfo immediately requirements subsidiary companies centrally using forward contracts hedge future repayments back originating cco also monitors credit rating counterparties currency changes ratings occur notifies treasury changes made investment levels authority limits appropriate order reduce foreign currency translation exposure seek addition relationship banks credit ratings reviewed denominate borrowings currencies principal assets regularly report presented annually tmg approval cash flows primarily denominated us dollars euros sterling borrowings swapped currencies required strategic report strategic report approved board directors march signed behalf simon dingemans chief financial officer march gsk annual report strategic report governance remuneration financial statements investor information corporate governance section chairmans governance statement board corporate executive team leadership effectiveness nominations committee report accountability audit risk committee report relations shareholders engagement activities corporate responsibility committee report directors report gsk annual report chairmans governance statement dear shareholder sir andrews leadership gsk successfully developed marketleading positions vaccines consumer pleased present corporate healthcare provide excellent governance report platforms sustainable longterm growth board remains committed highest confident emma successfully standards corporate governance build strengths integrity governance structure operates strengthen pharmaceuticals business board across group since appointment ceo designate believe critical underpinning september run ability deliver strategy create assuming role ceo april last year reported longterm value shareholders focusing completely transition steps taken refresh ceo executive management spending time sir andrew succession share knowledge experience nonexecutive last year reported steps taken make key introductions also representation refresh nonexecutive representation deepening understanding board address number planned business especially rd pharmaceuticals board address retirements year boards primary vaccines also started meet number planned focus executive succession major shareholders listen review talent leadership strategy views gsk share strategic retirements year annual item board overview vision group later nominations committee discussion year details induction plan boards primary oversight sir andrew witty indicated set focus executive march intention retire change made executive board early well placed representation board dr succession accelerate orderly ceo succession moncef slaoui chairman global vaccines transition plan process followed indicated intention retire described report nominations board addition dr patrick committee pages vallance president rd board unanimous supporting appointed board appointment emma walmsley would like express gratitude previously led gsks consumer healthcare sir andrew moncef dedication business new ceo felt service gsk years leadership skills history delivering professionalism support facilitating growth driving performance fresh orderly board succession process thinking made ideal choice gsk annual report strategic report governance remuneration financial statements investor information review board governance finance committee reviewing seek ensure everything arrangements role finance committee board board guided commitment board keeps functioning decided specific committee values compliance governance framework regular review longer required responsibilities local laws regulations within year made following reassigned board audit operate gsks code conduct enhancements risk committee code draws together number key policies lay foundations science committee board decided culture values commitments provides working guide establish science committee look chairman responsible leading way apply values science pipeline rd capital ensuring effective board across global operations allocation priorities chaired dr jesse also actively encourage culture goodman one designated scientific environment boardroom facilitates indeed board felt important medical experts members debate nonexecutive lead example chosen background life sciences directors able provide constructive undertake annual training either specialist commercial perspective challenge management pleased code obligations employees matter consideration advise believe board hard latest version code time timing working engaged appropriate updated strengthened april implementation driven balance skills experience newer available governance area following considerations appointees bringing fresh insights wwwgskcom perspectives improve decision science innovation underpins uk corporate governance code making recent annual board evaluation businesses pharmaceuticals compliance exercise carried company vaccines consumer healthcare pleased report full secretary centred identifying compliance requirements rd organisation continues deliver performance improvements evaluation financial reporting councils uk significant innovation group outcomes set corporate governance code uk code number decisions potential new board evaluation undertaken copy uk code available medicines vaccines coming independent external board review wwwfrcorguk following pages outline next two years committee help specialist last independent approach corporate governance bring greater focus boards evaluation carried deliberations rd critical phase commend report less important setting company shareholders tone organisation top board looking increase promoting valuesbased conduct scientific capabilities search behaviours people flow third scientific medical expert boardroom every artery establishing committee step business approach philip hampton chairman march gsk annual report board board composition gender diversity board date publication april male male sir philip hampton sir andrew witty female female nonexecutive chairman chief executive officer executive n date publication april nationality nationality male male british british female female appointed appointed january deputy chairman january chief executive april nonexecutive officer may sir nonexecutive chairman may andrew retiring board date publication april march skills experience male male prior joining gsk sir philip skills experience chaired major ftse companies sir andrew joined gsk female female including royal bank worked uk south scotland group plc j sainsbury africa us singapore plc also served group various senior roles tetneurne unroen enxeocnutievexecutive finance director lloyds tsb appointed president europe group bt group plc bg group joined gsks corporate executive april plc british gas plc british team andrew served years steel plc sir philip previously numerous advisory roles appointed executive director governments around world years lazards nonexecutive including south africa singapore years director rmc group plc guangzhou china uk years belgacom sa member prime chairman uk financial ministers business advisory group investments limited manages awarded uk governments shareholdings knighthood services c oucmpop tomos ipt ioyoenasristion banks e pc ho arn mom acy e un tid c ato l inth de u su tk ry years april external appointments new year honours list years sir philip currently senior years executive independent director anglo external appointments nonexecutive american plc chairman sir andrew uk business remuneration committee ambassador serves member audit committee chinabritain business council sir philip also chair advisory council edb hamptonalexander review international advisory committee ftse women leaders singapore sir andrew also independent review improving cochair uk eu life sciences einxetceurtniveational experience gender balance ftse leadership steering group advise uk ninotnerenxaectiuotnivael experience april government life science priorities context uk leaving eu visiting professor institute global health innovation imperial college london global us europe emap chancellor university nottingham key committee chair n nominations audit risk r remuneration c corporate responsibility science gsk annual report strategic report governance remuneration financial statements investor information emma walmsley simon dingemans dr moncef slaoui dr patrick vallance ceo designate chief financial officer chairman global vaccines president rd nationality nationality nationality nationality british british moroccan belgian american british appointed appointed appointed appointed january chief executive january chief financial may moncef retiring january officer april officer april board march skills experience skills experience skills experience skills experience patrick joined gsk emma joined gsk prior joining gsk simon moncef joined gsk vaccines head drug discovery responsibility consumer years experience engineered subsequently appointed senior healthcare europe investment banking sg warburg development robust vaccines vice president medicines discovery subsequently appointed president goldman sachs simon advised pipeline led worldwide development glaxosmithkline consumer gsk decade business development member gsks corporate healthcare member appointment closely pharmaceutical products executive team since gsks corporate executive team involved number gsks appointment lead rd appointed president since key strategic projects given overall responsibility pharmaceuticals rd january appointed ceo gsk consumer gsks oncology business patrick joined gsk healthcare joint venture external appointments gsk vaccines board january gsk novartis emma joined simon deputy chairman global franchises prior joining gsk patrick gsk board january group finance directors moncef chairman board clinical academic professor formally succeed sir andrew chairman directors galvani bioelectronics medicine led division witty gsk ceo retires early company launched november medicine university college march gsk jointly owns london years verily life sciences prior joining gsk emma worked experience research clinical loreal years moncef advised us medicine general internal medicine held variety marketing presidents council advisors cardiovascular medicine clinical general management roles paris science technology pharmacology elected london new york member board agency academy medical sciences based shanghai science technology research general manager consumer astar january products loreal china emma phrma foundation board external appointments nonexecutive director advisory patrick nonexecutive director diageo plc january committee director genome research limited september holds national institutes health uk biobank classics modern languages oxford university phd molecular biology external appointments immunology universit libre de bruxelles published none scientific papers presentations prior joining gsk moncef professor immunology university mons belgium external appointments moncef member biotechnology industry organization board us also adviser qatar foundation member qatar biomedical research institute scientific advisory committee moncef serves nonexecutive director international aids vaccine initiative iavi member board artizan biosciences inc gsk annual report board continued manvinder singh vindi banga professor sir roy anderson dr vivienne cox lynn elsenhans senior independent independent nonexecutive independent nonexecutive independent nonexecutive nonexecutive director director scientific expert director director n r n c r c c n nationality nationality nationality nationality indian british british american appointed appointed appointed appointed september senior october july july independent nonexecutive director may skills experience skills experience skills experience professor sir roy world vivienne wide experience lynn wealth experience skills experience renowned medical scientist business gained energy running global business prior joining gsk vindi spent advanced knowledge infectious natural resources publishing significant knowledge global years unilever plc disease epidemiology sectors also deep markets gsk operates last role amongst several senior currently professor infectious understanding regulatory served chair president chief positions president disease faculty medicine government relationships executive officer sunoco inc global foods home personal imperial college london worked bp plc years prior joining care businesses fellow royal society britain continental europe sunoco president member unilever executive academy medical sciences posts including executive vice chief executive officer lynn worked board vindi sat prime royal statistical society president chief executive royal dutch shell minister indias council trade honorary fellow institute bps gas power renewable joined held industry actuaries foreign associate business alternative energy number senior roles including board governors member national academy unit vivienne previously executive vice president global indian institute management medicine us national nonexecutive director bg manufacturing iim ahmedabad vindi also academy sciences french group plc rio tinto plc recipient padma bhushan academy sciences professor sir vivienne appointed commander external appointments one indias highest civilian roy brings scientific expertise order british empire lynn nonexecutive director honours boards deliberations new year honours baker hughes inc flowserve vindi nonexecutive director services uk economy corporation director thomson reuters corp external appointments sustainability texas medical center member hr committee professor sir roy member nonexecutive director first international advisory board external appointments tee greater houston also external appointments holdingham group vivienne senior independent trustee united way vindi partner private equity member science advisory director pearson plc non greater houston investment firm clayton dubilier board natural history executive director stena rice also chairman museum london also international chairman supervisory board mauser member vaccine international supervisory board vallourec group chairman kalle gmbh advisory board vacciab aj supplier energy industry senior independent director pharma holding sdn bhd also lead independent marks spencer group plc malaysia international director uk governments member nominations alzheimers consortium harvard department international remuneration committees vindi university boston chairman development governing board scientific advisory board indian school business isb sab netherlands centre hyderabad member one health ncoh indo uk ceo forum key committee chair n nominations audit risk r remuneration c corporate responsibility science gsk annual report strategic report governance remuneration financial statements investor information dr jesse goodman judy lewent urs rohner independent nonexecutive independent nonexecutive independent nonexecutive director scientific expert director director c n r r n nationality nationality nationality board members american american swiss sir deryck maughan senior independent non appointed appointed appointed executive director member january april january nominations audit risk remuneration committees skills experience skills experience skills experience retirement dr goodman previously served judy extensive knowledge urs broad range business board may senior leadership positions global pharmaceutical industry legal experience served us food drug administration corporate finance joined chairman number boards dr stephanie burns fda including recently merck co served recently credit suisse independent nonexecutive fdas chief scientist previously chief financial officer worldleading financial services director member deputy commissioner retired judy company prior joining credit remuneration corporate science public health previously nonexecutive director suisse urs served responsibility committees director center biologics purdue pharma inc napp chairman executive board retirement board evaluation research cber pharmaceutical holdings limited ceo prosieben may dr goodman played leadership certain mundipharma prosiebensat media ag dr daniel podolsky role developing fdas international limited companies followed number years private independent nonexecutive regulatory science medical december judy practice major law firms director member countermeasures initiatives previously served non switzerland us audit risk corporate worked collaboratively industry executive director dell inc admitted bars canton responsibility committees academia government global quaker oats company zurich state new retirement board public health regulatory partners motorola inc york may prepare respond major board determined external appointments hans wijers public health threats including judy recent relevant urs currently chairman independent nonexecutive emerging infectious diseases financial experience agreed board credit suisse group director member disasters terrorism led appropriate ag chairmans remuneration corporate fdas response west nile virus qualifications background governance committee responsibility committees hn influenza audit committee financial expert also chairman member retirement board pandemic served senior board trustees credit suisse may leadership team white external appointments house medical countermeasure judy nonexecutive director research institute credit suisse stacey cartwright foundation urs appointed review dr goodman brings thermo fisher scientific inc independent nonexecutive vicechairman governing scientific public health expertise motorola solutions inc also director member board swiss bankers boards deliberations trustee rockefeller family audit risk committee association trust chairperson audit retirement board external appointments committee rockefeller financial december dr goodman currently professor services life member medicine georgetown university massachusetts institute directs georgetown university technology corporation center medical product access member american academy safety stewardship arts sciences compass active clinician serves attending physician infectious diseases also serves president member board united states pharmacopeia usp member scientific advisory board sab coalition epidemic preparedness innovations cepi gsk annual report corporate executive team david redfern claire thomas chief strategy officer senior vice president human resources david joined cet chief strategy officer claire appointed cet senior vice responsible corporate president human resources development strategic planning claire joined company senior appointed chairman board manager human resources sales viiv healthcare ltd april marketing group uk pharmaceuticals nonexecutive director aspen becoming director human resources pharmacare ltd uk pharmaceuticals appointed previously senior vice president senior vice president human resources northern europe responsibility gsks pharmaceuticals europe senior vice pharmaceutical businesses region president human resources pharmaceuticals prior senior vice president international central eastern europe david joined prior gsk worked ford motor gsk company holding various positions human david bachelor science degree resources bristol university uk claire bachelor science degree chartered accountant economics management industrial relations university wales sir andrew witty chief executive officer emma walmsley ceo designate simon dingemans abbas hussain dan troy chief financial officer president global pharmaceuticals senior vice president general counsel patrick vallance president rd abbas joined cet appointed dan joined gsk cet senior vice president global pharmaceuticals president general counsel biographical details see pages joined company president emerging previously partner washington markets asia pacific joined law firm sidley austin llp principally viiv healthcare ltd board october represented pharmaceutical companies trade previously spent years eli lilly associations matters related us food held positions including president europe drug administration fda government also worked eli lilly australia us regulations dan formerly chief counsel india turkey germany several roles fda including business development sales dan holds bs industrial labor relations marketing management cornell university jd columbia degree medicinal chemistry university school law chairs us pharmacology loughborough university chamber commerce litigation center born madras india january gsk announced abbas decision leave company later year gsk annual report strategic report governance remuneration financial statements investor information phil thomson roger connor nick hirons senior vice president communications president global manufacturing senior vice president global ethics government affairs supply compliance phil joined cet appointed roger joined cet appointed nick appointed cet senior senior vice president communications president global manufacturing supply gms vice president global ethics compliance government affairs responsibility working year president responsible compliance risk management media relations investor relations corporate designate gms roger joined gsk corporate security investigations responsibility internal communications product astrazeneca worked number nick joined gsk international communications government affairs gsks finance manufacturing strategy roles auditor later head audit assurance global brand community partnerships prior current position vice combined five audit functions president office ceo corporate joined company commercial trainee independent team common riskbased strategy february moving pharmaceutical brand methodology nick relocated china marketing product communications holds degree mechanical establish governance model china became director media relations manufacturing engineering queens business created consistent approach director investor relations university belfast masters compliance returned corporate media manufacturing leadership cambridge nick fellow chartered institute relations vice president university also chartered accountant management accountants july became coopted member chinabritain business council phil earned degree english history durham university luc debruyne brian mcnamara president global vaccines ceo gsk consumer healthcare luc joined cet president global brian joined cet appointed information vaccines role held since joined ceo gsk consumer healthcare brian joined year dr moncef slaoui gsk worked commercial gsk march head europe member cet stood strategy director rd leading americas gsk consumer healthcare december see european commercial centre excellence following creation joint venture luc became general manager gsk novartis previously head january luke miels appointed netherlands senior vice novartiss otc division brian began career president global pharmaceuticals start president general manager italy procter gamble board member date gsk confirmed appointed senior vice president pharma world selfmedication industry association europe prior current role luc member earned undergraduate degree electrical international federation pharmaceutical engineering union college new york manufacturers associations ifpma vaccines mba finance university ceo roundtable well management cincinnati committee belgian federation enterprises holds masters degree physical education university leuven gsk annual report corporate governance continued leadership effectiveness corporate governance framework board coherent corporate governance framework clearly defined responsibilities accountabilities framework designed safeguard enhance longterm shareholder value provide robust platform realise groups strategy grow deliver simplify internal control risk management arrangements described pages integral part gsks governance framework board operate effectively give full consideration key matters board committees established set board chief audit risk remuneration nominations corporate science executive committee committee committee responsibility committee officer committee read read read read read corporate executive team see wwwgskcom see wwwgskcom see wwwgskcom see wwwgskcom see wwwgskcom terms reference terms reference terms reference terms reference terms reference board committee meeting attendance board audit risk remuneration nominations corporate responsibility maximum maximum maximum maximum maximum members attended possible attended possible attended possible attended possible attended possible sir philip hampton sir andrew witty simon dingemans dr moncef slaoui professor sir roy anderson vindi banga dr vivienne cox appointed july lynn elsenhans dr jesse goodman judy lewent urs rohner stacey cartwright retired december dr stephanie burns retired may sir deryck maughan retired may dr daniel podolsky retired may hans wijers retired may etails regular attendees committee meetings chairman ceo executive directors set reports committees reports included later corporate governance report gsk annual report strategic report governance remuneration financial statements investor information board programme areas focus strategic priorities link strategy boards oversight execution strategy included reports principal businesses rd gms organisations discussion approval strategic combination verily life sciences develop bioelectronic medicines resulting galvani joint venture holding joint board cet strategy day discuss evolution strategy external landscape changes competitor advantage governance arrangements reports pensions insurance tax treasury strategies review rd pipeline new products review viiv healthcare joint venture performance year board regularly discussed reports ceo heads principal businesses rd gms organisations groups financial performance annual budget forward looking three year plan progress finance transformation programme enhance processes service capabilities brexit impacts planning governance board undertook following corporate governance duties received reports board committees approved annual report agm preparation considered observations actions internal evaluation boards performance received reports corporate governance regulatory developments training corporate integrity agreement cia new market abuse regulations mar updated code conduct approved appointment new ceo directors approved appointment new auditor effect talent succession head hr briefed board talent leadership development strategy strategy key grow deliver simplify gsk annual report corporate governance continued leadership effectiveness continued key board roles responsibilities strong leadership ndependent oversight rigorous challenge chairman philip hampton nonexecutive directors leads manages business board provide strong independent element board provides direction focus constructively support challenge management ensures clear structure effective operation board scrutinise performance meeting agreed deliverables committees shape proposals strategy management sets board agenda ensures sufficient time allocated letter appointment setting terms promote effective debate support sound decision making conditions directorship ensures board receives precise timely clear devote time necessary proper performance information duties meets nonexecutive director annual basis expected attend board meetings additional discuss individual contributions performance together meetings required training development needs independence statement shares peer feedback provided part board evaluation process board considers nonexecutive directors meets nonexecutive directors independently identified pages including professor sir roy anderson executive directors tenure nine years demonstrate appropriate leads discussions shareholders degree independence character judgement responsible groups performance free business relationship could materially satisfied financial reporting councils uk corporate interfere exercise judgement independence governance code independence test appointment commitment nonexecutive directors served board six years subjected rigorous chairmans role description available wwwgskcom review chief executive officer senior independent nonexecutive director sir andrew witty vindi banga responsible management business acts sounding board chairman trusted develops groups strategic direction consideration intermediary directors approval board leads review annually chairmans performance implements agreed strategy canvassing views nonexecutive directors collectively supported members corporate executive team discusses results chairmans effectiveness review chief executive officers role description chairman available wwwgskcom leads search appointment process recommendation board new chairman acts additional point contact shareholders maintains understanding issues concerns major shareholders briefings investor relations team company secretary senior independent nonexecutive directors role description available wwwgskcom timely support advice company secretary acts secretary board board committees victoria whyte supports board committee chairmen annual agenda plan setting ensures information made available board members timely fashion facilitates flow information within board committees nonexecutive directors management supports chairman designing delivering board inductions coordinates ongoing business awareness training requirements nonexecutive directors undertakes internal board committee evaluations request chairman advises directors board practices procedures corporate governance matters chairs groups disclosure committee acts point contact shareholders corporate governance gsk annual report strategic report governance remuneration financial statements investor information board induction company secretary assists chairman individually new director receives general induction personalised designing facilitating induction programmes new directors induction devised individually tailored new designed purpose orientating familiarising directors background education experience role new directors industry organisation governance strategy grow deliver simplify year emma walmsley ceo designate dr jesse goodman new usbased science medical expert dr vivienne cox highly experienced ukbased nonexecutive director appointed board general board induction executive nonexecutive directors emma walmsley dr jesse goodman directors duties role executive dr vivienne cox responsibilities director gsks corporate role nonexecutive build relationship governance structure director chairman gsk corporate integrity gsk strategy board agreement cia training competitors fill capability gaps gsks code conduct external environment training meet cet members gsks financial structure customised executive director induction customised nonexecutive director induction emma walmsley dr jesse goodman dr vivienne cox ceo designate scientific medical expert maximise handover opportunity ceo rd vaccines briefing us business continue build knowledge business external deep dives commercial model environment site visits ware site visits ware engage broadly across business externally stevenage wavre stevenage wavre listening mode corporate responsibility remuneration define leadership brand ceo committee induction corporate responsibility committee inductions finalise strategy narrative financial plan define cultureways working cet wider gsk group legal responsibilities duties ceo board business awareness training chairman meets director annually onetoone ensure nonexecutive directors develop maintain basis discuss ongoing training development greater insight understanding business invited requirements board kept uptodate legal regulatory attend internal management meetings including meetings governance matters regular papers briefings cet research advisory board research development company secretary presentations internal management team rdmt portfolio discovery investment external advisers boards global pharma operations committee us board members undertook specific refresher commercial leadership team risk oversight training gsks cia new mar regulations compliance council rocc also meet employees agreed undertake training gsks code conduct informally visits groups operations receptions held around board meetings gsk annual report corporate governance continued leadership effectiveness continued internal evaluation board internally facilitated company secretary drew company secretary responses together chairmans request information gathering stages evaluation prepared online survey process discussed comprising small number chairman focused questions phase one phase two phase three phase four preparation interviews review outcomes company secretary company secretary followup facetoface prepared board paper telephone interviews january meeting board members discuss formed basis responses invite discussions board members provide learning pointssuccesses clarifications areas focus board insights perspectives identified set performance board successes areas focus ceo succession process create opportunities deeper strategic comprehensive reflective informative process discussions particularly evolution concluded successfully schedule pharmaceuticals industry competitive landscape therapy areas gsk culture performance work increase boards visibility understanding pipeline rd organisation identify ways improve boards appreciated decision making creation establishment science increase board oversight science committee would enhance boards innovation collaboration new science committee oversight groups rd consider data new systems new board members settled quickly contribute greater understanding hence help made immediate positive contributions following evolve business strategy comprehensive inductions board successfully created increased opportunity strategic debate gsk annual report strategic report governance remuneration financial statements investor information board performance action points progress conclusions board evaluation review internally facilitated company secretary set action points progressachievements strategy assist newer directors additional background briefing materials additional materials provided ahead debates strategy companys board portal arrange regular discussion medium longer term strategy board agenda compiled include fresh insights different perspectives opportunities consider strategy different perspectives implement suggestions enhance effectiveness board provided positive feedback annual board cet strategy meetings meetings held newly acquired siena sites executive increase focus executive succession plans ensure board well positioned operate succession effectiveness disaster recovery plan executive succession plans resulted ned refreshment appointments board cet described detail report nominations committee pages consider alternative suggestions nonexecutive director refreshment new approaches identifying potential scientific medical experts utilised supported external recruitment experts deep dives consider deep dives particularly board meeting programme adjusted sites visits rd strategy pipeline product launches us pricing joint ventures consider matters year new business models gms consider holding one site visit operational site year joint board cet strategy meetings september held siena italy manufacturing rd facilities acquired result novartis transaction board opportunity meet employees able learn firsthand facilities people processes integrated wider group shareholders review look enhance company communicates year board audit risk shareholders committee continued enhance quarterly reporting assist shareholders understanding companys performance standing board materials continue drive make boardcommittee materials concise logistics also effective highlighting issues concerns chairman committee chairmen aim less presentation time time discussion company secretary focused issues debate meetings preparations chairing meetings allow social time board members get know better given number new board members gsk annual report corporate governance continued leadership effectiveness continued nominations committee report dear shareholder philip hampton busy year committee nominations committee ceo sir andrew witty indicated march intention chairman retire board early nearly years ceo almost years gsk principal focus became ceo succession process related executive management succession planning ceo executive management succession committee years annually scrutinised robustness succession planning arrangements executive role directors executive management role annual review committee reviews recommends board talent leadership strategy key regular item structure size composition board board committee discussion oversight overall aim appointment directors members board process board committee seek assurance committees cet continuous adequate supply highquality internal succession board cet candidates potentially step board cet required membership committee engaged egon zehnder korn ferry committee members committee member since specialise recruitment high calibre board directors using philip hampton january firms ensured review process could truly global chairman companies inaccessible professor sir roy anderson october committee full participation nonexecutive vindi banga january directors spent time considering future strategic direction lynn elsenhans january company input executive recruitment firms judy lewent may compiled ceo role profile profile contained brief urs rohner january requirements desired skillset potential successor sir deryck maughan july may sir andrew would need brief drafted emphasise importance board committee placed ceo etails committee members skills experience great business leader team builder given biographies board pages executive recruitment firms initiated global searches see committee member attendance agreed profile across large global pharmaceutical levels healthcare companies yielded pool internal external company secretary secretary committee candidates reduced shortlist potential candidates attends meetings attendees committee meetings firms reported regularly committee process may include progressed regular attends shortlisted internal external candidates met key attendees attendee required board members first subjected interviews continuous chief executive officer assessments reviews extended period non head human resources executive director met shortlisted candidate least appropriate external advisers culminated onetoone discussions nonexecutive directors seek views candidates pleased nonexecutive director made clear considered right candidate succeed sir andrew emma walmsley ceo gsks consumer healthcare division committee met agree proposal board recommend emmas appointment ceo designate recommendation received unanimous board approval september announced emma would join board executive director effect january would become ceo effect april gsk annual report strategic report governance remuneration financial statements investor information nominations committee report continued committee wellpositioned appoint emmas successor new nonexecutive director appointment brian mcnamara head americas europe gsk addition search two new executive consumer healthcare succeeded end september directors usbased sme committee searched brian became cet member immediate effect joined another nonexecutive director egon zehnder engaged gsk march completion novartis transaction conduct search used broad selection criteria dossiers potential nonexecutive appointees considered since october emma focused attention completely committee candidates shortlisted interview merit transition role gsks next ceo details assessing relevant qualifications time commitments transition induction arrangements found interviewing selected candidates committee pleased year committee also conducted search recommend board dr vivienne cox nonexecutive appointment process new executive director dr moncef director appointed board effect july slaoui chairman global vaccines indicated june board considered many years international intention retire company years business experience global manufacturing organisations board years gsk moncef step challenging technologies would bring fresh insights boards board march retire company deliberations june board appointments retirements committee recommended dr patrick vallances appointment ongoing refreshment board led following board december board approved patricks planned changes appointment joined board executive director january director appointment date retirement date dr jesse goodman january addition luc debruyne president global vaccines since appointed cet member september dr vivienne cox july anticipation dr slaouis retirement cet december emma walmsley january dr patrick vallance january stephanie burns may luke miels appointed president global pharmaceuticals join gsk cet later year astrazeneca sir deryck maughan may executive vice president european business dr daniel podolsky may hans wijers may abbas hussain president global pharmaceuticals decided leave company serving nine years cet stacey cartwright december agreed leave gsk later year sir andrew witty march dr moncef slaoui march enhancing boards scientific capabilities boards scientific capabilities recently refreshed egon zehnder korn ferry provide recruitment consultancy appointment dr jesse goodman former chief scientist services committee addition recruitment hr us fda appointed board january services provide company succeeded dr daniel podolsky retired planned years service agm may designated usbased scientific medical expert sme committee currently seeking enhance boards science capabilities engaging korn ferry conduct global search nonexecutive director sme addition new wholly independent board committee science committee established december provide oversight gsks rd pipeline scientific research strategy committee recommended board science committee chaired dr jesse goodman nonexecutive directors appointed science committee included ukbased sme professor sir roy anderson judy lewent sme currently recruited also appointed science committee light new board committee ensure effective continuity professor sir roy anderson joined board agreed stand reelection shareholders stepping board agm board confirmed professor sir roy continues demonstrate characteristics independence carrying role board gsk annual report corporate governance continued leadership effectiveness continued nominations committee report continued board committee chairman membership changes year committee approved following changes membership board committees director committee membership appointment date retirement date vindi banga nominations audit risk remuneration january committees member professor sir roy anderson dr jesse goodman corporate responsibility committee members may dr vivienne cox corporate responsibility committee member july dr jesse goodman science committee chairman january professor sir roy anderson judy lewent science committee members january dr vivienne cox remuneration committee member january urs rohner nominations committee member january stephanie burns remuneration corporate responsibility may committees member sir deryck maughan nominations audit risk remuneration may committees member dr daniel podolsky remuneration corporate responsibility may committees member hans wijers remuneration corporate responsibility may committees member stacey cartwright audit risk committee member december board composition diversity representation women management positions gsk committee sought balance composition board illustrated part gender diversity gsks global committees refresh progressively time workforce alongside initiatives promote diversity inclusion draw upon experience longer serving directors throughout organisation also support engagement benefit new external perspectives insights executive search firms egon zehnder korn ferry recent appointees bring boards deliberations signed voluntary code conduct gender diversity best practice nonexecutive directors drawn wide range industries backgrounds including pharmaceuticals rd vaccines also noted recommendation set parker consumer products healthcare medical research academia review committees report beyond one published financial services wealth experience complex november ftse board least one organisations global reach majority board director colour adjusted diversity policy scientific mathematical background attuned industry accordingly reflect new target operate committee evaluation committed diversity boardroom gsk committees annual evaluation internally facilitated committed equal opportunities employees levels company secretary behalf committee chairman organisation board management seek encourage supplemented questionnaire circulated committee members diverse inclusive culture throughout gsk concluded committee continued operate effectively key requirement effective board comprises range balance skills experience knowledge gender agreed committee would seek identify independence individuals prepared challenge another experienced scientific medical expert additional work team needs backed diversity consideration would given ongoing basis performance personal attributes including character intellect sound judgement succession planning cet top talent gsks honesty courage performance culture committee would continue plan nonexecutive director retirements based evolution committee responsible developing measurable objectives group strategy support implementation boards diversity policy including gender monitoring progress towards achievement objectives diversity policy line lord davies new voluntary target least female board level representation currently women philip hampton board corporate executive team closing nominations committee chairman gap board cet gender representation march increasing pipeline female direct reports cet particular area attention female pipeline development also central theme review together dame alexander across ftse continuing developing valuable work lord davies initiated gsk annual report strategic report governance remuneration financial statements accountability investor information audit risk committee report dear shareholder judy lewent following pages report aim share insights audit risk committee activities undertaken overseen audit risk committee chairman committee year committee worked largely recurring structured programme activities devise programme company secretary agree content management external auditors start year adapted appropriate year progresses running concluding successful tender external audit contract significant undertaking committee supported role management year exercise together committee reviews responsible committees scrutiny enhancements simplifications financial internal reporting processes internal control risk management financial reporting integrity financial statements including systems processes covered annual report quarterly results announcements external auditors system internal controls conclusion audit tender last year advised shareholders identification management risks external committee putting external audit contract internal audit processes competitive tender process committee initiated july initiating audit tenders selection appointment process concluded december board external auditors remuneration oversight appointed committees preferred choice deloitte llp work deloitte companys new auditors current external membership auditor pricewaterhousecoopers llp pwc invited committee members committee member since participate tender due prevailing rules audit firm judy lewent april rotation continue office subject chairman reappointment shareholders agm retire vindi banga january completing audit lynn elsenhans january gsks financial year onwards deloitte appointed stacey cartwright april december pwcs place subject shareholder approval wish thank sir deryck maughan january may firm participated tender professionalism commitment demonstrated process dr daniel podolsky january may full report key steps governance arrangements outputs etails committee members financial accounting audit tender process given committees scientific experience expertise given judgement deloitte best placed succeed pwc biographies board pages see deliver high quality audit gsk committee member attendance levels committee currently overseeing transition pwc company secretary secretary committee deloitte ensure attends meetings entire board invited attend pwc continues discharge auditing responsibilities effectively committee meetings attendees include end time office regular attends deloitte takes necessary steps ensure independent attendee attendee required gsk time begins observe pwc appropriate general counsel juncture financial controller look forward reporting shareholders discharging head audit assurance activities associated transition gsks annual head global ethics compliance report chief medical officer chief product quality officer external auditor accordance frcs code board determined judy lewent recent relevant financial experience board also agreed judy lewent appropriate qualifications background audit committee financial expert defined us sarbanes oxley act determined independent within meaning us securities exchange act amended addition judy lewent vindi banga also members remuneration committee allows provide input committees review groups performance oversight risk factors relevant remuneration matters gsk annual report corporate governance continued accountability continued audit risk committee report continued financial reporting council audit quality review sec settlement gsk entered settlement committees confidence external auditors delivery us securities exchange commission sec relation high quality effective audit gsk reinforced inquiry past sales marketing practices china outcome frcs audit quality review teams aqr review settlement company obligations provide sec pwcs audit gsks financial statements gsk audit information framework evolution ongoing abac selected part aqrs annual inspection audit programme monitoring purposes committee reviews quality largest audit firms uk committee discussed considers updates provided sec agreed results outcome review aqrs findings settlement corroborated results committees independent infoprotect reflect fast evolving landscape potential evaluation pwc concluded external auditor impacts key enterprise risk multiyear infoprotect effective committee received report pwc detailing programme refreshed heightened attention audit would address small number findings identified paid areas business highest risk aqr team satisfied pwcs planned response exposure improvements prioritised delivery achieve competition markets authority compliance statement greatest risk reduction improve maturity information committee considers company security privacy processes chief information security complied mandatory audit processes audit committee officer ciso cfo boardlevel responsibility responsibility provisions competition markets authority enterprise risk continue ensure cyber security defences statutory audit services order report describes work remain strong effective cfo ciso brief committee committee discharging responsibilities regularly developments preapproval nonaudit services committee reviewed enhanced governance around reporting committee risk discussed adapting companys approach existing nonaudit oversight compliance council rocc receive internal control services policy comply new requirements set frcs risk management reports throughout year based revised ethical standards implementation eu audit respective governance responsibilities within wider regulation gsks financial year particular agreed organisational internal risk governance framework efficiency changes nonaudit services preapproval process line quality upward reporting mechanism crucial assisting new restrictions auditors supplying nonaudit services uk committee properly monitoring gsks internal framework listed companies changes outlined control risk management global risk office implemented following committee rocc reporting internal framework control risk management improvements business units across risk enterprise developments exposures core discipline committee following developments business units across enterprise committee reporting schedules improved risk areas communication reporting training analytics helped management reports business units presented strengthen culture compliance risk management rocc submitted committee means committees feedback properly incorporated anti bribery corruption abac third party oversight managements deliberations rocc addition business tpo programmes high priority committee units provide six monthly updates rocc concentrate overseen following areas progress made year progress top three risk management commitments abac global risk assessment new programme simplification helped foster focused discussion launched significantly enhance way abac risk rocc business units risk management priorities identified prioritised across group existing abac help committee improve understanding enterprise data centrally pooled global risk office help risk strategies gsks enterprise risk owners encouraged abac risk exposure measured enabled provide commentary organisations risk tolerance respect management target risk mitigation techniques companys specific risk responsible mitigating addition highest risk activities business units regions development risk performance dashboards abac tpo programme provides standard framework product quality research practices enhanced governs third party relationships moved design committees ability understand monitor risk exposure deployment phase supplier assessment programme levels ongoing basis operates large majority latin america south east compliance activities asia markets applied across range third parties building trust embedding values global ethics used particular assess suppliers deemed gsk high compliance gec function continues embed living risk risk levels corrective preventative action tracking values building trust strategy help motivate employees put managed via easytouse reporting system companys core values heart every decision make employees enrolled programme particular gec deployed enterprisewide training employees tpo programme expected cover coincide release april gsks updated code global operations ensure continued risk management conduct heart compliance programme improvements respect third party relationships focuses gsks core values patient focus integrity embedding basic tpo capability supplier lifecycle respect people transparency management software introducing buying experience simplifications gsk annual report strategic report governance remuneration financial statements investor information audit risk committee report continued addition delivering training employees across global reporting system platforms enterprise gec also introduced following training tools committee pleased oversee significant progress specifically aimed team leaders help reinforce values based made moving towards standardised global systems conduct teams support endtoend processes management continued deploy upgrades planned major system deployment leader led discussion toolkit launched enable completed first half schedule budget leaders teams meaningful discussions remaining deployments multiyear programme importance gsks values right first time culture completed early increasing discussions informal short length provide opportunities focus capturing benefits new standardised systems explore gsks values leaders teams think processes generate gsk quality means part companys business toolkits use combination external events research role academic studies around good employees finally role chair committee continues busy sometimes make poor decisions varied year significant interactions key senior executives auditors attended range management values maturity assessment leadership team self meetings including rocc consumer healthcare assessment tool allows teams assess well values finance gec global manufacturing supply leadership teams embedded business establishes values also led audit tender process met bidding firms audit improvement plan based outcome assessment partners teams familiarise qualities values maturity assessments vma capabilities gain impression could like undertaken gec across third gsks business units line work values objective set corporate executive team vma roll continuing across business units along board colleagues pleased visit manufacturing rd facilities siena italy gm certifications general manager gm confirmation process acquired part novartis transaction met local across pharmaceuticals vaccines continued throughout senior executives employees able learn firsthand requiring gms confirm adherence gsks internal facilities people processes integrated control framework revised confirmation process launched wider group also pleased learn gsks internal september focused specific risk areas including control risk management practices translated tpo health care professional government official interactions embedded business embedding abac risks associated pricing commercial terms consumer healthcare implemented personal note would like acknowledge sir andrews similar process gms confirm operation internal contribution company visionary leader driving control framework key risks minimum controls gsks values term ceo led positive change established industry ways working would like wish well corporate integrity agreement committee oversight next endeavours much look forward working companys responsibilities us corporate integrity successor emma walmsley succeeds ceo agreement cia signed us department health april human services final year although commitments certain states regarding salesforce compensation extend committee continued receive quarterly cia compliance assurance updates head gec also reviewed recommended board adoption judy lewent annual resolutions confirm adherence terms audit risk committee chairman cia inclusion certification reports company provides march appropriate us regulatory authorities year given success gm confirmation cia certification processes far cia due end committee keen retain best practice compliance disciplines cia result assessing gecs proposal rollout tailored business unit confirmation combines principles two processes proposed simplification designed provide committee consolidated assurance internal control framework requirements identified understood possible gaps identified addressed business units gsk annual report corporate governance continued accountability continued committee areas committee focus items discussed frequency financial reporting reviewed integrity draft financial statements appropriateness accounting policies going concern assumptions considered approval process confirming recommending annual report fair balanced understandable reviewed recommended approval annual report form f reviewed approved directors expenses reviewed recommended approval quarterly preliminary results announcements dividends q reviewed significant issues relation quarterly preliminary results q considered evolving market practice viability statement requirements reviewed recommended inclusion viability statement annual report p reviewed accounting developments impacts key accounting issues p reviewed gaap vs nongaap reporting p global internal control reviewed global pharmaceuticals vaccines rd gms consumer healthcare business unit assurance compliance reports reviewed gsks internal control framework confirmed compliance sarbanesoxley act reviewed audit assurance work approved planned work undertook corporate integrity agreement cia training undertook new market abuse regulation training received renewed cia compliance assurance reports q reviewed reports operational excellence programme q reviewed implementation new systems group support functions p received litigation reports updates received abac investigation status reports external auditors reviewed approved auditnonaudit expenditure incurred considered auditors report annual results performed evidencebased assessment external auditors effectiveness external audit considered qualifications expertise independence external auditors recommended reappointment external auditor committee agree auditors remuneration approved audit plan audit fee proposal set performance expectations auditors considered initial results audit p reviewed agreed preapproval budget auditors provide nonaudit services q undertook competitive audit tender process recommended board two audit firms including preferred firm appointed audit financial statements risk reviewed risk management framework compliance reviewed risk elements group treasury pensions risk insurance tax policies received status reports following enterprise risks abac commercialisation crisis continuity ehss p information protection management financial controls reporting product quality research practices received update integration following novartis transaction p received terrorism risk assessment reports p received update brexit implications p received risk oversight compliance council meeting updates considered emerging risks governance confirmed compliance uk corporate governance code matters discussed evaluation exercise committee agreed action plan improve operation committee reviewed committees terms reference met privately separately heads global ethics compliance audit assurance confirmed committees terms reference adhered received corporate governance updates p reviewed approved approach modern slavery act p met privately external auditors end meeting committee activity key annually q quarterly p periodically standing gsk annual report strategic report governance remuneration financial statements investor information significant issues relating financial statements considering quarterly financial results announcements financial results contained annual report committee reviewed significant issues judgements made management determining results committee reviewed papers prepared management setting key areas risk actions undertaken quantify effects relevant issues judgements made management appropriate accounting required address issues financial statements significant issues considered relation financial statements year ended december set following table together summary financial outcomes appropriate addition committee external auditors discussed significant issues addressed committee year areas particular audit focus described independent auditors report pages significant issues considered committee relation financial statements issue addressed committee going concern basis preparation committee considered outcome managements halfyearly reviews current forecast net financial statements debt positions various financing facilities options available group following review risk potential impact unforeseen events committee confirmed application going concern basis preparation financial statements continued appropriate revenue recognition including returns committee reviewed managements approach timing recognition revenue accruals rebates rar accruals customer returns rebates us pharmaceuticals vaccines accrual returns rebates billion december committee reviewed basis accrual made concurred managements judgements amounts involved fuller description process operated us pharmaceuticals vaccines business determining level accrual necessary set critical accounting policies provisions legal matters including committee received detailed reports actual potential litigation internal external investigations groups legal counsel together number detailed updates investigations groups commercial commercial practices practices management outlined levels provision corresponding disclosure considered necessary respect potential adverse litigation outcomes also areas yet possible determine provision necessary amount december provision legal matters billion set note financial statements provisions provisions uncertain tax positions committee considered current tax disputes areas potential risk concurred managements judgement levels tax contingencies required december groups balance sheet included tax payable liability billion impairments intangible assets committee reviewed managements process reviewing testing goodwill intangible assets potential impairment committee accepted managements judgements intangible assets required writing resulting impairment charge million see note financial statements intangible assets details valuation contingent consideration committee considered managements judgement following improved sales relation viiv healthcare performance tivicay triumeq significant weakening sterling latter part year necessary increase liability pay contingent consideration acquisition former shionogiviiv healthcare joint venture december groups balance sheet included contingent consideration liability billion relation viiv healthcare see note financial statements contingent consideration liabilities details consumer healthcare put option committee considered managements judgement valuation liability recognised respect novartis put option shareholding consumer healthcare joint venture included review unwinding impact discounting liability increase liability caused significant weakening sterling latter part year viiv healthcare put options committee considered amendments viiv healthcare shareholders agreement made year resulted recognition put options held shionogi pfizer q subsequent derecognition shionogi put option q committee reviewed agreed accounting put options concurred managements judgement valuation pfizer put option million december gsk annual report corporate governance continued accountability continued audit tendering pwc auditor company group since detailed market assessment number audit firms inception performance reviewed including firms outside big four approached annually audit partner rotation requirements observed participate process judy lewent made final pre selection audit lead partners request proposal indicated last years annual report gsk decided undertake data room issued opened bidding firms july external audit tender view replacing pwc site meetings took place gsk house three days financial year onwards done best interests september opportunity finance shareholders comply audit firm rotation requirements functional leaders meet bidding firms teams facetoface robust governance structure implemented headed meetings judy lewent oversaw esc audit risk committee arc manage support deliver colleagues means discussing gsks audit requirements successful audit tender process firm help develop proposals evaluate judy lewent chaired executive steering committee esc technical knowledge strengths weaknesses get feel overseen audit tender process evaluated audit firms could like work feedback gsks liaised arc members esc cfo participants discussed committee shared group financial controller company secretary group audit partners prior submission audit tender proposals financial controller chaired operations steering committee october made finance heads coordinated audit bidding firms proposals subject detailed evaluation tender process crossfunctional planning team provided key areas probe identified discussion audit daytoday support advice levels governance partners teams oral presentations committee purpose illustrated last years annual report gsk attendees took place november key objective arc deliver fair transparent information evaluation stages process site meetings successful audit contract tender process minimum disruption written proposal submissions oral presentations shared business endorsed weighted selection criteria discussed arc conclusion process evaluation methodology based gsks expectations enabled arc recommend board appointment external auditors equally divided audit quality deloitte preferred new auditor two shortlisted bidding service audit team capability competence firms recommendation board subsequently endorsed addition five critical success factors prioritised guided gsk entered transition phase process leading committee board making final recommendation deloitte taking external audit contract effect decision comprised january update activities disclosed audit approach strategy annual report high quality independent audit effective partnership risk transitioning auditors value money external audit tender process governance oversight key steps pretender evaluation decision making key steps invitation rfp issued site written oral arc board participate data meetings proposals presentations recommendation decision interview lead room evaluation arc panel partners opened may july september october november december governance arc chair executive executive arc executive arc arc board cfo operations operations operations executive group financial steering co steering co steering co steering co controller outputs short listing knowledge initial feedback proposal debrief recommended successful firm preselection building firms shared lead evaluation final evaluation two firms appointed lead partners partners input exam questions firm appointment effect development oral preference january proposals presentations expressed one firm gsk annual report strategic report governance remuneration financial statements investor information auditors appointment ongoing effectiveness quality external audit process committee committed ensuring ongoing basis gsk receives high quality effective audit evaluating effectiveness audit process prior making recommendation reappointment external auditor committee reviews effectiveness performance criteria agrees conjunction management beginning years audit activities committee typically undertakes year satisfy external audit quality effectiveness together timelines set auditor appointment auditor expectations formal auditor appointment committee evaluation process setting audit planning budget setting matters addressed matters addressed matters addressed matters addressed review effectiveness external agree performance shareholders vote agm review feedback committee auditor expectations set expectations auditor resolutions appoint auditor members independently part previous year upcoming audit determine remuneration annual committee evaluation review auditors independence review agree audit plan covering appropriate level qualifications upcoming audit relationship auditor expertise resources consider auditors quality control quality insights provide consider whether auditor procedures committee work exhibited appropriate level agree set statutory audit fee whether sufficient challengescepticism receive management feedback access auditor without work prior years audit process management consider whether initiate survey covering preapprove budget nonaudit defer audit contract tender robustness audit process services ideally satisfied recommend statutory audit fee following quality delivery people board auditor reappointment year service next agm january march may december detailed criteria committee uses judging effectiveness external auditor overriding responsibility deliver smooth running thorough efficiently executed audit set performance expectations gsks external auditor specific auditor discuss approach areas focus advance early engagement understanding implications gsks new operating model responsibilities ensure sarbanesoxley scope additional procedures discussed endorsed management communicated timely basis within gsk pwc avoid surprises timely reporting issues levels within group ensure clarity roles responsibilities auditor local management respond issues raised management timely basis meet agreed deadlines provide continuity succession planning key employees auditor provide sufficient time management consider draft auditor reports respond requests queries employ consistent communication local central audit teams wider auditor provide uptodate advice new viability statement requirement responsibilities provide uptodate knowledge technical governance issues including evolving market practice viability statement requirements serve industry resource communicating best practice industry trends reporting integrated reporting adhere independence policies including gsks policies financial reporting councils isa applicable securities exchange commission standards deliver focused consistent audit approach globally reflects local risks materiality liaise gsks audit assurance team avoid duplication work global ethics compliance team ensure common understanding audit outcomes provide consistency advice levels organisation ultimately provide high quality service board scrupulous scrutiny group act utmost integrity gsk annual report corporate governance continued accountability continued nonaudit services sarbanesoxley act prohibits engagement prohibitions gsks policy updated black list external auditor provision certain services legal prohibited nonaudit services new regulations applied actuarial internal audit outsourcing financial information systems across group gsks financial year onwards design external auditor permitted provide nonaudit subject exceptions outside eu committee services auditrelated tax services approve committee ensures auditor objectivity independence preapproval frcs new guidance audit committees restricts safeguarded policy requiring preapproval committee categorywide preapproval process gsks policy services contractual similar obligations policy updated nonaudit services restricting groups choice external auditor preapproved committee chairman nonaudit services put competitive cfo delegated committee tender financial service providers external auditor line groups procurement process unless skills preapproved experience external auditor make suitable group financial controller supplier nonaudit service consideration case approved designate group request proposal submitted relevant cet member financial controller cfo approval nonaudit services spending monitored fees paid companys auditor associates set committee quarterly basis discussed committee details given note financial chairman statements operating profit following policy guidelines engaging external auditor possible accounting firms engaged undertake provide nonaudit services observed nonaudit services ascertaining skills experience external auditor make suitable supplier nonaudit services ensuring adequate safeguards place objectivity auditnonaudit services three year comparison graph independence group audit threatened compromised ensuring total fee levels exceed annual audit fee except special circumstances would clear advantage companys auditor undertaking additional work policy maintained number years committee reviewed december compliance financial reporting councils frcs revised ethical standards eu audit regulation new regulations following three audit assurance services key policy guidelines considered committee part fee audit assurance services included million arising review novartis transaction subsequent increase complexity group approximately half expected recurring fee cap gsks existing nonaudit services fees cap services including tax regulatory compliance treasuryrelated annual audit fee gsks policy stringent frcs services new fees cap set average audit fees services related novartis transaction preceding three year period gsks existing policy cap retained fair balanced understandable assessment one key compliance requirements groups financial committee evaluation statements annual report fair balanced committees annual evaluation internally facilitated understandable coordination review groupwide company secretary supplemented questionnaire contributions annual report follows well established circulated committee members behalf committee documented process performed parallel chairman concluded committee continued formal process undertaken external auditor operate effectively terms enhancements committees deliberations following improvement points agreed committee received summary approach taken management preparation gsks annual report committee would focus ways improve ensure met requirements frcs code transparency companys reporting reflect best practice enabled committee board confirm committee considered ways working agreed gsks annual report taken whole fair enhancements reflect committees changing agenda balanced understandable committee asked management continue improve code conduct reporting lines crispness reports received also number well established policies including code conduct available governance section committee keen continue receive regular updates website confidential speak reporting lines cyber security understand data analytics technology reporting investigation unlawful conduct updated could help monitor employee supplier behaviour version code conduct published april companys values gsk annual report strategic report governance remuneration financial statements investor information internal control framework board recognises obligation present fair balanced ensure effective governance promote ethical culture understandable assessment gsks current position group place risk oversight compliance council prospects board accountable evaluating approving rocc team senior leaders authorised board effectiveness internal controls including financial assist audit risk committee committee overseeing operational compliance controls risk management risk management internal control activities also provides processes operated group business units framework risk management upward escalation significant risks business unit risk board internal control framework framework means structure reports rocc business unit risk group ensures compliance laws regulations management compliance boards rmcbs responsible reliability financial reporting comprehensive risk management promoting local tone top risk culture well framework supports continuous process boards ensuring effective oversight internal controls risk identification evaluation management groups principal management processes risks required financial reporting councils frcs uk corporate governance code uk code designed principal risk assigned risk owner member manage rather eliminate risk achieving business senior management risk owner responsible reporting objectives risk management strategy respective principal risk rocc committee least every two years fit purpose framework conjunction values speak processes ensures risks associated rocc rmcbs assisted global ethics business activities actively effectively controlled line compliance division gec responsible advancing risk agreed risk appetite believe framework provides management development practices drive compliance reasonable absolute assurance material policies support riskbased decision making gec actively misstatement loss promotes ethical behaviours enabling members organisation operate accordance values comply applicable laws regulations enterprise oversight audit assurance assurance ness monitoring discb eu p nl fs ii onl rn e cne ees mn em da nna tan ga eg im ne dm e b n v iat dn ua ss ut c aka sc lec ac icu cnu ot en ub et n sa n tlb ait st bi yli l w iy ty itw h ch mc cwo op rm nili ta ttp ren ol nc li sa e sn tc ne rd n e p e n e n b e p e n e nt e n e p e n usi b tn e n e p e ni p ro b le ser p n di n g mom na toa rg ine gma ec nt tiv e cs omm u nication training gnirotinom sseu nis ecnarussn gsk values gsk annual report audit assurance division aa line agreed boards review focuses company subsidiaries assurance plan provides independent assurance senior extend material associated undertakings joint management board risk managed across ventures investments although considers risk group assurance helps senior management board companys participation activities established meet oversight advisory responsibilities fulfilling procedures controls place identify entities whose results groups strategic objectives building trust patients must consolidated groups results stakeholders aa dual reporting line chief believe process followed board financial officer committee committee reviewing regularly system internal controls committee receives regular reports business units risk management processes accordance guidance principal risk owners gec aa areas significant risk risk management internal control related financial group related internal controls reports provide business reporting issued frc assessment internal control environment within review groups risk management approach principal risk area including enhancements strengthen discussed manage risk section strategic control environment following consideration reports report pages management principal risk committee concludes effectiveness control explained principal risks uncertainties pages environment reports board annually groups viability discussed group financial review accordance frcs uk code provisions board section strategic report authority delegated committee conducted robust assessment groups principal risks includes consideration nature extent risk willing take achieving groups strategic objectives board committee maintained oversight ensure effectiveness internal control environment risk management processes operation across group whole year date approval annual report governance structure risk management gnirotinom rof ytilibatnuocca gnitnemelpmi rof ytilibisnopser corporate governance continued accountability continued internal control framework continued board directors responsible system corporate governance strategy risk management financial performance audit risk committee responsible reviewing approving adequacy effectiveness risk management internal controls corporate executive team supports ceo managing business activities risk oversight authorised board assist audit risk committee overseeing compliance council risk management internal control activities group business units responsible system corporate governance strategy risk management financial performance risk management ensure appropriate internal controls effective risk management compliance boards implemented complemented country executive risk boards ensure consistent approach risk management across local geography level gsk annual report strategic report governance remuneration corporate governance continued financial statements relations shareholders investor information engagement activities work engage effectively shareholders regular communications agm investor relations activities governance remuneration meetings announce financial results quarterly basis annual results included annual report shareholders receive cornerstone investor calendar annual meetings annual summary advises annual report hold top shareholders key investment notice annual general meeting available website industry bodies influential proxy advisory firms discuss corporate governance remuneration matters year sir andrew witty simon dingemans gave sessions december attended presentations institutional investors analysts media chairman sid committee chairs covered full year results also available via webcast broad range governance issues held morning teleconference first second third quarter results afternoon allow uk overseas investors hold webcast teleconferences audience convenient opportunity participate discussions results available website philip hampton chairman shared updates key areas investor relations ir department offices london focus board including philadelphia acts focal point communications investors ceo cfo chairman maintain active dialogue oversight managements execution strategy institutional shareholders performance plans objectives performance programme regular meetings year held rd delivery assessment pipeline individual meetings investors also hosted ceo executive team succession including ceo approximately group meetings investors potential transition activities investors wider evolution refreshment board company secretary acts focal point communications corporate governance matters also small central urs rohner remuneration committee chairman took corporate responsibility cr team coordinates strategy opportunity discuss progress remuneration policy development reporting specifically respect cr committees review executive remuneration ahead matters meanwhile ir department communicates socially remuneration policy vote agm may responsible investors stakeholders addition judy lewent chairs audit risk committee lynn elsenhans chairs corporate chairman also meets regularly institutional shareholders responsibility committee provided overview work hear views discuss issues mutual importance respective committees communicates views members board senior independent nonexecutive director sid finally vindi banga sid provided insights nonexecutive directors available meet shareholders perspectives boards culture dynamics together impressions gsks senior team people businesses listening views shareholders receiving feedback sessions held run corporate reporting agm season helps us shape key areas corporate governance remuneration disclosures annual general meeting shareholders invited attend annual general meeting year like last held may qeii centre london provides opportunity put questions board chairmen board committees formal agm proceedings providing shareholders chance meet informally board directors make available meeting gsk annual report corporate governance continued corporate responsibility committee report dear shareholder lynn elsenhans committee acts custodian policies practices corporate responsibility define safeguard reputation company committee chairman chair committee continue together fellow committee members challenge shape companys responsible business agenda committee members bring wide range experience insight across different sectors provide oversight companys responsible business opportunities risks year long serving committee members dr stephanie burns role dr daniel podolsky stood committee committee reviews retired board may hans wijers served external issues potential serious impact committee three years also stood time upon gsks business retired board greatly appreciated reputation management knowledge insights brought work annual governance oversight gsks responsible business committee time commitments pleased welcome professor sir roy anderson membership dr jesse goodman dr vivienne cox new members committee roy jesse worldrenowned medical scientists committee members committee member since researchers helped maintain continuity scientific lynn elsenhans october advice committees deliberations vivienne brings chairman deep knowledge sustainable business practices developed professor sir roy anderson may many years service predominantly energy natural dr vivienne cox july resources sectors dr jesse goodman may work committee year focused issues dr stephanie burns december may material gsks mission strategy values dr daniel podolsky july may discussions included exploring company seeks hans wijers october may balance need return investment innovation need price products appropriately drive access broad ee committee member attendance levels range patients addition considered many ways company secretary secretary committee gsk seeks operate transparency integrity attends meetings attendees committee meetings approach rd commercial selling model may include relationships third parties regular attends year continued enjoy positive engagement attendee attendee required investors responsible business approach performance chief executive officer particular focus integrated groups company chairman business model strategy help enhance investment value chairman global vaccines create business opportunities mitigate risk well create general counsel broader social environmental value head communications government affairs head pharmaceuticals lynn elsenhans head pharmaceuticals rd corporate responsibility committee chairman head human resources head external market communication march head global corporate responsibility executives independent external corporate responsibility adviser augment engagement stakeholder opinion may sophia tickell appointed independent external adviser committee position previously held march july ms tickell extensive experience pharmaceuticals industry improving health systems productivity sustainability energy supply distribution climate change policy shorttermism financial markets cofounder director meteos directs pharma futures series aims align better societal shareholder value holds number board advisory roles ms tickell attended meetings committee provided independent advice guidance corporate social responsibility matters chairman ceo gsk annual report strategic report governance remuneration financial statements investor information corporate responsibility committee report continued main responsibilities people enabling people thrive develop committee rolling agenda receives reports individuals deliver mission members cet senior managers ensure progress planet growing business reducing meeting responsible business commitments within four areas environmental impact across value chain focus reviewed annual basis addition meeting committee considers possible health innovating address currently unmet health needs emerging issues may bearing companys improving access products irrespective people reputation interaction stakeholders committee live ability pay controlling eliminating diseases also reviews approves responsible business supplement affecting worlds vulnerable people available reference wwwgskcomresponsibility behaviour putting interests patients consumers first driven values everything backed robust policies strong compliance processes work committee committee focused primarily matters set areas committee focus items discussed health flexible open rd approach diseases developing world areas great medical need antibiotics dementia gsks approach pricing particular balance returns investment innovation alongside need support access medicines vaccines strategy support global public health priorities including pricing models malaria vaccine ebola response behaviour changes gsk engages healthcare professionals global incentive compensation program selling competency model embedding valuesbased decision making organisation including training compliance progress work align third parties gsks standards expectations conduct public disclosure clinical research transparency detailed data behind trial results patient safety replacement refinement reduction use animals research development people organisational change employee relations inclusion diversity leadership development approach performance management employee health safety wellbeing insights staff survey planet environmental performance across carbon water waste impacts committee evaluation committees annual evaluation internally facilitated company secretary supplemented questionnaire circulated committee members committees adviser behalf committee chairman concluded committee continued operate effectively terms enhancements committees deliberations following points agreed committees programme meeting agendas would devised ensure additional time allow fuller discussion issues consideration would given monitor groups cr work using scorecard approach directors directors powers determined uk legislation director may cease director articles association contain rules appointment becomes bankrupt replacement directors provide directors may appointed ordinary resolution members resolution ceases director virtue companies act directors provided latter instance director articles appointed way retires first agm following suffers mental physical ill health board resolves appointment shall cease director articles also provide directors normally subject missed directors meetings continuous period six reelection agm intervals three years annually months without permission board resolves held office continuous period nine years shall cease director however board agreed directors wish prohibited director law continue members board seek reelection annually accordance uk corporate governance code resigns offers resign board accepts offer required resign board gsk annual report corporate governance continued directors continued directors conflicts interest directors report directors duty companies act avoid purposes uk companies act directors situation could direct indirect conflict report glaxosmithkline plc year ended december interest possible conflict company articles provide comprises pages corporate governance general power board authorise conflicts report directors statements responsibilities pages pages investor information nominations committee authorised board strategic report sets matters required disclosed grant regularly review potential actual conflict directors report considered strategic authorisations recorded company secretary importance company follows noted board directors counted quorum authorisation actual potential conflicts risk management objectives policies pages ongoing basis directors responsible informing company secretary new actual potential conflicts likely future developments company throughout may arise changes circumstances may strategic report affect authorisation previously given even provided research development activities pages authorisation director absolved statutory duty promote success company actual conflict arises diversity inclusion postauthorisation board may choose exclude director provision information consultation employees receipt relevant information participation debate suspend director board last resort carbon emissions require director resign following information also incorporated nominations committee reviewed register potential directors report conflict authorisations january reported board conflicts appropriately authorised location annual report process authorisation continues operate effectively except interest capitalised financial statements described note financial statements related party notes transactions end financial year director publication unaudited financial information group financial review person closely associated material interest contract significance group company details longterm incentive schemes remuneration report waiver emoluments director applicable independent advice waiver future emoluments director applicable company agreed procedure directors take independent legal andor financial advice companys expense non preemptive issues equity cash applicable deem necessary non preemptive issues equity cash applicable unlisted major subsidiary undertaking indemnification directors parent company participation placing applicable qualifying third party indemnity provisions defined listed subsidiary companies act force benefit directors provision services controlling applicable former directors held office signing shareholder annual report shareholder waiver dividends financial statements change control essential contracts notes contracts arrangements individually shareholder waiver future dividends financial statements fundamental ability business operate effectively notes company party material agreements would take agreements controlling shareholders applicable effect altered terminate upon change control following takeover bid agreements director directors report drawn presented would provide compensation loss office employment accordance reliance upon english company law resulting takeover except provisions companys liabilities directors connection report shall share plans may cause options awards granted subject limitations restrictions provided law plans vest takeover details termination provisions directors report approved board directors companys framework contracts executive directors march signed behalf given full version companys remuneration policy report available wwwgskcom investors section philip hampton chairman march gsk annual report strategic report governance remuneration financial statements investor information remuneration section chairmans annual statement annual report remuneration remuneration policy summary remuneration policy report gsk annual report remuneration report chairmans annual statement dear shareholder remuneration outcomes behalf board directors awards relation made pleased present accordance remuneration policy remuneration report approved shareholders may includes annual statement annual key decisions made remuneration report remuneration summary committee committee follows remuneration policy bonus outcomes executive remuneration policy report directors determined reference provides full details new policy performance agreed annual report remuneration financial measures well developing new annual statement subject committees assessment advisory vote annual general individual levels performance gsk remuneration policy meeting agm may achieved performance excess spent considerable remuneration policy report relevant financial targets year subject binding vote conjunction assessments individual time listening performance resulted bonus context executive remuneration payments made target shareholders gsk maximum opportunities seen gsk perform strongly proposed approach details bonus outcomes year good sales growth across provided including provides better pharmaceuticals vaccines consumer enhanced disclosure bonus targets healthcare businesses excellent new alignment reduced product momentum disciplined cost control year details individual performance multipliers ipms pipeline progress results maximum pay levels applied executive director key financial measures greater simplicity target core earnings per share vesting performance share growth top end guidance plan psp awards matching addition total shareholder return awards deferred annual bonus tsr growth achieved plan dabp based agreed outperformed ftse index measures relative tsr adjusted year free cash flow rd new product performance equal weighting performance measured three years december threshold targets tsr cash flow measures met maximum rd target achieved resulting overall vesting level details vesting outcome psp dabp matching awards provided gsk annual report strategic report governance remuneration financial statements investor information review remuneration policy finalising proposals responding changes annual bonus structure committee reviewed number points raised remuneration policy objective shareholder consultation committee part remuneration policy review maintaining alignment strategic particularly thoughtful committee decided simplify goals aligning policy quantum incentives structure annual bonus individual best practice revised remuneration new policy implemented performance multiplier removed policy designed emma walmsley full details annual bonus operate final changes policy set additive basis bonus drive success company remuneration policy report pages opportunity subject single profit delivery business strategy metric core group pbit instead two create shareholder value separate measures profit applied executive director changes previous years remaining simplify pay arrangements implementation remuneration policy subject scorecard individual deliver appropriately competitive objectives ensures maximum package attract retain motivate new appointments board bonus opportunities delivered executive talent discussed elsewhere annual maximum targets achieved respect align remuneration arrangements report sir andrew witty stepping financial individual elements across senior layers ceo effect march plan succeeded emma organisation walmsley noted committee departing executives part remuneration policy review gave careful detailed consideration noted sir andrew witty included reviewing packages emmas remuneration package stepping ceo effect new ceo president rd taking account relevant factors march dr moncef slaoui also committee carried extensive included constructive feedback leaving board march consultation process significant received shareholders resulted remain company number major shareholders number refinements original june feedback received shareholders proposals termination payment made greatly valued given careful taking account fact either executive outstanding incentive consideration committee emmas first ceo role reductions awards treated accordance key changes proposed made elements remuneration remuneration policy detailed remuneration policy focus package comparison sir andrews summary treatment awards increasing alignment shareholders current arrangements overall package provided full details reducing maximum incentive c less payments made included future opportunities included received sir andrew committees annual reports remuneration removal bonus matching plan intention keep emmas package agm review coming years subject reduction maximum potential pay development performance role finally would like thank shareholders levels would engage shareholders input engagement remuneration policy review welcome simplification annual bonus regarding changes within limits shareholders feedback report scheme set remuneration policy look forward receiving support increase ceos share ownership summary emma walmsleys new new remuneration policy annual requirement package set end letter report remuneration agm details provided may annual report remuneration dr patrick vallance joined board role president rd january receive base salary pension arrangements urs rohner annual bonus psp opportunities remuneration committee chairman accordance set remuneration policy march gsk annual report remuneration report chairmans annual statement continued key changes remuneration policy increase level mandatory deferral annual bonus alignment shareholders significant increase share ownership requirement ceo x salary x salary reduction overall maximum overall maximum incentive opportunity executive directors reduced opportunity eg total remuneration package new ceo c less received current ceo removal matching awards dabp plan simplification alignment executive directors ontarget maximum bonus opportunities change multiplicative additive bonus structure overview new ceos remuneration package overview comparison previous ceo rationale reduction lower salary awarded base salary initial appointment salary significantly lower increase level bpeanssei osnalary contribution defined pension benefit pension contribution contribution plan previous ceos defined provided ms walmsley matched benefit arrangement prior joining contribution salary board remains aligned ie pension contribution provided executives immediately board target opportunity reduction target aligns annual bonus annual bonus salary bonus opportunity opportunity structure maximum opportunity salary executive directors salary maximum opportunity reduction removal matching ltis salary total longterm incentive awards dabp opportunity simplifies remuneration maximum package reduces salary included overall incentive opportunity awards psp psp opportunity matching awards also lower dabp previously awarded sir andrew witty salary significantly aligns share share ownership requirement current requirement ownership requirement salary maximum psp opportunity remuneration policy aligns interests ceo shareholders total reduction package c gsk annual report strategic report governance remuneration financial statements annual report remuneration investor information glance pay performance objectives kpis incentive scheme outcomes financial annual bonus financial performance grow balanced business core group operating profit core group pbit maximum vaccines performance target nonfinancial health increase access healthcare target behaviour putting patients consumers first people talent development diversity planet reducing environmental impacts threshold target core group core group vaccines operating profit pbit performance maximum performance target performance achieved longterm strategic objectives lti outcome performance period ended december strong rd innovation rd new products relative rd efficient global adjusted free cash flow tsr new products operating model rd rd three worldleading relative tsr businesses adjusted award lapsed free cash flow award vested rd highlights summary following shows breakdown total remuneration paid executive directors respect sir andrew witty ceo simon dingemans cfo dr moncef slaoui chairman global vaccines fixed pay salary benefits pension performance pay annual bonus ltis earned executive directors shareholdings audited share ownership vs sor align interests executive directors shareholders required build maintain significant sir andrew witty x holdings shares gsk time executive directors x base salary required continue satisfy shareholding requirements simon dingemans x minimum months following retirement x base salary company cet members also required build share dr moncef slaoui x ownership requirement sor x base salary x base salary current shareholdings compared sor illustrated x x x x x x x sor shareholding chart opposite f ollowing appointment ceo sor emma walmsley increase x base salary sor dr patrick vallance x base salary levels ownership march x x base salaries ceo president rd respectively gsk annual report annual report remuneration continued total remuneration audited value earned annual total salary benefits pension lti bonus remuneration awards fixed pay b pay performance total remuneration executive director set table dr moncef slaoui chairman sir andrew witty ceo simon dingemans cfo global vaccines fixed pay salary see benefits see pension see total fixed pay b pay performance annual bonus see pages lti awards matching awards dabp psp see total pay performance ab total remuneration notes details respect vesting psp dabp awards provided pages committee may specific circumstances line stated principles apply clawbackmalus determines appropriate following due consideration committee recovery sums paid clawback reduction outstanding awards vesting levels malus applied respect executive directors deferral annual bonus number shares number shares number ads amount bonus deferred number shares ads purchased gsk annual report strategic report governance remuneration financial statements investor information total remuneration audited continued following sections provide details element total global pharmaceutical comparator group also used remuneration including committee implemented basis tsr comparator group features longterm approved remuneration policy incentive awards comparator groups pay tsr following review pay comparator group year committee used two pay comparator groups roles comparators removed group considering executive pay primary group used bbvie amgen included remuneration benchmarking executive director follows included tsr comparator group uk crossindustry global pharmaceutical reviewing ceos remuneration committee also comparator group comparator group references pay group leading european companies sir andrew witty dr moncef slaoui whose selection based size complexity simon dingemans anglo american france sanofi astrazeneca switzerland novartis bg group roche holdings bhp billiton uk astrazeneca bp us abbvie british american tobacco amgen diageo bristolmyers squibb reckitt benckiser eli lilly rio tinto johnson johnson royal dutch shell merck co sab miller pfizer tesco unilever vodafone fixed pay audited salary benefits comprise expenses incurred ordinary course table sets base salaries executive directors business deemed taxable benefits individual last two years disclosed last year salary increases included table made aligned provided wider workforce details salary levels provided benefits benefits sir andrew witty base salary employee benefits change travel sir andrew witty benefits simon dingemans total dr moncef slaoui simon dingemans benefits employee benefits following table shows breakdown grossed cash value travel benefits received executive directors benefits employee benefits include employee share plans healthcare total car allowance personal financial advice life assurancedeath dr moncef slaoui service cover employee benefits travel expenses include car travel spousepartner costs travel associated accompanying executive director gsk benefits business deemed taxable benefits individual total dr moncef slaoui benefits include uk accommodation gsk annual report annual report remuneration continued fixed pay audited continued pensions executive director pension plan type member since sir andrew witty uk defined benefit simon dingemans cash payment lieu pension dr moncef slaoui us belgian plans sir andrews maximum pension entitlement twothirds final salary since april pensionable salary increases limited pa members plan closed new entrants since since becoming member sir andrew built pensionable service different tiers glaxo wellcome pension plan current pension entitlement product service progression within gsk simon dingemans receives cash payment lieu pension base salary line gsks defined contribution pension plan rates following table shows breakdown pension values set sir andrew witty simon dingemans dr moncef slaoui pension remuneration values uk defined benefit us defined benefit belgian defined benefit employer cash contributions member contributions defined benefit plans total pension remuneration value pension remuneration figures calculated accordance methodology set large mediumsized companies group accounts reports amendment regulations remuneration regulations calculating defined benefit pension values difference accrued pension december accrued pension december increased inflation uk defined benefit us defined benefit belgian defined benefit multiplied mounts translated euros us dollars using exchange rate sir andrew dr moncef slaoui details regarding pension values set table accrued pension december pension remuneration sir andrew witty pa pa value uk funded uk unfunded total accrued pension december pension remuneration dr moncef slaoui pa pa value us funded us unfunded belgium funded us k essp total since becoming member plans dr moncef slaoui built pensionable service belgian plan us cash balance supplemental pension plans annual employer cash contributions made k plan executive supplemental savings plan essp current pension entitlement product service progression within gsk mounts translated euros us dollars using exchange rate gsk annual report strategic report governance remuneration financial statements investor information pay performance audited annual bonus annual bonus opportunity based formal review performance stretching financial targets outcome adjusted reflect individual performance applying individual performance multiplier ipm ipm set committee taking account performance individual objectives multiplier may set performance targets financial measures weightings follows weighting performance performance positioning measure sir andrew witty simon dingemans dr moncef slaoui target outcome target core group operating profit core group pbit vaccines performance threshold maximum performance targets set target respectively core group operating profit core group pbit targets outcomes purposes annual bonus differ core group operating profit pbit disclosed elsewhere annual report primarily target outcome numbers calculated applying gsk budget exchange rates actual exchange rates following table shows actual bonuses earned compared opportunity bonus opportunity bonus outcome financial performance base salary target maximum outcome total total bonus salary salary salary ipm salary sir andrew witty simon dingemans dr moncef slaoui table sets matters committee considered respect financial measures weightings set executive directors financial performance core group operating group turnover increased cer reported basis billion cer proforma basis profit core group core group operating profit increased cer reported basis cer proforma basis core group pbit pbit grew cer reported basis ahead target performance maximum targets core operating margin percentage points higher percentage points higher cer terms proforma basis reflected improved operating leverage driven sales growth favourable mix across three businesses well delivery restructuring integration benefits tight control ongoing costs partly offset continued price pressure particularly respiratory supply chain rd investments vaccines performance vaccines sales increased cer reported basis million cer proforma basis overall results benefited strong performance bexsero well higher demand fluarixflulaval us international menveo international growth driven synflorix due market expansion international tender award europe boostrix grew europe international vaccines core operating profit increased cer terms operating profit margin percentage points higher cer terms proforma basis results driven primarily improved product mix enhanced operating leverage strong sales growth together integration restructuring benefits costs sales sga rd higher royalty income gsk annual report annual report remuneration continued pay performance audited continued determining appropriate individual performance multiplier ipm applied annual bonus outcome executive director committee took account performance number key strategic objectives set individual start year summary principal achievements executive respect objectives provided table personal performance achievements sir andrew witty delivered key financial objectives ahead financial plan achieved strong progress integration novartis businesses consumer vaccines new product sales doubled billion strong returns rd investment year approval submission targets late stage assets exceeded delivered sustained pipeline progress assets filed h shingrix closed triple benlysta sc sirukumab key phase iii starts q assets hiv respiratory anaemia delivered continued improvement quality risk profile across three businesses fully implemented new commercial business model maintained progress delivering responsible business commitments eg topping access medicines index th consecutive year embedded number critical simplification change programmes realising benefits global platforms provided effective leadership group year significant change also successfully transitioning towards new ceo simon dingemans delivered strong financial leadership group continued progress cost savings made total annual cost savings billion including currency benefit billion group remains track deliver targeted annual savings billion cer continued successful implementation new business operating systems bison ipt successfully went live legacy systems decommissioned cerps accounting systems successfully deployed markets merps system deployed nine sites one exit novartis transaction related service agreements completed core commercial cycle integrated financial planning process dr moncef slaoui led highly successful year vaccines business overall effectively managed vaccines leadership succession transition new head vaccines luc debruyne finalised successful creation galvani bioelectronics joint venture verily life sciences significant opportunity create value shareholders worked towards creation coalition epidemic preparedness innovations support biopreparedness established gsks place founding board amongst major vaccines organisations supported gsks external reputation building global public health arena working directly barda wellcome trust unga amr malus clawback policy companys policy malus clawback set companys remuneration policy report also available wwwgskcom investors section january respect financial year committee discloses whether recoupment committee exercised clawback malus disclosure made matter subject public reports misconduct fully resolved legally permissible disclose made without unduly prejudicing company therefore shareholders line disclosure guidelines neither committee recoupment committee exercised malus clawback gsk annual report strategic report governance remuneration financial statements investor information pay performance audited continued value earned longterm incentives ltis line committees agreed principles measure applicable lti awards actual performance targets reviewed adjustments made appropriate reflect impact novartis transaction business ensure vesting outcome reflects genuine underlying business performance committee satisfied adjusted targets remain suitably stretching details adjustments made provided time vesting awards performance period ended december committee reviewed performance psp dabp matching awards granted executive directors targets set performance achieved three years december vesting levels set table outcome vesting level performance measures relative weighting performance targets outcome maximum award rd new product rd new product sales performance measures aggregate threeyear sales new bn performance products launched threeyear performance period preceding two years rd ie original target adjusted target vesting maximum bn bn bn bn bn bn threshold bn bn adjusted free line companys agreed principles afcf figures included adjustments bn cash flow afcf number material distorting items including legal settlements exchange rate performance movements special pension contributions rd original target adjusted target vesting maximum bn bn bn bn bn bn threshold bn bn relative tsr ranked th tsr ranking within comparator group vesting performance maximum st nd rd rd th th threshold median th th sr comparator group astrazeneca bristolmyers squibb eli lilly gsk johnson johnson merck co novartis pfizer roche holdings sanofi vesting schedule based delivering vesting median performance comparator group ten companies median falls two companies total vesting respect awards gsk annual report annual report remuneration continued pay performance audited continued historical vesting gsks ltis year grant performance measures total vesting level r dabp matching awards made onwards dabp matching r b awards wholly subject tsr performance total vesting level awards subject r b measures psp vested line figures shown chart r b performance measures key r rd new product adjusted free cash flow tsr b business diversification lapsed update performance ongoing lti awards committee also reviewed performance psp dabp matching awards granted executive directors following charts provide estimate vesting levels taking account performance december actual vesting levels determined based performance full threeyear performance periods indications therefore regarded predictions final vesting levels award performance update award performance update ranked rd ranked rd bn threshold bn threshold maximum maximum commercially commercially median bn sensitive median bn sensitive threshold threshold tsr adjusted free rd new tsr adjusted free rd new rd cash flow product rd cash flow product estimated vesting level rd rd estimated vesting level rd rd threshold performance award vest respect rd new product afcf measures tsr element tsr comparator group remains unchanged shown respect awards longterm incentive awards levels participation dabp respect shown table together maximum matching awards granted respect deferrals bonuses table also shows psp award levels dabp matching awards psp awards total bonus number face value award level number face value deferred sharesadss award base salary sharesadss award sir andrew witty shares shares simon dingemans shares shares dr moncef slaoui adss adss face values awards calculated based share price share awards ads awards closing prices february performance period awards january december dabp matching awards uk executives made form nilcost options psp awards made form conditional shares awards us executives made adss form conditional shares gsk annual report strategic report governance remuneration financial statements investor information ceo pay comparison ceo total remuneration positioning historic ceo remuneration single figure remuneration annual bonus award maximum vesting lti awards maximum uk global european bonus amounts include amounts paid operational efficiency crossindustry pharmaceutical crossindustry bonus place years overall maximum bonus receivable still subject group group group limit base salary lower quartile median upper sir andrew wittys median quartile current position n respect psp awards sir andrew also outstanding awards share options granted respectively remuneration includes salary expected value incentives based lapsed full included total vesting percentage due committees agreed benchmarking methodology distorting effect aggregating conditional shares share options percentage change remuneration ceo performance graph sir andrew witty uk employees following graph sets performance company relative ftse index pharmaceutical performance change change comparator group eight year period december salary indices selected comparison purposes reflect benefits primary index gsk constituent industry annual bonus operates reflects salary earned benefits received annual bonus earned respect compared wider uk employee population salary increase includes annual salary review well additional changes year eg promotion increase benefits ceo result change benefit arrangements ceos benefits higher primarily result increased level financial planning fees partially offset lower level travel uk employee benefits unchanged previous year changes benefit policies levels reflect changes level benefits individual may received result change role eg promotion uk population considered relevant comparison closely reflects economic environment encountered ceo gsk total return gsk pharma peers ftse total return index total return index index comprises astrazeneca bristolmyers squibb eli lilly johnson johnson merck co novartis pfizer roche holdings sanofiaventis gsk annual report annual report remuneration continued additional remuneration disclosures relative importance spend pay shareholder votes remuneration matters table shows percentage changes total employee pay table provides details shareholder votes groups dividends paid shareholders recent resolutions respect annual remuneration report remuneration policy report change votes total employee pay total votes total votes total votes withheld agm cast billion million dividends remuneration report share buyback votes figures table reflect payments made total votes total votes total votes withheld year set pages however dividends agm cast billion million declared respect million remuneration policy million plus special dividend million ie increase excluding special dividend company expect external appointments executive directors make ordinary share repurchases executive directors held remunerated external appointments total employee pay based employees average payments past directors audited number people employed none service contracts payments loss office audited table sets relevant dates executive none directors service contracts available review companys registered office office hours executive directors service contracts contain month notice period set remuneration policy report date contract effective date expiry date sir andrew witty emma walmsley simon dingemans dr moncef slaoui dr patrick vallance appointed board january remuneration governance role committee membership role committee set companys remuneration membership committee together appointment policy gsk able recruit retain motivate dates set executives committee members committee member since remuneration policy regularly reviewed ensure consistent companys scale scope operations urs rohner january chairman supports business strategy growth plans helps drive creation shareholder value vindi banga january terms reference dr vivienne cox january committees full terms reference available judy lewent january companys website terms reference reviewed dr stephanie burns may may least annually last revised january reflect best practice corporate governance developments sir deryck maughan july may hans wijers october may governance board considers members committee committee meetings usually include closed session independent nonexecutive directors accordance members committee present individuals may uk corporate governance code also invited attend committee meetings year executives committee attendees involved decisions present discussions regarding remuneration details committee members skills experience given biographies board pages see committee member attendance levels gsk annual report strategic report governance remuneration financial statements investor information remuneration governance continued company secretary secretary committee attends deloitte provided independent commentary matters meetings attendees committee include consideration committee updates market practice legislative requirements deloittes fees advice provided committee attendees committee fees charged regular attends time materials basis deloitte also provided consulting attendee attendee required tax assurance services gsk year however ceo committee satisfied compromise cfo independence advice received deloitte head human resources following announcement deloitte replace head reward pricewaterhousecoopers llp auditors company committee adviser deloitte llp deloitte longer named advisers remuneration committee company currently undergoing tender process judy lewent vindi banga members audit risk intention new advisers appointed july remuneration committees provide input audit risk committees review groups performance oversight willis towers watson provided additional market data committee risk factors relevant remuneration decisions committee evaluation adviser committee committees annual evaluation internally facilitated committee access external advice required company secretary supplemented questionnaire committee carried formal review independent advisers circulated committee members behalf committee committee result review committee chairman concluded committee continued reappointed deloitte llp deloitte provide independent operate effectively terms enhancements committees advice executive remuneration committee chairman agrees work agreed would seek gain deeper protocols deloitte provides advice understanding performance systems culture committee satisfied advice received linkage remuneration arrangements groups top talent deloitte objective independent deloitte member remuneration consultants group voluntarily operates code conduct relation executive remuneration consulting uk code conduct found wwwremunerationconsultantsgroupcom committee areas committee focus items discussed remuneration policy committee sets broad structure remuneration policy determines remuneration executive directors chairman proposed remuneration policy corporate officers board approval engagement shareholders remuneration environment including wider employee trends salary review committee periodically reviews considers remuneration executive director cet benchmarking competitiveness gsk environment executive directors cet approving annual amendments comparator groups necessary executive director cet salary recommendations increases ceo executive director cet bonus recommendations annual bonus bonus objectives committee responsible setting specific performance measures annual bonus rd annual bonus target metric lti plans deferred annual bonus plan rules committee responsible approving lti plan rule changes grants assessments performance vesting lti awards executive lti performance outcomes vesting lti awards cet directors cet lti grants cet including share value plan awards committee evaluation process shareholder feedback annual investor meetings remuneration report remuneration considerations agm remuneration report feedback external remuneration governance areas focus environment performance target disclosure incentives plans committee adheres robust remuneration governance framework ensuring alignment internal actions external reporting chairmans fees compliance requirements remuneration report disclosures gsk annual report annual report remuneration continued nonexecutive directors fees chairman nonexecutive directors nonexecutive directors fees applied set company aims provide chairman nonexecutive table directors fees competitive paid per annum companies equivalent size complexity subject limits standard annual fee contained gsks articles association supplemental fees chairmans fees chairman audit risk committee chairman philip hampton paid fee per annum senior independent director scientificmedical experts elected take gsk shares chairmen remuneration corporate responsibility committees nonexecutive directors fees nonexecutive director undertaking intercontinental changes nonexecutive director fees made travel meetings per meeting year fees remained levels set january nonexecutive director minimum fees delivered shares deferred nonexecutive director steps board table audited sets value fees benefits received nonexecutive directors form cash shares ads details nonexecutive directors share allocation plan set nonexecutive directors fees paid gbp converted using average exchange rate reviewed time time nonexecutive directors fixed fees fixed fees emoluments audited cash sharesads benefits total pay cash sharesads benefits total pay professor sir roy anderson vindi banga dr vivienne cox lynn elsenhans dr jesse goodman philip hampton judy lewent urs rohner dr stephanie burns stacey cartwright sir deryck maughan dr daniel podolsky hans wijers dr jesse goodman joined board january accordance nonexecutive directors share allocation plan dr jesse goodmans fees retained reinvested companys adss future date mutually agreed dr vivienne cox joined board july dr stephanie burns sir deryck maughan dr daniel podolsky hans wijers retired board agm may stacey cartwright retired board december benefits primarily consist travel subsistence costs incurred normal course business relation meetings board committee matters gskhosted events considered taxable overseasbased nonexecutive directors includes travel meetings uk gsk annual report strategic report governance remuneration financial statements investor information directors interests shares audited interests directors company office december persons closely associated pca shown tables total share plan interests december total directors interests sharesads options aunvested unvested aunvested unvested march december january subject subject subject subject vested exercised performance performance performance performance exercised year executive directors shares sir andrew wittybcdfh simon dingemansbcdfh dr moncef slaouicdeg emma walmsleyk na na na na na na na na dr patrick vallancek na na na na na na na na ads dr moncef slaouicdeg share allocation plan nonexecutive directors total directors interests number shares ads december january march date date idividends december allocated december retirement appointment reinvested paid elected nonexecutive directors sharesi professor sir roy anderson vindi banga dr vivienne cox philip hampton urs rohner dr stephanie burnsj stacey cartwrightj hans wijersj adsi lynn elsenhans dr jesse goodmani judy lewent dr stephanie burnsj sir deryck maughanj dr daniel podolskyj u nvested shares subject performance sir andrew represent shares awarded end three year performance periods psp grants together subsequent reinvested dividends shares subject twoyear vesting periods sir andrews unvested options subject performance represent bonus deferrals share save options unvested options subject performance simon dingemans represent bonus deferrals share save options unvested ads subject performance dr moncef slaoui represent bonus deferrals deferrals psp plan share value plan awards pca b otal directors interests includes shares purchased glaxosmithkline share reward plan sir andrew witty simon dingemans awarded shares plan total number shares held within plan follows share reward plan shares march december january sir andrew witty simon dingemans emma walmsleyk na na dr patrick vallancek na na dr moncef slaoui eligible participate share reward plan open uk employees gsk annual report annual report remuneration continued directors interests shares audited continued c otal directors interests includes shares ads resulting deferral bonus subsequent reinvestment dividends dabp totals shown table include bonus deferrals exclude unvested matching awards subject ongoing performance criteria amounts represent gross share ads balances prior sale shares ads satisfy tax liabilities deferred annual bonus plan bonus deferrals march december january sir andrew witty shares simon dingemans shares dr moncef slaoui ads emma walmsleyk shares na na dr patrick vallancek shares na na otal directors interests march includes shares ads vested due performance met elements dabp psp awards less sold satisfy tax liabilities vested amounts see pages details e f dr moncef slaoui total directors interests includes ads purchased within k plan us executive supplemental savings plan essp ads awarded dr moncef slaouis pca svp relevant balances follows dr moncef slaoui ads march december january us retirement savings plans share value plan executive director dr moncef slaoui eligible receive awards svp svp awards shown reflect holdings dr slaouis pca also employee gsk awards subject threeyear vesting periods vesting contingent continued employment within gsk gains arising vesting included dr moncef slaouis total remuneration figures year pca granted ads september grant price face value dr moncef slaouis total share plan interests also include psp awards held pca awards subject performance criteria relevant employees cet december pca held ads psp comprising awards made ads ads ads amounts including dividend reinvestment f share save plan sir andrew witty simon dingemans unvested options subject performance include holdings respectively share save plan participate terms employees share save options granted sir andrew witty simon dingemans granted options plan november g ads vested unexercised options totalling dr moncef slaoui represent ads options held pca gsk annual report strategic report governance remuneration financial statements investor information directors interests shares audited continued h following table sets details options including nilcost options dabp exercised executive directors dr moncef slaoui exercise options year number shares market gain exercise type award date grant option date exercise grant price price exercise sir andrew witty dabp deferral dabp matching simon dingemans share save dabp deferral dabp matching respect options share save plan remuneration receivable executive director calculated date options first vest remuneration difference amount executive director required pay buy shares ads total value shares ads vesting date executive director chooses exercise options vesting date subsequent increase decrease amount realised due movements share ads price vesting date date exercise increase decrease value result investment decision executive director recorded remuneration respect nilcost options dabp bonus deferred director recorded remuneration annual bonus year relates gain recorded exercise nilcost option comprises remuneration total amounts received reinvested dividends prior vesting gains losses resulting movements share price dates grant exercise initial bonus amount deferred dates dividend reinvestment exercise reinvested dividends matching element dabp remuneration executive director recorded year performance period ends represents number vested shares multiplied price vesting gain recorded exercise nilcost option comprises total remuneration gain loss resulting movement share price vesting exercise sir andrew witty gain recorded following exercise nilcost options relating deferral bonus earned respect comprises remuneration recorded annual bonus net gain relating reinvestment dividends prior vesting movements share price grant dividend reinvestment dates exercise date gain recorded following exercise nilcost options relating dabp matching award comprises remuneration recorded relation dabp see investment loss relating movement share price vesting exercise dates simon dingemans gain resulted exercise options granted share save plan gain recorded following exercise nilcost options relating deferral bonus earned respect comprises remuneration recorded annual bonus net gain relating reinvestment dividends prior vesting movements share price grant dividend reinvestment dates exercise date gain recorded following exercise nilcost options relating dabp matching award comprises remuneration recorded relation dabp see investment gain relating movement share price vesting exercise dates f nonexecutive directors total interests include shares ads received part fees nonexecutive directors share allocation plan note dividends received shares ads plan january converted shares ads february accordance share allocation arrangements nonexecutive directors dr jesse goodmans fees retained reinvested companys ads future date mutually agreed j r stephanie burns sir deryck maughan hans wijers retired board may elected receive shares ads nonexecutive directors share allocation plan immediately upon retiring board dividend entitlements respect q q q dividends paid cash accordance plan rules dr daniel podolsky also retired may yet paid gsk ads nonexecutive directors share allocation plan elected defer payment q stacey cartwright retired board december elected receive gsk shares nonexecutive directors share allocation plan immediately following retirement k e mma walmsley dr patrick vallance appointed board january gsk annual report annual report remuneration continued directors interests shares audited continued deferred annual bonus plan matching awards following tables provide details executive director office december respect dabp matching awards market price grant vesting represent closing share prices business day prior dates performance period sir andrew witty shares market price grant unvested december granted face value grant dividends reinvested vested lapsed unvested december dividends reinvested vested lapsed unvested march vested shares number shares market price vesting gain remuneration remuneration performance period simon dingemans shares market price grant unvested december granted face value grant dividends reinvested vested lapsed unvested december granted face value grant dividends reinvested vested lapsed unvested march vested shares number shares market price vesting gain remuneration remuneration gsk annual report strategic report governance remuneration financial statements investor information directors interests shares audited continued deferred annual bonus plan matching awards continued performance period dr moncef slaoui ads market price grant unvested december granted face value grant dividends reinvested vested lapsed unvested december dividends reinvested vested lapsed unvested march vested ads number ads market price vesting gain remuneration remuneration emma walmsley dr patrick vallance appointed board january following table provides details dabp matching awards granted february granted shares emma walmsley dr patrick vallance performance period number shares market price grant face value grant unvested march gsk annual report annual report remuneration continued directors interests shares audited continued performance share plan awards following tables provide details executive director office december respect psp awards market price grant vesting represent closing share prices dates performance period sir andrew witty shares market price grant unvested december granted face value grant dividends reinvested vested lapsed unvested december dividends reinvested vested lapsed unvested march vested shares number shares market price vesting gain remuneration remuneration performance period simon dingemans shares market price grant unvested december granted face value grant dividends reinvested vested lapsed unvested december dividends reinvested vested lapsed unvested march vested shares number shares market price vesting gain remuneration remuneration gsk annual report strategic report governance remuneration financial statements investor information directors interests shares audited continued performance share plan awards continued performance period dr moncef slaoui ads market price grant unvested december granted face value grant dividends reinvested vested lapsed unvested december dividends reinvested vested lapsed unvested march vested ads number ads market price vesting gain remuneration remuneration gsk annual report annual report remuneration continued directors senior management information provided compensation interests directors senior management group group purpose group defined nonexecutive executive directors members cet company secretary financial year following table sets aggregate remuneration group periods served capacity remuneration total compensation paid aggregate increase accrued pension benefits net inflation aggregate payments defined contribution schemes members group one pca also employee gsk awarded shares ads companys various share plans set table awards dividend reinvestment awards awarded shares ads shares ads deferred annual bonus plan performance share plan deferred investment awardsa b share value planb march group pcas following interests shares ads company holdings issued various executive share plans described note financial statements employee share schemes interests march shares ads owned unexercised options deferred annual bonus plan performance share plan deferred investment awardsa b share value planb n otional shares ads b executive directors eligible receive deferred investment awards participate share value plan share plans dilution limits allemployee share plans dilution limits executive directors participate various allemployee share awards made plans incorporate dilution plans including share save share reward limits consistent guidelines published investment association limits rolling ten year period share save plan hm revenue customs approved plans rolling ten year period executive share plan open uk employees participants may save plans estimated dilution existing awards made last month net salaries fixed term three years ten years december follows end savings period option buy gsk shares discount market price set launch savings contract sir andrew witty simon dingemans contribute respectively month gsk employee share plans executive share plans share save plan share reward plan hm revenue customs approved plan open uk employees terms participants contribute month gross salaries purchase gsk shares company matches number gsk shares bought month arrangement sir andrew witty simon dingemans contribute maximum month buy shares share reward plan actual limit gsk annual report strategic report governance remuneration financial statements investor information implementation remuneration policy salary inevitably targets linked directly financial strategic plan committee determined following salary increases taking commercially sensitive committee consider account average increase wider workforce appropriate disclose annual bonus targets year may result competitive harm however details performance change targets disclosed retrospective basis annual wider workforce report sir andrew witty sir andrew dr moncef slaoui cease executive dr moncef slaoui directors year accordance remuneration simon dingemans policy receive prorata ontarget bonus payment emma walmsley na committee set role specific objectives dr patrick vallance na period two individuals cease executive directors new remuneration policy approved target bonus based average increase budget employees level cet uk opportunities set policy approved effective appointment role ceo april lower shareholders ie salary sir andrew received sir andrew witty emma walmsley appointed board january ceo designate base salary salary dr moncef slaoui effective appointment board january legacy awards matching awards dabp benefits last time matching awards made significant changes provision benefits proposed dabp awards relate bonus outcomes full details policy relation benefits please refer remuneration policy details remuneration policy report table provides details level participation pension dabp respect annual bonus payments associated table provides overview pension arrangements matching awards granted executive director sir andrew witty dr moncef slaoui receive matching pension contribution awards cease executive directors sir andrew witty uk defined benefit year however annual bonus payments subject dr moncef slaoui us belgian plans mandatory deferral simon dingemans base salary lieu pension total bonus matching emma walmsley base salary matching contributions deferred award number dr patrick vallance base salary lieu pension shares shares emma walmsley details provided simon dingemans member defined contribution plan eligible receive matching award first salary accordance terms plan dr patrick vallance ie matching awards based bonus earned respect prior appointment annual bonus plan board performance share plan psp awards number changes made operation intended awards psp made later year annual bonus plan simplify align following approval psp rules agm may executive directors awards made sir andrew witty dr moncef slaoui awards remaining executive directors made matching awards removed deferred following levels annual bonus plan dabp percentage bonus subject mandatory deferral shares psp award salary period three years increased emma walmsley financial performance measured reference simon dingemans one profit related measure core group pbit dr patrick vallance operating profit removed measure group pbit selected profit measure aligned performance measures shareholders metrics psp dabp matching awards remain calculation bonus operate additive unchanged awards continue based three basis removal individual performance multiplier equally weighted measures rd new product performance introduction scorecard individual objectives adjusted free cash flow relative tsr aligned strategic goals business year tsr continue measured global pharmaceutical peers prior years targets rd new products commercially sensitive time grant however committee bonus opportunity weighting salary performance measures intends disclose targets full following end core scorecard performance period addition committee continue group individual provide shareholders interim performance updates target maximum pbit objectives element course performance period adjusted emma walmsley free cash flow targets disclosed shareholders simon dingemans prospective basis time grant thereafter reported dr patrick vallance annual report remuneration gsk annual report annual report remuneration continued implementation remuneration policy continued termination arrangements sir andrew witty nonexecutive director fees dr moncef slaoui nonexecutive director fees reviewed year following announced sir andrew witty dr moncef last increase january slaoui leave board mutual agreement march agreed increase fees chairmen dr moncef slaoui remain employee group remuneration corporate responsibility committees june chairman new science committee termination payments made sir andrew witty also receive fee fees remain unchanged dr moncef slaoui defined benefit pension arrangements minimum fees continue delivered shares outstanding incentive awards treated accordance deferred nonexecutive director steps remuneration policy approved shareholders board full disclosure payments made upon cessation included annual report remuneration remuneration element summary treatment annual bonus receive ontarget bonus payment prorated proportion financial year worked psp award granted psp awards dabp matching award dabp matching awards granted respect bonuses psp vest normal vesting dates subject dabp matching awards achievement performance conditions assessed end performance periods awards respect bonuses deferred deferred bonuses respect prior years vest normal vesting dates addition executive directors required maintain shareholding equal respective share ownership requirements least months leaving company gsk annual report strategic report governance remuneration financial statements remuneration policy summary investor information remuneration policy review first remuneration policy approved shareholders addition changes policy made agm may required regulations align remuneration arrangements across senior layers shareholders asked approve new remuneration policy organisation agm may intended apply next three financial years deliver appropriately competitive package attract retain motivate executive talent committee reviewed remuneration policy ensure policy continues simplify pay arrangements aligned best practice committee consulted largest shareholders respect proposed changes took shareholders feedback account create shareholder value finalising revised remuneration policy table drive success company delivery provides overview main changes proposed business strategy respect remuneration policy full remuneration policy shareholders asked approve set pages remuneration element proposed changes policy rationale change mandatory deferral annual bonus increased bonus alignment shareholders earned aligns executives longterm interests shareholders simplification annual bonus simplify align structure executive simplification directors consistent approach executive directors reduce level payout threshold clearly communicated performance nil pay performance ensures higher levels bonus payout received significant performance annual bonus performance share plan provide additional flexibility committee flexibility psp performance measures determine performance measures used context appointment new annual basis three year life ceo considered appropriate provide remuneration policy sufficient flexibility ensure performance committee would consult metrics chosen next three years shareholders prior changing remain aligned key financial performance measures used strategic objectives company lti opportunities matching element dabp simplification removed going forward psp longterm incentive plan used maximum lti opportunity ceo reduction maximum opportunity reduced total lti opportunity executive directors salary reduced award ceo maximum opportunity salary share ownership requirements sor formally include shareholding guidelines alignment shareholders part remuneration policy provide alignment shareholders increased sor ceo x salary gsk annual report remuneration policy report future policy table subject shareholder approval companys agm may remuneration policy remuneration element outlined table salary material change purpose link strategy opportunity provide core reward role formal maximum limit ordinarily salary increases broadly line average increases wider gsk set level appropriate secure retain high calibre individuals workforce needed deliver groups strategic priorities however increases may higher reflect change scope operation individuals role responsibilities experience salary individuals role experience performance independently adjustments may also reflect wider market conditions sourced data relevant comparator groups considered geography individual operates determining salary levels details current salary levels set annual report salary increases typically take effect first quarter year remuneration salaries normally paid currency executive directors performance measures home country overall performance individual key consideration determining salary increases benefits material change purpose link strategy role executive directors also entitled car travel may levels set recruit retain high calibre individuals execute accompanied spousepartner business trips business strategy benefits include expenses incurred ordinary course business deemed taxable benefits individual operation executive directors eligible receive benefits line benefit provision tailored reflect market practice policy employees may vary location include geography executive director based different limited car allowances healthcare life assurance policies may apply current future executive directors based death service provided part individuals different country pension arrangements personal financial advice contractual opportunity postretirement benefits line policy employees formal maximum limit benefits costs fluctuate executive directors may eligible receive overseas relocation depending changes provider cost individual circumstances allowances international transferrelated benefits required executive directors also eligible participate allemployee details current benefits costs set annual report share schemes eg share save share reward plan remuneration subject terms employees performance measures order recognise high business travel requirements none pension material change purpose link strategy uk pension arrangements provide competitive level retirement salary contribution defined contribution plan income matched contributions subject relevant cap line implementation principles members plan operation pension arrangements structured accordance plans operated country individual likely retire salary cash payment lieu pension contribution individual chooses become member pension plan us cash lieu relevant pension contribution paid instead eligible benefits us senior executives executive directors uk entitled either join defined cash balance pension plan supplemental cash balance contribution pension plan receive cash payment lieu pension plan including executive pension credit provide maximum pension contribution contribution base salary across pension plans individual member gsk legacy defined benefit gsk k plan formerly us retirement savings plan plan defined contribution plan alternative pension plan executive supplemental savings plan core contributions arrangement subsequently appointed board salary bonus matched contributions may remain member plan salary bonus opportunity global policy current executive directors new external eligible appropriate equivalent arrangement excess recruits usuk arrangements performance measures none gsk annual report strategic report governance remuneration financial statements investor information future policy table continued annual bonus change purpose link strategy committee may apply judgement making appropriate incentivise recognise execution business strategy adjustments bonus outcomes ensure reflect underlying annual basis business performance rewards achievement stretching annual financial clawback andor malus provisions apply described strategic business targets delivery personal objectives opportunity operation maximum bonus opportunity executive directors financial operational business targets set start salary threshold performance bonus payout nil year committee bonus levels determined target performance bonus payout committee based performance targets maximum opportunity individual objectives set start year committee performance measures performance objectives assessed based combination financial targets individualstrategic committee performance objectives majority bonus assessed executive directors required defer bonus earned financial measures weighting different shares ads appropriate three years measures determined year according business priorities deferred bonus shares eligible dividend equivalents date vesting details including measures used financial year provided annual report remuneration selection annual bonus measures annual bonus designed drive achievement gsks majority annual bonus opportunity based formal annual financial strategic business targets delivery review performance stretching financial targets personal objectives remainder bonus subject balanced scorecard strategic individual targets aligned companys key objectives financial year performance share plan psp change purpose link strategy clawback andor malus provisions apply described incentivise recognise delivery longer term business opportunity priorities financial growth increases shareholder value normal maximum award limits may granted compared pharmaceutical companies psp individual one year set table addition provide alignment shareholder interests award ceo salary retention element encourage longterm shareholding salary discourage excessive risk taking ceo operation cfo conditional awards made annually vesting dependent executive directors achievement performance conditions three years subject additional twoyear holding period performance measures based combination financial share price related awards eligible dividend equivalents date strategic performance conditions aligned vesting release companys strategic plan awards vest committee may adjust formulaic vesting outcome either threshold performance details including performance ensure overall outcome reflects underlying targets attached psp respect year provided business performance vesting period annual report remuneration selection longterm incentive measures committee selects performance measures focus major adjustment calculation performance measures executive directors longterm remuneration delivery gsks disclosed shareholders vesting chairman audit key strategic priorities longer term addition setting risk committee members also members robust targets committee implemented number remuneration committee provide input audit risk safeguards ensure targets met sustainable way committees review groups performance oversight performance reflects genuine achievement targets risk factors relevant remuneration decisions therefore represents delivery value shareholders details rationale behind performance measures selected performance measure impact acquisition calculated set annual report divestment quantified adjusted event remuneration gsk annual report remuneration policy report continued future policy table continued legacy arrangements deferred annual bonus plan dabp removed onwards purpose performance measures incentivise recognise delivery longer term business outstanding matching awards subject measures priorities provide alignment shareholder interests awards made psp given year encourage longterm shareholding details outstanding awards provided pages operation maximum opportunity annual report remuneration matching awards bonus payments including bonus respect made dabp respect bonus executive directors required defer onwards bonus earned shares three years could also voluntarily defer additional bonus earned deferred shares matched maximum subject achievement performance conditions three years matching awards conditional shares nilcost options eligible dividend equivalents share ownership requirements increase requirement ceo align interests executive directors executive directors also required continue satisfy shareholders required build maintain significant requirements minimum months following retirement holdings shares gsk time requirements company executive director follows salary ceo executive directors clawback malus change event triggering event eg significant misconduct way respect financial year remuneration committee violation regulation law significant gsk policy disclose whether recoupment committee exercised code conduct company ability claw back clawback malus disclosure made matter three years annual deferred bonuses well vested subject public reports misconduct fully unvested ltis addition participant new psp resolved legally permissible disclose dabp shareholders asked approve agm made without unduly prejudicing company therefore subject investigation vesting awards may shareholders delayed outcome investigation additionally continuity responsibility separate recoupment committee established initiation adverse event emergence investigate relevant claims misconduct recoupment problem adverse event taken account committee exercises authority wider employee base assessing annual bonus awards lti vesting levels year comprises senior executives relevant oversight problem identified future periods remuneration appropriate experience including senior vice president global committee recoupment committee may make appropriate ethics compliance senior vice president general adjustments individual annual bonuses well grant counsel vesting levels lti awards reflect gsk annual report strategic report governance remuneration financial statements investor information approach recruitment remuneration committee determines remuneration package new committee mindful sensitivity relating recruitment executive directors casebycase basis depending packages particular buying rights relating role market operate experience previous employment therefore seek minimise total remuneration levels set reference relevant pay arrangements however certain circumstances enable comparator group appropriate allow future recruitment exceptional talent committee may determine development role arrangements best interests company shareholders arrangements possible expected new executive directors participate short likeforlike basis forfeited remuneration terms longterm incentive plans basis existing directors arrangements therefore vary depending plans however exceptional circumstances committee reserves arrangements put place previous employer may flexibility set incentive limit new executive director form cash shares may may subject additional existing limits performance conditions explanations provided committee retains flexibility recognition high payments made compensation previous remuneration levels variable pay gsks global pharmaceutical competitors forfeited however committee use flexibility remuneration arrangements newly appointed executive considered best interests company director disclosed soon practicable investors appointment pension arrangements external recruit executive director set remuneration policy table following policy principles apply roles chairman nonexecutive director benefits provided line policy existing chairman executive directors fees set level competitive paid companies equivalent size complexity fees required meet business needs relocation support paid partly shares provided line company policy internal appointments entitlements existing nonexecutive directors remuneration elements continue including pension fee levels new nonexecutive directors set entitlements outstanding awards however basis existing nonexecutive directors company already case internal appointments required move subject local laws regulations fees paid partly executive director contractual terms including termination shares provisions event nonexecutive director different role responsibilities appointed fee levels benchmarked set reference comparable roles companies equivalent size complexity gsk annual report remuneration policy report continued loss office payment policy company policy fixed term contracts generally notice period termination employing company contracts new appointments expire line applicable executive director calendar months policy retirement age since ability impose month noncompete period contracts existing executive directors expire dates shown nonsolicitation restriction executive director considered important company ability protect groups intellectual property staff light committee believes would appropriate provide mitigation contracts termination employment event executive directors employment company terminates following policies payments apply element remuneration loss office payment policy termination payment termination notice months annual salary payable termination company prorated part notice period worked termination payment made respect part notice period extends beyond contract expiry date bonus element normally included termination payment however terms contracts seek balance commercial imperatives best practice redundancy termination notice uk statutory redundancy pay apply us general severance policy apply retirement death illhealth injury disability termination payment lti awards psp dabp matching awards governed plan rules approved shareholders awards made prior approval psp dabp rules following provisions normally apply termination notice unvested awards lapse redundancy retirement generally awards continue vest original timescales subject original performance conditions awards made last months forfeited death illhealth injury disability reason generally performance assessed following end financial year cessation employment occurs awards vest months following cessation awards may prorated time awards made approved rules psp following provisions normally apply termination notice unvested awards lapse redundancy retirement death illhealth injury disability reason generally awards continue vest original timescales subject performance prorated time event change control psp dabp matching awards vest taking account performance date normally taking account proportion performance period elapsed alternatively awards may exchanged new awards annual bonus termination notice individual individual serves notice termination date falls december bonus forfeited termination notice company redundancy retirement death illhealth injury disability termination date falls financial year eligible prorated ontarget bonus employed december bonus payable based actual results dabp deferred dabp deferred bonus awards governed plan rules approved shareholders awards made prior approval bonus awards dabp rules following provisions normally apply termination notice awards vest full date termination original vesting date determined date grant redundancy retirement death illhealth injury disability reason generally awards vest full original vesting date awards made approved rules dabp following provisions normally apply termination gross misconduct generally unvested awards lapse reason generally awards vest full original vesting date event change control awards vest may exchanged new awards benefits generally benefits continue apply termination date committee may make payments connection existing legal obligation respect claim related cessation employment may include fees outplacement assistance legal andor professional advice termination notice company retirement us executives line policy applicable us senior executives chairman global vaccines may become eligible future date receive continuing medical dental insurance terminationretirement termination mutual agreement certain circumstances best interests company board manage proactively succession planning development senior talent pipeline circumstances board may therefore agree executives departure mutual agreement order apply committee need satisfied executive demonstrated performance line expectations required contributed orderly succession completed least years service group termination date case executive director would treated good leaver purposes gsks longterm incentive plans termination date falls financial year would eligible prorated ontarget bonus employed december bonus payable would based actual results gsk annual report strategic report governance remuneration financial statements investor information loss office payment policy continued committee anticipate exercise discretion executive director leaves company committee provided psp dabp plan rules respect termination carry assessment individuals performance payments manner would benefit executive director conduct time role determined individuals however may unforeseen circumstances performance conduct contrary legitimate expectations best interests company shareholders company committee reserves right apply necessary exercise discretion explanations provided appropriate mechanisms clawback reduction lapsing outstanding incentive awards malus ensure termination payments best interests company shareholders see differences remuneration policy executive directors employees setting remuneration levels executive directors salary benefits including pension tailored local committee considers prevailing market conditions market competitive environment comparison annual bonus plan applies wider employee population remuneration executives companies similar size complexity based business individual performance international reach positioning relativities pay employment conditions across broader gsk workforce combination performancerelated restricted share plans apply wider employee population particular committee considers range base salary rises workforces parts gsk executive allemployee share plans available employees uk directors employed considered relevant including hm revenue customs approved uk share save comparison populations reflect closely economic share reward plans environments encountered individuals employees formally consulted respect principles apply remuneration policy executive remuneration policy company conducts regular employee directors employees although remuneration offered surveys include feedback remuneration matters executive directors policy stronger emphasis wider organisation aligned performance performancerelated pay offered employees reward systems values since group performance system formally evaluates employees need also senior people disincentivise unethical working practices using clawback mechanism allows us recover performance related pay gsk annual report remuneration policy report continued scenarios future total remuneration charts opposite provide illustrations future total remuneration executive directors respect emma walmsley new ceo remuneration opportunity granted policy range potential outcomes provided executive director underlying assumptions set scenarios base salary used benefits pension figures used cfo ie based actual amounts received respect ongoing policy new ceo president rd role benefits value based value benefits excluding pensions provided current ceo cfo respectively amounts shown value psp awards based fixed expected maximum relevant multiples include amounts respect dividends reinvested factor changes share price vesting period simon dingemans cfo fixed none pay performance annual bonus psp would payable expected annual bonus assumed target performance achieved psp awards threshold levels vesting assumed maximum fixed expected maximum assumed annual bonus would payable maximum level awards psp would vest dr patrick vallance president rd full fixed expected maximum fixed pay annual bonus psp gsk annual report strategic report governance remuneration financial statements investor information nonexecutive director remuneration policy element purpose link strategy operation formal maximum however fees reviewed annually set reference review chairmans performance independently sourced market data committee responsible evaluating making recommendations board fees payable chairman chairman participate discussions provide inclusive flat rate fee respect fees competitive paid fees paid combination cash andor gsk shares ads via nonexecutive companies equivalent size complexity directors share allocation plan subject limits contained chairmans fees gsks articles association chairman fees reviewed annually set reference independently sourced data chairman ceo responsible evaluating making recommendations board fees payable companys nonexecutive directors minimum delivered form gsk shares ads using nonexecutive directors share allocation plan delivers shares ads nonexecutive basic fees director following retirement board compensate nonexecutive directors chairman taking supplemental additional board responsibilities additional fees committee chairmen senior independent nonexecutive director fees undertaking intercontinental travel science medical experts intercontinental travel travel subsistence costs nonexecutive directors incurred normal course business relation meetings board committee matters gskhosted events overseasbased nonexecutive directors includes travel meetings uk event necessary business purposes whilst normal practice non executive directors may accompanied spouse partner meetings events costs associated met company facilitate execution responsibilities instances deemed taxable therefore treated benefits non benefits duties required role executive director gsk annual report remuneration policy report continued operation scope remuneration policy proposed remuneration policy policy set pages performance share plan deferred annual bonus plan awards annual report intended policy subject terms relevant plan rules gsks executive nonexecutive directors apply award granted committee may adjust amend close companys annual general meeting may awards accordance provisions plan rules submitted committee approval includes making adjustments reflect oneoff corporate shareholders events change companys capital structure committee written policy principally relation committee may also make minor amendments policy remuneration arrangements executive directors whilst taking set report regulatory exchange control tax account possible recruitment replacement administrative purposes take account change legislation additional executive director operation policy without obtaining shareholder approval amendments committee intends policy operate period set statement consideration shareholder views entirety however may due consideration seek committee engages regular dialogue shareholders change policy period believes holds annual meetings gsks largest investors discuss appropriate longterm success company take feedback remuneration policy governance matters consultation shareholders sought shareholder approval general meeting annual meetings held december urs rohner committee chairman shared updates remuneration committee reserves right make remuneration matters last months proposals onwards payments andor payments loss office including exercising shareholder consultations carried february discretions available connection payments march committee chairman proposed notwithstanding line policy set remuneration policy committee took account feedback terms payment agreed shareholders determining policy shareholders agm may date companys first asked approve agm may shareholderapproved directors remuneration policy came effect ii policy set came effect provided terms payment consistent shareholderapproved remuneration policy force time agreed iii time relevant individual director company opinion committee payment consideration individual becoming director company purposes payments includes committee satisfying awards variable remuneration relation award shares ads terms payment agreed time award granted basis preparation directors remuneration report prepared accordance companies act large mediumsized companies groups accounts reports amendment regulations regulations accordance regulations following parts annual report remuneration subject audit total remuneration figures executive directors including details element remuneration salary benefits pension annual bonus longterm incentive awards nonexecutive directors fees emoluments received year directors interests shares including interests gsk share plans payments past directors payments loss office share ownership requirements holdings opinion thereon expressed remaining sections directors remuneration report subject audit pages referred within audited sections directors remuneration report approved board directors signed behalf urs rohner remuneration committee chairman march gsk annual report strategic report governance remuneration financial statements investor information financial statements section directors statement responsibilities independent auditors report financial statements notes financial statements financial statements glaxosmithkline plc prepared uk gaap gsk annual report directors statement responsibilities directors responsible preparing annual report strategic report risk sections annual report remuneration report group financial statements represent management report include fair review accordance applicable law regulations development performance business position group together description principal risks uk company law requires directors prepare financial uncertainties faces statements financial year law directors required prepare group financial statements accordance disclosure information auditors international financial reporting standards ifrs adopted directors office date annual report european union preparing group financial statements confirmed directors also elected comply ifrs issued far aware relevant audit information international accounting standards board iasb company companys auditors unaware law directors must approve group financial statements unless satisfied give true fair view state taken steps ought taken affairs group profit loss period director make aware relevant audit information establish companys auditors aware preparing financial statements directors information required confirmation given interpreted accordance select suitable accounting policies apply provisions section companies act consistently going concern basis make judgements accounting estimates pages contain information performance reasonable prudent group financial position cash flows net debt position state group financial statements comply ifrs borrowing facilities information including treasury risk adopted european union ifrs issued iasb management policies exposures market credit risk subject material departures disclosed explained hedging activities given note financial statements group financial statements financial instruments related disclosures assessed principal risks matters considered connection prepare financial statements going concern basis unless viability statement directors considered appropriate adopt inappropriate presume group continue going concern basis accounting preparing financial business statements directors responsible keeping adequate accounting internal control records sufficient show explain companys board audit risk committee reviewed transactions disclose reasonable accuracy time assessment risks internal control framework operates financial position group enable ensure gsk considered effectiveness system group financial statements remuneration report comply internal control operation group year covered companies act article ias regulation annual report date approval board also responsible safeguarding assets group directors hence taking reasonable steps prevention detection fraud irregularities uk corporate governance code board considers glaxosmithkline plc applies principles group financial statements year ended december complies provisions uk corporate governance comprising principal statements supporting notes code maintained financial reporting council described set financial statements pages corporate governance section pages board report responsibilities auditors relation group considers annual report taken whole fair financial statements set independent auditors report balanced understandable provides information pages necessary shareholders assess groups position group financial statements year ended december performance business model strategy included annual report published required financial conduct authoritys listing rules printed form made available website directors auditors considered directors statement compliance responsible maintenance integrity annual report relation points uk corporate governance code website accordance uk legislation governing specified review preparation dissemination financial statements access website available outside uk comparable annual report legislation may different annual report year ended december comprising report directors remuneration report current directors whose names functions listed financial statements additional information investors corporate governance section annual report approved board directors signed behalf confirms best knowledge group financial statements prepared accordance ifrs adopted eu ifrs philip hampton issued iasb give true fair view assets chairman liabilities financial position profit group march gsk annual report strategic report governance remuneration financial statements independent auditors report investor information members glaxosmithkline plc report group financial statements opinion areas focus refined reflect developments opinion glaxosmithkline plcs group financial statements groups business including continued competitive pricing pressure discounting us resolution give true fair view state groups affairs investigation groups commercial practices secdoj december profit cash flows year ended overview properly prepared accordance international materiality financial reporting standards ifrss adopted overall group materiality million represents european union profit tax adding back certain items adjusted profit tax million prepared accordance requirements companies act article ias regulation audit scope audit included full scope audits reporting components separate opinion relation ifrss issued iasb specific audit procedures performed reporting explained note group financial statements group components addition applying ifrss adopted european union also applied ifrss issued international accounting taken together components audit work standards board iasb performed accounted consolidated revenue consolidated profit tax adjusted profit opinion group financial statements comply ifrss tax covered components individually contributed issued iasb revenue profit tax adjusted profit tax audited areas focus group financial statements included within annual report rebates discounts allowances returns us comprise pharmaceuticals vaccines business consolidated balance sheet december carrying value goodwill intangible assets consolidated income statement consolidated statement acquisitionrelated liabilities comprehensive income year ended uncertain tax positions consolidated cash flow statement year ended litigation consolidated statement changes equity year ended finance transformation notes group financial statements include investigations groups commercial practices summary significant accounting policies explanatory scope audit areas focus information conducted audit accordance international standards certain required disclosures presented elsewhere auditing uk ireland isas uk ireland annual report rather notes financial statements designed audit determining materiality assessing crossreferenced financial statements risks material misstatement financial statements identified audited particular looked directors made subjective financial reporting framework applied judgements example respect significant accounting preparation group financial statements applicable law estimates involved making assumptions considering future ifrss adopted european union applicable law events inherently uncertain audits also addressed risk management override internal controls audit approach including evaluating whether evidence bias context directors represented risk material misstatement due context audit set groups activities fraud risk fraud revenue recognition procedures reduced extent finance transformation designed executed address risks included use data completion threepart transaction novartis enabled auditing techniques test journal entries postclose group increased pace change number adjustments testing evaluating managements key accounting markets migrating onto groups common enterprisewide estimates reasonableness consistency undertaking cutoff resource planning platforms erp moving financial transaction procedures verify proper cutoff revenue expenses processing accounting services business process testing existence accuracy revenue transactions outsourcing locations bpo inhouse business service addition incorporate element unpredictability centres bsc well establishing two new bpos europe audit work year one asia group also migrated new consolidation platform risks material misstatement greatest effect bison implemented new system tracking intercompany audit including allocation resources effort inventory transfers calculating intragroup unrealised profit identified areas focus table also set inventory ipt result transformation groups finance tailored audit address specific areas order processes included area focus report provide opinion financial statements whole addition group made certain changes comments make results procedures agreements pfizer shionogi respect noncontrolling read context complete list risks identified interest holds viiv healthcare changes together audit remeasurements viiv acquisitionrelated liabilities significant impact corresponding accounting valuation judgements therefore also included area focus gsk annual report independent auditors report continued report group financial statements continued area focus audit addressed area focus rebates discounts allowances returns us obtained managements calculations accruals applicable pharmaceuticals vaccines business schemes validated assumptions used reference refer notes group financial statements groups stated commercial policies terms applicable contracts third party data related patient enrolment us group makes sales various customers us fall government funded benefit schemes historical levels product certain commercial government mandated contracts returns reimbursement arrangements significant medicaid medicare group also provides right compared assumptions contracted prices historical rebates return customers certain products discounts allowances returns levels relevant current payment trends also considered historical accuracy arrangements result deductions gross sales arriving groups estimates previous years impact competitive turnover give rise obligations group provide pricing pressures greater discounting us market customers rebates discounts allowances right generally formed independent expectation largest return unsettled amounts recognised accrual elements accrual december using third party data focused area rebates discounts allowances compared expectation actual accrual recognised returns arrangements complex establishing group appropriate accrual requires significant judgement based procedures performed identify material estimation directors judgement particularly complex differences independent expectations accrual us healthcare environment competitive pricing pressure product discounting growing trends directors determined accrual million necessary december december million increase accrual primarily due foreign exchange rate impacts two factors driving increased accrual higher sales well greater discounts due competitive pressures particularly relation advair carrying value goodwill intangible assets deploying valuations specialists obtained groups refer notes group financial impairment analyses tested reasonableness key statements assumptions including profit cash flow growth decline terminal values impact expiry patents potential product group billion intangible assets december obsolescence selection discount rates challenged billion comprising significant licences patents management substantiate assumptions including comparing acquired trademarks excluding computer software relevant assumptions industry economic forecasts addition group billion goodwill december december billion interrogated integrity supporting calculations corroborated certain information third party sources including carrying values goodwill intangible assets expectations performance certain assets components contingent future cash flows risk assets business obtained evaluated managements sensitivity impaired cash flows meet groups analyses ascertain impact reasonably possible changes expectations impairment reviews performed group key assumptions performed independent sensitivity contained number significant judgements estimates calculations quantify downside changes managements including revenue growth success new product launches models required result impairment genericisation existing products following patent expiry profit margins cash conversion terminal values discount rate result work determined impairment charge changes assumptions could lead impairment million recorded intangible assets appropriate carrying value intangible assets goodwill intangible assets including goodwill management determined impairment required found judgements year group changed basis aggregating supported reasonable assumptions would require individual cash generating units cgus goodwill impairment unreasonable downside changes additional material testing purposes comprising global pharmaceuticals impairment necessary consumer healthcare vaccines exercise undertaken align groups operating segments respect aggregation cgus confirmed resulted aggregation pharmaceuticals viiv lowest level management monitors goodwill internal healthcare purposes consistent way groups results reported board corporate executive team focused intangible assets acquired historical acquisitions significant individually aggregate number indefinite lives including significant intangible assets acquired novartis group also recognised goodwill number acquisitions including threepart transaction novartis gsk annual report strategic report governance remuneration financial statements investor information report group financial statements continued area focus audit addressed area focus acquisitionrelated liabilities deployed valuations specialists evaluating certain key refer notes group financial assumptions including growth projections discount rate well statements integrity mechanical accuracy managements valuation models considered whether reasonably possible changes would recent years group completed number significant significant impact value recorded certain procedures specific transactions including individual liabilities included following threepart transaction novartis consumer healthcare put option redemption price contractually establishment viiv healthcare based multiple agreed gsk novartis acquisition viiv healthcare remaining interest consumer healthcares revenue profit compared earnings shionogiviiv healthcare forecast approved consumer healthcare board directors used management model actual earnings transactions resulted recognition understood reasons changes also considered measurement material acquisitionrelated liabilities appropriateness earnings multiples applied forecast necessitate significant management judgement balance assumption option exercise date sheet date viiv healthcare contingent consideration compared projections addition february group waived certain rights groups dolutegravir products third party expectations respect noncontrolling interests held pfizer shionogi growth considered potential upside downside impact viiv healthcare terms arrangement shionogi products launched expected launched groups amended december competitors significant acquisitionrelated liabilities outlined viiv healthcare put options obtained reviewed written agreements group pfizer shionogi certain consumer healthcare put option group recorded liability assumptions related forecast revenue dolutegravir products used present value expected redemption price written valuation liabilities consistent viiv healthcare put option novartis noncontrolling interest consumer contingent consideration components valuation healthcare december liability carrying considered appropriateness assumptions made forecast value million million growth rates margins reference historical performance board approved budgets third party forecast data viiv healthcare contingent consideration acquisition remaining interest shionogiviiv healthcare joint venture three acquisitionrelated liabilities subject significant million recorded contingent consideration estimation uncertainty range possible outcomes broad represented fair value expected payments made however comfortable value liability december shionogi contingent future sales dolutegravir products reasonable reflects managements best estimates time liability required remeasured fair value reviewed disclosures acquisitionrelated liability reporting date since initial recognition increased including managements commentary estimation uncertainty response actual future sales significantly exceeding original range alternative outcomes satisfied disclosures expectations including impact changes foreign exchange appropriate rates december liability million million viiv healthcare put options pfizer shionogi granted written put options group enabled put noncontrolling interest back group future including december financial liabilities recorded two options arrangement contained clauses enabled group avoid acquiring interests certain conditions met february group unilaterally waived certain rights result liabilities aggregate value million recognised december agreement reached shionogi whereby agreed forego rights exercise written put option result groups associated liability million de recognised december december liability respect pfizers written put option carrying value million addition liabilities group recorded certain acquisitionrelated liabilities december including million relation contingent consideration payable acquisition novartis vaccines business focused area carrying value financial liabilities material determined management judgements estimates including projections future sales products potential impact competitor products delivery anticipated synergies addition valuation sensitive changes assumptions including discount rates tax rates gsk annual report independent auditors report continued report group financial statements continued area focus audit addressed area focus uncertain tax positions conjunction uk us international tax transfer pricing refer notes group financial statements specialists evaluated challenged managements judgements respect estimates tax exposures contingencies order group operates complex multinational tax environment assess adequacy groups tax provisions included open tax transfer pricing matters uk obtaining evaluating certain third party tax opinions group overseas tax authorities addition time time group obtained assess appropriateness assumptions used enters transactions complicated accounting tax consequences including threepart transaction novartis understanding evaluating managements judgements judgement required assessing level provisions considered status recent current tax authority audits required respect uncertain tax positions december enquiries outturn previous claims judgemental positions taken group recorded provisions million tax returns current year estimates developments tax respect uncertain tax positions million environment noted assumptions judgements required formulate provisions mean range possible outcomes broad however based evidence obtained considered level provisioning acceptable context group financial statements taken whole considered managements disclosures regard agree managements view material change groups estimates tax exposures expected within next months litigation discussed status significant known actual potential refer notes group financial litigation inhouse legal counsel obtained substantively statements tested evidence support decisions rationale provisions held decisions record provisions including correspondence pharmaceuticals industry heavily regulated increases legal counsel also monitored considered external inherent litigation risk group engaged number legal information sources identify potential legal actions actions including product liability antitrust related private litigation significant disclosed notes developed independent expectation litigation provisions based product litigation history available evidence challenge valuation completeness provisions recognised focused area eventual outcome claims group obtained confirmations external legal counsel uncertain positions taken directors based confirm understanding settled outstanding litigation application material judgement estimation accordingly asserted claims evaluated significant adjustments legal unexpected adverse outcomes could significantly impact provisions recorded year determine indicative groups reported profit balance sheet position management bias december group held provisions million disclosed notes group financial statements respect legal actions december million eventual outcome legal proceedings dependent outcome future events position taken group inherently judgemental found context group financial statements taken whole judgements made management reasonable disclosures made respect provisions contingent liabilities appropriate gsk annual report strategic report governance remuneration financial statements investor information report group financial statements continued area focus audit addressed area focus finance transformation centrally managed work performed component audit teams group continues rationalise simplify finance bpos bscs consisted controls substantive testing processes including rollout enterprisewide resource conducted oversight visits key bsc bpo sites group planning system erp migrations accounting services audit scope namely india malaysia romania us uk inhouse business service centres bscs third party direct work performed business process outsourcing locations bpos addition evaluated design tested operating effectiveness group migrated onto new platforms consolidation key automated manual controls migration tracking intercompany inventory transfers calculating centralised processing environment including general controls intragroup unrealised profit inventory controls respect data migration erp systems changes represent financial reporting risk migrations also substantively tested accuracy completeness data happening controls processes migration new erp along controls process established embedded number years updated note significant exceptions similar procedures migrated new environment increased risk performed migrations onto consolidation intercompany breakdown internal financial controls transition profit tracking systems respect latter increased risk inaccurate incomplete migration financial significance intercompany profit inventory adjustment data would turn increase risk material misstatements performed detailed testing calculation component group group financial statements level supported validation key manual controls process note significant unresolved exceptions testing investigations groups commercial practices met directors management inhouse legal counsel refer notes group financial spoke groups external advisors assess risk statements occurrence inappropriate activities status ongoing investigations potential fines penalties secdoj investigation groups commercial practices included understanding evaluating groups internal concluded september resulting group paying investigations processes assess risks allegations reported penalty million group remains subject ongoing various channels including whistleblowing hotlines also investigation sfo uk december evaluated ongoing enhancements changes group concluded sufficient clarity made control processes business practices recent years likely timing completion investigation able make sufficiently reliable estimate fine penalty deploying forensic specialists assessed scope findings sfo might impose group completion investigative work performed group well risk investigation result group stated note assessment exercise management performed third party unable recognise provision estimate interaction engagement broadly used output eventual outcome assessment instruct ten component teams including certain markets otherwise included group audit scope undertake riskfocused addition group continues carry investigations audit procedures address audit risk group financial number markets ascertain whether inappropriate statements might materially misstated due potential financial commercial practices may taken place implications alleged illegal acts focused following risks might material respect secdoj investigation verified settlement impact groups financial statements agreement payment respect sfo investigation fine penalty might forthcoming respect independently circularised external legal counsel engaged group ongoing investigation groups commercial practices obtain views status investigation ascertain sfo could give rise need material reasonableness managements assertions respect likely provision outcome inappropriate activities occurred could based procedures satisfied groups also give rise material fines penalties result asset provisioning decisions december adequacy impairment disclosures given status investigations gsk annual report independent auditors report continued report group financial statements continued tailored audit scope specific audit procedures central functions group tailored scope audit ensure performed consolidation areas significant judgement including taxation enough work able give opinion financial statements goodwill intangible assets treasury postretirement benefits whole taking account geographic structure elimination unrealised intercompany profit inventory group accounting processes controls industry directly led group audit team group operates taken together territories functions performed group financial statements consolidation audit work accounted consolidated revenue reporting components identified reporting components consolidated profit tax adjusted profit tax view required audit complete financial information considering contribution audit evidence due size risk characteristics excludes central performing audit work divisional group levels adjustment entities audited group level specific audit including testing monitoring controls disaggregated analytical procedures significant balances transactions review procedures covers significant portion groups performed reporting components give appropriate smaller lower risk components directly included coverage material balances reporting group audit scope addition obtained indirect audit components supported shared financial service centres evidence certain outofscope components centres also included group audit scope none procedures undertook groups shared service centres reporting components included group audit scope encompassing bpos bscs centralised individually contributed consolidated revenue infrastructure processes standardised profit tax adjusted profit tax work performed component auditors determined level involvement needed audit work reporting component units result overseas components visited senior members group audit team including groups financially significant components us visited least annually well belgium japan china switzerland germany ireland italy addition visited four overseas shared service centres supporting reporting components group audit scope components group audit scope site visit undertaken involvement included regular dialogue component teams review component auditor work papers participation certain component audit clearance meetings gsk annual report strategic report governance remuneration financial statements investor information report group financial statements continued materiality scope audit influenced application materiality set certain quantitative thresholds materiality together qualitative considerations helped us determine scope audit nature timing extent audit procedures individual financial statement line items disclosures evaluating effect misstatements individually financial statements whole based professional judgement determined materiality financial statements whole follows overall group materiality million million determined profit tax adding back certain items including remeasurement charges shionogiviiv healthcare contingent consideration million vaccines contingent consideration million remeasurement charges consumer healthcare million viiv healthcare million put options major restructuring costs million legal costs million impairment intangible assets million deducting net income relating gain disposal assets million rationale benchmark applied groups principal measure earnings comprises core results adds back statutory results number items income expenditure including detailed management uses measure believes eliminates volatility inherent oneoff items took measure account determining materiality except adjust profit tax add back amortisation intangible assets certain smaller noncore items view recurring items introduce volatility groups earnings agreed audit risk committee would report misstatements identified audit million million well misstatements amount view warranted reporting qualitative reasons going concern noted directors statement directors concluded listing rules required review directors appropriate adopt going concern basis preparing statement set relation going concern group financial statements going concern basis presumes nothing report performed review group adequate resources remain operation directors intend least one year date isas uk ireland also required report group financial statements signed part audit anything material add draw attention relation concluded directors use going concern basis directors statement whether considered appropriate appropriate adopt going concern basis preparing group financial statements nothing material add draw attention however future events conditions predicted statements guarantee groups ability continue going concern gsk annual report independent auditors report continued required reporting consistency information compliance strategic report directors report applicable requirements prepared accordance applicable legal requirements companies act reporting addition light knowledge understanding group opinion based work undertaken course environment obtained course audit audit required report identified material misstatements information given strategic report directors strategic report directors report nothing report financial year financial statements report respect prepared consistent financial statements isas uk ireland reporting isas uk ireland required report opinion information annual report exceptions materially inconsistent information audited group financial statements report apparently materially incorrect based materially inconsistent knowledge group acquired course performing audit otherwise misleading statement given directors accordance provision c uk corporate governance exceptions code code consider annual report taken whole fair balanced understandable report provides information necessary members assess groups position performance business model strategy materially inconsistent knowledge group acquired course performing audit section annual report required provision c code describing work audit exceptions committee appropriately address matters communicated us audit committee report directors assessment prospects group principal risks would threaten solvency liquidity group isas uk ireland required report anything material add draw attention relation directors confirmation annual report accordance provision c code nothing material carried robust assessment principal risks facing group including would threaten business add draw attention model future performance solvency liquidity disclosures annual report describe risks explain managed mitigated nothing material add draw attention directors explanation annual report accordance provision c code nothing material assessed prospects group period done consider period add draw attention appropriate statement whether reasonable expectation group able continue operation meet liabilities fall due period assessment including related disclosures drawing attention necessary qualifications assumptions listing rules required review directors statement carried robust assessment principal risks facing group directors statement relation longerterm viability group review substantially less scope audit consisted making enquiries considering directors process supporting statements checking statements alignment relevant provisions code considering whether statements consistent knowledge acquired us course performing audit nothing report performed review adequacy information explanations received corporate governance statement companies act required report listing rules required review part opinion received information corporate governance statement relating ten provisions explanations require audit exceptions uk corporate governance code nothing report report arising responsibility performed review directors remuneration companies act required report opinion certain disclosures directors remuneration specified law made exceptions report arising responsibility gsk annual report strategic report governance remuneration financial statements investor information responsibilities financial statements audit responsibilities directors reasonableness significant accounting estimates made explained fully directors statement responsibilities directors set directors responsible preparation overall presentation financial statements group financial statements satisfied give true fair view primarily focus work areas assessing directors judgements available evidence forming responsibility audit express opinion financial judgements evaluating disclosures financial statements accordance applicable law isas uk statements ireland standards require us comply auditing practices boards ethical standards auditors test examine information using sampling auditing techniques extent consider necessary provide report including opinions prepared reasonable basis us draw conclusions obtain audit companys members body accordance chapter evidence testing effectiveness controls substantive part companies act purpose procedures combination giving opinions accept assume responsibility purpose person report addition read financial nonfinancial information shown whose hands may come save expressly annual report identify material inconsistencies agreed prior consent writing audited financial statements identify information apparently materially incorrect based materially inconsistent audit financial statements involves knowledge acquired us course performing audit involves obtaining evidence amounts audit become aware apparent material misstatements disclosures financial statements sufficient give reasonable inconsistencies consider implications report assurance financial statements free material respect strategic report directors report consider misstatement whether caused fraud error includes whether reports include disclosures required applicable assessment legal requirements whether accounting policies appropriate groups circumstances consistently applied adequately disclosed matters reported separately parent company financial notes statements glaxosmithkline plc year ended december maintenance integrity glaxosmithkline plc website responsibility directors work carried parent company passed resolution accordance auditors involve consideration matters section companies act senior statutory accordingly auditors accept responsibility auditors name stated changes may occurred financial statements since initially presented website b l egislation united kingdom governing preparation dissemination financial statements may differ legislation pricewaterhousecoopers llp jurisdictions chartered accountants statutory auditors london march gsk annual report consolidated income statement year ended december notes turnover cost sales gross profit selling general administration research development royalty income operating incomeexpense operating profit finance income finance expense profit disposal interest associates share tax profits associates joint ventures profit taxation taxation profit taxation year profitloss attributable noncontrolling interests profit attributable shareholders basic earnings per share pence p p p diluted earnings per share pence p p p consolidated statement comprehensive income year ended december profit year items may subsequently reclassified income statement exchange movements overseas net assets net investment hedges reclassification exchange liquidation disposal overseas subsidiaries deferred tax exchange movements fair value movements availableforsale investments deferred tax fair value movements availableforsale investments reclassification fair value movements availableforsale investments deferred tax reversed reclassification availableforsale investments fair value movements cash flow hedges deferred tax fair value movements cash flow hedges reclassification cash flow hedges income statement share comprehensive expenseincome associates joint ventures items reclassified income statement exchange movements overseas net assets noncontrolling interests remeasurement lossesgains defined benefit plans tax remeasurement defined benefit plans comprehensive incomeexpense year total comprehensive income year total comprehensive income year attributable shareholders noncontrolling interests total comprehensive income year gsk annual report strategic report governance remuneration financial statements consolidated balance sheet investor information december notes noncurrent assets property plant equipment goodwill intangible assets investments associates joint ventures investments deferred tax assets noncurrent assets total noncurrent assets current assets inventories current tax recoverable trade receivables derivative financial instruments liquid investments cash cash equivalents assets held sale total current assets total assets current liabilities shortterm borrowings contingent consideration liabilities trade payables derivative financial instruments current tax payable shortterm provisions total current liabilities noncurrent liabilities longterm borrowings deferred tax liabilities pensions postemployment benefits provisions contingent consideration liabilities noncurrent liabilities total noncurrent liabilities total liabilities net assets equity share capital share premium account retained earnings reserves shareholders equity noncontrolling interests total equity financial statements pages approved board march signed behalf philip hampton chairman gsk annual report consolidated statement changes equity year ended december shareholders equity share share retained noncontrolling total capital premium earnings reserves total interests equity january profit year comprehensive expenseincome year total comprehensive incomeexpense year distributions noncontrolling interests dividends shareholders changes noncontrolling interests forward contract relating noncontrolling interest ordinary shares issued ordinary shares purchased cancelled held treasury shares ordinary shares acquired esop trusts writedown shares held esop trusts sharebased incentive plans tax sharebased incentive plans december profitloss year comprehensive expenseincome year total comprehensive incomeexpense year distributions noncontrolling interests dividends shareholders gains transfer net assets consumer healthcare joint venture consumer healthcare joint venture put option changes noncontrolling interests loss transfer equity investment investment associate ordinary shares issued ordinary shares acquired esop trusts writedown shares held esop trusts sharebased incentive plans tax sharebased incentive plans december profit year comprehensive income year total comprehensive income year distributions noncontrolling interests dividends shareholders recognition liabilities noncontrolling interests derecognition liabilities noncontrolling interests changes noncontrolling interests ordinary shares issued ordinary shares acquired esop trusts writedown shares held esop trusts sharebased incentive plans tax sharebased incentive plans december gsk annual report strategic report governance remuneration financial statements consolidated cash flow statement investor information year ended december notes cash flow operating activities profit taxation year adjustments reconciling profit tax operating cash flows cash generated operations taxation paid net cash inflow operating activities cash flow investing activities purchase property plant equipment proceeds sale property plant equipment purchase intangible assets proceeds sale intangible assets purchase equity investments proceeds sale equity investments contingent consideration paid purchase businesses net cash acquired disposal businesses investments associates joint ventures proceeds disposal subsidiary interest associate increasedecrease liquid investments interest received dividends associates joint ventures equity investments net cash outflowinflow investing activities cash flow financing activities shares acquired esop trusts issue share capital purchase shares cancellation held treasury shares purchase noncontrolling interests increase longterm loans increase shortterm loans repayment shortterm loans net repayment obligations finance leases interest paid dividends paid shareholders distributions noncontrolling interests financing cash flows net cash outflow financing activities decreaseincrease cash bank overdrafts cash bank overdrafts beginning year exchange adjustments decreaseincrease cash bank overdrafts cash bank overdrafts end year cash bank overdrafts end year comprise cash cash equivalents overdrafts comparative figures restated see details gsk annual report notes financial statements presentation financial statements description business accounting principles policies gsk major global healthcare group engaged financial statements prepared using historical creation discovery development manufacture marketing cost convention modified revaluation certain items pharmaceutical products including vaccines overthecounter otc stated accounting policies going concern basis medicines healthrelated consumer products gsks principal financial statements prepared accordance pharmaceutical products include medicines following groups accounting policies approved board therapeutic areas respiratory antivirals central nervous system described note accounting principles policies cardiovascular urogenital metabolic antibacterials information application accounting policies dermatology rare diseases immunoinflammation vaccines including areas estimation judgement given note hiv key accounting judgements estimates compliance applicable law ifrs preparation financial statements conformity financial statements prepared accordance generally accepted accounting principles requires management companies act article ias regulation make estimates assumptions affect reported international accounting standards ias international financial amounts assets liabilities disclosure contingent reporting standards ifrs related interpretations adopted assets liabilities date financial statements european union reported amounts revenues expenses reporting financial statements also compliance ifrs issued period actual results could differ estimates international accounting standards board implementation new accounting standards composition financial statements following agenda decision ifrs interpretations committee consolidated financial statements drawn sterling regarding offsetting cash pooling arrangements group functional currency glaxosmithkline plc accordance revised disclosure cash pooling arrangements ifrs accounting presentation financial statements change results cash flows year december comprise impact balance sheet december impact january increase cash consolidated income statement cash equivalents shortterm borrowings million consolidated statement comprehensive income amendment ifrs joint arrangements consolidated balance sheet implemented january revision consolidated statement changes equity material impact results financial position group financial period consolidated cash flow statement financial statements cover financial year january notes financial statements december comparative figures financial years composition group january december appropriate list subsidiary associated undertakings january december opinion directors principally affected amount profit parent company financial statements net assets group given note principal financial statements parent company glaxosmithkline plc group companies prepared accordance uk gaap uk accounting presentation company balance sheet presented accounting policies given accounting principles policies consolidation group ability exercise joint control consolidated financial statements include rights net assets entities entities accounted joint ventures group ability exercise joint assets liabilities results cash flows control arrangement rights specified assets company subsidiaries including esop trusts obligations specified liabilities arrangement groups share results net assets associates arrangement accounted joint operation group joint ventures ability exercise significant influence entities groups share assets liabilities revenue expenses accounted associates results assets liabilities joint operations associates joint ventures incorporated consolidated financial statements using equity method accounting financial statements entities consolidated made groups rights assets liabilities revenue expenses joint december year operations included consolidated financial statements entities group power direct relevant accordance rights obligations activities affect returns group generally interests acquired entities consolidated date control financial operating policies accounted group acquires control interests sold deconsolidated subsidiaries date control ceases gsk annual report strategic report governance remuneration financial statements investor information accounting principles policies continued transactions balances subsidiaries eliminated revenue profit tax taken sales subsidiaries revenue recognised income statement goods products sold customers outside group relevant services supplied made available external customers proportion profits transactions joint ventures joint orders received title risk loss passed customer operations associates also deferred products reliable estimates made relevant deductions relevant sold third parties transactions noncontrolling interests obligations fulfilled earnings process recorded directly equity deferred tax relief unrealised intra regarded complete group profit accounted extent considered turnover represents net invoice value deduction recoverable discounts allowances given accruals estimated future goodwill capitalised separate item case subsidiaries rebates returns methodology assumptions used part cost investment case joint ventures estimate rebates returns monitored adjusted regularly associates goodwill denominated currency operation light contractual legal obligations historical trends past acquired experience projected market conditions market conditions evaluated using wholesaler thirdparty analyses market cost acquisition fair value net assets research data internally generated information value added tax acquired difference recognised directly income sales taxes excluded revenue statement group copromotes product counterparty business combinations records sale group records share revenue co business combinations accounted using acquisition promotion income within turnover nature copromotion accounting method identifiable assets liabilities contingent activities group records costs sales liabilities acquired measured fair value acquisition date pharmaceutical turnover includes copromotion revenue consideration transferred measured fair value million million million addition includes fair value contingent consideration initial eventbased milestone income excluding royalty income consideration transferred together noncontrolling interest arising development marketing collaborations groups exceeds fair value net assets liabilities contingent compounds products parties recognised turnover liabilities acquired excess recorded goodwill costs milestone income nil included turnover nil acquisition charged income statement period million incurred royalty income recognised accruals basis accordance equity subsidiary acquired non terms relevant licensing agreements controlling interest recognised either fair value non controlling interests share net assets subsidiary expenditure casebycase basis changes groups ownership percentage expenditure recognised respect goods services received subsidiaries accounted within equity supplied accordance contractual terms provision made obligation exists future liability respect foreign currency translation past event amount obligation reliably foreign currency transactions booked functional currency estimated manufacturing startup costs validation group company exchange rate ruling date achievement normal production expensed incurred transaction foreign currency monetary assets liabilities advertising promotion expenditure charged income retranslated functional currency rates exchange ruling statement incurred shipment costs intercompany transfers balance sheet date exchange differences included charged cost sales distribution costs sales customers income statement included selling general administrative expenditure consolidation assets liabilities including related goodwill restructuring costs recognised provided overseas subsidiaries associates joint ventures translated appropriate respect direct expenditure business sterling rates exchange ruling balance sheet date reorganisation plans sufficiently detailed well results cash flows overseas subsidiaries associates advanced appropriate communication affected joint ventures translated sterling using average rates undertaken exchange exchange adjustments arising opening net assets profits year retained overseas subsidiaries associates joint ventures translated sterling less exchange differences arising related foreign currency borrowings hedge groups net investment operations taken separate component equity translating sterling assets liabilities results cash flows overseas subsidiaries associates joint ventures reported currencies hyperinflationary economies adjustments made material reflect current price levels loss net monetary assets charged consolidated income statement gsk annual report notes financial statements continued accounting principles policies continued research development employee share plans research development expenditure charged income incentives form shares provided employees statement period incurred development share option share award schemes expenditure capitalised criteria recognising asset fair values options awards calculated met usually regulatory filing made major grant dates using blackscholes option pricing model charged market approval considered highly probable property plant income statement relevant vesting periods equipment used research development capitalised depreciated accordance groups policy group provides finance esop trusts purchase company shares meet obligation provide shares employees environmental expenditure exercise options awards costs running esop trusts environmental expenditure related existing conditions resulting charged income statement shares held esop past current operations current future trusts deducted reserves transfer made benefit discernible charged income statement group reserves retained earnings vesting periods recognises liability sitebysite basis reliably related share options awards reflect ultimate proceeds estimated liability includes groups portion total costs receivable employees exercise also portion potentially responsible parties costs probable able satisfy respective property plant equipment shares cleanup obligation recoveries reimbursements property plant equipment ppe stated cost recorded assets virtually certain purchase construction less provisions depreciation impairment financing costs capitalised within cost legal disputes qualifying assets construction provision made anticipated settlement costs legal disputes group outflow resources depreciation calculated write cost less residual value considered probable reliable estimate made likely ppe excluding freehold land using straightline basis outcome addition provision made legal expenses expected useful life residual values lives reviewed arising claims received disputes respect product appropriate adjusted annually normal expected useful liability claims related certain products sufficient history lives major categories ppe claims made settlements enable management make reliable estimate provision required cover unasserted claims freehold buildings years certain cases incurred reported ibnr actuarial leasehold land buildings lease term years technique used determine estimate plant machinery years group may become involved legal proceedings respect equipment vehicles years possible make reliable estimate expected financial effect could result ultimate resolution disposal ppe cost related accumulated depreciation proceedings cases appropriate disclosure impairments removed financial statements cases would included provision would made costs net amount less proceeds taken income statement associated claims made group third parties leases charged income statement incurred leasing agreements transfer group substantially pensions postemployment benefits benefits risks ownership asset treated finance costs providing pensions defined benefit schemes leases asset purchased outright assets calculated using projected unit credit method spread included ppe computer software capital elements period benefit expected derived leasing commitments shown obligations finance employees services consistent advice qualified actuaries leases assets held finance leases depreciated basis pension obligations measured present value estimated consistent similar owned assets lease term shorter future cash flows discounted rates reflecting yields high interest element lease rental included income quality corporate bonds pension scheme assets measured statement leases operating leases rental costs fair value balance sheet date charged income statement straightline basis lease term costs postemployment liabilities calculated similar way defined benefit pension schemes spread goodwill period benefit expected derived goodwill stated cost less impairments goodwill deemed employees services accordance advice qualified indefinite useful life tested impairment least actuaries annually actuarial gains losses effect changes actuarial fair value interest acquired entitys assets assumptions recognised statement comprehensive liabilities contingent liabilities exceeds consideration paid income year arise excess recognised immediately gain income statement groups contributions defined contribution plans charged income statement incurred gsk annual report strategic report governance remuneration financial statements investor information accounting principles policies continued intangible assets availableforsale investments intangible assets stated cost less provisions amortisation liquid investments investments classified available impairments forsale investments initially recorded fair value plus transaction costs remeasured subsequent reporting licences patents knowhow marketing rights separately dates fair value unrealised gains losses availableforsale acquired acquired part business combination investments recognised directly comprehensive income amortised estimated useful lives generally exceeding impairments arising significant prolonged decline fair years using straightline basis time available value equity investment reduce carrying amount asset use estimated useful lives determining amortisation directly charged income statement charge take account patent lives applicable well value obtained periods nonexclusivity asset lives disposal impairment investments gains reviewed appropriate adjusted annually contingent losses deferred comprehensive income milestone payments recognised point contingent reclassified income statement dividends equity event becomes probable development costs incurred investments recognised income statement group associated acquired licences patents knowhow groups right receive payment established equity investments marketing rights written income statement recorded noncurrent assets unless expected incurred unless criteria recognition internally generated sold within one year intangible asset met usually regulatory filing purchases sales equity investments accounted made major market approval considered highly probable trade date purchases sales availableforsale acquired brands valued independently part fair value investments accounted settlement date businesses acquired third parties brand value inventories substantial long term brands either inventories included financial statements lower contractual legal nature sold separately rest cost including raw materials direct labour direct costs businesses acquired brands amortised related production overheads net realisable value cost estimated useful lives years except considered generally determined first first basis prelaunch inventory useful economic life indefinite held asset high probability regulatory costs acquiring developing computer software internal approval product point provision made use internet sites external use capitalised intangible carrying value recoverable amount provision fixed assets software site supports significant reversed point high probability regulatory business system expenditure leads creation approval determined durable asset erp systems software amortised seven trade receivables ten years computer software three five years trade receivables carried original invoice amount less impairment noncurrent assets provisions doubtful debts provisions made carrying values noncurrent assets reviewed evidence risk nonpayment taking account ageing impairment either standalone basis part larger cash previous experience general economic conditions trade generating unit indication assets might receivable determined uncollectable written firstly impaired additionally goodwill intangible assets indefinite provision available income statement useful lives intangible assets yet available use subsequent recoveries amounts previously provided tested impairment annually provision impairment credited income statement longterm receivables charged income statement year concerned discounted effect material impairments goodwill reversed impairment losses borrowings noncurrent assets reversed change borrowings initially recorded amount proceeds estimates used determine recoverable amounts received net transaction costs borrowings subsequently extent revised recoverable amounts exceed carried amortised cost difference proceeds carrying values would existed net depreciation net transaction costs amount due redemption amortisation impairments recognised recognised charge income statement period investments associates joint ventures joint operations relevant borrowing investments associates joint ventures carried consolidated balance sheet groups share net assets date acquisition postacquisition retained profits losses together goodwill arising acquisition group recognises rights assets liabilities revenue expenses joint operations gsk annual report notes financial statements continued accounting principles policies continued taxation derivative financial instruments classified heldfortrading current tax provided amounts expected paid applying carried balance sheet fair value derivatives tax rates enacted substantively enacted designated hedging instruments classified inception balance sheet date cash flow hedges net investment hedges fair value hedges deferred tax provided full temporary differences arising changes fair value derivatives designated cash flow tax bases assets liabilities carrying hedges recognised comprehensive income amounts financial statements deferred tax assets extent hedges effective ineffective portions recognised extent probable future taxable profits recognised profit loss immediately amounts deferred available temporary differences comprehensive income reclassified income utilised deferred tax provided temporary differences arising statement hedged item affects profit loss investments subsidiaries associates joint ventures except net investment hedges accounted similar way cash timing reversal temporary difference flow hedges controlled probable temporary difference reverse foreseeable future deferred tax provided using rates changes fair value derivatives designated fair value tax enacted substantively enacted hedges recorded income statement together balance sheet date changes fair value hedged asset liability derivative financial instruments hedging changes fair value derivative instruments derivative financial instruments used manage exposure qualify hedge accounting recognised immediately market risks principal derivative instruments used gsk income statement foreign currency swaps interest rate swaps foreign exchange discounting forward contracts options group hold issue time value money material balances derivative financial instruments trading speculative discounted current values using appropriate discount rates purposes unwinding discounts recorded finance income finance expense key accounting judgements estimates preparing financial statements management required taxation make estimates assumptions affect amounts tax charge year million million assets liabilities revenue expenses reported financial december current tax payable million statements actual amounts results could differ million current tax recoverable million estimates following considered key accounting million deferred tax liabilities million judgements estimates made million deferred tax assets million million turnover group turnover million current tax provided amounts expected paid million deferred tax provided temporary differences tax bases assets liabilities carrying amounts rates revenue recognised title risk loss passed enacted substantively enacted balance customer reliable estimates made relevant deductions sheet date relevant obligations fulfilled earnings process regarded complete deferred tax assets recognised extent probable future taxable profits available gross turnover reduced rebates discounts allowances temporary differences utilised based managements product returns given expected given vary product assumptions relating amounts timing future taxable arrangements buying groups arrangements profits factors affecting tax charge future years set purchasing organisations dependent upon submission note taxation change groups effective tax rate claims time initial recognition sale accruals would changed total tax charge year made time sale estimated rebates discounts approximately million allowances payable returns made based available market information historical experience group open tax issues number revenue authorities outflow funds believed probable reliable amounts estimated may fully reflect estimate outcome dispute made management final outcome amounts subject change dependent provides best estimate liability calculating upon amongst things types buying group product liability gsk applies risk based approach takes account sales mix appropriate probability group would able obtain level accrual rebates returns reviewed adjusted compensatory adjustments international tax treaties regularly light contractual legal obligations historical estimates take account specific circumstances trends past experience projected market conditions market dispute relevant external advice inherently judgemental conditions evaluated using wholesaler thirdparty could change substantially time new facts emerge analyses market research data internally generated information dispute progresses future events could cause assumptions accruals based change could affect future results group gsk annual report strategic report governance remuneration financial statements investor information key accounting judgements estimates continued gsk continues believe made adequate provision assumptions relating future cash flows estimated useful liabilities likely arise open assessments december lives discount rates based business forecasts group recognised provisions million therefore inherently judgemental future events could cause respect uncertain tax positions million assumptions used impairment tests change open issues exist ultimate liability matters may vary consequent adverse effect future results group amounts provided dependent upon outcome contingent consideration put option liabilities negotiations relevant tax authorities necessary income statement charge contingent consideration litigation proceedings put option liabilities million million legal disputes december liability contingent consideration legal costs year million million amounted million million amount december provisions legal disputes million million relates acquisition amounted million million former shionogiviiv healthcare joint venture group provides anticipated settlement costs million million relates acquisition outflow resources considered probable reliable estimate vaccines business novartis may made likely outcome dispute legal contingent consideration included consideration payable expenses arising claims group estimates business combination recorded fair value date take account specific circumstances dispute acquisition fair values generally based riskadjusted relevant external advice inherently judgemental could change future cash flows discounted using appropriate posttax discount substantially time new facts emerge dispute rates fair values reviewed regular basis least progresses details status various uncertainties involved annually changes reflected income statement significant unresolved disputes set note legal see note contingent consideration liabilities proceedings group granted put option novartis respect companys directors taken legal advice novartis shareholding consumer healthcare joint venture established provisions taking account relevant facts certain circumstances novartis right require gsk circumstances matter accordance accounting acquire shareholding consumer healthcare joint requirements respect product liability claims related certain venture marketbased valuation right exercisable products sufficient history claims made settlements certain windows may exercised either enable management make reliable estimate provision respect novartis entire shareholding four instalments required cover unasserted claims group may become involved gsk recognised financial liability million legal proceedings respect possible make noncurrent liabilities december million reliable estimate expected financial effect result represents present value estimated redemption value ultimate resolution proceedings cases gsk event full exercise right novartis appropriate disclosure cases would included calculated applying relevant public company multiples provision would made contingent liability quantified premium discount forecast future profits accordance ultimate liability legal claims may vary amounts shareholder agreements sensitivity analysis given note provided dependent upon outcome litigation noncurrent liabilities proceedings investigations possible settlement negotiations pfizer may request ipo viiv healthcare time either position could change time therefore gsk consent ipo offering completed assurance losses result outcome legal within nine months pfizer could require gsk acquire proceedings exceed amount provisions reported shareholding liability put option recognised groups financial statements material amount groups balance sheet initial value goodwill intangible asset impairments million gsk also recognised liabilities future preferential december goodwill million dividends anticipated become payable pfizer shionogi million intangible assets million groups balance sheet liability pfizer put million option million december recognised trade payables sensitivity analysis also given note goodwill deemed indefinite life amortised trade payables annual impairment tests cash generating units goodwill allocated performed impairment tests based shionogi also held put option shareholding viiv established market multiples riskadjusted future cash flows healthcare gsk recognised liability discounted using appropriate discount rates assumptions used put option groups balance sheet initial value impairment tests set note goodwill million q shionogi irrevocably agreed waive put option result gsk derecognised liability put case valuations indicate sufficient headroom option groups balance sheet directly equity value reasonably possible change key assumptions unlikely result liability million derecognised see impairment related goodwill noncontrolling interests viiv healthcare full impairment tests intangible assets undertaken events details put options occur call question carrying values assets assumptions relating future cash flows discount rates brands intangible assets yet available based business forecasts therefore inherently use amortised subject annual impairment judgemental future events could cause assumptions underlying tests valuations impairment tests based established projections marketbased multiples used market multiples riskadjusted future cash flows estimated value liabilities contingent consideration put options useful life asset limited discounted using appropriate change consequent adverse effect future results discount rates set note intangible assets group gsk annual report notes financial statements continued key accounting judgements estimates continued pensions postemployment benefits expected longterm rates return bonds determined costs providing pensions postemployment benefits based portfolio mix indexlinked government corporate charged income statement accordance ias bonds equity risk premium added equities employee benefits period benefit derived discount rates derived aa rated corporate bond yields employees services costs assessed basis except countries deep market corporate assumptions selected management assumptions bonds government bond yields used sensitivity analysis include future earnings pension increases discount rates provided note pensions postemployment expected longterm rates return assets mortality rates benefits reduction discount rate would lead disclosed note pensions postemployment increase net pension deficit approximately million benefits surplus defined benefit scheme arises increase annual pension cost approximately million potential surplus arise committed future selection different assumptions could affect future results contributions rights trustees prevent group group obtaining refund surplus future considered determining whether necessary restrict amount surplus recognised new accounting requirements following new amended accounting standards ifrs financial instruments issued final form july issued iasb likely affect future annual reports implemented group january standard replace majority ias covers ifrs revenue contracts customers issued may classification measurement de recognition financial assets implemented group january financial liabilities impairment financial assets provides standard provides single principlesbased approach new hedge accounting model recognition revenue contracts customers focuses identification performance obligations contract group currently assessing new ifrs expect requires revenue recognised performance able quantify impact potential changes later obligations satisfied group currently assessing new ifrs expect ifrs leases issued january able quantify impact potential changes later implemented group january standard replace ias leases require lease liabilities right use assets recognised balance sheet almost leases group early stages assessing potential impact new ifrs exchange rates group uses average exchange rates prevailing period translate results cash flows overseas average rates subsidiaries joint ventures associates sterling period us end rates translate net assets entities currencies euro influence translations relevant exchange rates follows yen period end rates us euro yen gsk annual report strategic report governance remuneration financial statements investor information segment information operating segments reported based financial information provided chief executive officer responsibilities corporate executive team cet completion novartis transaction march changed balance group gsk changed segment reporting reflect effect january gsk reported results four segments pharmaceuticals includes hiv pharmaceuticals rd vaccines consumer healthcare individual members cet responsible segment comparative information restated accordingly groups management reporting process allocates intragroup profit product sale market sale recorded profit analyses presented basis pharmaceuticals rd segment responsibility president pharmaceuticals rd reported separate segment corporate unallocated turnover costs included results several vaccines consumer healthcare products held sale number markets order meet antitrust approval requirements together costs corporate functions restated restated turnover segment pharmaceuticals vaccines consumer healthcare segment turnover corporate unallocated turnover restated restated pharmaceuticals turnover therapeutic area respiratory cardiovascular metabolic urology immunoinflammation pharmaceuticals established products hiv us operations pharmaceuticals vaccines businesses made sales three wholesalers approximately million million million million million million million million million respectively allocating finalcustomer discounts wholesalers restated restated consumer healthcare turnover category wellness oral care nutrition skin health gsk annual report notes financial statements continued segment information continued restated restated segment profit pharmaceuticals pharmaceuticals rd pharmaceuticals including rd vaccines consumer healthcare segment profit corporate unallocated costs reconciling items segment profit operating profit operating profit finance income finance costs profit disposal interest associates share tax profits associates joint ventures profit taxation taxation profit taxation year reconciling items segment profit operating profit comprise items specifically allocated segment profit include impairment amortisation intangible assets major restructuring charges legal charges expenses settlement litigation government investigations disposals businesses products associates certain items related major acquisition disposal activity restated restated depreciation amortisation segment pharmaceuticals pharmaceuticals rd pharmaceuticals including rd vaccines consumer healthcare segment depreciation amortisation corporate unallocated depreciation amortisation reconciling items segment depreciation amortisation total depreciation amortisation total depreciation amortisation gsk annual report strategic report governance remuneration financial statements investor information segment information continued restated restated ppe intangible asset goodwill impairment segment pharmaceuticals pharmaceuticals rd pharmaceuticals including rd vaccines consumer healthcare segment impairment corporate unallocated impairment reconciling items segment impairment total impairment total impairment restated restated ppe intangible asset impairment reversals segment pharmaceuticals pharmaceuticals rd pharmaceuticals including rd vaccines consumer healthcare segment impairment reversals corporate unallocated impairment reversals reconciling items segment impairment reversal total impairment reversal total impairment reversals restated net assets segment pharmaceuticals pharmaceuticals rd pharmaceuticals including rd vaccines consumer healthcare segment net operating assets corporate unallocated net operating assets net operating assets net debt investments associates joint ventures derivative financial instruments current deferred taxation assets held sale net assets pharmaceuticals segment includes shionogiviiv healthcare contingent consideration liability million million pfizer put option million nil consumer healthcare segment includes put option liability million million gsk annual report notes financial statements continued segment information continued geographical information uk regarded groups country domicile restated turnover location customer uk us international external turnover turnover location subsidiary uk us international turnover including intersegment turnover uk us international intersegment turnover uk us international external turnover operating profit location subsidiary uk us international total operating profit noncurrent assets location subsidiary uk us international noncurrent assets noncurrent assets location excludes amounts relating investments deferred tax assets derivative financial instruments pension assets amounts receivable insurance contracts certain noncurrent receivables gsk annual report strategic report governance remuneration financial statements investor information operating incomeexpense impairment equity investments disposal equity investments disposal businesses assets fair value remeasurements contingent consideration recognised business combinations remeasurement viiv healthcare put option liabilities preferential dividends remeasurement consumer healthcare put option liability fair value adjustments derivative financial instruments incomeexpense disposal businesses assets included milestone income million relation divestment ofatumumab number smaller divestments included disposal oncology business novartis million initial million divestment ofatumumab fair value remeasurements contingent consideration recognised business combinations comprised million related acquisition former shionogiviiv healthcare joint venture million related contingent consideration payable novartis related vaccines acquisition partially offset hedging gains smaller items fair value adjustments derivative financial instruments arise foreign exchange forward contracts options taken hedge foreign currency movements sales purchases denominated foreign currencies see note financial instruments related disclosures included unrealised loss million arising number forward exchange contracts entered following announcement proposed novartis transaction protect sterling value net us dollar proceeds due group completion transaction operating profit following items included operating profit employee costs note advertising distribution costs depreciation property plant equipment impairment property plant equipment net reversals amortisation intangible assets impairment intangible assets net reversals net foreign exchange lossesgains inventories cost inventories included cost sales writedown inventories reversal prior year writedown inventories operating lease rentals minimum lease payments contingent rents sublease payments fees payable companys auditor associates relation group see reversals prior year writedowns inventories principally arise reassessment usage demand expectations prior inventory expiration included within operating profit major restructuring charges million million million see note major restructuring costs gsk annual report notes financial statements continued operating profit continued restated fees payable companys auditor associates audit parent company consolidated financial statements audit companys subsidiaries attestation sarbanesoxley act audit auditrelated services taxation compliance taxation advice assurance services services assurance services provided auditor relate agreed upon procedures assurance services outside statutory audit requirements services provided auditor primarily related advisory services year ended december addition fees paid respect gsk pension schemes audit services employee costs wages salaries social security costs pension postemployment costs including augmentations note cost sharebased incentive plans severance costs integration restructuring activities group provides benefits employees commensurate local practice individual countries including markets healthcare insurance subsidised car schemes personal life assurance cost sharebased incentive plans analysed follows share value plan performance share plan share option plans plans gsk annual report strategic report governance remuneration financial statements investor information employee costs continued average monthly number persons employed group including directors year number number number manufacturing selling general administration research development average monthly number group employees excludes temporary contract staff numbers group employees end financial year given financial record monthly average number persons employed glaxosmithkline plc nil nil compensation directors senior management members cet aggregate follows wages salaries social security costs pension postemployment costs cost sharebased incentive plans major restructuring costs major restructuring costs charged arriving operating profit include restructuring costs arising major change programme initiated pharmaceuticals restructuring programme announced october following novartis transaction completed combined programme total restructuring costs million incurred following areas restructuring rd organisation predominantly united kingdom north america japan projects simplify eliminate processes leading staff reductions support functions restructuring pharmaceuticals business emerging markets europe leading staff reductions sales force administration transformation manufacturing vaccines businesses deliver step change quality cost productivity continued integration enhanced vaccines business consumer healthcare joint venture analysis costs charged operating profit programmes follows increase provision major restructuring programmes see note amount provision reversed unused see note impairment losses recognised noncash charges cash costs provision reversals million million million reflect release legacy support function novartis integration provisions asset impairments million million nil noncash charges totalling million million million noncash items principally fixed asset write downs across support function manufacturing research facilities accelerated depreciation asset lives rd manufacturing shortened result major restructuring programme charges settled cash include termination leases site closure costs consultancy project management fees gsk annual report notes financial statements continued finance income interest income arising cash cash equivalents availableforsale investments derivatives fair value profit loss loans receivables fair value adjustments derivatives fair value profit loss derivatives accounted fair value profit loss designated effective hedging instruments see note financial instruments related disclosures classified heldfortrading financial instruments ias finance expense interest expense arising financial liabilities amortised cost derivatives fair value profit loss fair value hedges fair value movements derivatives designated hedging instruments fair value adjustments hedged items fair value movements derivatives fair value profit loss reclassification cash flow hedge comprehensive income unwinding discounts provisions finance expense derivatives accounted fair value profit loss designated effective hedging instruments see note financial instruments related disclosures classified heldfortrading financial instruments ias interest expense arising derivatives fair value profit loss relates swap interest expense gsk annual report strategic report governance remuneration financial statements investor information associates joint ventures groups share tax profits losses associates joint ventures set share tax profits associates share tax losses joint ventures december group held one significant associate innoviva inc summarised income statement information respect innoviva set periods group accounted investment innoviva associate groups share tax profits associates comprehensive income includes profit million comprehensive income nil respect innoviva since september turnover profit taxation comprehensive income total comprehensive income results innoviva included summarised income statement information represent estimated earnings innoviva relevant periods innovivas turnover royalty income gsk relation relvarbreo ellipta anoro ellipta sales march group divested half shareholding aspen pharmacare holdings limited ceased account remaining investment associate aspen groups significant associate summarised income statement information respect aspen set periods group accounted investment aspen associate march turnover profit taxation comprehensive income total comprehensive income results aspen included summarised income statement information represent estimated earnings aspen group relevant periods adjusted transactions gsk aspen aggregated financial information respect gsks share associated undertakings joint ventures set share turnover share tax lossesprofits share comprehensive income share total comprehensive incomeexpense groups sales associates joint ventures million million million gsk annual report notes financial statements continued taxation taxation charge based profits year uk current year charge rest world current year charge credit respect prior periods total current taxation total deferred taxation gsk made payments million uk corporation tax hmrc january gsk made payments million relation uk corporation tax amounts corporation tax include various business taxes borne gsk year significant component deferred tax credit prior periods arose respect remeasurement contingent consideration relation former shionogiviiv healthcare joint venture credit also included unwind deferred tax liabilities disposal groups oncology business novartis following table reconciles tax charge calculated uk statutory rate group profit tax actual tax charge year reconciliation taxation group profits profit tax uk statutory rate taxation differences overseas taxation rates benefit intellectual property incentives rd credits remeasurement nontaxable put option liabilities losses recognisedpreviously unrecognised losses permanent differences disposals acquisitions permanent differences reassessments prior year estimates respect current deferred taxes tax unremitted earnings tax chargetax rate gsk substantial business presence many countries around world impact differences overseas taxation rates arose profits earned countries tax rates higher uk statutory rate significant us france india partly offset increased benefit intellectual property incentives uk patent box belgian patent income deduction regimes regimes provide reduced rate corporate income tax profits earned qualifying patents group also incurred material nondeductible charges following revaluation liabilities viiv healthcare consumer healthcare joint venture put options impact higher overseas tax rates reduced permanent differences arising disposals groups overall effective tax rate influenced significant transactionrelated remeasurement charges arising viiv healthcare contingent consideration liability consumer healthcare joint venture viiv healthcare put option liabilities remeasurement liabilities gave rise charge profit tax million related tax credit million excluding items effective tax rate year would details consumer healthcare joint venture put option set note noncurrent liabilities viiv healthcare arrangements future tax charges therefore effective tax rate may affected factors acquisitions disposals restructuring location research development activity tax regime reforms resolution open matters continue bring tax affairs date around world tax items charged equity statement comprehensive income current taxation sharebased payments defined benefit plans deferred taxation sharebased payments defined benefit plans exchange movements fair value movements cash flow hedges fair value movements availableforsale investments total creditcharge equity statement comprehensive income items charged statement comprehensive income except tax share based payments gsk annual report strategic report governance remuneration financial statements investor information taxation continued issues relating taxation groups tax charge sum total current deferred tax expense calculation groups total tax charge necessarily involves degree estimation judgement respect certain items whose tax treatment finally determined resolution reached relevant tax authority appropriate formal legal process december group held provisions million respect uncertain tax positions million increase recognised provisions primarily driven foreign exchange impact revaluing overseas exposures ultimate liability matters may vary amounts provided dependent upon outcome agreements relevant tax authorities litigation appropriate group continues believe made appropriate provision periods open yet agreed tax authorities integrated nature groups worldwide operations involves significant investment research strategic manufacturing limited number locations consequential crossborder supply routes numerous endmarkets gsks biggest risk respect taxation despite adherence oecds established arms length principle different tax authorities seek attribute profit activities undertaken jurisdiction potentially resulting double taxation gsk applies riskbased approach determine transactions likely subject challenge probability group would able obtain compensatory adjustments international tax treaties group also open items several jurisdictions concerning matters deductibility particular expenses tax treatment certain business transactions group consider major sources estimation uncertainty end reporting period significant risk resulting material adjustment carrying amounts taxrelated assets liabilities within next financial year continues significant international focus tax reform including oecds beps project european commission initiatives including increased use fiscal state aid investigations together domestic initiatives around world may result significant changes established tax principles increase tax authority disputes turn could adversely affect effective tax rate result higher cash tax liabilities aggregate amount unremitted profits balance sheet date approximately billion billion majority unremitted profits would subject tax repatriation uk legislation relating company distributions provides exemption tax overseas profits subject certain exceptions provision deferred tax liabilities million million made respect withholding tax would arise distribution profits certain overseas subsidiaries remainder unremitted profits deferred tax provided billion december billion deferred tax distribution remaining profits provided grounds group able control timing reversal remaining temporary differences probable reverse foreseeable future movement deferred tax assets liabilities pensions share accelerated post option net capital intangible contingent intragroup employment tax award temporary allowances assets consideration profit benefits losses schemes differences total assetliability january exchange adjustments credit income statement credit statement comprehensive income assetliability december deferred tax credit income statement million includes million rd incentives recognised within operating profit taxation charge income statement deferred tax liabilities provided relation intangible assets predominately relate temporary differences arising assets liabilities acquired part historic business combinations group continues recognise deferred tax assets future obligations respect contingent consideration amounts payable minority shareholders payments tax deductible point time payment made deferred tax asset recognised intragroup profits arising intercompany stock eliminated within consolidated accounts intragroup profits eliminated individual entities tax returns temporary difference arises reverse point time stock sold externally deferred tax asset recognised tax losses comprises million million asset related trading losses million nil asset related capital losses net temporary differences include accrued expenses tax deduction available paid basis offsetting deferred tax assets liabilities appropriate within territories net deferred tax asset comprises deferred tax assets deferred tax liabilities gsk annual report notes financial statements continued taxation continued restated unrecognised unrecognised deferred tax deferred tax tax losses asset tax losses asset unrecognised tax losses trading losses expiring within years years available indefinitely december capital losses december deferred tax assets recognised probable future taxable profit available utilise losses amount unrecognised trading losses revised following reassessment available losses deferred tax recognised earnings per share pence pence pence basic earnings per share diluted earnings per share basic earnings per share calculated dividing profit attributable shareholders weighted average number shares issue period deducting shares held esop trusts treasury shares trustees waived rights dividends shares held esop trusts diluted earnings per share calculated adjusting weighted average number shares used basic calculation assume conversion potentially dilutive shares potentially dilutive share forms part employee share schemes exercise price average market price gsk shares period performance conditions attaching scheme met balance sheet date numbers shares used calculating basic diluted earnings per share reconciled weighted average number shares issue millions millions millions basic dilution share options awards diluted dividends dividend total dividend total dividend total per share dividend per share dividend per share dividend paidpayable pence paid pence paid pence first interim july july july second interim october october october third interim january january january fourth interim april april april total special dividend april ifrs interim dividends recognised financial statements paid declared gsk normally pays dividend two quarters quarter relates one quarter declared financial statements recognise dividends paid namely third fourth interim dividends special dividend declared first second interim dividends amounts recognised year follows dividends shareholders gsk annual report strategic report governance remuneration financial statements investor information property plant equipment plant land equipment assets buildings vehicles construction total cost january exchange adjustments additions business combinations additions capitalised borrowing costs disposals writeoffs reclassifications transfer assets held sale cost december exchange adjustments additions capitalised borrowing costs disposals writeoffs reclassifications transfer assets held sale cost december depreciation january exchange adjustments charge year disposals writeoffs transfer fromto assets held sale depreciation december exchange adjustments charge year disposals writeoffs transfer assets held sale depreciation december impairment january exchange adjustments disposals writeoffs impairment losses reversal impairments transfer assets held sale impairment december exchange adjustments disposals writeoffs impairment losses reversal impairments transfer assets held sale impairment december total depreciation impairment december total depreciation impairment december net book value january net book value december net book value december weighted average interest rate capitalised borrowing costs year disposals writeoffs year include number assets nil net book value longer use business gsk annual report notes financial statements continued propertyplant equipment continued net book value december groups land buildings comprised freehold properties million million properties leases years million million properties leases less years million million included land buildings december leased assets cost million million accumulated depreciation million million impairment million nil net book value million million included plant equipment vehicles december leased assets cost million million accumulated depreciation million million impairment nil nil net book value million million lease agreements include renewal purchase options escalation clauses impairment losses principally arose decisions rationalise facilities calculated based either fair value less costs disposal value use fair value less costs disposal valuation methodology uses significant inputs based observable market data therefore valuation technique classified level fair value hierarchy calculations determine net present value projected riskadjusted posttax cash flows relevant asset cash generating unit applying discount rate group posttax weighted average cost capital wacc adjusted appropriate relevant specific risks value use calculations impairment indicated pretax cash flow calculation expected give materially different result test would reperformed using pretax cash flows pretax discount rate group wacc equivalent pretax discount rate approximately net impairment losses charged cost sales million million rd million million sga million million included million million arising major restructuring programmes reversals impairment arose subsequent reviews impaired assets conditions gave rise original impairments deemed longer apply reversals credited cost sales carrying value december assets impairments charged reversed year million million million million computer software reclassified assets construction intangible assets becoming ready use goodwill cost january exchange adjustments additions business combinations note transfer assets held sale cost december net book value january net book value december gsk acquired hiv rd preclinical discovery stage portfolio bristol myers squibb goodwill million arose acquisition allocated pharmaceuticals goodwill allocated groups segments follows allocations revised reflect current segment structure pharmaceuticals vaccines consumer healthcare net book value december gsk annual report strategic report governance remuneration financial statements investor information goodwill continued recoverable amounts cash generating units assessed using fair value less costs disposal model fair value less costs disposal calculated using discounted cash flow approach posttax discount rate applied projected riskadjusted posttax cash flows terminal value discount rate used based group wacc cash generating units integrated operations across large parts group discount rate adjusted appropriate specific country currency risks valuation methodology uses significant inputs based observable market data therefore valuation technique classified level fair value hierarchy details relating discounted cash flow models used impairment tests pharmaceuticals vaccines consumer healthcare cash generating units follows valuation basis fair value less costs disposal key assumptions sales growth rates profit margins terminal growth rate discount rate taxation rate determination assumptions growth rates internal forecasts based internal external market information margins reflect past experience adjusted expected changes terminal growth rates based managements estimate future longterm average growth rates discount rates based group wacc adjusted appropriate taxation rates based appropriate rates region period specific projected cash flows five years terminal growth rate discount rate terminal growth rate discount rate pharmaceuticals pa vaccines pa consumer healthcare pa terminal growth rates exceed longterm projected growth rates relevant markets reflect impact future generic competition take account new product launches case valuations indicated sufficient headroom reasonably possible change key assumptions unlikely result impairment related goodwill goodwill monitored segmental level pharmaceuticals cash generating unit comprises collection smaller cash generating units including assets indefinite lives carrying value million million consumer healthcare cash generating unit also comprises collection smaller cash generating units including brands indefinite lives carrying value billion billion details indefinite life brands given note intangible assets gsk annual report notes financial statements continued intangible assets computer licences amortised indefinite life software patents etc brands brands total cost january exchange adjustments capitalised development costs capitalised borrowing costs additions business combinations additions reclassifications disposals asset writeoffs transfer assets held sale cost december exchange adjustments capitalised development costs capitalised borrowing costs additions business combinations additions disposals asset writeoffs transfer assets held sale reclassifications cost december amortisation january exchange adjustments charge year disposals asset writeoffs transfer assets held sale amortisation december exchange adjustments charge year disposals asset writeoffs transfer assets held sale amortisation december impairment january exchange adjustments impairment losses disposals asset writeoffs transfer assets held sale impairment december exchange adjustments impairment losses disposals asset writeoffs transfer assets held sale impairment december total amortisation impairment december total amortisation impairment december net book value january net book value december net book value december weighted average interest rate capitalised borrowing costs year net book value computer software included million million internally generated costs charge impairments year includes impairments oncomed ansolar maxinutrition carrying value december intangible assets impairments charged reversed year following impairments reversals million million patent expiry dates groups significant assets relevant set pages gsk annual report strategic report governance remuneration financial statements investor information intangible assets continued amortisation impairment losses net reversals charged income statement follows amortisation net impairment losses cost sales selling general administration research development licences patents etc includes large number acquired licences patents knowhow agreements marketing rights either marketed use still development note acquisitions disposals gives details additions business combinations year book values largest individual items follows dolutegravir benlysta menveo bexsero men abcwy fluarixflulaval hiv assets acquired bms selzentry okairos technology platform others indefinite life brands comprise portfolio consumer healthcare products primarily acquired acquisitions sterling winthrop inc block drug company inc cns inc novartis consumer healthcare business together number pharmaceutical brands acquisition stiefel laboratories inc book values major brands follows voltaren otrivin fenistil theraflu panadol sensodyne lamisil breathe right stiefel trade name excedrin physiogel polident others brands considered indefinite life given strength durability brand level marketing support brands relatively similar stable profitable market sectors similar risk profiles size diversification market shares mean risk marketrelated factors causing reduction lives brands considered relatively low group aware material legal regulatory contractual competitive economic factors could limit useful lives accordingly amortised increase carrying value year primarily reflects impact exchange rate movements brand tested annually impairment amortised intangible assets tested indicators impairment arise testing applies fair value less costs disposal methodology generally using posttax cash flow forecasts terminal value calculation discount rate equal group posttax wacc adjusted appropriate country currency specific risks valuation methodology uses significant inputs based observable market data therefore valuation technique classified level fair value hierarchy main assumptions include future sales price volume growth product contribution future expenditure required maintain products marketability registration relevant jurisdictions exchange rates assumptions based past experience reviewed part managements budgeting strategic planning cycle changes market conditions sales erosion competition terminal growth rates applied nil managements estimates future longterm average growth rates relevant markets case valuations indicate sufficient headroom reasonably possible change key assumptions unlikely result impairment intangible assets gsk annual report notes financial statements continued investments associates joint ventures joint joint ventures associates total ventures associates total january exchange adjustments additions disposals transfer investments distributions received movements lossprofit tax recognised consolidated income statement comprehensive income recognised consolidated statement comprehensive income december group held one significant associate december innoviva inc december group owned million shares innoviva biopharmaceutical company listed nasdaq company partnered gsk development long acting beta agonist vilanterol currently receives royalty income sales products contain component namely relvarbreo ellipta anoro ellipta also retains economic interest future royalties paid gsk sales closed triple approved commercialised remaining economic interest royalties due theravance biopharma inc company spun innoviva group holds common stock investment innoviva market value million december million summarised balance sheet information based results information respect innoviva set december december noncurrent assets current assets current liabilities noncurrent liabilities net liabilities interest associated undertaking goodwill fair value adjustments carrying value december gsk annual report strategic report governance remuneration financial statements investor information investments january exchange adjustments additions fair value gain reclassification investment associate net fair value movements impairment losses transfer investments associates joint ventures disposals december investments comprise noncurrent equity investments availableforsale investments recorded fair value balance sheet date investments traded active market fair value determined reference relevant stock exchange quoted bid price investments fair value estimated management reference relevant available information including current market value similar instruments discounted cash flows underlying net assets investments included listed investments million million decrease carrying value year primarily due sale groups remaining stake aspen pharmacare holdings limited book value december million significant investments held december theravance biopharma inc group holds common stock investment fair value december million million investments include equity stakes companies gsk research collaborations provide access biotechnology developments potential interest interests companies arise business divestments disposal investments fair value movements reclassified equity income statement based average cost shares acquired different times impairment losses recorded recognised income statement year within operating income together amounts reclassified fair value reserve recognition impairments impairments initially result prolonged significant declines fair value equity investments acquisition cost subsequent declines fair value immediately taken income statement carrying value december investments impaired follows original cost cumulative impairments recognised income statement subsequent fair value increases carrying value december noncurrent assets amounts receivable insurance contracts pension schemes surplus receivables gsk annual report notes financial statements continued inventories raw materials consumables work progress finished goods trade receivables trade receivables net provision bad doubtful debts accrued income prepayments interest receivable employee loans advances receivables trade receivables included million million due associates joint ventures receivables included million nil due associates joint ventures bad doubtful debt provision january exchange adjustments charge year subsequent recoveries amounts provided utilised december cash cash equivalents cash bank hand shortterm deposits assets held sale property plant equipment goodwill intangibles inventory noncurrent assets disposal groups transferred assets held sale expected carrying amounts recovered principally disposal sale considered highly probable held lower carrying amount fair value less costs sell included within assets held sale assets written fair value less costs sell million million valuation methodology uses significant inputs based observable market data therefore valuation classified level fair value hierarchy gsk annual report strategic report governance remuneration financial statements investor information trade payables trade payables wages salaries social security viiv healthcare put option payables deferred income customer return rebate accruals accruals trade payables included million million due associates joint ventures customer return rebate accruals provided group point sale respect estimated rebates discounts allowances payable customers included million million respect us pharmaceuticals vaccines fully described group financial review accruals made time sale actual amounts paid based claims made time initial recognition sale amounts estimated may fully reflect final outcome subject change dependent upon amongst things types buying group product sales mix level accrual reviewed adjusted quarterly light historical experience actual rebates discounts allowances given returns made changes arrangements future events could cause assumptions accruals based change could affect future results group pfizers put option shareholding viiv healthcare recognised currently exercisable table shows indicative basis income statement balance sheet sensitivity pfizer put option reasonably possible changes key assumptions increasedecrease financial liability lossgain income statement cent appreciation us dollar cent depreciation us dollar cent appreciation euro cent depreciation euro explanation accounting viiv healthcare set pensions postemployment benefits restated restated pension postemployment costs uk pension schemes us pension schemes overseas pension schemes unfunded postretirement healthcare schemes analysed funded defined benefithybrid pension schemes unfunded defined benefit pension schemes unfunded postretirement healthcare schemes defined benefit schemes defined contribution pension schemes costs defined benefit pension postretirement healthcare schemes charged income statement follows cost sales selling general administration research development gsk annual report notes financial statements continued pensions postemployment benefits continued gsk entities operate pension arrangements cover groups material obligations provide pensions retired employees arrangements developed accordance local practices countries concerned pension benefits provided state schemes defined contribution schemes whereby retirement benefits determined value funds arising contributions paid respect employee defined benefit schemes whereby retirement benefits based employee pensionable remuneration length service pension costs defined benefit schemes accounting purposes calculated using projected unit method certain countries pension benefits provided unfunded basis administered trustee companies formal independent actuarial valuations groups main plans undertaken regularly normally least every three years actuarial movements year recognised statement comprehensive income discount rates derived aa rated corporate bond yields except countries deep market corporate bonds government bond yields used discount rates selected reflect term expected benefit payments projected inflation rate pension increases longterm predictions based yield gap longterm indexlinked fixed interest gilts uk mortality rates determined adjusting saps standard mortality tables reflect recent scheme experience rates projected reflect improvements life expectancy line cmi projections longterm rate improvement per year males females us mortality rates calculated using rp white collar table adjusted reflect recent experience rates projected using scale bbd allow future improvements life expectancy average life expectancy assumed individual age projected apply individual age follows uk us male female male female years years years years current projected assets funded schemes generally held separately administered trusts either specific assets proportion general fund insurance contracts assets invested different classes order maintain balance risk return investments diversified limit financial effect failure individual investment group reviewed investment strategy uk plans asset allocation uk plans adjusted approximately return seeking assets liability matching assets target asset allocation us plans also updated return seeking assets liability matching assets pension plans exposed risk arises estimated market value plans assets might decline investment returns might reduce estimated value plans liabilities might increase line agreed mix return seeking assets generate future returns liability matching assets better match future pension obligations group defined overall longterm investment strategy plans investments across broad range assets main market risks within asset hedging portfolio credit risk interest rates longterm inflation equities property bank counterparty risk plan liabilities series future cash flows relatively long duration ias r basis cash flows sensitive changes expected longterm inflation rate discount rate aa corporate bond yield curve increase longterm inflation corresponds increase liabilities increase discount rate corresponds decrease liabilities uk defined benefit pension schemes operated benefit former glaxo wellcome employees former smithkline beecham employees remain separate schemes closed new entrants subsequent uk employees entitled join defined contribution scheme us former glaxo wellcome smithkline beecham defined benefit schemes merged addition group operates number postretirement healthcare schemes principal one us group applied following financial assumptions assessing defined benefit liabilities uk us rest world pa pa pa pa pa pa pa pa pa rate increase future earnings discount rate expected pension increases na na na cash balance creditconversion rate na na na inflation rate gsk annual report strategic report governance remuneration financial statements investor information pensions postemployment benefits continued amounts recorded income statement statement comprehensive income three years ended december relation defined benefit pension postretirement healthcare schemes follows postretirement pensions benefits uk us rest world group group amounts charged operating profit current service cost past service cost net interest cost gains settlements expenses remeasurements recorded statement comprehensive income postretirement pensions benefits uk group restated us rest world restated group amounts charged operating profit current service cost past service costcredit net interest cost gains settlements expenses remeasurements recorded statement comprehensive income postretirement pensions benefits uk group restated us rest world restated group amounts charged operating profit current service cost past service costcredit net interest creditcost gains settlements expenses remeasurements recorded statement comprehensive income amounts included within past service costs include million million million augmentation costs million arising major restructuring programmes see note provisions gsk annual report notes financial statements continued pensions postemployment benefits continued summarised balance sheet presentation group defined benefit pension schemes postretirement benefits set table recognised noncurrent assets pension schemes surplus recognised pensions postemployment benefits pension schemes deficit postretirement benefits fair values assets liabilities uk us defined benefit pension schemes together aggregated data defined benefit pension schemes group follows uk us rest world group december equities listed unlisted property unlisted corporate bonds listed unlisted government bonds listed insurance contracts assets fair value assets present value scheme obligations net obligation included noncurrent assets included pensions postemployment benefits actual return plan assets indexlinked gilts held part uk repo programme included government bonds related loan included within assets value million million million uk group restated us rest world restated december equities listed unlisted property unlisted corporate bonds listed unlisted government bonds listed insurance contracts assets fair value assets present value scheme obligations net obligation included noncurrent assets included pensions postemployment benefits actual return plan assets gsk annual report strategic report governance remuneration financial statements investor information pensions postemployment benefits continued uk group restated us rest world restated december equities listed unlisted property unlisted corporate bonds listed unlisted government bonds listed insurance contracts assets fair value assets present value scheme obligations net obligation included noncurrent assets included pensions postemployment benefits actual return plan assets postretirement pensions benefits uk group restated us rest world restated group movements fair values assets assets january exchange adjustments interest income expenses settlements curtailments remeasurement employer contributions scheme participants contributions benefits paid assets december exchange adjustments additions business combinations interest income expenses settlements curtailments remeasurement employer contributions scheme participants contributions benefits paid assets december exchange adjustments interest income expenses settlements curtailments remeasurement employer contributions scheme participants contributions benefits paid assets december addition assets assets held uk defined contribution plans amounting million december million million previously included figures prior year figures restated reflect change group made special funding contributions uk pension schemes totalling million million million nil million nil us scheme gsk reached agreement trustees uk pension schemes make additional contributions eliminate pension deficit identified december actuarial funding valuation based funding agreements following valuation additional contributions eliminate pension deficit expected million contributions based government bond yield curve approach selecting discount rate rate chosen included allowance expected investment returns reflected asset mix schemes employer contributions including special funding contributions estimated approximately million respect defined benefit pension schemes million respect postretirement benefits gsk annual report notes financial statements continued pensions postemployment benefits continued postretirement pensions benefits uk group restated us rest world restated group movements defined benefit obligations obligations january exchange adjustments service cost past service cost interest cost settlements curtailments movements remeasurement scheme participants contributions benefits paid obligations december exchange adjustments additions business combinations service cost past service cost interest cost settlements curtailments remeasurement scheme participants contributions benefits paid obligations december exchange adjustments service cost past service cost interest cost settlements curtailments remeasurement scheme participants contributions benefits paid obligations december addition obligations obligations uk defined contribution plans amounting million december million million previously included figures prior year figures restated reflect change defined benefit pension obligation analysed follows restated restated funded unfunded liability us postretirement healthcare scheme assessed using assumptions us pension scheme together assumption future medical inflation grading thereafter december us postretirement healthcare scheme obligation million million million post retirement benefits unfunded gsk annual report strategic report governance remuneration financial statements investor information pensions postemployment benefits continued movement net defined benefit liability follows restated restated january exchange adjustments additions business combinations service cost past service cost interest costincome settlements curtailments remeasurements return plan assets excluding amounts included interest gainloss change demographic assumptions lossgain change financial assumptions experience lossesgains employer contributions expensesother movements december remeasurements included within postretirement benefits detailed gain change demographic assumptions lossgain change financial assumptions experience gainslosses gsk annual report notes financial statements continued pensions postemployment benefits continued defined benefit pension obligation analysed membership category follows active retired deferred postretirement benefit obligation analysed membership category follows active retired deferred weighted average duration defined benefit obligation follows years years years pension benefits postretirement benefits sensitivity analysis effect changes assumptions used benefit obligations annual defined benefit pension post retirement costs decrease discount rate would following approximate effect increase annual pension cost decrease annual postretirement benefits cost increase pension obligation increase postretirement benefits obligation one year increase life expectancy would following approximate effect increase annual pension cost increase annual postretirement benefits cost increase pension obligation increase postretirement benefits obligation increase rate future healthcare inflation would following approximate effect increase annual postretirement benefits cost increase postretirement benefits obligation increase inflation would following approximate effect increase annual pension cost increase pension obligation gsk annual report strategic report governance remuneration financial statements investor information provisions legal major employee restructuring related disputes programmes provisions provisions total january exchange adjustments charge year reversed unused unwinding discount utilised reclassifications movements transfer pension obligations december settled within one year settled one year december legal disputes major restructuring programmes group involved substantial number legal group initiated major change restructuring disputes including notification possible claims set programme focused opportunities simplify supply chain note legal proceedings provisions legal disputes processes build groups capabilities manufacturing include amounts relating product liability antitrust government rd restructure european pharmaceuticals business investigations principally relating sfo related investigation pharmaceuticals restructuring programme announced contract terminations self insurance environmental cleanup october focused rescaling commercial charge year million net reversals operations global support functions certain rdmanufacturing estimated insurance recoveries primarily related provisions operations across pharmaceuticals addition integration product liability cases regarding paxil products restructuring programme initiated following commercial disputes various government investigations completion novartis transaction restructuring integration programmes reported together one combined discount provisions increased million major restructuring programme decreased million due higher discount rates compared discount calculated using provisions staff severance payments made management riskadjusted projected cash flows riskfree rates return made formal decision eliminate certain positions communicated groups employees affected respect product liability claims related certain products appropriate consultation procedures completed appropriate sufficient history claims made settlements enable provision made staff severance payments made management make reliable estimate provision required immediately cover unasserted claims ultimate liability matters may vary amounts provided dependent upon outcome pension augmentations arising staff redundancies litigation proceedings investigations possible settlement million million charged negotiations year transferred pension obligations provision shown note pensions postemployment benefits nature groups business number asset writedowns recognised impairments matters may subject negotiation litigation property plant equipment note property plant many years litigation proceedings including various appeal equipment majority amounts provided expected procedures often take many years reach resolution utilised next two years outofcourt settlement discussions also often protracted employee related provisions group potential settlement discussions number employee related provisions include obligations certain medical disputes amounts provided based benefits disabled employees spouses us current assessment progress disputes december provision benefits amounted estimates million amount provided december million million employee benefits reflect settled within one year december variety provisions severance costs jubilee awards expected nil nil provision made legal longservice benefits disputes reimbursed third party insurers discussion legal issues see note legal proceedings provisions included provisions insurance provisions million million onerous property lease provisions million million number provisions including vehicle insurance regulatory matters gsk annual report notes financial statements continued noncurrent liabilities accruals deferred income consumer healthcare put option liability payables consumer healthcare put option liability relates ability novartis put shares consumer healthcare joint venture gsk certain points future commencing liability recorded present value estimated redemption value applying discount rate expected redemption amount calculated using average relevant public company multiples approach premium discount based forecast revenue earnings consumer healthcare joint venture forms part gsks consumer healthcare segment remeasurement charge year million million see note operating incomeexpense table shows indicative basis income statement balance sheet sensitivity reasonably possible changes key assumptions increasedecrease financial liability lossgain income statement increase sales forecasts sales multiple applied decrease sales forecasts sales multiple applied cent appreciation us dollar cent depreciation us dollar cent appreciation euro cent depreciation euro net debt listing exchange current assets liquid investments cash cash equivalents shortterm borrowings commercial paper bank loans overdrafts obligations finance leases us us medium term note new york stock exchange us us medium term note new york stock exchange european medium term note london stock exchange longterm borrowings us us medium term note new york stock exchange european medium term note london stock exchange us us medium term note new york stock exchange european medium term note london stock exchange us us medium term note new york stock exchange us us medium term note new york stock exchange european medium term note london stock exchange european medium term note london stock exchange european medium term note london stock exchange european medium term note london stock exchange us us medium term note london stock exchange us us medium term note new york stock exchange european medium term note london stock exchange european medium term note london stock exchange us us medium term note new york stock exchange european medium term note london stock exchange obligations finance leases net debt gsk annual report strategic report governance remuneration financial statements investor information net debt continued current assets liquid investments classified availableforsale investments december included us treasury notes government bonds effective interest rate liquid investments december approximately approximately liquid investment balances december earning interest floating rates amount million million liquid investment balances december earning interest fixed rates amount nil million effective interest rate cash cash equivalents december approximately approximately cash cash equivalents december earning interest floating fixed rates amount million million respectively million nil gsks policy regarding credit quality cash cash equivalents referred note financial instruments related disclosures shortterm borrowings gsk billion billion us commercial paper programme billion billion issue december issuances gsk also billion five year committed facilities billion billion day committed facilities fiveyear committed facilities agreed september extended one year september day committed facilities agreed september liquid investments cash cash equivalents shown table weighted average interest rate commercial paper borrowings december issuances weighted average interest rate current bank loans overdrafts december average effective preswap interest rate notes classified short term december longterm borrowings yearend gsk longterm borrowings billion billion billion billion falls due five years average effective preswap interest rate notes issue december approximately approximately longterm borrowings repayable five years carry interest effective rates repayment dates range pledged assets group held pledged investments us treasury notes par value million million million million security irrevocable letters credit issued groups behalf respect groups selfinsurance activity provisions respect selfinsurance included within provisions legal disputes discussed note provisions addition million million assets included note noncurrent assets form part net debt pledged collateral future rental payments operating lease arrangements entered human genome sciences inc prior acquisition group finance lease obligations rental payments due within one year rental payments due one two years rental payments due two three years rental payments due three four years rental payments due four five years rental payments due five years total future rental payments future finance charges total finance lease obligations contingent liabilities december contingent liabilities comprising guarantees discounted bills items arising normal course business amounted million million december million nil financial assets pledged collateral contingent liabilities provision made outcome tax legal disputes probable group suffer outflow funds possible make reliable estimate outflow december disputes provision made possible make reliable estimate potential outflow funds might required settle disputes possibility outflow remote descriptions significant tax legal disputes group party set note taxation note legal proceedings gsk annual report notes financial statements continued share capital share premium account share ordinary shares p premium number share capital authorised december december december share capital issued fully paid january issued employee share schemes december issued employee share schemes december issued employee share schemes ordinary shares acquired esop trusts december december december number shares issuable employee share schemes number unissued shares option december issued share capital shares held esop trusts shares held treasury shares shares free issue issued shares fully paid nominal carrying market values shares held esop trusts disclosed note employee share schemes gsk annual report strategic report governance remuneration financial statements investor information movements equity retained earnings reserves amounted million december million million million million million relates joint ventures associated undertakings cumulative translation exchange equity follows net translation exchange included non total retained fair value controlling translation earnings reserve interests exchange january exchange movements overseas net assets reclassification exchange liquidation disposal overseas subsidiaries december exchange movements overseas net assets december exchange movements overseas net assets december analysis comprehensive income equity category follows non retained controlling earnings reserves interests total items may subsequently reclassified income statement exchange movements overseas net assets net investment hedges fair value movements availableforsale investments reclassification fair value movements availableforsale investments deferred tax reclassification fair value movements availableforsale investments reclassification cash flow hedges income statement fair value movements cash flow hedges deferred tax fair value movements cash flow hedges items reclassified income statement exchange movements overseas net assets noncontrolling interests remeasurement gains defined benefit plans tax remeasurement gains defined benefit plans comprehensive income year non retained controlling earnings reserves interests total items may subsequently reclassified income statement exchange movements overseas net assets net investment hedges fair value movements availableforsale investments deferred tax fair value movements availableforsale investments reclassification fair value movements availableforsale investments deferred tax reclassification fair value movements availableforsale investments reclassification cash flow hedges income statement fair value movements cash flow hedges share comprehensive income associates joint ventures items reclassified income statement exchange movements overseas net assets noncontrolling interests remeasurement gains defined benefit plans tax remeasurement gains defined benefit plans comprehensive expenseincome year gsk annual report notes financial statements continued movements equity continued non retained controlling earnings reserves interests total items may subsequently reclassified income statement exchange movements overseas net assets net investment hedges reclassification exchange liquidation disposal overseas subsidiaries deferred tax exchange movements fair value movements availableforsale investments deferred tax fair value movements availableforsale investments reclassification fair value movements availableforsale investments deferred tax reclassification fair value movements availableforsale investments reclassification cash flow hedges income statement fair value movements cash flow hedges deferred tax fair value movements cash flow hedges share comprehensive income associates joint ventures items reclassified income statement exchange movements overseas net assets noncontrolling interests remeasurement losses defined benefit plans deferred tax remeasurement losses defined benefit plans comprehensive expenseincome year analysis reserves follows esop trust fair value cash flow shares reserve hedge reserve reserves total january transferred income expense year disposals net fair value movement year ordinary shares acquired esop trusts writedown shares held esop trusts forward contract noncontrolling interest december transferred income expense year disposals transferred income expense year impairments net fair value movement year ordinary shares acquired esop trusts writedown shares held esop trusts december transferred income expense year disposals transferred income expense year impairments net fair value movement year ordinary shares acquired esop trusts writedown shares held esop trusts december reserves include various nondistributable merger premerger reserves amounting million december million million reserves also include capital redemption reserve created result share buyback programme amounting million december million million gsk annual report strategic report governance remuneration financial statements investor information related party transactions december gsk owned million shares innoviva inc biopharmaceutical company listed nasdaq gsk began recognising innoviva associate september royalties due gsk innoviva year million million september december december balance payable gsk innoviva million december gsk held interest japan vaccine co ltd jvc subsidiary glaxosmithkline kk joint venture daiichi sankyo co ltd primarily responsible development marketing certain prophylactic vaccines japan gsk sold million million vaccine products joint venture december trading balance due gsk jvc million balance payable gsk jvc nil loans million jvc million medicxi ventures lp million index ventures life vi jersey lp remained due gsk december aggregate compensation directors cet given note employee costs adjustments reconciling profit tax operating cash flows profit tax tax profits share tax profits associates joint ventures finance expense net finance income depreciation amortisation intangible assets impairment assets written profit sale businesses profit sale intangible assets profit sale investments associates profit sale equity investments changes working capital decreaseincrease inventories increasedecrease trade receivables increase trade payables decreaseincrease receivables contingent consideration paid see note noncash increase contingent consideration liabilities increase payables decreaseincrease pension provisions sharebased incentive plans fair value adjustments cash generated operations gsk annual report notes financial statements continued reconciliation net cash flow movement net debt net debt beginning year increasedecrease cash bank overdrafts decreaseincrease liquid investments net increase longterm loans net increase inrepayment shortterm loans net repayment obligations finance leases exchange adjustments noncash movements movement net debt net debt end year january reclass december exchange ifications acquisitions cash flow analysis changes net debt liquid investments cash cash equivalents overdrafts debt due within one year commercial paper european us medium term notes debt due one year european us medium term notes net debt information significant changes net debt see note net debt gsk annual report strategic report governance remuneration financial statements investor information acquisitions disposals details acquisition disposal significant subsidiaries associates joint ventures businesses given acquisitions gsk completed two small business acquisitions cash consideration million paid year acquire hiv rd preclinical discovery stage portfolio bristol myers squibb consideration contingent commercial milestones future sales performance may due initial estimate million recognised contingent consideration intangible assets acquired valued million goodwill million recognised gsk formed galvani bioelectronics limited year acquired intangible assets million cash cash equivalents million verily life sciences llc return shareholding galvani bioelectronics fair value shareholding million gsk also recognised credit million noncontrolling interests representing verilys share net assets contributed business disposals gsk also made number small business disposals period net cash consideration million addition deferred consideration receivable million recognised cash flows business business acquisitions disposals cash consideration paidreceived purchase adjustments cash cash equivalents acquired cash inflow addition gsk made cash investments million associates joint ventures acquisitions novartis consumer healthcare vaccines businesses threepart interconditional transaction novartis ag involving consumer healthcare vaccines oncology businesses completed march gsk novartis contributed respective consumer healthcare businesses consumer healthcare joint venture noncash transaction gsk equity interest majority control joint venture addition gsk acquired novartis global vaccines business excluding influenza vaccines initial cash consideration billion billion contingent consideration representing subsequent potential milestone payments billion billion arising achievement specified development targets ongoing royalties based future sales performance certain products total amount payable unlimited first milestone million million paid march business acquisitions addition gsk completed one smaller vaccines business acquisition cash consideration million net cash acquired fair value existing investments million represented goodwill million intangible assets million less net liabilities million gsk annual report notes financial statements continued acquisitions disposals continued fair values assets acquired business combinations including goodwill set table novartis consumer novartis healthcare vaccines business business net assets acquired intangible assets property plant equipment inventory trade receivables assets including cash cash equivalents trade payables deferred tax liabilities liabilities noncontrolling interest goodwill consideration settled shares gsk consumer healthcare holdings cash consideration paid purchase adjustments fair value equity investment disposal contingent consideration deferred tax contingent consideration loss settlement preexisting relationships total consideration noncontrolling interest consumer healthcare joint venture calculated applying full goodwill method represents novartis share net assets contributed joint venture together attributable goodwill goodwill businesses acquired represents potential synergies arising combining acquired businesses gsks existing businesses together value workforce acquired majority goodwill recognised expected deductible tax purposes total transaction costs recognised acquisitions novartis amounted million march december turnover million arising novartis consumer healthcare vaccines businesses included group turnover businesses acquired beginning year estimated group turnover would approximately million higher businesses integrated groups existing activities practical identify impact group profit period disposals oncology gsk divested marketed oncology business related rd activities rights akt inhibitor also granted commercialisation partner rights future oncology products novartis consideration billion million purchase adjustments business disposals gsk also made number small business disposals period net cash consideration million profit disposal businesses determined follows oncology cash consideration including currency forwards purchase adjustments net assets sold goodwill intangible assets property plant equipment inventory cash net assets loss currency forwards booked disposal costs profit disposal gsk annual report strategic report governance remuneration financial statements investor information acquisitions disposals continued investments associates joint ventures march gsk sold half shareholding aspen representing issued share capital company million cash result sale group longer considered ability exert significant influence aspen groups remaining investment transferred investments associates investments cash consideration net book value shares reclassification exchange comprehensive income transaction fees items profit disposal business business associates acquisitions disposals jv disposals total cash flows cash consideration paidreceived purchase adjustments cash cash equivalents acquireddivested deferred cash proceeds contingent consideration paid transaction costs cash outflowinflow addition gsk made cash investments million associates joint ventures acquisitions acquisitions acquisition integration costs million arising proposed threepart interconditional transaction novartis ag expensed million paid cash year disposals year million received deferred consideration sale anticoagulant business completed million disposal associate gsk also made cash investments million associates business acquisitions associates disposals joint ventures total cash flows cash consideration paid transaction costs paid purchase businesses associates net cash proceeds disposals gsk annual report notes financial statements continued contingent consideration liabilities consideration certain acquisitions includes amounts contingent future events development milestones sales performance group provided fair value contingent consideration follows shionogi viiv novartis healthcare vaccines total january remeasurement goodwill remeasurement income statement cash payments operating cash flows cash payments purchases businesses movements december additions business combinations remeasurement income statement cash payments operating cash flows cash payments purchases businesses movements december additions business combinations remeasurement income statement cash payments operating cash flows cash payments purchases businesses movements december additions year represented recognition preferential dividends payable shionogi million contingent consideration liability acquisition hiv business bms million contingent consideration payable december million million expected paid within one year consideration payable acquisition shionogiviiv healthcare joint venture novartis vaccines business expected paid number years result total estimated liabilities discounted present values shown shionogi viiv healthcare contingent consideration liability discounted novartis vaccines contingent consideration liability discounted partly partly shionogiviiv healthcare contingent consideration liability calculated based forecast sales performance specified products principally dolutegravir life products table shows indicative basis income statement balance sheet sensitivity reasonably possible changes key inputs valuations contingent consideration liabilities shionogi novartis viiv healthcare vaccines increasedecrease financial liability lossgain income statement increase sales forecasts decrease sales forecasts increase discount rate decrease discount rate increase probability milestone success decrease probability milestone success cent appreciation us dollar cent depreciation us dollar cent appreciation euro cent depreciation euro explanation accounting viiv healthcare set gsk annual report strategic report governance remuneration financial statements investor information noncontrolling interests group two subgroups material noncontrolling interests viiv healthcare limited subsidiaries gsk consumer healthcare holdings limited subsidiaries summarised financial information respect viiv healthcare group gsk consumer healthcare joint venture set viiv healthcare turnover loss taxation comprehensive income total comprehensive expense noncurrent assets current assets total assets current liabilities noncurrent liabilities total liabilities net liabilities net cash inflow operating activities net cash outflow investing activities net cash outflow financing activities increase cash bank overdrafts year financial information relates viiv healthcare group standalone basis impact grouprelated adjustments primarily related recognition preferential dividends loss taxation million loss taxation million loss taxation million stated charging preferential dividends payable gsk shionogi pfizer charge million million million remeasurement contingent consideration payable acquisition former shionogiviiv healthcare joint venture consideration expected paid number years following amounts attributable viiv healthcare group included gsks consolidated statement comprehensive income consolidated statement changes equity consolidated balance sheet total comprehensive expense year attributable noncontrolling interests dividends paid noncontrolling interests noncontrolling interests consolidated balance sheet gsk annual report notes financial statements continued noncontrolling interests continued consumer healthcare joint venture turnover profitloss taxation comprehensive income total comprehensive income noncurrent assets current assets total assets current liabilities noncurrent liabilities total liabilities net assets net cash inflow operating activities net cash outflow investing activities net cash outflow financing activities decrease cash bank overdrafts year financial information relates consumer healthcare joint venture standalone basis since formation march impact grouprelated adjustments major restructuring charges following amounts attributable consumer healthcare joint venture included gsks consolidated statement comprehensive income consolidated statement changes equity consolidated balance sheet total comprehensive income year attributable noncontrolling interests noncontrolling interests consolidated balance sheet gsk annual report strategic report governance remuneration financial statements investor information commitments contractual obligations commitments contracted provided financial statements intangible assets property plant equipment investments purchase commitments pensions commitments interest loans finance lease charges commitments related intangible assets include milestone payments dependent successful clinical development meeting specified sales targets represent maximum would paid milestones however unlikely achieved amounts riskadjusted discounted number commitments made licensing agreements including arrangements janssen sciences ireland uc miltenyi biotec gmbh new arrangements offset reduced commitments due prior year transactions including amendments agreement oncomed pharmaceuticals inc five prime therapeutics inc gsk reached agreement trustees uk pension schemes make additional contributions eliminate pension deficit identified december actuarial funding valuation payment million due subsequent year including table includes commitment excludes normal ongoing annual funding requirement uk approximately million group also commitments principally relate revenue payments made licences alliances commitments respect future interest payable loans disclosed taking account effect interest rate swaps commitments noncancellable operating leases disclosed million million provided commitments groups balance sheet commitments noncancellable operating leases rental payments due within one year rental payments due one two years rental payments due two three years rental payments due three four years rental payments due four five years rental payments due five years total commitments noncancellable operating leases gsk annual report notes financial statements continued financial instruments related disclosures gsk uses variety financial instruments finance operations market risk derivative financial instruments manage market risks interest rate risk management operations derivatives principally comprising interest gsks objective minimise effective net interest cost rate swaps foreign exchange forward contracts swaps used balance mix debt fixed floating interest rates swap borrowings liquid assets currencies required time policy interest rate risk management limits amount group purposes manage exposure financial risks floating interest payments prescribed percentage changes foreign exchange rates interest rates operating profit gsk hold issue derivatives speculative purposes foreign exchange risk management treasury policies specifically prohibit activity foreign currency transaction exposures arising external trade transactions financial instruments undertaken manage flows normally hedged foreign currency transaction risks arising underlying business activities exposures arising internal trade flows selectively hedged capital management groups objective minimise exposure overseas operating gsks financial strategy supports groups strategic priorities subsidiaries transaction risk matching local currency income regularly reviewed board gsk manages capital local currency costs possible gsks internal trading structure group appropriate mix debt equity transactions matched centrally intercompany payment terms managed reduce foreign currency risk foreign currency cash capital structure group consists net debt flows hedged selectively including hedges foreign billion see note net debt shareholders equity exchange risk arising acquisitions disposals assets billion see consolidated statement changes equity possible gsk manages cash surpluses borrowing total capital including provided noncontrolling requirements subsidiary companies centrally using forward interests billion contracts hedge future repayments back originating longterm credit rating standard poors stable currency outlook moodys investor services moodys order reduce foreign currency translation exposure group negative outlook groups shortterm credit ratings seeks denominate borrowings currencies principal p standard poors moodys respectively assets cash flows primarily denominated us liquidity risk management dollars euros sterling borrowings swapped gsks policy borrow centrally order meet anticipated currencies required funding requirements strategy diversify liquidity sources borrowings denominated swapped foreign currencies using range facilities maintain broad access financial match investments overseas group assets may treated markets hedge relevant assets forward contracts major december gsk billion borrowings currencies also used reduce exposure groups repayable within one year held billion cash cash investment overseas assets see net investment hedges equivalents liquid investments billion held section note details centrally gsk access shortterm finance billion billion us commercial paper programme billion billion issue december issuances gsk also billion five year committed facilities billion billion day committed facilities fiveyear committed facilities agreed september extended one year september day committed facilities agreed september facilities undrawn december gsk considers level committed facilities adequate given current liquidity requirements gsk billion european medium term note programme december billion notes issue programme group also billion billion notes issue december us shelf registration gsk currently process renewing us shelf registration statement order maintain access us debt markets gsks borrowings mature dates put options owned minority interest partners viiv healthcare consumer healthcare jv business exercisable immediately respectively reviewing liquidity requirements gsk considers sufficient financing options available put options exercised gsk annual report strategic report governance remuneration financial statements investor information financial instruments related disclosures continued credit risk december million cash categorised held group considers maximum credit risk december unrated subinvestment grade rated counterparties lower million december million bbbbaa million cash transit total groups financial assets exception remaining exposure concentrated overseas banks used local investments comprising equity investments bear cash management investment purposes including million equity risk rather credit risk see details nigeria held united bank africa zenith bank stanbic groups total financial assets december gsks ibtc bank million btv austria million greatest concentration credit risk billion citibank islandsbanki iceland million produbanco ecuador aa billion citibank aa million bank balances deposits held bbb treasuryrelated credit risk baa rated counterparties million held bbbbaa gsk sets global counterparty limits gsks banking rated counterparties including balances deposits million investment counterparties based longterm credit ratings state bank india million hdfc bank india moodys standard poors usage limits monitored banks used either local cash management local daily investment purposes gsk actively manages exposure credit risk reducing surplus cash balances wherever possible part gsks strategy regionalise cash management concentrate cash centrally much possible table sets credit exposure counterparties rating liquid investments cash cash equivalents derivatives gross asset position derivative contract considered purpose table although isda agreements amount risk net position counterparty table e sets groups financial assets liabilities offset basis bbba aaaaaa aaaa aa bbbbaa unrated total bank balances deposits us treasury treasury repo money market funds liquidity funds government securities rd party financial derivatives total bbba aaaaaa aaaa aa bbbbaa unrated total bank balances deposits us treasury treasury repo money market funds liquidity funds government securities rd party financial derivatives total credit ratings assigned standard poors moodys respectively opinions two rating agencies differ gsk assigns lower rating two counterparty local rating agency fitch data source available ratings converted global ratings equivalent standard poors moodys using published conversion tables gsk annual report notes financial statements continued financial instruments related disclosures continued gsks centrally managed cash reserves amounted billion following methods assumptions used estimate december available within three months includes fair values billion centrally managed cash held viiv healthcare cash cash equivalents approximates carrying amount owned subsidiary group invested centrally managed liquid assets bank deposits aaaaaa rated us treasury treasury liquid investments based quoted market prices calculated repo money market funds aaaaaa rated liquidity funds based observable inputs case marketable securities based principal amounts case nonmarketable wholesale retail credit risk securities short repricing periods outside us customer accounts investments equity investments traded active market groups trade receivables balance determined reference relevant stock exchange quoted bid us line pharmaceutical companies group price equity investments determined reference sells products small number wholesalers addition current market value similar instruments reference hospitals pharmacies physicians groups sales discounted cash flows underlying net assets three largest wholesalers amounted approximately shortterm loans overdrafts commercial paper sales us pharmaceuticals vaccines businesses approximates carrying amount short maturity december group trade receivables due instruments three wholesalers totalling million million group exposed concentration credit risk longterm loans based quoted market prices case respect wholesalers one european us medium term notes fixed rate encounters financial difficulty could materially adversely borrowings level fair value measurement approximates affect groups financial results carrying amount case floating rate bank loans loans groups credit risk monitoring activities relating wholesalers include review quarterly financial information contingent consideration business acquisitions based standard poors credit ratings development gsk internal present values expected future cash flows risk ratings establishment periodic review credit limits interest rate swaps foreign exchange forward contracts swaps however group believes credit risk provision options based present value contractual cash required excess normal provision bad doubtful debts flows option valuation models using market sourced data see note trade receivables exchange rates interest rates balance sheet date fair value financial assets liabilities receivables payables including put options approximates table presents carrying amounts fair carrying amount values groups financial assets liabilities december december companyowned life insurance policies based cash surrender value fair values financial assets liabilities included price would received sell asset paid transfer lease obligations approximates carrying amount liability orderly transaction market participants fair value investments gsk shares measurement date december employee share ownership plan esop trusts held gsk shares carrying value million million fair value million million based quoted market price shares held esop trusts satisfy future exercises options awards employee incentive schemes carrying value lower cost expected proceeds shares recognised deduction reserves december gsk held treasury shares cost million million deducted retained earnings gsk annual report strategic report governance remuneration financial statements investor information financial instruments related disclosures continued carrying fair carrying fair value value value value notes availableforsale investments liquid investments government bonds investments loans receivables cash cash equivalents e trade receivables certain noncurrent assets scope ias b financial assets fair value profit loss noncurrent assets scope ias b derivatives designated fair value profit loss e derivatives classified held trading ias e total financial assets financial liabilities measured amortised cost borrowings excluding obligations finance leases bonds designated hedging relationship bonds bank loans overdrafts e commercial paper total borrowings excluding obligations finance leases f obligations finance leases total borrowings trade payables provisions certain noncurrent liabilities scope ias c financial liabilities fair value profit loss contingent consideration liabilities c derivatives designated fair value profit loss e derivatives classified held trading ias e total financial liabilities net financial assets financial liabilities valuation methodology used measure fair value table described categorised trade receivables noncurrent assets trade payables provisions noncurrent liabilities contingent consideration liabilities reconciled relevant notes pages gsk annual report notes financial statements continued financial instruments related disclosures continued financial instruments held fair value following tables categorise groups financial assets liabilities held fair value valuation methodology applied determining fair value possible quoted prices active markets used level prices available asset liability classified level provided significant inputs valuation model used based observable market data one significant inputs valuation model based observable market data instrument classified level investments classified level tables comprise equity investments unlisted entities group entered research collaborations also investments emerging life science companies level level level total december financial assets fair value availableforsale financial assets liquid investments investments financial assets fair value profit loss noncurrent assets derivatives designated fair value profit loss derivatives classified held trading ias financial liabilities fair value financial liabilities fair value profit loss contingent consideration liabilities derivatives designated fair value profit loss derivatives classified held trading ias level level level total december financial assets fair value availableforsale financial assets liquid investments investments financial assets fair value profit loss noncurrent assets derivatives designated fair value profit loss derivatives classified held trading ias financial liabilities fair value financial liabilities fair value profit loss contingent consideration liabilities derivatives designated fair value profit loss derivatives classified held trading ias movements year financial instruments measured using level valuation methods presented january net losses recognised income statement net gains recognised comprehensive income contingent consideration liabilities businesses acquired year payment contingent consideration liabilities additions disposals transfers level exchange december gsk annual report strategic report governance remuneration financial statements investor information financial instruments related disclosures continued net losses million million attributable level financial instruments recognised income statement attributable financial instruments held end year net losses reported operating income million million arose remeasurement contingent consideration payable acquisition former shionogiviiv healthcare joint venture million million arose remeasurement contingent consideration payable acquisition novartis vaccines business net gains million million attributable level equity investments reported comprehensive income fair value movements availableforsale investments included net gains million net losses million respect equity investments held end year financial liabilities measured using level valuation methods december included million million respect contingent consideration payable acquisition former shionogiviiv healthcare joint venture consideration expected paid number years vary line future performance specified products movements certain foreign currencies also included million million respect contingent consideration acquisition novartis vaccines business consideration expected paid number years vary line future performance specified products achievement certain milestone targets movements certain foreign currencies sensitivity analysis balances provided note contingent consideration liabilities b trade receivables noncurrent assets scope ias following table reconciles financial instruments within trade receivables noncurrent assets fall within scope ias relevant balance sheet amounts financial assets predominantly noninterest earning financial instruments within noncurrent assets balance include companyowned life insurance policies nonfinancial instruments include tax receivables pension surplus balances prepayments outside scope ias fair value non fair value non loans financial financial loans financial financial profit loss receivables instruments instruments total profit loss receivables instruments instruments total trade receivables note noncurrent assets note following table shows ageing financial assets past due provision bad doubtful debts made past due days past due days past due days past due days past due days gsk annual report notes financial statements continued financial instruments related disclosures continued c trade payables provisions noncurrent liabilities contingent consideration liabilities scope ias following table reconciles financial instruments within trade payables provisions noncurrent liabilities contingent consideration liabilities fall within scope ias relevant balance sheet amounts financial liabilities predominantly noninterest bearing accrued wages salaries included within financial liabilities nonfinancial instruments includes payments account tax social security payables provisions arise contractual obligations deliver cash another financial asset outside scope ias fair value fair value financial nonfinancial financial nonfinancial profit loss liabilities instruments instruments total profit loss liabilities instruments instruments total trade payables note provisions note noncurrent liabilities note contingent consideration liabilities note derivative financial instruments hedging programmes following table sets fair values derivatives held gsk derivatives maturity less one year fair value fair value assets liabilities assets liabilities net investment hedges foreign exchange contracts principal amount million million cash flow hedges foreign exchange contracts principal amount million million derivatives designated fair value profit loss foreign exchange contracts principal amount million million embedded derivatives derivatives classified held trading ias total derivative instruments foreign exchange contracts classified held trading ias principal amount foreign exchange contracts absolute total outstanding positions balance sheet date groups foreign exchange contracts periods months less december group held outstanding foreign exchange contracts net asset fair value million million asset less million liability december fair value million net asset million asset less million liability overall decrease net asset fair value due weakening sterling major currencies particular impacting hedging euro us dollar denominated intercompany loan balances designated accounting hedges fair value movements taken income statement period offset exchange gains losses related intercompany loan balances gsk annual report strategic report governance remuneration financial statements investor information financial instruments related disclosures continued fair value hedges december group designated fair value hedges net investment hedges year certain foreign exchange contracts designated net investment hedges respect foreign currency translation risk arising consolidation groups net investment european euro foreign operations shown table hedges relating japanese yen foreign operations closed year carrying value bonds includes million million designated hedging instruments net investment hedges cash flow hedges group entered forward foreign exchange contracts designated cash flow hedges hedging foreign exchange exposure arising euro us dollar denominated coupon payments relating groups european us medium term notes number highly probable forecast transactions denominated us dollars addition group carries balance reserves arose prehedging fluctuations longterm interest rates pricing bonds issued prior years balance reclassified finance costs life bonds e offsetting financial assets liabilities following tables set financial assets financial liabilities subject offsetting enforceable master netting arrangements similar agreements amounts set financial assets liabilities groups balance sheet set trade receivables trade payables derivative financial assets derivative financial liabilities amounts offset balance sheet could offset certain circumstances also set net financial gross gross financial assets related financial liabilities liabilities amounts assets assets per balance set liabilities set sheet balance sheet net december trade receivables derivative financial assets cash cash equivalents trade payables derivative financial liabilities bank loans overdrafts net financial gross gross financial assets related financial liabilities liabilities amounts assets assets per balance set liabilities set sheet balance sheet net december trade receivables derivative financial assets cash cash equivalents trade payables derivative financial liabilities bank loans overdrafts gross financial assets liabilities set balance sheet primarily relate cash pooling arrangements banks amounts meet criteria offsetting balance sheet could settled net certain circumstances principally relate derivative transactions isda international swaps derivatives association agreements party option settle amounts net basis event default party gsk annual report notes financial statements continued financial instruments related disclosures continued f debt interest rate repricing table following table sets exposure group interest rates debt including commercial paper maturity analysis fixed rate debt stated contractual maturity floating rate debt interest rate repricing dates purpose table debt defined classes borrowings obligations finance leases total debt total floating fixed rate debt less one year one two years two three years three four years four five years five ten years greater ten years total original issuance profile fixed rate interest floating rate interest total interest bearing noninterest bearing g sensitivity analysis foreign exchange interest rate sensitivity analysis prepared assumption amount net debt ratio fixed floating interest rates debt derivatives portfolio proportion financial instruments foreign currencies constant basis hedge designations december financial instruments affected market risk include cash cash equivalents borrowings trade receivables payables derivative financial instruments following analyses intended illustrate sensitivity financial instruments changes foreign exchange interest rates foreign exchange sensitivity foreign currency exposures arise translation financial assets liabilities functional currency entity holds cash cash equivalents bank loans overdrafts intercompany loans deposits receivables payables trade receivables payables derivative financial instruments hedging legal provisions activities arising acquisitions disposals assets group primarily exposed foreign exchange risk relation sterling movements us dollar euro japanese yen based groups net financial assets liabilities december weakening sterling currencies variables held constant illustrated table table excludes financial instruments expose group foreign exchange risk risk fully hedged another financial instrument increasedecrease increasedecrease income income income statement impact nonfunctional currency foreign exchange exposures cent appreciation us dollar cent appreciation euro yen appreciation yen equivalent depreciation currencies would cause following increasedecrease income million million million million million million us dollar euro yen exchange rates respectively gsk annual report strategic report governance remuneration financial statements investor information financial instruments related disclosures continued equity impact shown foreign exchange sensitivity relates derivative nonderivative financial instruments hedging groups net investments european euro foreign operations cash flow hedges foreign exchange exposure arising euro us dollar denominated coupon payments relating groups european us medium term notes number highly probable forecast transactions denominated us dollars increasedecrease increasedecrease equity equity equity impact nonfunctional currency foreign exchange exposures cent appreciation us dollar cent appreciation euro yen appreciation yen equivalent depreciation currencies would cause following decreaseincrease equity million million nil nil million million us dollar euro yen exchange rates respectively table presents groups sensitivity foreign exchange rates based composition net debt shown note adjusting effects foreign exchange derivatives part net debt affect future foreign currency cash flows increasedecrease increasedecrease net debt net debt impact foreign exchange movements net debt cent appreciation us dollar cent appreciation euro yen appreciation yen equivalent depreciation currencies would following impact net debt million million million us dollar euro yen exchange rates respectively million million million interest rate sensitivity group exposed interest rate risk outstanding borrowings investments changes interest rates affect future cash flows fair values financial instruments majority debt issued fixed interest rates changes floating rates interest significantly affect groups net interest charge although majority cash liquid investments earn floating rates interest table hypothetically shows groups sensitivity changes interest rates relation sterling us dollar euro variable rate financial assets liabilities interest rates applicable floating rate financial assets liabilities increased basis points assuming variables remained constant estimated groups finance income would increased approximately million million increase basis points movement interest rates deemed material effect equity increasedecrease increasedecrease income income income statement impact interest rate movements basis points increase sterling interest rates basis points increase us dollar interest rates basis points increase euro interest rates gsk annual report notes financial statements continued financial instruments related disclosures continued h contractual cash flows nonderivative financial liabilities derivative instruments following tables provides analysis anticipated contractual cash flows including interest payable groups nonderivative financial liabilities undiscounted basis group use interest rate swaps manage interest rate risk purpose table debt defined classes borrowings except obligations finance leases interest calculated based debt held december without taking account future issuance floating rate interest estimated using prevailing interest rate balance sheet date cash flows foreign currencies translated using spot rates december contractual cash flows respect operating lease vacant space provisions excluded table included commitments noncancellable operating leases table note commitments obligations finance charge trade payables interest finance obligations liabilities debt debt leases finance leases net debt total december due less one year one two years two three years three four years four five years five ten years greater ten years gross contractual cash flows finance charge trade payables obligations obligations interest finance finance liabilities debt debt leases leases net debt total december due less one year one two years two three years three four years four five years five ten years greater ten years gross contractual cash flows increase contractual cash flows nonderivative financial liabilities billion year resulted partially initial recognition viiv healthcare put option liability billion addition increase billion forecast future cash flows respect contingent consideration payable acquisition former shionogiviiv healthcare joint venture acquisition novartis vaccines business anticipated contractual cash flows repayment debt debt interest increased billion year principally due retranslation us dollar denominated debt adversely impacted weakening sterling due volatility markets compounded political economic events throughout table provides analysis anticipated contractual cash flows groups derivative instruments excluding embedded derivatives equity options material using undiscounted cash flows cash flows foreign currencies translated using spot rates december gross cash flows foreign exchange contracts presented purpose table although practice group uses standard settlement arrangements reduce liquidity requirements instruments amounts receivable payable less one year increased compared december result hedging us commercial paper programme increased hedging euro receivables receivables payables receivables payables due less one year one two years gross contractual cash flows gsk annual report strategic report governance remuneration financial statements investor information employee share schemes gsk operates several employee share schemes including share value plan whereby awards granted employees acquire shares ads glaxosmithkline plc cost three year vesting period performance share plan whereby awards granted employees acquire shares ads glaxosmithkline plc cost subject achievement group specified performance targets granting restricted share awards replaced granting options employees cost schemes readily equates potential gain made employee group also operates savings related share option schemes whereby options granted employees acquire shares glaxosmithkline plc discounted price grants restricted share awards normally exercisable end three year vesting performance period awards normally granted employees acquire shares ads glaxosmithkline plc circumstances may settled cash grants savingsrelated share option schemes normally exercisable three years saving accordance uk practice majority options savingsrelated share option schemes granted price market price ruling date grant options historical share option schemes granted market price ruling date grant total charge sharebased incentive plans million million million amount million million million arose share value plan see note employee costs details glaxosmithkline share award schemes share value plan share value plan share awards granted certain employees cost awards vest two half three years performance criteria attached fair value awards determined based closing share price day grant deducting expected future dividend yield duration award shares weighted ads weighted number shares ads issuable number fair value number fair value january awards granted awards exercised awards cancelled december awards granted awards exercised awards cancelled december awards granted awards exercised awards cancelled december performance share plan performance share plan share awards granted directors senior executives cost percentage award vests based upon performance group defined measurement period dividends reinvested period awards granted directors members cet performance conditions based three equally weighted measures three year performance period adjusted free cash flow tsr rd new product performance awards made eligible employees performance conditions based gsks eps growth compared increase uk retail prices index three year measurement period adjusted free cash flow addition businesses element award based strategic operational business measure three year measurement period specific employees business area fair value awards determined based closing share price day grant tsr performance elements adjusted likelihood condition met assessed time grant awards made million shares weighted fair value million ads weighted fair value december outstanding awards million shares million ads share options savingsrelated options purposes valuing savingsrelated options arrive share based payment charge blackscholes option pricing model used assumptions used model follows grant grant grant riskfree interest rate dividend yield volatility expected life years years years savingsrelated options grant price including discount gsk annual report notes financial statements continued employee share schemes continued share option share option savingsrelated options outstanding schemes shares schemes ads share option schemes weighted weighted weighted number exercise number exercise number exercise price price price december range exercise prices options outstanding year end weighted average market price exercise year weighted average remaining contractual life years years years options million shares granted year savingsrelated share option scheme weighted average fair value december million savingsrelated share options exercisable share options ads options currently exercisable expire exercised july change effective exercise price outstanding options year employee share ownership plan trusts group sponsors employee share ownership plan esop trusts acquire hold shares glaxosmithkline plc satisfy awards made employee incentive plans options granted employee share option schemes trustees esop trusts purchase shares finance provided group way loans contributions treasury shares carrying value million purchased uk esop trust satisfy future awards costs running esop trusts charged income statement shares held esop trusts deducted reserves amortised value proceeds receivable employees exercise transfer retained earnings trustees waived rights dividends shares held esop trusts shares held share award schemes number shares nominal value carrying value market value shares held share option schemes number shares nominal value carrying value market value post balance sheet events february gsk completed sale anaesthesia portfolio aspen excluding us canada markets million together milestones million gsk annual report strategic report governance remuneration financial statements investor information principal group companies following represent principal subsidiaries countries incorporation group december equity share capital entities wholly owned group except percentage interest shown otherwise companies incorporated principal country operation except stated england us glaxo group limited block drug company inc glaxo operations uk limited corixa corporation glaxosmithkline capital plc glaxosmithkline capital inc glaxosmithkline consumer healthcare holdings limited glaxosmithkline consumer healthcare lp glaxosmithkline consumer healthcare uk trading limited glaxosmithkline holdings americas inc glaxosmithkline export limited glaxosmithkline llc glaxosmithkline finance plc human genome sciences inc glaxosmithkline holdings limited novartis consumer health inc glaxosmithkline research development limited stiefel laboratories inc glaxosmithkline services unlimited viiv healthcare company glaxosmithkline uk limited setfirst limited smithkline beecham limited viiv healthcare limited viiv healthcare uk limited europe others glaxosmithkline biologicals sa belgium glaxosmithkline argentina sa argentina glaxosmithkline pharmaceuticals sa belgium glaxosmithkline australia pty ltd australia glaxosmithkline biologicals sas france glaxosmithkline consumer healthcare australia pty ltd australia glaxosmithkline sante grand public sas france glaxosmithkline brasil limitada brazil laboratoire glaxosmithkline france glaxosmithkline consumer healthcare inc canada viiv healthcare sas france glaxosmithkline inc canada glaxosmithkline consumer healthcare gmbh co kg id biomedical corporation quebec canada germany glaxosmithkline limited china hong kong glaxosmithkline gmbh co kg germany sinoamerican tianjin smith kline french laboratories ltd china gsk vaccines gmbh germany glaxosmithkline consumer healthcare limited india glaxosmithkline consumer healthcare spa italy glaxosmithkline pharmaceuticals limited india glaxosmithkline spa italy glaxosmithkline consumer healthcare japan kk japan gsk vaccines srl italy glaxosmithkline kk japan glaxosmithkline bv netherlands viiv healthcare kabushiki kaisha japan glaxosmithkline pharmaceuticals sa poland glaxosmithkline pakistan limited pakistan gsk services sp z oo poland glaxo wellcome manufacturing pte ltd singapore glaxosmithkline trading services limited republic ireland glaxosmithkline korea limited republic korea glaxosmithkline sa spain glaxosmithkline llaclari sanayi ticaret turkey laboratorios viiv healthcare sl spain novartis consumer health sa switzerland e xempt provisions section companies act ireland accordance exemptions noted section act subsidiaries disclosed pages exempt provisions also consolidated group financial statements directly held wholly owned subsidiary glaxosmithkline plc subsidiaries associates listed principally affect figures groups financial statements glaxosmithkline capital inc glaxosmithkline capital plc whollyowned finance subsidiary company company fully unconditionally guaranteed securities issued glaxosmithkline capital inc glaxosmithkline capital plc see pages complete list subsidiary undertakings associates joint ventures form part financial statements gsk annual report notes financial statements continued legal proceedings group involved significant legal administrative advair hfa flovent hfa ventolin hfa proceedings principally product liability intellectual property tax september mylan pharmaceuticals mylan filed antitrust governmental investigations well related private petition inter partes review ipr united states patent litigation significant matters tax trademark office uspto seeking invalidate patent us matters described group makes provision patent patent patent claims method proceedings regular basis summarised note treatment formulation containing active medication accounting principles policies note provisions propellant known substantially free surfactant use group may become involved significant legal proceedings hydrofluoroalkane hfa metered dose inhalers advair respect possible make reliable estimate flovent ventolin group exclusively licenses patent expected financial effect could result ultimate first right enforce defend patent resolution proceedings cases appropriate expires december listed orange book disclosures cases would included note november group entered settlement agreement provision would made cases mylan resolving ipr terms settlement agreement confidential patent subject ipr respect legal proceedings described settlement one number patents covering advair flovent provision made group ventolin use hfa metered dose inhalers unable make reliable estimate expected financial effect stage group believe information february group received paragraph iv amount sought plaintiffs known would meaningful certification teva flovent hfa first paragraph iv respect legal proceedings due number certification group received generic pharmaceutical factors including limited stage proceedings company seeking make ab rated version flovent hfa three entitlement parties appeal decision clarity theories patents issue teva alleges generic version flovent liability damages governing law infringe two patents directed actuation indicators listed orange book teva also alleges patent legal expenses incurred provisions related legal claims subject mylan ipr proceeding settled charged selling general administration costs provisions november valid group evaluating tevas made taking appropriate legal specialist advice paragraph iv certification deadline filing patent outflow resources considered probable reliable infringement suit would trigger month stay statutory estimate made likely outcome dispute certain preclusion anda approval generic product months product liability claims group make provision date groups receipt notice paragraph iv sufficient history claims made settlements enable certification hatchwaxman act april management make reliable estimate provision required cover unasserted claims december groups bexseromen b vaccines aggregate provision legal disputes including tax following acquisition novartis vaccine business matters described note taxation million group taken litigation originally filed novartis ultimate liability legal claims may vary amounts provided pfizer inc pfizer uk italy united states related dependent upon outcome litigation proceedings meningococcal b men b vaccines february novartis investigations possible settlement negotiations filed suit pfizer uk high court patents court groups position could change time therefore declaration european patent owned pfizer infringed assurance losses result outcome bexsero invalid pfizer filed statement defence legal proceedings exceed material amount may counterclaimed infringement trial held amount provisions reported groups financial march may judge ruled pfizers statements happen could material adverse patent valid infringed bexsero product group impact results operations group reporting appealed decision appeal hearing expected period judgements incurred settlements heard week december entered february novartis filed suit pfizer court intellectual property rome declaration european patent owned pfizer intellectual property claims include challenges validity infringed bexsero invalid group assumed enforceability groups patents various products responsibility matter group also prosecuting lawsuit processes well assertions noninfringement pfizer originally filed novartis declaration patents loss cases could result loss patent european patent issued pfizer related meningitis b vaccines protection product issue consequences infringed bexsero pfizer counterclaimed seeking loss could significant decrease sales product declaration bexsero infringes patents order could materially affect future results operations group damages group actively pursuing actions gsk annual report strategic report governance remuneration financial statements investor information legal proceedings continued february novartis filed suit pfizer us coreg cr district court district new jersey patent infringement mylan sent paragraph iv certification dated august complaint asserts six patents pfizer alleging pfizers group flamel ireland ltd flamel stating submitted sale trumenba infringes patents april abbreviated new drug application anda us food group filed first amended complaint pfizer reasserting drug administration fda seeking approval generic version six patents originally asserted novartis also asserting coreg cr notice asserted patents listed orange one additional recentlygranted patent group filed second book coreg cr either invalid infringed mylans amended complaint march asserting additional five product october flamel filed civil complaint us patents covering trumenba pfizer dates set district court northern district west virginia alleging summary judgement motions trial mylans product infringes flamels orange booklisted extended release formulation patent expires march july pfizer filed suit uk high court group exclusive licensee patent coreg cr mylan group novartis craig venter institute seeking answered december asserting flamels patent invalidate six uk patents owned group relevance invalid infringed mylan also filed third party complaint pfizers trumenba six patents formerly owned novartis group requesting declaration groups patent also opposed european patent office epo carvedilol phosphate hemihydrate invalid infringed pfizer two six patents revoked epo opposition december parties settled matter terms division however september one patents confidential upheld epo board appeal another one upheld epo opposition division group believes trumenba kivexa infringes patents two trials set cover patent covering combination lamivudine abacavir patents issue first trial date january second kivexa corresponding supplementary protection certificates trial date february spcs challenged independently teva mylan several october group filed suit seeking injunctive relief major european markets challenges withdrawn pfizer ireland claiming infringement four group patents pursuant confidential settlement agreement teva dated including group patent upheld epo board appeals may confidential settlement agreement mylan september patent maintained first dated may instance virtue manufacture trumenba proposed q challenges validity spc combination commercialisation ireland groups application enter patent kivexa brought germany betapharm dr commercial division irish high court order expedite reddys hexal sandoz hormosan lupin viiv healthcare case successful hearing likely scheduled commenced proceedings injunctive relief three q companies viiv healthcares application injunctive relief october day group filed suit hexal denied october confidential settlement pfizer uk ireland group filed suit austria seeking agreement reached dr reddys covering number injunctive relief boehringer ingelheim bi pfizers contract european markets pursuant agreement german actions manufacturer antigens trumenba claiming infringement involving betapharm withdrawn trial dates group patent upheld epo board appeal september set hexal hormosan actions bi filed response complaint trial likely sandoz also filed nullity actions austria germany spain scheduled time sweden september october alleging november pfizer filed suit canadian federal kivexa spc invalid underlying patent covering court group infringement pfizer canadian patent combination lamivudine abacavir invalid sandoz covering trumenba pfizer seeks damages seeking launched abacavirlamivudine product austria spain injunction trial likely occur sweden viiv healthcare commenced proceedings injunctive relief austria sweden decisions injunctive relief expected first half viiv healthcare also counterclaimed infringement within nullity action spain trial dates set jurisdictions gsk annual report notes financial statements continued legal proceedings continued doc generici filed action september court avandia rome seeking declaration italian spc covering kivexa group named product liability lawsuits behalf invalid based upon invalid combination patent individuals asserting personal injury claims arising use company eurogenerics joined action trial date avandia economic loss actions also filed seeking set restitution penalties consumer protection laws federal cases filed group part multidistrict portugal viiv healthcare initiated arbitration proceedings litigation proceeding pending us district court eastern lupin vale pharmaceuticals zentiva patent covering district pennsylvania mdl court cases also combination lamivudine abacavir three companies filed number state courts addition county santa filed marketing approval generic version kivexa sandoz clara california brought action behalf california joined proceedings future holder lupin marketing residents pending mdl court alleging violations approval arbitration date yet scheduled californias false advertising act seeking restitution damages actions civil penalties december accord healthcare ltd accord filed february group reached agreements settle revocation action spc uk action substantial majority federal state cases pending us resolved confidential settlement accord group february kyowa pharmaceuticals filed nullity action four purported class actions us seeking economic relating kivexa japan viiv healthcare evaluating options damages behalf third party payers tpps asserting claims regard action arising various state federal laws including racketeer influenced corrupt organizations act rico state unfair trade lexiva practices andor consumer protection laws mdl court february lupin filed petition us patent consolidated four actions pretrial proceedings trademark office uspto seeking challenge validity appointed plaintiffs steering committee group patent claims covering lexiva inter partes review ipr successful obtaining initial case management order second petition ipr lupin filed patent requires four named plaintiffs produce documentation relating earlier petition uspto instituted ipr broad claims merits claims two four named plaintiffs patent denied instituting challenge specific claims filed motions dismiss voluntarily claims group lexiva challenged patent expires opposed order require plaintiffs comply june august uspto granted petition discovery obligations group filed motion summary instituted trial remaining claims lexiva patent oral judgement basis preemption tpp actions oral hearing scheduled april relevant rules argument motions heard february uspto must issue decision ipr august court taken matter advisement additionally february lupin sent viiv healthcare santa clara county action group pending motion paragraph iv certification hatchwaxman act alleging summary judgement basis preemption also patent covering lexiva valid patent expires seeking partial summary judgement countys restitution claim december pediatric exclusivity extending june however decision expected mdl court first disposes viiv healthcare evaluating certification santa claras motion dismiss based lack federal product liability jurisdiction oral argument heard november preclinical clinical trials conducted development santa claras motion dismiss lack jurisdiction court potential products determine safety efficacy products yet issued decision use humans following approval regulatory bodies fifteen class actions canada two active notwithstanding efforts drugs vaccines two active cases class certification hearings held introduced marketplace unanticipated safety issues may december court issued decision certifying nationwide become claimed evident group class users avandia group filed notice intent currently defendant number product liability lawsuits related appeal groups pharmaceutical vaccine consumer healthcare products group able make reliable estimate expected financial effect matters discussed category included provision appropriate matters provision legal disputes matters group made provision also noted note provisions gsk annual report strategic report governance remuneration financial statements investor information legal proceedings continued seroxatpaxil paxil cr canada bartram action certified national group received numerous lawsuits claims alleging class action british columbia settled december use paxil paroxetine caused variety injuries eliminating need trial singh action alberta also lawsuits contain one following allegations proposed national class action seeks certify class relating use paxil pregnancy caused congenital malformations birth defects generally hearing motion certify class persistent pulmonary hypertension ii paxil treatment caused previously scheduled early adjourned plaintiffs patients commit suicidal violent acts iii group request additional evidence could filed revised hearing failed warn patients could experience certain symptoms date set likely mid also discontinuing paxil treatment one inactive proposed national class action british columbia wakeman new class action jensen alleging paxil pregnancy ssri use autism filed saskatchewan january group reached agreements settle majority us claims relating use paxil pregnancy february acts violence number claims related use pregnancy still february six pending claims cases pending various courts us matters concerning allegations patients took paroxetine paxil dismissed without payment committed attempted commit suicide acts violence five claims cases us one case canada trial one nine cases pending philadelphia pennsylvania mass us cases dolin begins march federal court tort program mtp rader v gsk went trial march chicago illinois april judge presiding trial granted groups motion nonsuit ending trial groups favour discontinuation ruled plaintiff failed introduce necessary uk one hundred three cases remain evidence proceed june court denied plaintiffs subject hearing held december judgement motion posttrial relief sought new trial plaintiffs appeal hearing published february allowed docketed july proceeding remaining claims continue court management case management conferences held july following loss rader plaintiffs counsel asked mtp february new timetable ordered proceedings court stay remaining eight cases issue rader addressed pennsylvania appellate courts group zofran opposed request april mtp court granted plaintiffs allege children suffered birth defects result plaintiffs counsels request entered order staying mothers ingestion zofran andor generic ondansetron cases resolution rader appeal group pregnancyrelated nausea vomiting plaintiffs assert moved lift order granting stay arguing host group sold zofran knowing unsafe pregnant women failed dispositive issues cases depend outcome warn risks illegally marketed zofran offlabel use rader appeal court denied groups motions pregnant women february group defendant july personal injury lawsuits us three hundred two eight cases pending single california state court cases part multidistrict litigation proceeding mdl pursuant coordination order motions quash personal district massachusetts mdl cases discovery jurisdiction forum non conveniens denied december january mdl court issued order denying group filed writs seeking review california court groups motion dismiss claims grounds appeals court yet issued ruling preempted federal law group may renew motion later date mdl continues monthly status conferences fourteen cases filed state court st louis missouri issues sufficiency pleadings scope group removed cases federal court discovery addressed group continues seek eastern district missouri concurrently filed motions dismissal individual cases appropriate dismiss lack personal jurisdiction alternative transfer federal court plaintiffs respective home states significant activity ten state court february fourteen cases dismissed cases us eight located california group also defendant four proposed class actions canada october parties agreed settlement significant activity canadian class plaintiff case state court st louis missouri meyers actions denial groups motion dismiss personal jurisdiction grounds affirmed illinois appellate court elmassri connecticut federal court granted groups motion summary judgement february kiker case set trial january settled gsk annual report notes financial statements continued legal proceedings continued sales marketing regulation average wholesale price groups marketing promotion pharmaceutical attorney general illinois filed suit group vaccine products subject certain governmental number pharmaceutical companies claiming damages investigations private lawsuits brought litigants various restitution due average wholesale price awp andor wholesale theories law group able make reliable estimate acquisition cost wac price reporting pharmaceutical products expected financial effect matters discussed covered states medicaid programmes case alleges category included provision matters group reported caused reported false awp wac provision legal disputes except noted prices turn allegedly caused state medicaid agency matters group made provision also noted reimburse providers money covered medicines note provisions agency intended state sought recovery behalf payer behalf instate patients consumers case secdoj sfo anticorruption enquiries ongoing trial date yet set september group reached global resolution us securities exchange commission sec regarding cidra thirdparty payer litigation secs investigation us foreign corrupt practices act july number major us healthcare insurers filed suit fcpa groups commercial practices countries outside group philadelphia pennsylvania county court us part resolution group agreed pay civil common pleas seeking compensation reimbursements penalty million us government us department made medicines manufactured groups former cidra plant justice doj also confirmed concluded investigation puerto rico insurers claim group knowingly groups commercial practices would take action illegally marketed sold adulterated drugs manufactured group sec doj investigations initiated conditions noncompliant cgmp current good manufacturing part industrywide inquiry whether pharmaceutical practices thirdparty insurers unlawfully companies violated us fcpa group agreed induced pay suit alleges us federal various resolution without admitting denying secs allegations state law causes action court denied groups motion dismiss discovery scheduled completed may uk serious fraud office sfo began formal trial expected scheduled sometime criminal investigation groups commercial operations number countries including china sfo requested antitrustcompetition information group commercial operations certain governmental actions private lawsuits brought countries group responding sfos requests group alleging violation competition antitrust laws group unable make reliable estimate expected financial group able make reliable estimate expected effect investigations provision made financial effect matters discussed category included provision matters provision legal disputes except noted matters group us vaccines subpoena made provision also noted note provisions february group received subpoena us attorneys office southern district new york requesting uk competition markets authority investigation documents relating groups vaccines business group february uk competition markets authority responding subpoena group unable make reliable cma issued decision fining group two estimate expected financial effect matter pharmaceutical companies infringement competition act provision made cma imposed fine million group well fines totalling million companies relates us subpoena relating imitrex amerge agreements settle patent disputes group march group received subpoena us potential suppliers generic paroxetine formulations entered attorneys office southern district new york requesting group terminated agreements documents relating groups us contracts imitrex issue group believes strong grounds appeal amerge group responding subpoena group cmas finding competition appeal tribunal cat unable make reliable estimate expected financial effect fine overturned substantially reduced appeal matter provision made cat due commence march provision made matter avandia group defending action county santa clara california brought californias consumer protection laws seeking civil penalties restitution result groups marketing avandia group filed number dispositive motions pending mdl court county santa clara recently filed motion dismiss action federal court lack federal jurisdiction motion briefed argued parties gsk annual report strategic report governance remuneration financial statements investor information legal proceedings continued lamictal securitieserisa class actions stiefel purported classes direct indirect purchasers filed suit currently three outstanding private lawsuits brought us district court district new jersey alleging former stiefel laboratories inc stiefel employees alleging group teva pharmaceuticals unlawfully conspired delay stiefel officers directors violated us employee generic competition lamictal resulting overcharges retirement income security act erisa federal state purchasers entering allegedly anticompetitive reverse securities laws inducing stiefel employees sell shares payment settlement resolve patent infringement litigation employee stock plan back stiefel greatly undervalued price separate count accuses group monopolising market without disclosing employees stiefel sold june court appeals reversed trial courts group decision dismiss case remanded action back fried case currently appeal us court appeals trial court october trial court denied groups eleventh circuit oral argument taken place motion stay set schedule early dispositive motions february stiefel complete defence verdict matter discovery group filed petition certiorari us jury trial federal court florida october supreme court february november plaintiff appealed trial second florida case stayed us supreme court denied groups petition certiorari pending resolution fried matter discovery also continues trial court march groups motion judgement case pending new york federal court pleadings granted large part dismissing statute limitations grounds claims alleged purported addition private litigant suits december us indirect purchaser class may trial court denied securities exchange commission sec filed formal complaint indirect purchaser class plaintiffs motion reconsideration stiefel charles stiefel us district court result indirect purchaser class representatives agreed district florida alleging stiefel principals violated settlement exit case resolve remaining claims terms federal securities laws inducing stiefel employees sell settlement confidential case continue move shares employee stock plan back company greatly forward document production witness depositions undervalued price without disclosing employees regard claims direct purchasers company sold case stayed returned active status early summer since wellbutrin xl parties engaged discovery rebriefed summary plaintiffs claimed antitrust injury related allegedly sham patent judgement motions courts request however although briefing litigation filed biovail generic companies pursuing andas motions completed july court yet generic wellbutrin xl group initially named party ruled motions plaintiff two patent infringement actions later withdrew environmental matters matters group party remaining two group notified potential responsibility relating patent infringement actions relating wellbutrin xl plaintiffs past operations past waste disposal practices certain alleged conspiracy delay generic approval existed sites primarily us matters subject biovail group court granted summary judgement litigation including proceedings initiated us federal state favour group claims sole remaining claims governments waste disposal site remediation costs tort matter relate plaintiffs allegations group entered actions brought private parties anticompetitive reverse payment settlement resolve patent infringement litigation district court granted summary group advised may responsible party judgement favour group claims matter approximately sites appear national priority currently pending appeal us court appeals list created comprehensive environmental response third circuit court compensation liability act superfund proceedings seek require operators hazardous waste facilities commercial corporate transporters waste sites generators hazardous waste group defendant certain cases allege violation disposed sites clean sites reimburse us us federal securities erisa laws group able government cleanup costs instances group make reliable estimate expected financial effect involved alleged generator hazardous waste matters discussed category included provision matters provision legal disputes except although superfund provides defendants jointly noted matters group made provision severally liable cleanup costs proceedings frequently also noted note provisions resolved basis nature quantity waste disposed generator site groups proportionate liability cleanup costs substantially determined sites referred groups potential liability varies greatly site site cost investigation study remediation sites could time significant group routinely accrues amounts related share liability matters gsk annual report financial statements glaxosmithkline plc prepared uk gaap including frs reduced disclosure framework directors statement responsibilities relation companys financial statements directors responsible preparing parent company disclosure information auditors glaxosmithkline plc financial statements remuneration directors office date annual report report accordance applicable law regulations confirmed uk company law requires directors prepare financial far aware relevant audit information statements financial year law directors companys auditors unaware elected prepare parent company financial statements taken steps ought taken accordance united kingdom accounting standards director make aware relevant audit applicable law united kingdom generally accepted accounting information establish companys auditors aware practice company law directors must approve information parent company financial statements unless satisfied give true fair view state affairs parent confirmation given interpreted accordance company profit loss period provisions section companies act preparing financial statements directors required going concern basis assessed principal risks matters considered select suitable accounting policies apply connection viability statement directors considered consistently appropriate adopt going concern basis accounting make judgements accounting estimates reasonable preparing financial statements prudent uk corporate governance code state regard parent company financial statements board considers glaxosmithkline plc applies principles applicable uk accounting standards followed subject complies provisions uk corporate governance material departures disclosed explained parent code maintained financial reporting council described company financial statements corporate governance section pages board considers annual report taken whole fair prepare financial statements going concern basis unless balanced understandable provides information inappropriate presume parent company necessary shareholders assess groups position continue business performance business model strategy directors responsible keeping adequate accounting required financial conduct authoritys listing rules records sufficient show explain companys auditors considered directors statement compliance transactions disclose reasonable accuracy time relation points uk corporate governance code financial position company enable ensure specified review parent company financial statements remuneration report pages comply companies act also responsible safeguarding assets company hence taking reasonable steps prevention detection fraud irregularities philip hampton parent company financial statements year ended chairman december comprising balance sheet year ended december supporting notes set pages march report responsibilities auditors relation parent company financial statements set independent auditors report pages financial statements year ended december included annual report published printed form made available website directors responsible maintenance integrity annual report website accordance uk legislation governing preparation dissemination financial statements access website available outside uk comparable legislation may different strategic report risk sections annual report represent management report include fair review development performance business position company group taken whole together description principal risks uncertainties faces gsk annual report strategic report governance remuneration financial statements independent auditors report investor information members glaxosmithkline plc report parent company financial statements opinion isas uk ireland reporting opinion glaxosmithkline plcs parent company financial international standards auditing uk ireland isas statements financial statements uk ireland required report opinion information annual report give true fair view state parent companys affairs materially inconsistent information audited financial statements december apparently materially incorrect based materially inconsistent properly prepared accordance united kingdom knowledge company acquired course generally accepted accounting practice performing audit prepared accordance requirements otherwise misleading companies act exceptions report arising responsibility audited financial statements included within annual report adequacy accounting records information comprise explanations received companies act required report company balance sheet december opinion company statement changes equity year received information explanations ended require audit notes financial statements include summary adequate accounting records kept parent significant accounting policies explanatory information company returns adequate audit received certain required disclosures presented elsewhere branches visited us annual report rather notes financial statements financial statements part directors crossreferenced financial statements remuneration report audited agreement identified audited financial reporting framework accounting records returns applied preparation financial statements applicable law united kingdom accounting standards united kingdom exceptions report arising responsibility generally accepted accounting practice including frs directors remuneration reduced disclosure framework companies act required report required reporting opinion certain disclosures directors remuneration specified law made exceptions report consistency information arising responsibility companies act opinion opinion based work undertaken course directors remuneration report companies act opinion audit opinion part directors remuneration report audited properly prepared accordance information given strategic report directors companies act report financial year financial statements prepared consistent financial statements companies act reporting companies act required report strategic report directors report opinion certain disclosures directors remuneration prepared accordance applicable legal requirements specified law made exceptions report addition light knowledge understanding group arising responsibility environment obtained course audit required report identified material misstatements strategic report directors report nothing report respect gsk annual report independent auditors report members glaxosmithkline plc continued report parent company financial statements continued responsibilities financial statements audit addition read financial nonfinancial information responsibilities directors annual report identify material inconsistencies explained fully directors statement audited financial statements identify information responsibilities set directors responsible apparently materially incorrect based materially inconsistent preparation financial statements satisfied knowledge acquired us course performing give true fair view audit become aware apparent material misstatements inconsistencies consider implications report responsibility audit express opinion financial respect strategic report directors report consider statements accordance applicable law isas uk whether reports include disclosures required applicable ireland standards require us comply auditing legal requirements practices boards ethical standards auditors matters report including opinions prepared reported separately group financial statements companys members body accordance chapter glaxosmithkline plc year ended december part companies act purpose information directors remuneration report giving opinions accept assume responsibility described audited purpose person report shown whose hands may come save expressly company passed resolution accordance section agreed prior consent writing companies act senior statutory auditors audit financial statements involves name stated conducted audit accordance isas uk ireland audit involves obtaining evidence amounts disclosures pricewaterhousecoopers llp financial statements sufficient give reasonable assurance chartered accountants statutory auditors financial statements free material misstatement london whether caused fraud error includes assessment whether accounting policies appropriate parent march companys circumstances consistently applied adequately disclosed reasonableness significant accounting estimates made directors overall presentation financial statements primarily focus work areas assessing directors judgements available evidence forming judgements evaluating disclosures financial statements test examine information using sampling auditing techniques extent consider necessary provide reasonable basis us draw conclusions obtain audit evidence testing effectiveness controls substantive procedures combination gsk annual report strategic report governance remuneration financial statements company balance sheet uk gaap investor information including frs reduced disclosure framework december notes fixed assets investments f current assets trade receivables g cash bank total current assets bank overdrafts trade payables h total current liabilities net current assets total assets less current liabilities provisions noncurrent liabilities j net assets capital reserves called share capital k share premium account k reserves retained earnings january lossprofit year changes retained earnings l equity shareholders funds financial statements pages approved board march signed behalf philip hampton chairman glaxosmithkline plc registered number company statement changes equity year ended december share share premium retained capital account reserves earnings total january profit attributable shareholders dividends shareholders shares issued employee share schemes december loss attributable shareholders dividends shareholders shares issued employee share schemes treasury shares transferred esop trust december gsk annual report notes company balance sheet uk gaap including frs reduced disclosure framework presentation financial statements b accounting policies description business foreign currency transactions glaxosmithkline plc parent company gsk major global foreign currency transactions recorded exchange rate healthcare group engaged creation discovery ruling date transaction foreign currency assets development manufacture marketing pharmaceutical liabilities translated rates exchange ruling balance products including vaccines overthecounter otc medicines sheet date healthrelated consumer products dividends paid received preparation financial statements dividends paid received included financial statements financial statements prepared using historical period related dividends actually paid cost convention modified include revaluation certain received financial instruments going concern basis prepared expenditure accordance financial reporting standard reduced expenditure recognised respect goods services received disclosure framework uk accounting presentation supplied accordance contractual terms provision companies act december comparative made obligation exists future liability respect figures december past event amount obligation reliably permitted section companies act estimated income statement company presented annual report investments subsidiary companies investments subsidiary companies held cost less company included group financial statements provision impairment also adjusted movements glaxosmithkline plc publicly available contingent consideration following exemptions requirements ifrs applied preparation financial statements impairment investments accordance frs carrying value investments reviewed impairment indication investment might impaired paragraphs b ifrs sharebased payment provision resulting impairment review charged ifrs financial instruments disclosures income statement year concerned paragraphs ifrs fair value measurement share based payments paragraph ias presentation financial statements issuance company subsidiaries grant comparative information requirements respect companys shares represents additional capital contributions paragraph iv ias company subsidiaries additional investment paragraphs f b subsidiaries results corresponding increase shareholders ias presentation financial statements equity additional capital contribution based fair value ias statement cash flows grant issued allocated underlying grants vesting period paragraph ias accounting policies changes accounting estimates errors taxation current tax provided amounts expected paid applying paragraph ias related party disclosures tax rates enacted substantively enacted requirement ias disclose related party transactions balance sheet date entered two members group deferred tax provided full using liability method temporary differences arising tax bases assets accounting convention standards liabilities carrying amounts financial statements balance sheet prepared using historical deferred tax assets recognised extent cost convention complies applicable uk accounting considered recoverable future taxable profits standards deferred tax measured average tax rates expected accounting principles policies apply periods temporary differences preparation balance sheet conformity generally expected realised settled deferred tax liabilities assets accepted accounting principles requires management make discounted estimates assumptions affect reported amounts assets liabilities disclosure contingent assets financial guarantees liabilities date balance sheet actual amounts could liabilities relating guarantees issued company behalf differ estimates subsidiaries initially recognised fair value amortised life guarantee balance sheet prepared accordance companys accounting policies approved board legal disputes described note b policies consistently applied company provides anticipated settlement costs unless otherwise stated outflow resources considered probable reliable estimate may made likely outcome dispute legal expenses arising claims company december provisions legal disputes amounted million million gsk annual report strategic report governance remuneration financial statements investor information c key accounting judgements estimates ultimate liability legal claims may vary amounts legal disputes provided dependent upon outcome litigation company provides anticipated settlement costs proceedings investigations possible settlement negotiations outflow resources considered probable reliable position could change time therefore estimate may made likely outcome dispute assurance losses result outcome legal legal expenses arising claims company proceedings exceed amount provisions reported estimates take account specific circumstances companys financial statements material amount dispute relevant external advice inherently perating profit judgemental could change substantially time new fee relating audit facts emerge dispute progresses company charged operating profit companys directors taken legal advice e dividends established provisions taking account relevant facts circumstances matter accordance accounting directors declared four interim dividends resulting dividend requirements december provisions legal year pence line dividend disputes amounted million million details see note group financial statements dividends f fixed assets investments shares glaxosmithkline services unlimited shares glaxosmithkline holdings one limited shares glaxosmithkline holdings limited shares glaxosmithkline mercury limited capital contribution relating share based payments contribution relating contingent consideration g trade receivables amounts due within one year uk corporation tax recoverable receivables amounts owed group undertakings amounts due one year amounts owed group undertakings gsk annual report notes company balance sheet uk gaap including frs reduced disclosure framework continued h trade payables amounts due within one year creditors contingent consideration payable amounts owed group undertakings company guaranteed debt issued subsidiary companies one receives annual fee aggregate company outstanding guarantees billion debt instruments amounts due subsidiary company relation guarantee fees recovered life bonds disclosed within trade receivables see note g provisions january exchange adjustments charge year utilised december provisions relate number legal disputes company currently involved j noncurrent liabilities contingent consideration payable contingent consideration relates amount payable acquisition novartis vaccines portfolio current year liability included within trade payables k called share capital share premium account share premium ordinary shares p account number share capital authorised december december share capital issued fully paid january issued employee share schemes december issued employee share schemes treasury shares transferred esop trust december december december number shares issuable employee share schemes number unissued shares option december issued share capital shares held esop trusts shares held treasury shares shares free issue issued shares fully paid nominal carrying market values shares held esop trusts disclosed note employee share schemes l reserves loss glaxosmithkline plc year million million profit dividends million million gave retained loss million million loss treasury shares purchased year nil effect million treasury shares transferred subsidiary company nil retained earnings december stood million million million unrealised million group companies see pages complete list subsidiaries associates joint ventures forms part financial statements gsk annual report strategic report governance remuneration financial statements investor information investor information section quarterly trend pharmaceuticals vaccines turnover five year record product development pipeline products competition intellectual property principal risks uncertainties share capital share price dividends financial calendar annual general meeting tax information shareholders shareholder services contacts us law regulation group companies glossary terms gsk annual report financial record quarterly trend unaudited analysis group results provided quarter sterling financial year income statement total months q q q q reported reported reported reported reported proforma proforma cer cer cer cer cer cer cer turnover pharmaceuticals vaccines consumer healthcare corporate unallocated turnover total turnover cost sales selling general administration research development royalty income operating income operating profitloss net finance costs share tax profitslosses associates joint ventures profitloss taxation taxation tax rate profitloss taxation period profitloss attributable noncontrolling interests profitloss attributable shareholders basic earningsloss per share pence p p p p p diluted earningsloss per share pence p p p p p income statement core total turnover cost sales selling general administration research development royalty income operating profit net finance costs share tax profitslosses associates joint ventures profit taxation taxation tax rate profit taxation period profit attributable noncontrolling interests profit attributable shareholders adjusted earnings per share pence p p p p p calculation core results described gsk annual report strategic report governance remuneration financial statements investor information quarterly trend continued unaudited analysis group results provided quarter sterling financial year income statement total months q q q q reported reported reported reported reported proforma proforma cer cer cer cer cer cer cer turnover pharmaceuticals vaccines consumer healthcare corporate unallocated turnover total turnover cost sales selling general administration research development royalty income operating income operating profitloss net finance costs share tax profitslosses associates joint ventures profitloss taxation taxation tax rate profitloss taxation period profitloss attributable noncontrolling interests profitloss attributable shareholders basic earningsloss per share pence p p p p p diluted earningsloss per share pence p p p p p income statement core total turnover cost sales selling general administration research development royalty income operating profit net finance costs share tax profitslosses associates joint ventures profit taxation taxation tax rate profit taxation period profit attributable noncontrolling interests profit attributable shareholders adjusted earnings per share pence p p p p p calculation core results described gsk annual report financial record continued pharmaceuticals turnover therapeutic area total us europe international restated growth growth growth growth therapeutic areamajor products cer cer cer cer respiratory anoro ellipta arnuity ellipta avamysveramyst flixotideflovent incruse ellipta nucala relvarbreo ellipta seretideadvair ventolin cardiovascular metabolic urology cvmu avodart eperzantanzeum immunoinflammation benlysta pharmaceuticals dermatology augmentin antibacterials rare diseases oncology established products coreg hepsera imigranimitrex lamictal lovaza requip serevent seroxatpaxil valtrex zeffix hiv combivir epzicomkivexa lexivatelzir selzentry tivicay triumeq trizivir pharmaceuticals vaccines turnover total us europe international restated growth growth growth growth major products cer cer cer cer rotarix synflorix fluarix flulaval bexsero menveo boostrix infanrix pediarix hepatitis priorix priorix tetra varilrix cervarix vaccines cer represents growth constant exchange rates represents growth actual exchange rates gsk annual report strategic report governance remuneration financial statements investor information pharmaceuticals turnover therapeutic area total us europe international restated restated growth growth restated growth growth therapeutic areamajor products cer cer cer cer respiratory anoro ellipta avamysveramyst flixotideflovent relvarbreo ellipta seretideadvair ventolin cardiovascular metabolic urology cvmu avodart immunoinflammation benlysta pharmaceuticals dermatology augmentin antibacterials rare diseases oncology established products coreg hepsera imigranimitrex lamictal lovaza requip serevent seroxatpaxil valtrex zeffix hiv combivir epzicomkivexa lexivatelzir selzentry tivicay triumeq trizivir pharmaceuticals vaccines turnover total us europe international restated growth growth growth restated growth major products cer cer cer cer rotarix synflorix fluarix flulaval bexsero menveo boostrix infanrix pediarix hepatitis rabipurrabavert cervarix vaccines cer represents growth constant exchange rates represents growth actual exchange rates gsk annual report financial record continued five year record record financial performance provided analysed accordance current reporting practice information included five year record prepared accordance ifrs adopted european union also ifrs issued international accounting standards board effect january gsk reported turnover three segments pharmaceuticals includes hiv vaccines consumer healthcare comparative turnover information four years restated accordingly comparative information also restated reflect current breakdown group geographic region comparative information also reported including effect divestments completed restated restated restated restated group turnover geographic region us europe international divestments total turnover including divestments group turnover segment pharmaceuticals vaccines consumer healthcare segment turnover corporate unallocated turnover divestments completed pharmaceuticals turnover therapeutic area respiratory cardiovascular metabolic urogenital immunoinflammation pharmaceuticals established products hiv pharmaceuticals vaccine turnover consumer healthcare turnover wellness oral care nutrition skin health gsk annual report strategic report governance remuneration financial statements investor information five year record continued financial results total turnover operating profit profit taxation profit taxation pence pence pence pence pence basic earnings per share diluted earnings per share millions millions millions millions millions weighted average number shares issue basic diluted financial results core turnover operating profit profit taxation profit taxation pence pence pence pence pence core earnings per share return capital employed return capital employed calculated total profit taxation percentage average net assets year gsk annual report financial record continued five year record continued restated restated restated balance sheet noncurrent assets current assets total assets current liabilities noncurrent liabilities total liabilities net assets shareholders equity noncontrolling interests total equity number employees us europe international manufacturing selling administration research development geographic distribution employees table based location gsks subsidiary companies number employees number permanent employed staff end financial period excludes employees employed managed gsk contract basis exchange rates guide holders ads following tables set periods indicated information exchange rate us dollars sterling reported bank england pm buying rate average purpose table average rate year calculated average pm buying rates day year mar feb jan dec nov oct sep high low pm buying rate march us gsk annual report strategic report governance remuneration financial statements pipeline products competition investor information pharmaceuticals vaccines product development pipeline key inlicence alliance relationship third party month first submission v iiv healthcare global specialist hiv company bla biological licence application gsk pfizer inc shionogi limited shareholders maa marketing authorisation application europe responsible developing delivering hiv medicines nda new drug application us lso developed indications another phase e valuation clinical pharmacology usually conducted therapeutic area volunteers optionbased alliance ionis pharmaceuticals phase ii etermination dose initial evaluation efficacy optionbased alliance adaptimmune ltd conducted small number patients optionbased alliance oncomed pharmaceuticals phase iii l arge comparative study compound versus placebo ptionbased alliance telethon ospedale andor established treatment patients establish san raffaele clinical benefit safety optionbased alliance valneva maa ndabla regulatory review milestones shown table achieved future filing dates included list achieved regulatory review milestones compound type indication phase maa ndabla hiv infectious diseases dolutegravir hiv integrase inhibitor nonnucleoside hiv infections two drug maintenance regimen iii rilpivirine reverse transcriptase inhibitor nnrti dolutegravir hiv integrase inhibitor nucleoside reverse hiv infections iii lamivudine transcriptase inhibitor nrti hiv attachment inhibitor hiv infections iii cabotegravir hiv integrase inhibitor longacting parenteral hiv preexposure prophylaxis iii formulation cabotegravir hiv integrase inhibitor nonnucleoside hiv infections iii rilpivirine reverse transcriptase inhibitor nnrti longacting parenteral formulations tafenoquine aminoquinoline plasmodium vivax malaria iii relenza iv neuraminidase inhibitor iv influenza iii gepotidacin type topoisomerase inhibitor bacterial infections ii danirixin iv chemokine cxc motif receptor influenza ii cxcr antagonist rg nonstructural protein b nsb polymerase hepatitis c ii inhibitor antimir antisense oligonucleotide antibacterial cephalosporin bacterial infection hiv maturation inhibitor hiv infections hbv antisense oligonucleotide hepatitis b hbv lica antisense oligonucleotide hepatitis b respiratory fluticasone furoate glucocorticoid agonist longacting beta chronic obstructive pulmonary disease copd submitted dec nov vilanterol agonist muscarinic acetylcholine antagonist umeclidinium mepolizumab interleukin il monoclonal antibody copd iii fluticasone furoate glucocorticoid agonist longacting beta asthma iii vilanterol agonist muscarinic acetylcholine antagonist umeclidinium muscarinic acetylcholine antagonist beta copd ii agonist maba muscarinic acetylcholine antagonist beta copd ii fluticasone furoate agonist maba glucocorticoid agonist danirixin chemokine cxc motif receptor cxcr copd ii antagonist oral phosphatidylinositol kinase delta pik copd acute chronic ii inhibitor recombinant human angiotensin converting acute lung injury ii enzyme rhace tumour necrosis factor receptor tnfr acute lung injury ii domain antibody mepolizumab interleukin il monoclonal antibody hypereosinophilic syndrome ii mepolizumab interleukin il monoclonal antibody nasal polyposis ii tolllike receptor tlr agonist asthma ii sirukumab interleukin il human monoclonal antibody sc severe asthma ii gsk annual report pipeline products competition continued pharmaceuticals vaccines product development pipeline continued achieved regulatory review milestones compound type indication phase maa ndabla respiratory continued phosphatidylinositol kinase delta activated pik delta syndrome pik inhibitor interleukin r ilr monoclonal severe asthma antibody recombinant human angiotensin pulmonary arterial hypertension converting enzyme rhace alpha v beta integrin antagonist idiopathic pulmonary fibrosis phosphatidylinositol kinase bronchietasis delta pik inhibitor oncology nyeso autologous engineered sarcoma multiple myeloma nonsmall cell lung ii tcrt cells engineered tcr cancer melanoma ovarian cancer tarextumab notch monoclonal antibody small cell lung cancer ii ox agonist monoclonal antibody solid tumours haematological malignancies enhancer zeste homologue solid tumours haematological malignancies ezh inhibitor bet family bromodomain inhibitor solid tumours haematological malignancies lysinespecific demethylase lsd acute myeloid leukemia small cell lung cancer inhibitor bcell maturation antigen antibody multiple myeloma drug conjugate protein arginine methyltransferase cancer prmt inhibitor induced tcell costimulator icos cancer agonist antibody tolllike receptor tlr agonist cancer phosphatidylinositol kinase pik castration resistant prostate cancer beta inhibitor immunoinflammation sirukumab interleukin il human monoclonal rheumatoid arthritis submitted sep sep antibody benlysta b lymphocyte stimulator monoclonal systemic lupus erythematosus submitted sep sep antibody sc sirukumab interleukin il human monoclonal giant cell arteritis iii antibody granulocyte macrophage colony osteoarthritis ii stimulating factor monoclonal antibody granulocyte macrophage colony rheumatoid arthritis ii stimulating factor monoclonal antibody benlysta rituxan b lymphocyte stimulator monoclonal sjogrens syndrome ii antibody sc cluster differentiation cd monoclonal antibody iv receptorinteracting protein rip psoriasis rheumatoid arthritis ii kinase inhibitor macrophage targeted histone rheumatoid arthritis ii deacetylase inhibitor oncostatin osm monoclonal systemic sclerosis antibody receptorinteracting protein rip ulcerative colitis kinase inhibitor interleukin il receptor monoclonal sjogren 's syndrome antibody spleen tyrosine kinase syk inhibitor chronic urticaria topical lymphocyte activation gene lag autoimmune disease protein monoclonal antibody chemokine cc motif ligand psoriatic arthritis ccl monoclonal antibody rearranged transfection ret inflammatory disorders bowel kinase inhibitor gsk annual report strategic report governance remuneration financial statements investor information pharmaceuticals vaccines product development pipeline continued achieved regulatory review milestones compound type indication phase maa ndabla rare diseases strimvelis exvivo stem cell gene therapy adenosine deaminase severe combined immune approved may deficiency adascid transthyretin ttr production inhibitor transthyretinmediated amyloidosis iii exvivo stem cell gene therapy metachromatic leukodystrophy iii exvivo stem cell gene therapy wiscottaldrich syndrome iii mepolizumab interleukin il monoclonal antibody eosinophilic granulomatosis polyangiitis iii serum amyloid p component sap amyloidosis ii monoclonal antibody sap depleter cphpc exvivo stem cell gene therapy betathalassemia ii focal adhesion kinase inhibitor pulmonary arterial hypertension pah vaccines shingrix recombinant herpes zoster prophylaxis submitted nov oct zoster vaccine mmr live attenuated measles mumps rubella prophylaxis iii us na ebola recombinant viral vector ebola haemorrhagic fever prophylaxis ii group b conjugated group b streptococcus prophylaxis ii streptococcus maternal immunisation pneumoniae recombinant conjugated streptococcus pneumoniae disease prophylaxis ii next generation copd recombinant reduction frequency moderate severe acute ii exacerbations copd patients targetting non typeable haemophilus influenzae moraxella catarrhalis hepatitis c recombinant viral vector hepatitis c virus prophylaxis ii malaria next generation recombinant malaria prophylaxis plasmodium falciparum ii men abcwy recombinant conjugated meningococcal abcw disease prophylaxis ii adolescents shigella conjugated outer membrane shigella diarrhea prophylaxis ii tuberculosis recombinant tuberculosis prophylaxis ii rsv recombinant respiratory syncytial virus prophylaxis ii maternal immunisation rsv replicationdefective recombinant respiratory syncytial virus prophylaxis ii viral vector hiv recombinant proteins hiv infection prophylaxis ii pharmaceuticals metabolic retosiban oxytocin antagonist spontaneous preterm labour iii daprodustat prolyl hydroxylase inhibitor oral anaemia associated chronic renal disease iii ileal bile acid transport ibat inhibitor cholestatic pruritus ii transient receptor potential cation heart failure ii channel v trpv antagonist interleukin il neutralisation mab delayed graft function renal transplantation ii otelixizumab cluster differentiation cd new onset type diabetes ii monoclonal antibody daprodustat prolyl hydroxylase inhibitor topical wound healing diglyceride acyltransferase dgat nonalcoholic steatohepatitis inhibitor selective androgen receptor modulator muscle wasting oxytocin inhaled oxytocin postpartum hemorrhage dermatology mepolizumab interleukin il monoclonal antibody atopic dermatitis ii nonsteroidal antiinflammatory topical atopic dermatitis ii nonsteroidal antiinflammatory topical psoriasis ii ror gamma inverse agonist topical psoriasis ii neurosciences ionisgskl ocular target lica antisense geographic atrophy agerelated macular disease oligonucleotide brand names appearing italics trademarks either owned andor licensed glaxosmithkline associated companies gsk annual report pipeline products competition continued pharmaceutical products competition intellectual property major patent expiry dates products compounds indications competitor brands us eu respiratory anoro ellipta umeclidinium bromide copd spiriva handihaler vilanterol terfenatate respimat stiolto nce nce spiolto respimat ultibro breezhaler deviceformulation deviceformulation duaklir genuair bevespi aerosphere arnuity ellipta fluticasone furoate asthma qvar pulmicort na asmanex alvesco nce deviceformulation avamysveramyst fluticasone furoate rhinitis nasonex flixotideflovent fluticasone propionate asthmacopd qvar singulair expired expired diskus device diskus device hfadevice hfadevice incruse ellipta umeclidinium bromide copd spiriva handihaler respimat eklira genuair nce nce deviceformulation deviceformulation nucala mepolizumab severe eosinophilic asthma xolair cinqair expired relvarbreo ellipta fluticasone furoate asthmacopd symbicort foster vilanterol terfenatate flutiform dulera nce nce deviceformulation deviceformulation seretideadvair salmeterol xinafoate asthmacopd symbicort foster expired expired fluticasone propionate flutiform dulera diskus device diskus device hfadevice hfadevice serevent salmeterol xinafoate asthmacopd foradil spiriva expired expired handihalerrespimat diskus device diskus device onbrez hfadevice ventolin hfa albuterol sulphate asthmacopd generic companies hfadevice hfadevice antivirals valtrex valaciclovir genital herpes coldsores shingles famvir expired expired zeffixepivirhbv lamivudine chronic hepatitis b hepsera expired expired central nervous system lamictal lamotrigine epilepsy bipolar disorder keppra dilantin expired expired imigranimitrex sumatriptan migraine zomig maxalt relpax expired expired seroxatpaxil paroxetine depression various anxiety effexor cymbalta expired expired disorders lexapro cardiovascular urogenital eperzantanzeum albiglutide type diabetes victoza byetta bydureon lyxumia trulicity avodart dutasteride benign prostatic hyperplasia proscar flomax expired finasteride coreg cr carvedilol phosphate mildtosevere heart failure toprol xl na hypertension left ventricular formulation dysfunction post mi see principal risks uncertainties details uncertainty timing followon competition see note financial statements legal proceedings generic competition possible includes supplementary protection certificates granted multiple countries eu patent term extensions granted us data exclusivity expires eu us generic competition exists markets gsk annual report strategic report governance remuneration financial statements investor information pharmaceutical products competition intellectual property continued major patent expiry dates products compounds indications competitor brands us eu antibacterials augmentin amoxicillinclavulanate common bacterial generic products na expired potassium infections rare diseases volibris ambrisentan pulmonary hypertension tracleer revatio na immunoinflammation benlysta belimumab systemic lupus erythematosus hiv epzicomkivexa lamivudine abacavir hivaids truvada atripla expired descovy genvoya combination odefsey lexivatelzir fosamprenavir hivaids prezista kaletra reyataz selzentrycelsentri maraviroc hivaids isentress intelence prezista tivicay dolutegravir hivaids isentress prezista reyataz kaletra triumeq dolutegravir lamivudine hivaids truvada atripla abacavir descovy genvoya odefsey trizivir lamivudine zidovudine hivaids truvada atripla expired expired abacavir descovy genvoya odefsey vaccines products competition intellectual property major patent expiry dates products compounds indications competitor brands us eu bexsero meningococcal groupb meningitis group b prevention trumenba vaccine boostrix diphtheria tetanus acellular diphtheria tetanus acellular adacel pertussis pertussis booster vaccination infanrix hexapediarix diphtheria tetanus pertussis prophylaxis diphtheria pentacel pediacel expired polio hepatitis b haemophilus tetanus pertussis polio pentaxim pentavac influenzae type b eu hepatitis b haemophilus hexaxim hexyon influenzae type b eu vaxelis cervarix hpv virus like human papilloma virus gardasil silgard particles vlps type adjuvant mpl aluminium hydroxide fluarix tetra split inactivated influenza seasonal influenza prophylaxis intenza flumist qiv antigens virus subtypes vaxigrip qiv subtype b fluzone qiv fluzone high dose flulaval split inactivated influenza seasonal influenza prophylaxis vaxigrip mutagrip antigens virus subtypes fluzone influvac subtype b aggripal fluad intenza flumist menveo meningococcal group c w meningitis group c w mencevax menactra conjugate vaccine prophylaxis prepandrix derived split inactivated pandemic hn influenza aflunov vepacel influenza virus antigen prophylaxis adjuvant priorix priorix tetraab live attenuated measles mumps measles mumps rubella mmr ii mmrvaxpro expired varilrixb rubella varicella vaccine chickenpox prophylaxis proquad varivax rotarix human rotavirus rix strain rotavirus prophylaxis rotateq synflorix conjugated pneumococcal prophylaxis invasive prevenar prevnar na polysaccharide disease pneumonia acute otitis media see note financial statements legal proceedings refers priorix priorix tetra patents varilrix expired generic competition commenced many markets related compoundsindications measles mumps rubella vaccineprophylaxis includes supplementary protection certificates granted b related compound varicella vaccine multiple countries eu patent term extensions granted us gsk annual report pipeline products competition continued consumer healthcare products competition brand products application markets competition wellness panadol tablets caplets infant paracetamolbased treatment global except us advil pfizer panadol cold syrup drops headache joint pain fever aspirin bayer flu cold symptoms tylenol johnson johnson voltaren topical gel nonsteroidal diclofenac based global advil pfizer antiinflammatory aspirin bayer tylenol johnson johnson otrivin nasal spray nasal decongestant germany poland afrin merck russia sweden ukraine nasivin merck theraflu tablets syrups cold flu relief russia poland ukraine tylenol cold flu us johnson johnson mucinex reckitt benckiser lemsip reckitt benckiser flonase nasal spray allergy relief us claritin bayer nasacort sanofi flixonase piriton nasal spray tablets allergy relief uk ireland benadryl johnson johnson eno effervescent immediate relief antacid global except us estomazil hypermarca gelusil pfizer tums chewable tablets immediate relief antacid us alkaseltzer bayer gaviscon reckitt benckiser rolaids sanofi nicorette us lozenges gum transdermal treatment nicotine withdrawal global nicorette johnson johnson nicoderm patches aid smoking reduction niquitin perrigo nicotinell cessation ex australia oral health sensodyne toothpastes toothbrushes relief dentinal hypersensitivity global colgate sensitive prorelief pronamel mouth rinse pronamel additionally protects colgatepalmolive acid erosion elmex colgatepalmolive oral b procter gamble parodontax toothpaste medicated helps prevent bleeding gums germany ireland colgate total gum health corsodyl mouthwash gel spray treats prevents gingivitis italy united kingdom colgatepalmolive yunnan baiyao state enterprise china polident denture adhesive denture improve retention comfort global fixodent kukident poligrip cleanser dentures cleans dentures procter gamble corega steradent reckitt benckiser aquafresh toothpastes toothbrushes aids prevention dental cavities global colgate colgatepalmolive mouthwashes maintains healthy teeth gums crest procter gamble fresh breath oralb procter gamble skin health zovirax topical cream lip care treat prevent global compeed johnson johnson abreva nonmedicated patch onset cold sores carmex carma labs blistex blistex incorporated retail label nutrition horlicks malted drinks foods nutritional indian subcontinent bournvita mondelez beverages food united kingdom ireland complan heinz gsk annual report strategic report governance remuneration financial statements principal risks uncertainties investor information principal risks discussed risks uncertainties similarly business exposes us litigation government relevant business financial condition results operations investigations including limited product liability litigation may affect performance ability achieve objectives patent antitrust litigation sales marketing litigation risks believe could cause actual litigation government investigations including related provisions results differ materially expected historical results may make unfavourable outcomes increases related costs insurance premiums could materially adversely must adapt comply broad range laws affect financial results regulations requirements apply research development manufacturing testing approval distribution sales marketing detail status various uncertainties involved pharmaceutical vaccine consumer healthcare products significant unresolved disputes potential litigation set affect cost product development also time note legal proceedings pages required reach market likelihood uk regulations require discussion mitigating activities successfully company takes address principal risks uncertainties moreover rules regulations change governmental summary activities group takes manage interpretation rules regulations evolves nature principal risks accompanies description principal particular risk may change changes certain regulatory regimes risk principal risks uncertainties listed may substantial change failure comply order significance applicable law regulations could materially adversely affect financial results patient safety risk definition individual medical officers within pharmaceutical vaccines failure appropriately collect review follow report adverse consumer healthcare businesses groups substantial events potential sources act relevant findings safety pharmacovigilance organisation keep track adverse timely manner issues reported products course clinical studies group product approved marketing group risk impact extensive postmarketing surveillance signal detection impact risk potentially compromise ability system information possible side effects products received conduct robust safety signal detection interpretation several sources including unsolicited reports health ensure appropriate decisions taken respect risk professionals patients regulatory authorities medical benefit profile products including completeness scientific literature media policy employees accuracy product labels pursuit additional studies required report immediately issues relating safety analyses appropriate could lead potential harm quality products country managers responsible patients reputational damage product liability claims monitoring exception tracking training helps assure litigation governmental investigation regulatory action collection safety information reporting information fines penalties loss product authorisation relevant central safety department accordance group policy context legal requirements preclinical clinical trials conducted development information changes riskbenefit profile one groups investigational pharmaceutical vaccine consumer healthcare products result certain actions characterise communicate products determine safety efficacy products use minimise risk proposed actions discussed humans notwithstanding efforts make determine regulatory authorities include modifying prescribing safety products appropriate preclinical clinical information communications physicians healthcare trials unanticipated side effects may become evident providers restrictions product prescribingavailability help products widely introduced marketplace questions assure safe use sometimes carrying clinical trials safety products may raised certain cases may appropriate stop clinical trials ongoing safety surveillance postmarketing studies also withdraw medicine market groups global safety governmental agencies thirdparties may analyse publicly board gsb comprising senior physicians representatives available clinical trial results supporting functions integral component system group currently defendant number product liability gsb including subsidiary boards dedicated consumer lawsuits including class actions involve significant claims healthcare products vaccines reviews safety damages related products litigation particularly us investigational marketed products across group inherently unpredictable class actions seek sweep together authority stop clinical trial continued conduct trial persons take products increase potential liability ethically scientifically justified light information claims pain suffering punitive damages frequently emerged since start trial asserted product liability actions allowed represent addition medical governance framework within group potentially openended exposure thus could materially described group uses several mechanisms foster adversely affect groups financial results early evaluation mitigation resolution disputes mitigating activities arise potential claims even arise goal chief medical officer cmo responsible medical programmes create culture early identification governance group global policy policy evaluation risks claims actual potential order safeguarding human subjects clinical trials patients minimise liability litigation take products paramount importance cmo authoritative role evaluating addressing matters human safety gsk annual report principal risks uncertainties continued intellectual property risk definition expiration dates patents major products may failure appropriately secure maintain enforce intellectual affect dates generic versions products may property rights introduced set pages listed annual expiration dates meant indicate certainty exclusivity risk impact listed products patents may designed around failure obtain subsequent loss patent protection invalidated prior expiration resulting earlier entry market including reducing availability scope patent rights generic product legal proceedings involving patent challenges compulsory licensing government forces manufacturer set note financial statements legal proceedings license patents specific products competitor could materially adversely affect financial results market generic drug manufacturers also exhibited readiness absence adequate patent data exclusivity protection market market generic versions many important products prior could limit opportunity rely market future sales expiration patents efforts may involve challenges growth products could also materially adversely validity enforceability patent assertions affect financial results market generic product infringe patents result may continue involved legal proceedings involving patent context challenges may materially adversely affect financial innovative pharmaceutical vaccine consumer healthcare results moreover us become common patent products company seek obtain appropriate intellectual infringement actions prompt claims antitrust laws property protection products ability obtain enforce violated prosecution patent litigation patents proprietary rights regard products involving defence patent claims direct critical business strategy success pharmaceutical indirect purchasers payers typically filed class products usually protected copied generic actions relief sought may include treble damages restitution manufacturers period exclusivity provided issued claims similarly antitrust claims may brought government patent related intellectual property rights regulatory data entities private parties following settlement patent litigation protection orphan drug status following expiration certain alleging settlements anticompetitive violation intellectual property rights generic manufacturer may lawfully antitrust laws successful antitrust claim private party produce generic version product government entity could materially adversely affect financial operate markets intellectual property laws patent results offices still developing governments may unwilling mitigating activities grant enforce intellectual property rights fashion similar global patents group focuses securing maintaining developed regions eu japan us enforcing patent rights global group maintains internal developing countries limited threatened limit effective processes designed seek ensure successful procurement patent protection pharmaceutical products order facilitate enforcement defence patents goal lawfully early competition within markets generic manufacturers maintaining exclusive rights markets products face competition manufacturers proprietary generic global patents group monitors new developments pharmaceutical products major markets introduction international patent law seek ensure appropriate protection generic products particularly us highest assets sometimes acting trade associations work turnover margins typically leads rapid dramatic loss local governments seek secure effective balanced sales reduces revenues margins proprietary intellectual property laws designed meet needs patients products since abbreviated pathway leads payers supporting longterm investment innovation substitutable generic vaccines competition market arises branded products generic branded products erosion sales revenues margins less dramatic addition proprietary technology used manufacture capital investment facilities create barriers entry vaccine markets depend certain key products significant portion sales one product respiratory pharmaceutical product seretideadvair accounts significant group sales worldwide patent compositions containing combination active substances seretideadvair expired generic products containing combination active substances seretideadvair dry powder inhalers metered dose inhalers launched several manufacturers number european markets new drugs applications andas filed us generic competitors seretideadvair diskus date approvals uncertain time could come early march timing anda advair hfa us uncertain patents formulation device used metered dose inhaler although protection afforded patents uncertain present similar patents exist ventolin hfa flovent hfa gsk annual report strategic report governance remuneration financial statements investor information product quality risk definition extensive global network quality compliance professionals failure comply current good manufacturing practices aligned business unit provide oversight assist cgmp inadequate controls governance quality delivery quality performance operational compliance supply chain covering supplier standards manufacturing site level senior management level management oversight distribution products activities accomplished hierarchy quality councils independent chief product quality risk impact officer global product quality office introduced failure ensure product quality could far reaching revised approach monitoring regulated quality gxp implications terms patient consumer safety resulting performance provide corporate executive team product launch delays supply interruptions product recalls integrated assessment key performance indicators kpis would potential damage gsks reputation defined kpis cover manufacturing practice clinical practice associated regulatory legal financial consequences could pharmacovigilance practice regulatory practice drug safety materially adversely affect company reputation financial assessment animal welfare results implemented riskbased approach assessing context managing third party suppliers provide materials used patients consumers healthcare professionals trust quality finished products contract manufacturers making products products product quality may influenced many factors expected comply gsk standards regularly including product process understanding consistency audited provide assurance standards met manufacturing components compliance gmp accuracy labelling reliability external supply chain embodiment staff members regularly trained ensure cgmp overarching quality culture internal external standards behaviours based values followed environment continues evolve new products new markets additionally advocacy communication programmes routinely new legislation introduced increasing scrutiny data deployed ensure consistent messages conveyed across integrity supply continuity drug shortages review inspections organisation whether originate changes regulation conducted across industry national regulatory authorities learnings inspections regulatory submissions highlighted ongoing focus data integrity third continued emphasis value quality performance metrics party oversight timely escalation pertinent issues facilitate improvement foster culture right first time regulatory authorities mitigating activities developed implemented single pharmaceutical quality system pqs defines quality standards systems businesses associated pharmaceuticals vaccines consumer healthcare products clinical trial materials system broad scope applicable throughout product lifecycle rd mature commercial supply single external quality standard system governs detailed global regulatory expectations quality medicinal products requirements often complex fragmented across national regional boundaries consequently adopted internationally recognised principles ich q pharmaceutical quality systems framework basis gsk pqs industry standard incorporates quality concepts throughout product lifecycle gsk pqs augmented consolidation numerous regulatory requirements defined markets across world assures gsk pqs meets external expectations product quality markets supplied pqs regularly updated ensure keeps pace evolving external regulatory environment new scientific understanding operational improvements incorporated pqs support delivery consistent reliable products gsk annual report principal risks uncertainties continued financial controls reporting risk definition continues significant international focus tax reform failure comply current tax law incurring significant losses including oecds base erosion profit shifting beps due treasury activities failure report accurate financial project european commission initiatives increased information compliance accounting standards applicable use fiscal state aid investigations together domestic legislation failure maintain adequate governance oversight initiatives around world may result significant changes thirdparty relationships established tax principles increase tax authority disputes regardless merit outcomes costly divert risk impact management attention may adversely impact reputation noncompliance existing new financial reporting disclosure requirements changes recognition income third parties critical business delivery integral expenses could expose us litigation regulatory action part solution improve productivity quality service could materially adversely affect financial results changes innovation rely third parties including suppliers distributors tax laws application respect matters individual contractors licensees pharmaceutical transfer pricing foreign dividends controlled companies rd tax biotechnology collaboration partners discovery manufacture credits taxation intellectual property restriction tax relief marketing products important business processes allowed interest intragroup debt could impact third party business relationships present material risk effective tax rate significant losses may arise inconsistent example share critical sensitive information application treasury policies transactional settlement errors marketing plans clinical data employee data specific counterparty defaults changes substance application third parties conducting relevant outsourced business governing tax laws failure comply tax laws operations inadequate protection misuse information significant losses due treasury activities could materially third parties could significant business impact similarly use adversely affect financial results distributors agents range activities promotion failure adequately manage third party relationships could result tendering inherent risks inappropriate promotion business disruption exposure risk ranging suboptimal unethical business practices insufficient internal compliance contractual terms conditions severe business sanctions controls distributors could affect reputation risks significant reputational damage consequences could increased complexities working large materially adversely affect business operations financial numbers third parties results mitigating activities context group maintains control environment designed identify group required laws various jurisdictions disclose material errors financial reporting disclosure design publicly financial results events could materially affect operating effectiveness key financial reporting controls financial results group regulators routinely review regularly tested management via independent business financial statements listed companies compliance new monitoring provides us assurance controls revised existing accounting regulatory requirements key financial reporting disclosure processes operated group believes complies appropriate regulatory effectively requirements concerning financial statements disclosure keep date latest developments financial material information including transactions relating business reporting requirements working external auditors restructuring acquisitions divestitures however legal advisors subject investigation potential noncompliance accounting disclosure requirements may lead shared accountability financial results across restatements previously reported results significant penalties businesses financial results reviewed approved regional management reviewed financial controller treasury group deals high value transactions mostly foreign chief financial officer cfo allows financial controller exchange cash management transactions daily basis cfo assess evolution business time transactions involve market volatility counterparty risk evaluate performance plan significant judgements reviewed groups effective tax rate reflects rates tax jurisdictions confirmed senior management business reorganisations group operates higher lower newly acquired activities integrated risk assessments uk rate takes account regimes encourage innovation appropriate controls reviews applied counterparty exposure investment science providing tax incentives subject defined limits approved board credit changed could affect groups tax rate addition worldwide rating individual counterparties nature operations crossborder supply routes result conflicting claims tax authorities profits taxed created finance risk controls centre individual countries tax charge included financial excellence maintain finance control framework added statements best estimate groups tax liability pending resources ensure processes controls maintained audits tax authorities business transformation upgrade financial systems processes ongoing integration former novartis businesses control reporting framework additional risk mitigation introduced amending programme timelines system upgrades gsk annual report strategic report governance remuneration financial statements investor information financial controls reporting continued group maintains disclosure committee reporting business unit leadership team retains ultimate accountability board reviews groups quarterly results annual managing third party interactions risks working report form f determines throughout year third parties employees expected manage external consultation legal advisors whether necessary interactions commitments responsibly expectation disclose publicly information group stock embedded values code conduct responsibility exchange announcements treasury management group activities performed safely compliance meets regular basis seek ensure liquidity interest applicable laws values standards code conduct rate counterparty foreign currency transaction foreign seek guide enforce global principles interactions currency translation risks managed line third parties place policy framework applicable conservative approach detailed associated risk buying goods services managing external spend paying strategies policies adopted board working third parties policy framework applies oversight treasurys role managing counterparty risk line employees complementary workers worldwide framework agreed policy performed corporate compliance officer complemented technical local standards designed seek operates independently treasury details mitigation ensure alignment nature third party interactions treasury risks found pages note good manufacturing practice adherence local laws financial instruments related disclosures tax risk managed regulations independent business monitoring key financial set policies procedures seek ensure consistency operational controls place supplemented periodic compliance tax legislation seek maintain open checks companys independent audit assurance function positive relationships governments tax authorities continuous monitoring performance third parties enhanced worldwide monitor government debate tax policy key third party oversight programme managed jurisdictions deal proactively potential future changes global ethics compliance organisation global programme tax law engage advisors legal counsel review tax completed deployment across latam south east asia legislation implications business relevant countries takes enterprise wide view third party related active providing relevant business input tax policy makers risks programme strengthening risk assessment due significant decisions considered agreed tax diligence efforts third parties improving overall governance board meets quarterly made senior management third party risks lifecycle personnel across finance group third party engagement centralised team dedicated specialists responsible managing transactional tax reporting compliance submit tax returns according statutory time limits engage tax authorities seek ensure tax affairs current entering arrangements continuous audit programmes advance pricing agreements provide longterm certainty tax treatment appropriate exceptional cases matters settled agreement tax authorities may resolve disputes formal appeals proceedings gsk annual report principal risks uncertainties continued antibribery corruption risk definition mitigating activities failure gsk employees consultants third parties comply code conduct values behaviours commitment antibribery corruption abac principles zero tolerance integral mitigate risk light standards well applicable legislation complexity geographic breadth risk constantly evolve oversight activities data reinforce employees risk impact contractors clear expectations regarding acceptable behaviours failure mitigate risk could expose group associated maintain ongoing communications group headquarters persons governmental investigation regulatory action civil local markets criminal liability group enterprisewide abac programme designed addition legal penalties failure prevent bribery ensure compliance groups abac policies prevent complying abac legislation regulations could risk bribery corruption builds values business substantial implications reputation company standards form comprehensive practical approach credibility senior leaders erosion investor confidence compliance flexible evolving nature business governance risk management abac programme built best class principles range context features collectively enable us manage risk top exposed bribery corruption risk global bottom example programme comprises business operations markets government structure toplevel commitment group board directors rule law less developed bearing leadership global risk assessment enable targeted intervention bribery corruption risk exposure addition global nature compliance monitoring activities programme underpinned business healthcare sector highly competitive global abac policy written standards address subject regulation increases instances commercial practices give rise abac risk exposed activities interactions bribery corruption risk ongoing training communications addition programme group subject number abac inquiries mandates enhanced controls interactions government reached resolution us authorities regarding officials business development transactions abac inquiry whilst inquiry uk authorities ongoing employees required complete comprehensive abac training investigations discussed note legal dependent role requirements proceedings programme governance provided groups abac governance board includes representation key functional areas business units dedicated abac team responsible implementation evolution programme response developments internal external environment complemented independent oversight assurance undertaken audit assurance independent business monitoring teams continually benchmark abac programme large multinational companies use external expertise drive improvements programme gsk annual report strategic report governance remuneration financial statements investor information commercialisation risk definition mitigating activities failure execute business strategies effectively manage strategic objectives designed ensure group achieves competitive opportunities threats accordance letter mission helping people feel better live longer spirit legal industry groups requirements group continues strive new product launches competitive resourced effectively well healthy proportion risk impact sales ratio attributable new product innovation sales failure manage risks related commercialisation could materially innovation helps group defray effect example adversely affect ability grow diversified global business downward price pressure major markets declining emerging deliver products value patients consumers market growth negative foreign exchange impact failure comply applicable laws rules regulations may result governmental investigation regulatory action legal establishing new products priced balance expectations proceedings brought group governmental private patients consumers hcps payers shareholders plaintiffs failure provide accurate complete information community enables group maintain strong global business related products may result incomplete awareness remain relevant needs patients consumers riskbenefit profile products possibly suboptimal treatment values provide guide lead make decisions patients consumers consequences could constantly strive right thing deliver quality products materially adversely affect group seeking ensure behaviours reflect values mission company practices found misaligned values could also result reputational damage dilute trust established taken action levels group enhance external stakeholders improve standards procedures promotional interactions based values transparency respect integrity patient context focus policies standards governing promotional operate global basis industry highly activities undertaken group behalf competitive highly regulated competitors may make activities conduct worldwide must conform high ethical significant product innovations technical advances may regulatory industry standards local standards differ intensify price competition light competitive environment global standards stringent two applies continued development commercially viable new products development additional uses existing products critical group harmonised policies procedures guide achieve strategic objectives pharmaceutical vaccine country commercial practices processes well clarified consumer companies group faces downward price applicable standards engaging markets business pressure major markets declining emerging market growth unit within group adopted gsks internal control framework negative foreign exchange impact support assessment management risks commercial practices activities appropriate monitoring programmes developing new pharmaceutical vaccine consumer healthcare oversight business unit risk management compliance products costly lengthy uncertain process product boards country executive boards manage risks across candidate may fail stage including significant group incountry business activities economic human resources invested competitors products pricing strategies failure promotional materials activities must reviewed part develop commercially successful products develop approved according groups policies standards additional uses existing products could materially adversely conducted accordance local laws regulations seek affect ability achieve strategic objectives ensure materials activities fairly represent products services group necessary committed ethical responsible commercialisation disciplined including termination employees products support mission improve quality engaged misconduct broadened ability claw back human life enabling people feel better live longer remuneration senior management event misconduct accomplish mission engage healthcare community various ways provide important information medicines group continues evolve commercial operating model embedding industry leading changes compensation model promotion approved products seeks ensure healthcare sales professionals managers interact hcps professionals hcps globally access information need changes eliminated rewards based sales market share patients consumers access information prescription products individuals territories favour rewards products need products prescribed recommended based quality individuals interactions hcps used manner provides maximum healthcare benefit furthermore beginning gsk stopped paying patients consumers committed communicating hcps deliver promotional presentations gsk hcps information related approved products responsible legal sponsor travel medical educational conferences ethical manner business units within group confronted common types commercialisation risks differences exist types risks present degree risk presented business unit consequently risks managed reflects different nature profile business units across group gsk annual report principal risks uncertainties continued research practices risk definition mitigating activities failure adequately conduct ethical sound preclinical established office animal welfare ethics strategy clinical research addition failure engage scientific activities oawes led chief animal welfare ethics strategy consistent letter spirit law industry seek ensure humane responsible care animals groups requirements increase knowledge application nonanimal alternatives group oawes embeds framework animal welfare risk impact governance promotes application rs replacement refinement impacts risk include harm human subjects reputational reduction animals research explores opportunities damage failure obtain necessary regulatory approvals crossindustry data sharing conducts quality assessments products governmental investigation legal proceedings brought group governmental private plaintiffs product make information available studies including summaries liability suits claims damages regulatory action results whether positive negative gsk first fines penalties loss product authorisation company publish clinical study reports form basis consequences could materially adversely affect financial submissions regulatory agencies publically posted results clinical study reports addition study result summaries detailed patientlevel data context approximately clinical studies requested research relating animals raise ethical concerns accessed clinicalstudydatarequestcom attempt address proactively animal studies remain vital part research many cases method global human biological samples management hbsm used investigate effects potential new medicine living governance framework place oversee ethical lawful body tested humans generally mandated acquisition management human biological samples regulators ethically imperative animal research provide global hbsm network champions hbsm activities provides critical information causes diseases experienced group support internal sample custodians develop nonetheless continually seeking ways best practice remains important priority enhance minimise use animals research whilst complying data integrity controls data integrity committee place regulatory requirements throughout year provide oversight data integrity quality assurance team began conducting assessments intended clinical trials healthy volunteers patients used assess provide independent business monitoring internal controls demonstrate investigational products efficacy safety rd activities evaluate product approved marketing also work human biological samples chief regulatory officer oversees activities samples fundamental discovery development safety regulatory governance board includes promoting monitoring products integrity data essential compliance regulatory requirements groupwide success stages research data lifecycle design standards making regulatory services efficient agile generation recording management analysis reporting aligning regulatory capabilities international business storage retrieval research data governed legislation needs enterprise local levels group strictly prohibits regulatory requirements research data supporting promotional practices prior marketing authorisation care documents core components various stages pipeline taken seek ensure se activity promotional progression decisionmaking also form content specific accountability authorisation se resides within regulatory submissions poor data integrity compromise medical governance framework overseen global research efforts medical topic board gmtb accountable chief medical innate complexities interdependencies required officer gmtb responsible oversight applicable policies regulatory filings particularly given global research seeking ensure highest level integrity continuous development footprint rapid changes submission requirements development se gsk framework seeks ensure developing countries continue increase complexity right level accountability clear programme guidance worldwide product registration scientific engagement se defined country across rd business units local operating interaction exchange information gsk companies external communities order advance scientific medical research practices risk aligned new enterprise understanding including appropriate development use framework seeks ensure strengthened governance across products essential part scientific discourse rd businesses pharmaceutical vaccines consumer nonpromotional engagement external stakeholder groups healthcare leadership chief research practices vital gsks mission necessary scientific medical officer management risk take practical approach advance scope se activities includes advisory boards information sharing streamlining risk identification escalation scientific consultancies preplanned informal discussions ensuring ownership stays business unit level allows healthcare professionals hcp sharing medical information proportional risk treatment plan publications including abstracts congresses scientific interactions payers patients governments media support independent medical education se activities essential present legal regulatory reputational risk sharing data invited media coverage payments service providers perceived promotional intent risks particularly high hcp engagement associated financial andor transfer value disclosures required gsk gsk annual report strategic report governance remuneration financial statements investor information environment health safety sustainability risk definition mitigating activities failure manage environment health safety substainability corporate executive team cet responsible ehss ehss risks line objectives policies governance group global policy policy relevant laws regulations cet seeks ensure control framework place manage risks impacts legal compliance issues relate risk impact ehss assigning responsibility senior managers failure manage ehss risks could lead significant harm providing maintaining controls individual managers seek people environment communities operate fines ensure ehss control framework effective well failure meet stakeholder expectations regulatory requirements implemented respective business area fully litigation regulatory action damage groups reputation compliant applicable laws regulations adequately could materially adversely affect financial results resourced maintained communicated monitored additionally context employee personally responsible ensuring group subject health safety environmental laws applicable local standard operating procedures followed various jurisdictions laws impose duties protect people expected take responsibility ehss matters environment communities operate well riskbased proactive approach articulated refreshed potential obligations remediate contaminated sites global ehss standard supports ehss policy also identified potentially responsible party objective discover develop manufacture supply sell us comprehensive environmental response compensation products without harming people environment addition liability act number sites remediation costs relating design provision safe facilities plant equipment use ownership sites us failure manage operate rigorous procedures help us eliminate hazards environmental risks properly could result litigation regulatory practicable protect employees health wellbeing action additional remedial costs may materially continuing efforts improve environmental sustainability adversely affect financial results see note financial reduced value chain carbon intensity per pack water statements legal proceedings discussion consumption waste generation actively manage environmental related proceedings involved environmental remediation obligations seek ensure practices routinely accrue amounts related liabilities environmentally sustainable compliant ehss matters performance results shared externally year responsible business supplement information protection risk definition mitigating activities risk gsk business activities information becomes disclosed group global information protection policy authorised see information systems fail supported dedicated programme activity increase available corrupted focus information security group established information protection privacy function provide strategy risk impact direction oversight enhancing global information failure adequately protect critical sensitive systems security capabilities information may result loss commercial strategic advantage damage reputation litigation business disruption assess changes information protection risk environment including regulatory sanction could materially adversely briefings government agencies subscription affect financial results commercial threat intelligence services knowledge sharing pharmaceutical crossindustry companies context rely critical sensitive systems data corporate aim use industry best practices part information strategic plans sensitive personally identifiable information pii security policies processes technologies invest strategies intellectual property manufacturing systems trade secrets commensurate changing nature security potential computer systems information may threat landscape privacy centre excellence exposed misuse unauthorised disclosure also established ensure compliance prior deadline subject various laws govern processing pli new general data protection requirements gdprs employees required complete training appropriate handling maintaining pii groups binding corporate rules bcrs approved uk information commissioners office human resource research activities data bcrs recognised european states switzerland allowing us transfer pii internationally groups entities without individual privacy agreements european union country approval remaining two countries greece romania expected gsk annual report principal risks uncertainties continued supply continuity crisis management risk definition mitigating activities failure deliver continuous supply compliant finished product supply chain model designed ensure supply quality inability respond effectively crisis incident timely manner security products globally far possible closely recover sustain critical operations including key supply monitor supply chain governance committees chains risk previously called crisis continuity inventory status delivery products aim ensure management customers pharmaceutical vaccines consumer healthcare products need risk impact recognise failure supply products adversely improved links commercial forecasting manufacturing impact consumers patients rely material made possible core commercial cycle time interruption supply exclusion healthcare programmes reduce risk associated demand fluctuations impact could expose us litigation regulatory action financial ability supply cost writeoffs products penalties could adversely affect groups financial results exceed expiry date node supply chain periodically reviewed ensure adequate safety stock balancing working groups international operations partners capital endtoend supply chain safety stocks backup expose workforce facilities operations information supply arrangements medically critical highrevenue products technology potential disruption natural events eg storm place help mitigate risk addition routinely monitor earthquake manmade events eg civil unrest terrorism global compliance manufacturing external suppliers order emergencies eg ebola outbreak flu pandemic important identify manage risks supply base practical gsk robust crisis management recovery plans place minimise dependence single sources supply critical manage events items alternative sourcing arrangements possible context inventory strategy aims protect supply chain unanticipated supply chain operations subject review approval disruption various regulatory agencies effectively provide licence continue implement anticounterfeit systems product operate failure manufacturing distribution facilities serialisation accordance emerging supply chain requirements suppliers key services materials could lead litigation around world corporate policy requires business unit regulatory action product recalls seizures interruption functional area head ensure effective crisis management supply delays approval new products suspension business continuity plans place include authorised manufacturing operations pending resolution manufacturing response recovery strategies key areas responsibility logistics issues clear communication routes business disruption occurs rely materials services provided third party suppliers corporate security supports business coordinating crisis make products including active pharmaceutical ingredients management business continuity training facilitating simulation api antigens intermediates commodities components exercises assessing group preparedness recovery capability manufacture packaging pharmaceutical vaccine providing assurance oversight groups central repository consumer healthcare products third party services plans supporting critical business processes business procured services provided contract manufacturing unit governance board performs risk oversight clinical research organisations support development key monitoring including identifying new emerging threats products important ensure continuous operation group coordinated approach evaluate manage businesses implications business regarding uks exit although undertake business continuity planning single sourcing european union certain components bulk api finished products services activities help ensure appropriate level readiness creates supply risk event regulatory noncompliance response capability maintained also develop maintain physical disruption manufacturing sites logistics system partnerships external bodies like business continuity small number singlesource third party suppliers institute un international strategy disaster risk service providers use fail fulfil contractual obligations reduction helps improve business continuity initiatives timely manner experience regulatory noncompliance physical disasterprone areas supports development community disruption logistics manufacturing sites could also resilience disasters result delays service interruptions use effective crisis management business continuity planning provide health safety people minimise impact group maintaining functional operations following natural manmade disaster public health emergency gsk annual report strategic report governance remuneration financial statements shareholder information investor information share capital control details issued share capital number shares share buyback programme held treasury december found board authorised issue allot ordinary shares note financial statements share capital share article companys articles association power premium account article authority company make purchases shares subject shareholder authorities ordinary shares listed london stock exchange sought annual basis annual general meeting agm also quoted new york stock exchange nyse shares purchased company may cancelled held form american depositary shares ads ads treasury shares used satisfying share options grants represents two ordinary shares details listed debt group employee share plans listed refer note financial statements net debt programme covers purchases shares cancellation held treasury shares accordance authority holders ordinary shares ads entitled receive renewed shareholders agm may dividends declared companys annual report attend company authorised purchase maximum speak general meetings company appoint proxies million shares details shares purchased cancelled exercise voting rights held treasury shares subsequently transferred restrictions transfer limitations holding treasury satisfy awards groups share plans ordinary shares ads requirements obtain approval disclosed note financial statements share capital prior transfers ordinary shares ads carry special share premium account rights regard control company determining specific share repurchase levels company restrictions voting rights major shareholders voting considers development free cash flow year given rights per share shareholders known impact sustained strength sterling free cash flow arrangements financial rights held person company suspended share repurchase programme holder shares known agreements shares purchased financial years restrictions share transfers voting rights ended shares acquired share schemes plans rank equally company confirms currently intend make shares issue special rights market purchases company review trustees employee share ownership plan trusts waived potential future share buybacks line rights dividends shares held trusts usual annual cycle subject return ratings criteria exchange controls limitations affecting security holders market capitalisation certain economic sanctions may force market capitalisation based shares issue excluding time time currently applicable laws decrees treasury shares gsk december billion regulations force uk restricting import export date gsk fifth largest company market capital affecting remittance dividends payments capitalisation ftse index holders companys shares nonresidents uk similarly certain economic sanctions may share price force time time limitations relating nonresidents uk english law companys articles january association right holder vote respect december companys shares increasedecrease interests voting rights high year stated far aware low year persons significant direct indirect holdings company information provided company pursuant financial table sets middle market closing prices conduct authoritys fca disclosure transparency rules companys share price increased compares dtrs published regulatory information service increase ftse index year companys website wwwgskcom share price march march company received notifications accordance fcas dtrs following notifiable interests uk us voting rights companys issued share capital percentage issued shares capital blackrock inc p ercentage ordinary shares issue excluding treasury shares acquired disposed interests shares period review exception transferred treasury satisfy awards groups share plans uk share price uk us ads price us gsk annual report shareholder information continued share capital control continued nature trading market following tables set periods indicated high low middle market closing quotations pence shares london stock exchange high low closing prices us dollars ads nyse ordinary shares ads pence per share us dollars per share high low high low march february january december november october september quarter ended december quarter ended september quarter ended june quarter ended march quarter ended december quarter ended september quarter ended june quarter ended march year ended december year ended december year ended december year ended december year ended december march analysis shareholdings december number total total number accounts accounts shares shares holding shares held nominee companies investment trust companies insurance companies individuals corporate bodies bny nominees limited held treasury shares glaxosmithkline bny mellon depositary companys ads listed nyse ordinary shares representing companys adr programme managed depositary registered name bny nominees limited march bny nominees limited held ordinary shares representing issued share capital excluding treasury shares date march number holders ordinary shares us holdings ordinary shares number registered holders ads holdings ads certain ordinary shares ads held brokers nominees result number holders record registered holders us representative number beneficial holders residence beneficial holders gsk annual report strategic report governance remuneration financial statements investor information dividends company pays dividends quarterly continues return cash dividend calendar shareholders dividend policy dividends remain ads exdividend exdividend essential component total shareholder return company quarter date date record date payment date committed increasing dividend longterm details q february february february april dividends declared amounts payment dates q may may may july given note financial statements dividends q august august august october dividends per share q november november november january table sets dividend per share per ads last five years dividend per ads translated us dollars applicable exchange rates year dividend pence us special q interim ordinary dividend special dividend receivable adr holders calculated based exchange rate april annual fee per ads per ads per quarter charged depository cumulative dividend receivable adr holders q q q us special dividend related return part net cash proceeds novartis transaction completed march paid fourth quarter ordinary dividend financial calendar results announcements event date results announcements issued london stock exchange quarter results announcement aprilmay available news service also sent annual general meeting may us securities exchange commission nyse issued quarter results announcement july media made available website quarter results announcement october financial reports preliminaryquarter results announcement february company publishes annual report made available annual report publication februarymarch website date publication shareholders may annual report distribution march elect receive annual report contacting registrar information company including share price available alternatively shareholders may elect receive notification website wwwgskcom information made available email publication financial reports registering website constitute part annual report wwwshareviewcouk copies previous financial reports available website printed copies obtained registrar uk see contact details gsk annual report shareholder information continued annual general meeting pm uk time thursday may adr holders wishing attend meeting must obtain proxy queen elizabeth ii centre broad sanctuary westminster bny mellon depositary notifying request london swp ee enable attend vote business transacted adr holders may instruct bny mellon way agm companys principal forum communication shares represented adr voted private shareholders addition formal business completing returning voting card provided depositary presentation ceo performance group future development opportunity documents display questions asked board chairmen boards articles association company directors service committees take questions relating committees contracts applicable letters appointment directors company subsidiaries side investors holding shares nominee service arrange letters relating severance terms pension arrangements nominee service appointed proxy respect available inspection companys registered office shareholding order attend vote meeting made available inspection agm tax information shareholders summary certain uk tax us federal income tax uk tax years onwards dividend tax credits consequences holders shares adr citizens longer apply uk resident individuals entitled instead uk us set complete analysis dividend tax allowance first possible tax consequences purchase ownership sale dividends received tax year free tax proposals securities intended general guide holders announced march reduce allowance advised consult advisers respect tax tax year onwards dividends excess consequences purchase ownership sale shares allowance taxed basic rate taxpayers adr consequences state local tax laws higher rate taxpayers additional rate taxpayers us implications current ukus tax conventions uk resident shareholders corporation taxpayers note us holders adr generally treated owners dividends payable ordinary shares generally entitled underlying shares purposes current usuk double exemption corporation tax taxation conventions relating income gains income tax taxation capital gains convention estate gift taxes estate gift tax convention uk shareholders may liable uk tax gains disposal purposes internal revenue code amended shares adr different rates apply taxation capital gains code across tax years uk shareholders disposals individuals uk tax year summary applies uk resident shareholder holds subject availability exemption relief annual shares capital assets exempt amount taxable capital gain accruing disposal taxation dividends shares adr taxed allowable deductions different regimes apply taxation dividend income payable shareholders taxable income tax year exceeds basic uk resident individuals uk tax years april rate income tax limit cases taxable capital gain accruing tax years commencing april disposal shares adr may taxed combination rates april rates reduced uk tax years including uk resident respectively shareholders generally subject uk income tax full amount dividends paid grossed amount tax credit corporation taxpayers may entitled indexation allowance tax credit may set individuals income tax liability applies reduce capital gains extent gains respect gross dividend repayable shareholders arise due inflation indexation allowance may reduce chargeable tax liability less associated tax credit extent gain create allowable loss individuals income exceeds basic rate limit inheritance tax higher rate limit upper dividend rate applies set individual ukdomiciled otherwise shareholders may liable grossed dividend figure whose uk inheritance tax transfer shares adr tax may income exceeds higher rate limit additional charged amount value shareholders dividend rate normally apply estate reduced result transfer way lifetime gift disposal less full market value case bequest death tax may charged value shares date shareholders death gift disposal subject uk inheritance tax us estate gift tax estate gift tax convention would generally provide tax paid us credited tax payable uk gsk annual report strategic report governance remuneration financial statements investor information tax information shareholders continued stamp duty stamp duty reserve tax dividends qualified subject taxation us uk stamp duty andor stamp duty reserve tax sdrt subject federal graduated tax rates maximum rate certain exemptions payable transfer shares rate types dividends automatically excluded qualified rounded nearest case stamp duty dividends even meet requirements include consideration transfer notwithstanding provided limited instrument executed pursuance agreement gave rise capital gains distributions charge sdrt instrument stamped within six years agreement including stamped exempt dividends bank deposits sdrt charge cancelled sdrt already ividends held corporation employee stock ownership paid repaid plan esop us shareholders dividends paid taxexempt corporations summary applies shareholder citizen resident us domestic corporation person us state local tax rates qualified nonqualified dividends otherwise subject us federal income tax net income basis may vary would assessed addition federal tax rates respect shares adr holds shares adr capital communicated assets resident uk uk tax purposes taxation capital gains hold shares purposes trade profession vocation generally us holders subject uk capital gains tax carried uk branch agency subject us tax capital gains realised sale summary also address tax treatment holders disposal shares adr gains longterm capital gains subject special tax rules banks taxexempt entities subject reduced rates taxation individual holders insurance companies dealers securities currencies persons shares adr held one year date hold shares adr part integrated investment shares vestedreleased shortterm capital gains including straddle comprised share adr one subject taxation rates whereas longterm capital positions persons directly indirectly gains may subject rates state local tax voting stock company address tax rates capital gains may also apply treatment may applicable result international income information reporting backup withholding tax treaties dividends payments proceeds sale shares taxation dividends adr paid within us certain usrelated financial gross amount dividends received treated foreign source intermediaries subject information reporting may dividend income us tax purposes eligible dividend subject backup withholding unless us holder corporation received deduction allowed us corporations dividends adr exempt recipient provides taxpayer identification number payable us dollars dividends shares payable pounds certifies loss exemption occurred nonus holders sterling dividends paid pounds sterling included income generally subject information reporting backup us dollar amount calculated reference exchange rate withholding may required provide certification day dividends received holder subject nonus status connection payments received amounts certain exceptions shortterm hedged positions individual withheld allowed refund credit holders us eligible us holder subject us taxation maximum rate federal income tax liability provided required information respect qualified dividends qualified dividend furnished internal revenue service defined us internal revenue service dividend meets estate gift taxes following criteria estate gift tax convention us shareholder ust issued us corporation corporation incorporated generally subject uk inheritance tax us possession corporation eligible stamp duty benefits comprehensive income tax treaty deemed uk stamp duty andor sdrt subject certain exemptions satisfactory published irs payable transfer shares adr custodian dividends listed irs dividends depository rate amount consideration qualify provided transferred sale value transferred consideration required dividend holding period met shares must owned days however stamp duty sdrt payable transfer holding period defined day period agreement transfer adr begins days exdividend date day stock trades without dividend priced example stocks exdividend date october shares must held days period august november year order count qualified dividend gsk annual report shareholder information continued shareholder services contacts registrar companys registrar equiniti limited aspect house spencer road lancing bn da wwwshareviewcouk tel uk tel outside uk equiniti provides range services shareholders service offers participate dividend reinvestment plan alternative receiving cash dividends may choose drip election form downloaded drip reinvest dividends buy gsk shares wwwshareviewcouk requested telephoning equiniti dividend payment direct bank account currently receive dividends cheque post dividend bank mandate form bank mandate instead paid directly bank building downloaded wwwshareviewcouk society account quicker secure avoids risk requested telephoning equiniti cheque going astray dividend payment direct bank account instead waiting sterling cheque arrive post equiniti details service costs overseas shareholders convert dividend local currency send direct involved please contact equiniti local bank account service available countries worldwide electronic communications shareholders may elect receive electronic notifications company register wwwshareviewcouk communications including annual report dividend payments paid way bank mandate access electronic tax vouchers availability online voting general meetings time gsk mails hard copy shareholder documents receive email containing link document relevant website shareview portfolio service enables create free online portfolio view share register wwwshareviewcouk balance movements update address dividend payment instructions register votes agm duplicate publications mailings receive duplicate copies report mailings please please contact equiniti contact equiniti arrange accounts merged one convenience avoid waste unnecessary costs share dealing service shareholders may trade shares either held certificated form held internet transactions please log corporate sponsored nominee internet telephone wwwshareviewcoukdealing please note market trading hours postal dealing service provided equiniti financial services limited pm uk time telephone transactions please monday friday excluding public holidays call uk england wales outside uk postal transactions please call request dealing form corporate sponsored nominee account convenient way manage shares without requiring application form requested share certificate service provides facility hold wwwshareviewcouk shares nominee account sponsored company telephoning equiniti continue receive dividend payments annual reports attend vote companys general meetings shareholders names appear publicly available share register service free join individual savings accounts isas company arranged equiniti financial services limited details available provide gsk corporate isa hold gsk ordinary shares wwwshareviewcouk requested telephoning equiniti lines open pm dealing pm enquiries monday friday excluding public holidays england wales uk lines open pm monday friday excluding public holidays england wales provision share dealing details intended invitation inducement engage investment activity advice share dealing obtained stockbroker independent financial adviser gsk annual report strategic report governance remuneration financial statements investor information shareholders services contacts continued adr depositary contacts investor relations adr programme administered bank new york mellon investor relations may contacted follows uk bny mellon shareowner services great west road po box brentford middlesex tw gs college station tx tel overnight correspondence sent us bny mellon shareowner services crescent drive quality circle suite philadelphia pa college station tx tel us toll free wwwmybnymdrcom tel outside us tel us toll free gsk response center tel outside us tel us toll free email shrrelationscpushareownerservicescom share scam alert depositary also provides global buydirect direct ads receive unsolicited telephone call offering sell buy purchasesale dividend reinvestment plan adr holders shares please take extra care caller may part highly details enrol please visit wwwmybnymdrcom organised financial scam call helpline number obtain enrolment pack uk shareholder please contact financial conduct glaxo wellcome smithkline beecham authority information similar activities corporate peps wwwfcaorgukconsumers consumer helpline share centre limited oxford house oxford road aylesbury bucks hp sz tel uk tel tel outside uk wwwsharecom lines open pm uk time monday friday except uk public donating shares save children holidays pm saturdays gsk embarked ambitious global partnership responsible business supplement save children share expertise resources publishing responsible business supplement aim helping save lives one million children online outline gsks approach performance key responsible business areas health behaviour shareholders small number shares value people planet makes uneconomical sell may wish consider donating save children donated shares aggregated sold save children use funds raised help reach goal obtain share donation form please contact registrar equiniti managing donation sale uk shares save children free charge provision share dealing details intended invitation inducement engage investment activity advice share dealing obtained stockbroker independent financial adviser gsk annual report statutory disclosures us law regulation number provisions us law regulation apply responsible establishing maintaining internal company shares quoted new york stock control financial reporting provides reasonable assurance exchange nyse form adss regarding reliability financial reporting preparation financial statements external purposes accordance nyse rules generally accepted accounting principles general nyse rules permit company follow uk corporate governance practices instead applied us disclosed annual report form f provided explain significant variations explanation changes internal controls financial reporting contained form f accessed period covered annual report form f securities exchange commissions sec edgar database materially affected reasonably likely affect materially via website nyse rules came effect require us companys internal control financial reporting file annual interim written affirmations concerning audit disclosed based recent evaluation internal control risk committee statement significant differences financial reporting external auditors arc corporate governance significant deficiencies material weaknesses design operation internal controls financial reporting sarbanesoxley act reasonably likely affect adversely companys ability record following number corporate accounting scandals us process summarise report financial information fraud congress passed sarbanesoxley act sarbanesoxley regardless materiality involving persons significant wideranging piece legislation concerned largely financial role companys internal control financial reporting reporting corporate governance group carried evaluation supervision recommended sec company established participation management including ceo disclosure committee committee reports ceo cfo cfo effectiveness design operation groups audit risk committee chaired company disclosure controls procedures december secretary members consist senior managers finance legal corporate communications investor relations inherent limitations effectiveness system disclosure controls procedures including possibility external legal counsel external auditors internal experts human error circumvention overriding controls invited attend meetings periodically responsibility procedures accordingly even effective disclosure controls considering materiality information timely basis procedures provide reasonable assurance achieving determining disclosure information responsibility control objectives timely filing reports sec formal review annual report form f committee met ceo cfo expect complete certifications times report conclusions effectiveness disclosure controls procedures march following certificates sarbanesoxley requires annual report form f filed sec part groups form f contain statement whether member audit risk committee arc audit committee financial expert defined section managements annual report internal control sarbanesoxley statement relevant member financial reporting arc judy lewent included audit risk committee report accordance requirements section sarbanes biography additional disclosure oxley following report provided management respect requirements arise section section sarbanes companys internal control financial reporting defined oxley respect disclosure controls procedures internal rules af df us securities exchange act control financial reporting amended exchange act section corporate responsibility financial reports management responsible establishing maintaining sarbanesoxley also introduced requirement ceo adequate internal control financial reporting group cfo complete formal certifications confirming internal control financial reporting designed provide reasonable assurance regarding reliability financial reporting reviewed annual report form f preparation financial statements external purposes based knowledge annual report form f accordance ifrs contains material misstatements omissions management conducted evaluation effectiveness based knowledge financial statements internal control financial reporting based framework financial information fairly present material respects internal control integrated framework issued financial condition results operations cash flows committee sponsoring organisations treadway dates periods presented annual report commission coso form f changes groups internal control responsible establishing maintaining disclosure financial reporting materially affected controls procedures ensure material information reasonably likely affect materially groups internal control made known evaluated effectiveness financial reporting controls procedures yearend results management assessed effectiveness internal control evaluation contained annual report financial reporting december form f conclusion filed part groups form f gsk annual report strategic report governance remuneration financial statements investor information us law regulation continued pricewaterhousecoopers llp audited consolidated group direct knowledge identity distributors financial statements group year ended december downstream customers iran possible also assessed effectiveness groups internal customers include entities governmentowned hospitals control financial reporting auditing standard pharmacies owned controlled directly public company accounting oversight board united states indirectly iranian government persons entities audit report filed groups form f sanctioned connection terrorism proliferation activities group direct knowledge distributors section r exchange act customers establish proportion gross revenue section r exchange act requires issuers make specific sales potentially attributable entities affiliated iranian disclosure annual reports certain types dealings government parties sanctioned disclosable activities iran including transactions dealings governmentowned result group reporting entire gross revenues million entities well dealings entities sanctioned activities net profits million groups sales iran related terrorism proliferation weapons mass destruction even activities prohibited us law group also aware hospitals medical involve us persons group legal entity based facilities lebanon may affiliated controlled hezbollah iran export certain pharmaceutical vaccine products designated united states terrorist organisation iran via sales nonus entities two privately held iranian group deal directly facilities sells distributors group also business via nonus entities distributors group also unable identify jurisdictions targeted sanctions laws including syria certainty degree nature affiliation end customers crimea north korea sudan hezbollah group unable establish proportion gross revenue sales potentially attributable reportable believe groups direct dealings iran entities result group reporting entire gross revenues require specific disclosure requirements group million net profits million groups sales limits sales iran north korea syria sudan cuba essential lebanon medicines determined part using criteria set world health organization donations political organisations political expenditure effect january ensure consistent approach notwithstanding policy companies act requires political contributions across group introduced global companies continue obtain shareholder approval policy stop voluntarily corporate political contributions make donations eu political organisations incur eu political expenditure therefore make intend period january december group make donations eu political parties organisations make political donations eu noneu organisations incur eu political expenditure definitions political notwithstanding introduction policy accordance donations political expenditure political organisations used federal election campaign act us continue legislation wide annually seek shareholder support employeeoperated political action committee pac authorisation inadvertent expenditure particular facilitates voluntary political donations eligible gsk definition eu political organisations may extend bodies employees concerned policy review law reform representation pac controlled gsk decisions amounts business community special interest groups recipients contributions made participating employees concerned environment company exercising legal right pool resources make political subsidiaries might wish support result definitions may contributions subject strict limitations total cover legitimate business activities ordinary sense us us donated political considered political donations political expenditure organisations gsk employee pac activities designed support political party independent election candidate authority board sought annually precautionary measure ensure company subsidiaries inadvertently breach legislation authorisation process expenditure year dates back agm held may following introduction political parties elections referendums act authority since renewed annually gsk annual report statutory disclosures continued group companies accordance section companies act full list subsidiaries associates joint ventures joint arrangements address registered office effective percentage equity owned december disclosed unless otherwise stated share capital disclosed comprises ordinary shares indirectly held glaxosmithkline plc percentage held class share stated less unless otherwise stated subsidiary companies registered office country incorporation subsidiary companies resident tax purposes country incorporation unless otherwise stated name security registered address wholly owned subsidiaries alberta ulc common nd street sw calgary ab tp j canada action potential venture capital limited ordinary great west road brentford middlesex tw gs england adechsa gmbh iv ordinary co prv provides treuhandgesellschaft ag dorfstrasse baar switzerland affymax research institute common corporation service company gateway oaks drive suite n sacramento california ca united states alenfarma especialidades farmaceuticas ordinary quota rua dr antonio loureiro borges arquiparque miraflores alges limitada iv portugal allen hanburys limited iv ordinary great west road brentford middlesex tw gs england allen hanburys pharmaceutical nigeria limited ordinary abimbola way ilasamaja isolo lagos nigeria allen farmaceutica sa ordinary severo ochoa parque tecnologico de madrid tres cantos madrid spain allen pharmazeutika gesellschaft mbh ordinary wagenseilgasse euro plaza gebude stock vienna austria aners sa iv nonendorsable nominative tucuman piso ciudad autonoma de buenos aires ordinary caaa argentina barrier therapeutics inc common corporation services company centerville road suite wilmington delaware de united states beecham group p l c p shares ' ' p shares b great west road brentford middlesex tw gs england beecham pharmaceuticals pte limited ordinary quality road jurong industrial estate jurong singapore beecham pharmaceuticals sa iv vi nominative av de agosto n naciones unidas edificio electroectuatoriana piso quito ecuador beecham portuguesaprodutos farmaceuticos e ordinary quota rua dr antonio loureiro borges arquiparque miraflores alges quimicos lda portugal beecham sa iv ordinary parc de la noire epine rue fleming wavre belgium biddle sawyer limited equity dr annie besant road mumbai india biovesta ilalari ltd sti iv nominative bykdere caddesi levent plaza b blok kat levent istanbul turkey burroughs wellcome co australia pty limited liquidation ordinary mountain highway boronia vic australia burroughs wellcome co bangladesh limited ordinary fouzderhat industrial area dhaka trunk road north kattali chittagong bangladesh burroughs wellcome international limited ordinary great west road brentford middlesex tw gs england cascan gmbh co kg partnership capital industriestrasse bad oldesloe germany castleton investment ltd vi ordinary co dtos ltd th floor standard charted tower cybercity ebene mauritius cellzome gmbh ordinary meyerhofstrasse heidelberg germany cellzome limited ordinary great west road brentford middlesex tw gs england cellzome therapeutics inc iv ordinary corporation service company centerville road suite wilmington delaware de united states cellzome inc ordinary corporation service company centerville road suite series preferred wilmington delaware de united states series b preferred series c convertible preferred series c convertible preferred charles midgley limited iv ordinary great west road brentford middlesex tw gs england cumulative preference chiron behring vaccines private limited ordinary wing floral deck plaza opp rolta bhavan central midc road mumbai andheri east india clarges pharmaceuticals limited ordinary great west road brentford middlesex tw gs england preference colleen corporation common corporation service company centerville road suite wilmington delaware de united states corixa corporation common corporation service company centerville road suite wilmington delaware de united states coulter pharmaceutical inc iv common corporation service company centerville road suite wilmington delaware de united states dealcyber limited ordinary great west road brentford middlesex tw gs england desarrollo energia solar alternativa sl ordinary severo ochoa parque tecnologico de madrid tres cantos madrid spain domantis limited ordinary great west road brentford middlesex tw gs england duncan flockhart australia pty limited iv vi ordinary mountain highway boronia vic australia gsk annual report strategic report governance remuneration financial statements investor information group companies continued name security registered address wholly owned subsidiaries continued edinburgh pharmaceutical industries limited ordinary preference shewalton road irvine ayrshire ka ap scotland eskaylab limited p ordinary great west road brentford middlesex tw gs england etex farmaceutica ltda social capital avenue andres bello piso las condes santiago cp chile europharm sa ordinary poienelor street brasov romania fipar thailand ltd liquidation ordinary th floor wave place wireless road lumpini pathumwan bangkok thailand genelabs technologies inc common corporation service company gateway oaks drive suite n sacramento california ca united states glaxo iv ordinary klaus torgrds vei oslo norway glaxo group limited ordinary great west road brentford middlesex tw gs england glaxo kabushiki kaisha iv ordinary sendagaya shibuyaku tokyo japan glaxo laboratories nigeria limited iv ordinary marine road apapa lagos nigeria glaxo laboratories limited iv ordinary great west road brentford middlesex tw gs england glaxo new zealand pension plan trustee limited ordinary level ii zurich house queen street auckland new zealand glaxo operations uk limited ordinary great west road brentford middlesex tw gs england glaxo properties bv ordinary huis ter heideweg lz zeist netherlands glaxo verwaltungs gmbh vi ordinary industriestrasse bad oldesloe germany glaxo wellcome australia pty ltd iv vi ordinary mountain highway boronia vic australia glaxo wellcome farmaceutica limitada ordinary quota rua dr antonio loureiro borges arquiparque miraflores alges portugal glaxo wellcome holdings limited liquidation ordinary baker street london wu eu england glaxo wellcome international bv v ordinary huis ter heideweg lz zeist netherlands glaxo wellcome manufacturing pte ltd ordinary pioneer sector jurong industrial estate jurong singapore glaxo wellcome production sas ordinary route de versailles marly le roi france glaxo wellcome pst pty ltd liquidation ordinary mountain highway boronia vic australia glaxo wellcome uk limited ordinary great west road brentford middlesex tw gs england glaxo wellcome vidhyasom limited iv ordinary th floor wave place wireless road lumpini pathumwan bangkok thailand glaxo wellcome sa ordinary poligono industrial allendeduero avenida de extremadura aranda de duero burgos spain glaxo sa ordinary severo ochoa parque tecnologico de madrid tres cantos madrid spain glaxoallenburys nigeria limited iv ordinary creek road apapa lagos pmb nigeria glaxochem uk unlimited ordinary great west road brentford middlesex tw gs england ordinary b ordinary c glaxochem pte ltd v ordinary beach road gateway west singapore glaxosmithkline produtos farmaceuticos limitada ordinary quota rua dr antonio loureiro borges arquiparque miraflores alges portugal glaxosmithkline cambodia co ltd ordinary th floor dksh building preah monivong boulevard corner street sangkat phsar deum thakov khan chamkarmon phnom penh cambodia glaxosmithkline china investment co ltd ordinary room building ocean international center mid th east ring road bejing chaoyang district china glaxosmithkline china rd company limited equity building halei road zhang jiang hi tech park pudong new area shanghai china glaxosmithkline cyprus limited ordinary arch makariou iii capital center th floor nicosia pc cyprus glaxosmithkline gsk srl ordinary costache negri street opera center floor zone district bucharest romania glaxosmithkline ireland limited ii ordinary riverwalk citywest business campus dublin ireland glaxosmithkline israel ltd ordinary basel street po box petachtikva israel glaxosmithkline private limited iv ordinary unit anthony road msasa harare zimbabwe glaxosmithkline thailand limited ordinary th floor wave place wireless road lumpini pathumwan bangkok thailand glaxosmithkline aebe ordinary kifissias avenue halandri athens greece glaxosmithkline ab ordinary hemvarnsg solna sweden glaxosmithkline ag ordinary talstrasse muenchenbuchsee switzerland glaxosmithkline angola unipessoal limitada quotas estrada de cacuaco bairro petrangol luanda angola glaxosmithkline argentina sa ordinary tucumn piso ciudad autonoma de buenos aires caaa argentina glaxosmithkline ordinary klaus torgrds vei oslo norway glaxosmithkline asia pvt limited equity patiala road nabha dist patiala punjab india gsk annual report statutory disclosures continued group companies continued name security registered address wholly owned subsidiaries continued glaxosmithkline australia pty ltd ordinary mountain highway boronia vic australia glaxosmithkline bv ordinary huis ter heideweg lz zeist netherlands glaxosmithkline beteiligungs gmbh ordinary prinzregentenplatz munchen germany glaxosmithkline biologicals shanghai ltd ordinary niudun road zhangjiang hiteck park shanghai china glaxosmithkline biologicals kft ordinary gdll homoki nagy istvn utca hungary glaxosmithkline biologicals sas ordinary rue des aulnois saintamand les eaux france glaxosmithkline biologicals sa ordinary preference rue de l'institut b rixensart belgium glaxosmithkline brasil limitada quotas estrada dos banderiantes camorim jacarepagua rio de janeiro brazil glaxosmithkline business services sa ordinary metros al este de la rotonda de la betania mercedes de montes dissolved january de oca sabanilla montes de oca san jose costa rica glaxosmithkline capital inc ordinary wilmington trust sp services inc north market street suite wilmington delaware de united states glaxosmithkline capital plc ordinary great west road brentford middlesex tw gs england glaxosmithkline caribbean limited ordinary great west road brentford middlesex tw gs england glaxosmithkline chile farmaceutica limitada social capital avenue andrs bello piso las condes santiago cp chile glaxosmithkline colombia sa ordinary avenida el dorado bpiso bogota colombia glaxosmithkline consumer healthcare investments ordinary cork airport business park kinsale road cork county cork ireland limited ii v ireland glaxosmithkline consumer healthcare ireland ip limited ii v ordinary currabinny carrigaline county cork ireland glaxosmithkline consumer holding bv ordinary huis ter heideweg lz zeist netherlands glaxosmithkline doo quota zmja od bosne broj sarajevo bosnia herzegovina glaxosmithkline doo equity capital ulica damira tomljanovica gavrana zagreb croatia glaxosmithkline doo beograd ordinary omladinskih brigada new belgrade city belgrade serbia glaxosmithkline ecuador sa ordinary av de agosto n naciones unidas edificio electroectuatoriana piso quito ecuador glaxosmithkline eesti ou ordinary ltsa tallinn estonia glaxosmithkline ehf ordinary thverholt reykjavik iceland glaxosmithkline el salvador sa de cv ordinary avenida el boqueron calle izalco parque industrial el boqueron santa elen antiguo custatlan la libertad el salvador glaxosmithkline eood ordinary g tsarigradsko shose blvd floor mladost region sofia bulgaria glaxosmithkline export limited ordinary great west road brentford middlesex tw gs england glaxosmithkline export panama sa ordinary panama city republic panama panama glaxosmithkline far east bv ordinary huis ter heideweg lz zeist netherlands glaxosmithkline finance plc ordinary great west road brentford middlesex tw gs england glaxosmithkline gmbh co kg partnership capital prinzregentenplatz munchen germany glaxosmithkline guatemala sa ordinary novena avenida zona guatemala city guatemala glaxosmithkline holding ordinary klaus torgrds vei oslo norway glaxosmithkline holdings americas inc common wilmington trust sp services inc north market street suite wilmington delaware de united states glaxosmithkline holdings ireland limited ordinary deferred great west road brentford middlesex tw gs england glaxosmithkline holdings one limited ordinary great west road brentford middlesex tw gs england glaxosmithkline holdings limited ordinary great west road brentford middlesex tw gs england glaxosmithkline holdings pty ltd ordinary mountain highway boronia vic australia glaxosmithkline honduras sa ordinary tegucigalpa mdc honduras glaxosmithkline ihc limited ordinary great west road brentford middlesex tw gs england glaxosmithkline ilaclari sanayi ticaret nominative bykdere caddesi levent plaza b blok kat levent istanbul turkey glaxosmithkline inc class common mississauga road north mississauga ln l canada class c preference glaxosmithkline insurance ltd ordinary parlaville road hamilton hm bermuda glaxosmithkline intellectual property limited ordinary great west road brentford middlesex tw gs england glaxosmithkline intellectual property development limited ordinary great west road brentford middlesex tw gs england glaxosmithkline intellectual property holdings limited ordinary b ordinary great west road brentford middlesex tw gs england glaxosmithkline intellectual property limited ordinary deferred great west road brentford middlesex tw gs england glaxosmithkline intellectual property management limited ordinary great west road brentford middlesex tw gs england glaxosmithkline international limited ordinary great west road brentford middlesex tw gs england glaxosmithkline investigacin desarrollo sl ordinary severo ochoa parque tecnologico de madrid tres cantos madrid spain glaxosmithkline investment holdings limited ordinary great west road brentford middlesex tw gs england glaxosmithkline investment services limited ordinary great west road brentford middlesex tw gs england glaxosmithkline investments ireland limited ii v ordinary currabinny carrigaline county cork ireland gsk annual report strategic report governance remuneration financial statements investor information group companies continued name security registered address wholly owned subsidiaries continued glaxosmithkline investments pty ltd ordinary mountain highway boronia vic australia glaxosmithkline kk ordinary sendagaya shibuyaku tokyo japan glaxosmithkline korea limited ordinary f ls yongsan tower hangangdaero yongsangu seoul republic korea glaxosmithkline latin america sa ordinary panama city republic panama panama glaxosmithkline latvia sia ordinary duntes iela riga latvia glaxosmithkline lietuva uab ordinary ukmerges st vilnius lt lithuania glaxosmithkline limited ordinary units f tower gateway canton road harbour city tsimshatsui kowloon hong kong glaxosmithkline llc llc interests corporation service company centerville road suite wilmington delaware de united states glaxosmithkline malta limited ordinary first floor de la cruz avenue qormi qrm malta glaxosmithkline manufacturing spa ordinary via alessandro fleming verona italy glaxosmithkline maroc sa ordinary angle bd rachidi et abou hamed el glaza casablanca morocco glaxosmithkline medical healthcare products limited ordinary h csorsz utca budapest hungary glaxosmithkline mercury limited ordinary great west road brentford middlesex tw gs england glaxosmithkline mexico sa de cv ordinary calzada mexicoxochimilco colonia san lorenzo huipulco delegacion tlalpan mexico glaxosmithkline nz limited ordinary level zurich house queen street auckland new zealand glaxosmithkline oy ordinary piispansilta po box espoo fin finland glaxosmithkline peru sa ordinary av javier prado oeste san isidro lima peru glaxosmithkline pharma ordinary nykaer brondby dk denmark glaxosmithkline pharma gmbh ordinary wagenseilgasse euro plaza gebude stock vienna austria glaxosmithkline pharmaceutical kenya limited ordinary lr th floor icea lion centre riverside park west wing chiromo road westlands po box nairobi kenya glaxosmithkline pharmaceutical nigeria limited ordinary industrial avenue ilupeju ikeja lagos pm b nigeria glaxosmithkline pharmaceutical sdn bhd ordinary level quill jalan semangat petaling jaya selangor darul ehsan malaysia glaxosmithkline pharmaceuticals pvt ltd ordinary galle road kaldemulla moratuwa sri lanka glaxosmithkline pharmaceuticals suzhou limited ordinary su hong xi road suzhou industrial park suzhou china glaxosmithkline pharmaceuticals costa rica sa ordinary metros al este de la rotonda de la betania mercedes de montes de oca sabanilla montes de oca san jose costa rica glaxosmithkline pharmaceuticals sa ordinary ordinary b ul grunwaldzka poznan poland ordinary c ordinary glaxosmithkline pharmaceuticals sa ordinary site apollo avenue pascal wavre belgium glaxosmithkline pharmaceuticals ukraine llc chartered capital pavla tychyny avenue v kiev ukraine glaxosmithkline pte ltd ordinary beach road gateway west singapore glaxosmithkline puerto rico inc common centro internacional de mercadeo road tower ii suite guaynabo puerto rico glaxosmithkline republica dominicana sa ordinary av lope de vega torre novocentro local santo domingo dominican republic glaxosmithkline research development limited ordinary great west road brentford middlesex tw gs england glaxosmithkline sa ordinary severo ochoa parque tecnologico de madrid tres cantos madrid spain glaxosmithkline spa ordinary via alessandro fleming verona italy glaxosmithkline sro ordinary hvezdova c prague czech republic glaxosmithkline services gmbh co kg vi partnership capital prinzregentenplatz munchen germany glaxosmithkline services inc iv common corporation services company centerville road suite wilmington delaware de united states glaxosmithkline services unlimited ordinary great west road brentford middlesex tw gs england glaxosmithkline sl holdings llc llc interests corporation service company centerville road suite wilmington delaware de united states glaxosmithkline sl llc llc interests corporation services company centerville road suite wilmington delaware de united states glaxosmithkline sl lp iv partnership great west road brentford middlesex tw gs england glaxosmithkline slovakia sro ordinary galvaniho bratislava slovakia glaxosmithkline south africa pty limited ordinary flushing meadows building campus sloane street bryanston south africa glaxosmithkline superannuation company pty ltd ordinary mountain highway boronia vic australia liquidation glaxosmithkline trading services limited ii v ordinary currabinny carrigaline county cork ireland glaxosmithkline trading zao ordinary yakimanskaya nab moscow russian federation glaxosmithkline tunisia sarl ordinary immeuble les quatres r rue du lac lochness berges du lac tunis tunisia gsk annual report statutory disclosures continued group companies continued name security registered address wholly owned subsidiaries continued glaxosmithkline uk limited ordinary great west road brentford middlesex tw gs england glaxosmithkline uruguay sa registered shares provisory salto cp montevideo uruguay stock glaxosmithkline venezuela ca ordinary urbanizacion la trinidad calle luis de camoems edif apatado posta caracas venezuela glaxosmithkline vietnam limited liability company iv vi equity capital metropolitan dong khoi ben nghe ward district ho chi minh city viet nam glycovaxyn ag vi common preferred grabenstrasse schlieren switzerland preferred b preferred c group laboratories south africa pty limited iv vi ordinary flushing meadows building campus sloane street bryanston south africa groupe glaxosmithkline sas ordinary route de versailles marly le roi france gsk business service centre sdn bhd ordinary level quill jalan semangat petaling jaya selangor darul ehsan malaysia gsk commercial sp z oo ordinary ul rzymowskiego warsaw poland gsk doo ljubljana ordinary amerika ulica ljubljana slovenia gsk kazakhstan llp partnership interest furmanov street almaty kazakhstan gsk services sp z oo ordinary ul grunwaldzka poznan poland gsk vaccines gmbh ordinary emilvonbehringstr marburg germany gsk vaccines institute global health srl quotas via fiorentina siena italy gsk vaccines srl quotas via fiorentina siena italy gsk vaccines vertriebs gmbh ordinary rudolfdieselring holzkirchen germany herbridge unlimited company ii vi ordinary currabinny carrigaline county cork ireland hgs france sarl iv vi ordinary avenue victor hugo boulognebillancourt france horlicks limited ordinary great west road brentford middlesex tw gs england human genome sciences pacific pty ltd iv vi ordinary mountain highway boronia vic australia human genome sciences inc common corporation service company centerville road suite wilmington delaware de united states id biomedical corporation quebec common boul du parc technologique qubec gp r canada id biomedical corporation washington iv common corporation service company centerville road suite wilmington delaware de united states instituto luso farmaco limitada iv ordinary quota rua dr antonio loureiro borges arquiparque miraflores alges portugal interpharma dienstleistungen gmbh quota wagenseilgasse euro plaza gebude stock vienna austria jj technologies lc iv llc interests corporation service company bank america th floor east main street richmond virginia va united states laboratoire glaxosmithkline ordinary route de versailles marly le roi france laboratoire pharmaceutique algrien lpa production spa ordinary zone industrielle est boudouaou boumerdes algeria laboratoire pharmaceutique algrien spa ordinary zone industrielle est boudouaou boumerdes algeria laboratoires paucourt iv ordinary route de versailles marly le roi france laboratoires saintgermain iv ordinary route de versailles marly le roi france laboratorios dermatologicos darier sa de cv ordinary calzada mexico xochimilco san lorenzo huipulco district federal mexico mexico laboratorios farmaceuticos stiefel portugal ltda iv ordinary quota rua dr antonio loureiro borges arquiparque miraflores alges portugal laboratorios phoenix sociedad anonima industrial nonendorsable nominative tucuman piso ciudad autonoma de buenos aires caaa comercial financiera ordinary shares argentina laboratorios stiefel de chile compaa limitada social capital avenue andrs bello piso las condes santiago cp chile laboratorios stiefel de venezuela sa ordinary calle luis de camoens edificio glaxosmithkline urb la trinidad caracas venezuela laboratorios stiefel ltda ordinary rua professor joao cavalheiro salem guarulhos sao paulo brazil laboratorios wellcome de portugal limitada iv ordinary quota rua dr antonio loureiro borges arquiparque miraflores alges portugal maxinutrition limited liquidation ordinary baker street london wu eu england mixis genetics limited ordinary great west road brentford middlesex tw gs england ordinary euro montrose fine chemical company ltd ordinary shewalton road irvine ayrshire ka ap scotland montrose pharma company limited ordinary quota h csorsz utca budapest hungary montrose pharma uab liquidation ordinary agostauto vilnius lt lithuania novartis vaccines diagnostics ag liquidation ordinary co obc suisse ag aeschenvorstadt basel switzerland novartis vaccines diagnostics pty ltd iv vi ordinary mountain highway boronia australia gsk annual report strategic report governance remuneration financial statements investor information group companies continued name security registered address wholly owned subsidiaries continued okairos ag iv vi common preferred co obc suisse ag aeschenvorstadt basel preferred b switzerland penn labs inc iv common corporation service company centerville road suite wilmington delaware de united states sr one international bv ordinary huis ter heideweg lz zeist netherlands sr one limited units common corporation service company interstate drive suite harrisburg pennsylvania pa united states setfirst limited ordinary great west road brentford middlesex tw gs england smith kline french laboratories limited ordinary great west road brentford middlesex tw gs england smith kline french portuguesaprodutos ordinary quota rua dr antonio loureiro borges arquiparque miraflores alges farmaceuticos lda iv portugal smithkline beecham australia pty ltd liquidation ordinary mountain highway boronia vic australia smithkline beecham bangladesh private limited iv ordinary topkhana road segunbagicha dhaka bangladesh smithkline beecham cork limited ii ordinary currabinny carrigaline county cork ireland smithkline beecham export limited ordinary great west road brentford middlesex tw gs england smithkline beecham h limited noncumulative great west road brentford middlesex tw gs england nonredeemables ordinary smithkline beecham investments limited ordinary great west road brentford middlesex tw gs england smithkline beecham manufacturing limited ii ordinary currabinny carrigaline county cork ireland smithkline beecham swg limited ordinary great west road brentford middlesex tw gs england smithkline beecham animal health company liquidation common upper water sreet suite halifax ns bj n canada smithkline beecham biologicals us partnership partnership interests corporation service company centerville road suite wilmington delaware de united states smithkline beecham egypt llc quotas amoun street po box el salam city cairo egypt smithkline beecham farma sa ordinary severo ochoa parque tecnologico de madrid tres cantos madrid spain smithkline beecham holdings australia pty limited ordinary mountain highway boronia vic australia liquidation smithkline beecham interamerican corporation iv shares par value common corporation service company centerville road suite wilmington delaware de united states smithkline beecham limited ordinary p great west road brentford middlesex tw gs england smithkline beecham marketing technical services limited ordinary great west road brentford middlesex tw gs england smithkline beecham nominees limited ordinary great west road brentford middlesex tw gs england smithkline beecham overseas limited ordinary great west road brentford middlesex tw gs england smithkline beecham pension plan trustee limited iv ordinary great west road brentford middlesex tw gs england smithkline beecham pension trustees limited iv ordinary great west road brentford middlesex tw gs england smithkline beecham pharma gmbh co kg partnership capital prinzregentenplatz munchen germany smithkline beecham pharma verwaltungs gmbh ordinary prinzregentenplatz munchen germany smithkline beecham pharmaceuticals pty limited iv vi ordinary flushing meadows building campus sloane street bryanston south africa smithkline beecham pharmaceuticals co shares par value common corporation service company centerville road suite wilmington delaware de united states smithkline beecham port louis limited vi ordinary co cim global business edith cavell street port louis mauritius smithkline beecham retirement plan nominees ordinary mountain highway boronia vic australia pty limited liquidation smithkline beecham senior executive pension plan ordinary great west road brentford middlesex tw gs england trustee limited iv stiefel distributors ireland limited ii iv ordinary finisklin business park sligo ireland stiefel dominicana srl iv vi ordinary ave lope de vega torre novocentro local santo domingo dominican republic stiefel farma sa ordinary severo ochoa parque tecnologico de madrid tres cantos madrid spain stiefel gmbh co kg partnership capital industriestrasse bad oldesloe germany stiefel india private limited equity wing floral deck plaza opp rolta bhavan central midc road mumbai andheri east india stiefel laboratories ireland limited ii ordinary finisklin business park sligo ireland stiefel laboratories maidenhead ltd ordinary eurasia headquarters concorde road maidenhead berkshire sl england stiefel laboratories uk ltd ordinary eurasia headquarters concorde road maidenhead berkshire sl england stiefel laboratories limited iv ordinary eurasia headquarters concorde road maidenhead berkshire sl england stiefel laboratories pte limited iv ordinary gul circle singapore stiefel laboratories pty ltd liquidation ordinary mountain highway boronia vic australia gsk annual report statutory disclosures continued group companies continued name security registered address wholly owned subsidiaries continued stiefel laboratories inc common corporation service company centerville road suite wilmington delaware de united states stiefel maroc sarl ordinary boulevard zerktouni casablanca morocco stiefel research australia holdings pty ltd vi ordinary mountain highway boronia vic australia stiefel research australia pty ltd vi ordinary mountain highway boronia vic australia stiefel west coast llc llc interests corporation service company centerville road suite wilmington delaware de united states strebor inc common corporation service company centerville road suite wilmington delaware de united states tempero pharmaceuticals inc series preference corporation service company centerville road suite series b preference common wilmington delaware de united states sydney ross co iv ordinary corporation service company bear tavern road west trenton new jersey nj united states wellcome foundation limited ordinary great west road brentford middlesex tw gs england ucb pharma asia pacific sdn bhd iv ordinary level symphony house pusat dagangan dana jalan pju petaling jaya selangor darul ehsan malaysia wellcome consumer healthcare limited iv ordinary great west road brentford middlesex tw gs england wellcome consumer products limited iv ordinary great west road brentford middlesex tw gs england wellcome developments pty ltd iv vi ordinary mountain highway boronia vic australia wellcome limited ordinary great west road brentford middlesex tw gs england wellcome operations pty ltd iv vi ordinary mountain highway boronia vic australia effective name security ownership registered address subsidiaries effective interest less amoun pharmaceutical industries co sae new monetary shares el salam city po box cairo egypt beecham enterprises inc iv common corporation service company centerville road suite wilmington delaware de united states block drug company inc common corporation service company princeton south corporate center suite charles ewing blvd ewing new jersey united states block drug corporation iv common par value corporation service company princeton south corporate center suite charles ewing blvd ewing new jersey united states british pharma group limited capital great west road brentford middlesex tw gs england de micln ordinary priemyselny park gena ul e sachsa levice slovakia duncan consumer healthcare philippines inc common chino roces avenue makati city philippines duncan pharmaceuticals philippines inc common chino roces avenue city makati philippines exlax inc common fgr corporate services inc oriental center suite p munoz rivera avenue san juan puerto rico galvani bioelectronics inc common corporate service company centerville road suite wilmington delaware de united states galvani bioelectronics limited ordinary great west road brentford middlesex tw gs england b ordinary glaxo saudi arabia limited ordinary po box area warehouse city first stage al khomrah jeddah saudi arabia glaxo wellcome ceylon limited ordinary galle road kaldemulla moratuwa sri lanka ordinary b glaxosmithkline tianjin co ltd ordinary fifth avenue tai feng industrial park tianjin economic technolog tianjin china glaxosmithkline algrie spa ordinary zone industrielle est boudouaou wilaya de boumerdes algeria glaxosmithkline bangladesh limited ordinary fouzderhat industrial area dhaka trunk road north kattali chittagong bangladesh glaxosmithkline brasil produtos para consumo e saude ltda quotas bl vitor civita street barra tijuca rio de janeiro brazil glaxosmithkline consumer healthcare china co ltd ordinary rooms b f headquarters building tibet road shanghai china glaxosmithkline consumer healthcare hong kong limited ordinary units f tower gateway canton road harbour city tsimshatsui kowloon hong kong glaxosmithkline consumer healthcare ireland limited ii ordinary riverwalk citywest business campus dublin ireland glaxosmithkline consumer healthcare overseas limited ordinary great west road brentford middlesex tw gs england gsk annual report strategic report governance remuneration financial statements investor information group companies continued effective name security ownership registered address subsidiaries effective interest less continued glaxosmithkline consumer healthcare thailand limited ordinary th floor unit wave place wireless road lumpini pathumwan bangkok thailand glaxosmithkline consumer healthcare uk ip limited ordinary great west road brentford middlesex tw gs england glaxosmithkline consumer healthcare uk trading limited ordinary great west road brentford middlesex tw gs england glaxosmithkline consumer healthcare us ip llc llc interests corporation service company centerville road suite wilmington delaware de united states glaxosmithkline consumer healthcare ordinary nykaer brondby dk denmark glaxosmithkline consumer healthcare ab vii ordinary nykaer dk brondby denmark glaxosmithkline consumer healthcare australia pty ltd ordinary hughes avenue ermington nsw australia glaxosmithkline consumer healthcare bv ordinary huis ter heideweg lz zeist netherlands glaxosmithkline consumer healthcare colombia sas ordinary avenida el dorado bpiso bogota colombia glaxosmithkline consumer healthcare czech republic sro ordinary hvezdova c prague czech republic glaxosmithkline consumer healthcare finance limited ordinary great west road brentford middlesex tw gs england glaxosmithkline consumer healthcare finance limited ordinary great west road brentford middlesex tw gs england glaxosmithkline consumer healthcare finland oy ordinary piispansilta fin espoo finland glaxosmithkline consumer healthcare gmbh ordinary wagenseilgasse euro plaza gebude stock vienna austria glaxosmithkline consumer healthcare gmbh co kg partnership capital barthstr mnchen germany glaxosmithkline consumer healthcare greece societe ordinary kifissias avenue halandri athens greece anonyme glaxosmithkline consumer healthcare holdings us llc llc interests corporation service company centerville road suite wilmington delaware de united states glaxosmithkline consumer healthcare holdings limited ordinary great west road brentford middlesex tw gs england ordinary b glaxosmithkline consumer healthcare inc common mississauga road th floor mississauga ln l canada glaxosmithkline consumer healthcare investments ordinary knockbrack dungarvan co waterford x ry ireland ireland unlimited company ii v glaxosmithkline consumer healthcare investments ordinary knockbrack dungarvan co waterford x ry ireland ireland limited ii v glaxosmithkline consumer healthcare japan kk ordinary sendagaya shibuyaku tokyo japan glaxosmithkline consumer healthcare korea co ltd ordinary f ls yongsan tower hangangdaero yongsangu seoul republic korea glaxosmithkline consumer healthcare llc llc interests corporation service company interstate drive suite harrisburg pennsylvania pa united states glaxosmithkline consumer healthcare limited equity patiala road nabha dist patiala punjab india glaxosmithkline consumer healthcare mexico ordinary calzada mexicoxochimilco colonia san lorenzo huipulco de rl de cv delegacion tlalpan mexico df mexico glaxosmithkline consumer healthcare new zealand limited ordinary level zurich house queen street auckland new zealand glaxosmithkline consumer healthcare norway ordinary klaus torgrds vei oslo norway glaxosmithkline consumer healthcare pakistan limited ordinary sykes building dockyard road west wharf karachi pakistan glaxosmithkline consumer healthcare philippines inc common chino roces avenue makati city philippines glaxosmithkline consumer healthcare pte ltd ordinary beach road gateway west singapore glaxosmithkline consumer healthcare sa ordinary site apollo avenue pascal wavre belgium glaxosmithkline consumer healthcare sa ordinary severo ochoa parque tecnologico de madrid tres cantos madrid spain glaxosmithkline consumer healthcare spa ordinary via zambeletti sncbaranzate milan italy glaxosmithkline consumer healthcare sdn bhd ordinary lot jalan enggang ampangulu klang industrial estate selangor darul ehsan malaysia glaxosmithkline consumer healthcare slovakia r ownership interest galvaniho bratislava slovakia glaxosmithkline consumer healthcare south africa pty ltd ordinary flushing meadows building campus sloane street bryanston south africa glaxosmithkline consumer healthcare spzoo common ul rzymowskiego warsaw poland glaxosmithkline consumer healthcare sri lanka ordinary great west road brentford middlesex tw gs england holdings limited glaxosmithkline consumer healthcare srl ordinary costache negri street opera center floor zone district bucharest romania glaxosmithkline consumer healthcare lp partnership interest corporation service company centerville road suite wilmington delaware de united states glaxosmithkline consumer healthcare produtos para ordinary quota rua dr antonio loureiro borges arquiparque miraflores alges saude e higiene lda portugal glaxosmithkline consumer healthcare vietnam charter capital floor metropolitan dong khoi ben nghe ward district company limited ho chi minh city vietnam glaxosmithkline consumer nigeria plc iii ordinary industrial avenue ilupeju ikeja lagos pm b nigeria glaxosmithkline consumer private limited equity patiala road nabha dist patiala punjab india gsk annual report statutory disclosures continued group companies continued effective name security ownership registered address subsidiaries effective interest less continued glaxosmithkline consumer trading services limited ordinary great west road brentford middlesex tw gs england glaxosmithkline costa rica sa ordinary san jose este de la rotonda betania carretera sabanilla costa rica glaxosmithkline dungarvan limited ii ordinary knockbrack dungarvan co waterford x ry ireland glaxosmithkline healthcare ao ordinary presnenskaya nab moscow russian federation glaxosmithkline healthcare gmbh ordinary barthstr munchen germany glaxosmithkline healthcare ukraine ooo ownership interest pavla tychyny avenue v kiev ukraine glaxosmithkline landholding company inc common chino roces avenue city makati philippines glaxosmithkline limited ordinary likoni road po box nairobi kenya glaxosmithkline otc pvt limited ordinary sykes building dockyard road west wharf karachi pakistan glaxosmithkline pakistan limited ordinary sykes building dockyard road west wharf karachi pakistan glaxosmithkline panama sa ordinary panama city republic panama panama glaxosmithkline paraguay sa ordinary oficial gilberto aranda planta alta casi salvador del mundo asuncion paraguay glaxosmithkline pharmaceuticals limited equity dr annie besant road mumbai india glaxosmithkline philippines inc common chino roces avenue city makati philippines glaxosmithkline sae ordinary boomerang office building land zone j st district town center th tagammoe new cairo city egypt glaxosmithkline sante grand public sas ordinary route de versailles marly le roi france glaxosmithkline tuketici sagligi nominative bykdere caddesi levent plaza b blok levent istanbul turkey glaxosmithklineconsumer hungary limited liability company membership h csorsz utca budapest hungary gsk consumer healthcare singapore pte ltd ordinary beach road gateway west singapore gsk ch argentina sa nominative non tucuman piso ciudad autonoma de buenos aires caaa endorseable ordinary argentina shares gsk ch kazakhstan llp charter capital manasa str bostandyk district almaty kazakhstan gsk consumer healthcare schweiz ag ordinary suurstoffi rotkreuz switzerland gsk consumer healthcare services inc common corporation services company centerville road suite wilmington delaware de united states gskgebro consumer healthcare gmbh ordinary bahnhofbichl fieberbrunn kitzbhel austria iodosan spa ordinary via zambeletti sncbaranzate milan italy kuhs gmbh ordinary barthstr munchen germany laboratorios viiv healthcare sl ordinary severo ochoa parque tecnologico de madrid tres cantos madrid spain modern pharma trading company llc quotas amoun street po box el salam city cairo egypt novartis consumer health australasia pty ltd iv vi ordinary hughes avenue ermington nsw australia redeemable preference nch nutrition consumer health ltd ordinary hamephalsim st petach tikva israel novartis consumer health gmbh ordinary barthstr mnchen germany novartis consumer health sa ordinary route de i'etraz prangins switzerland novartis consumer health services sa registered shares route de l'etraz prangins switzerland novartis consumer health uk limited ordinary park view riverside way watchmoor park camberley surrey gu yl england novartis consumer health inc common corporation service company centerville road suite wilmington delaware de united states pt smithkline beecham pharmaceuticals shares jl pulobuaran raya kav iii dd kawasan industri pulogadung b shares jakarta indonesia pt sterling products indonesia shares graha paramita building th f jalan denpasar raya blok jakarta b shares indonesia panadol gmbh ordinary barthstr mnchen germany phivco jersey ii limited iv v ordinary castle street st helier je ut jersey phivco jersey limited iv v ordinary castle street st helier je ut jersey phivco uk ii limited ordinary great west road brentford middlesex tw gs england phivco uk limited ordinary great west road brentford middlesex tw gs england phivco llc llc interests corporation service company centerville road suite wilmington delaware de united states phivco llc llc interests corporation service company centerville road suite wilmington delaware de united states pt glaxo wellcome indonesia shares jl pulobuaran raya kav iii dd kawasan industri pulogadung timur b shares jakarta indonesia pt gsk consumer healthcare indonesia ordinary graha paramita b floor ji denpasar raya blok kuningan jakarta indonesia pt bina dentalindo liquidation ordinary gedung graha ganesha lantai jl raya bekasi km jakarta timur indonesia gsk annual report strategic report governance remuneration financial statements investor information group companies continued effective name security ownership registered address subsidiaries effective interest less continued shionogiviiv healthcare llc common interests corporation service company centerville road suite wilmington delaware de united states sinoamerican tianjin smith kline french laboratories ltd ordinary cheng lin zhuang industrial zone dong li district tianjin china smithkline beecham private limited ordinary world trade center level west tower echelon square colombo sri lanka smithkline beecham research limited ordinary great west road brentford middlesex tw gs england smithkline beecham sa ordinary ctra de ajalvir km alcala de henares madrid spain smithkline beechambiomed ooo participation interest nab kosmodamianskaya building rd floor moscow russian federation staffordmiller ireland limited ii ordinary clocherane youghal road dungarvan co waterford ireland staffordmiller limited ordinary great west road brentford middlesex tw gs england noncumulative non redeemable preference sterling drug malaya sdn berhad ordinary lot jalan enggang ampangulu klang industrial estate selangor darul ehsan malaysia sterling products international incorporated iv common corporation service company centerville road suite wilmington delaware de united states stiefel consumer healthcare uk limited ordinary great west road brentford middlesex tw gs england stiefel egypt llc iv quota amoun street el salam city cairo egypt stiefel manufacturing ireland limited ii ordinary finisklin business park county sligo ireland viiv healthcare south africa proprietary limited ordinary flushing meadows building campus sloane street bryanston south africa viiv healthcare bv ordinary huis ter heideweg lz zeist netherlands viiv healthcare company common corporation service company centerville road suite wilmington delaware de united states viiv healthcare finance limited ordinary great west road brentford middlesex tw gs england viiv healthcare finance limited ordinary great west road brentford middlesex tw gs england viiv healthcare finance limited ordinary redeemable great west road brentford middlesex tw gs england preference viiv healthcare gmbh ordinary prinzregentenplatz munchen germany viiv healthcare gmbh ordinary talstrasse muenchenbuchsee switzerland viiv healthcare hong kong limited ordinary f tower gateway harbour city canton road tsimshatsui kowloon hong kong viiv healthcare kabushiki kaisha ordinary sendagaya shibuyaku tokyo japan viiv healthcare limited class shares deferred great west road brentford middlesex tw gs england class b shares class c shares class class class e cumulative preference viiv healthcare overseas limited ordinary great west road brentford middlesex tw gs england viiv healthcare pty ltd ordinary mountain highway boronia vic australia viiv healthcare puerto rico llc llc interests centro international de mercadeo carr torre suite guaynabo puerto rico viiv healthcare srl quota via alessandro fleming verona italy viiv healthcare sas ordinary route de versailles marly le roi france viiv healthcare sprl ordinary site apollo avenue pascal wavre belgium viiv healthcare trading llc participation interest krylatskaya str moscow russian federation viiv healthcare trading services uk limited ordinary great west road brentford middlesex tw gs england viiv healthcare uk limited v ordinary castle street st helier je ut jersey viiv healthcare uk limited ordinary great west road brentford middlesex tw gs england viiv healthcare uk limited ordinary great west road brentford middlesex tw gs england viiv healthcare uk limited ordinary great west road brentford middlesex tw gs england viiv healthcare uk limited ordinary great west road brentford middlesex tw gs england viiv healthcare ulc common nd street sw calgary ab tp j canada viiv healthcare venture llc llc interests corporation service company centerville road suite wilmington delaware de united states viiv hiv healthcare unipessoal lda quota rua dr antonio loureiro borges arquiparque miraflores alges portugal winster pharmaceuticals limited ordinary association avenue ilupeju industrial estate lagos po box nigeria zhejiang tianyuan biopharmaceutical co ltd ordinary tian road yuhang economic development zone hangzhou zhejiang province china gsk annual report statutory disclosures continued group companies continued effective name security ownership registered address subsidiaries effective interest less continued associates apollo therapeutics llp partnership interest calci medica inc series junior preferred index ventures life vi jersey lp partnership interest innoviva inc common japan vaccine distribution co ltd ordinary jcr pharmaceuticals co ltd common kurma biofund ii fcpr partnership interest longwood founders fund lp partnership interest medicxi ventures lp partnership interest river vision development corp series preferred joint ventures chiron panacea vaccines private ltd liquidation th floor wing sagar tech plaza saki naka andheri east mumbai maharashtra india japan vaccine co ltd yonbancho chiyodaku tokyo japan qualivax pte limited robinson road singapore qura therapeutics llc corporation service company centerville road suite wilmington delaware de united states key directly owned glaxosmithkline plc iv dormant company ii e xempt provisions section companies act v tax resident uk ireland accordance exemptions noted section act vi entity expected disposed removed iii c onsolidated subsidiary accordance section vii incorporated sweden companies act grounds dominant influence gsk annual report strategic report governance remuneration financial statements investor information glossary terms terms used annual report us equivalent brief description accelerated capital allowances tax allowance excess depreciation arising purchase fixed assets delay charging payment tax equivalent tax depreciation american depositary receipt adr r eceipt evidencing title ads gsk adr represents two ordinary shares american depositary shares ads listed new york stock exchange represents two ordinary shares basic earnings per share basic income per share called share capital ordinary shares issued fully paid cer growth growth constant exchange rates company glaxosmithkline plc corporate integrity agreement cia company entered settlement us federal government related past sales marketing practices part settlement company entered corporate integrity agreement us department health human services currency swap exchange two currencies coupled subsequent reexchange currencies agreed exchange rates dates defined benefit plan pension plan specific employee benefits often called final salary scheme defined contribution plan pension plan specific contributions level pension dependent upon growth pension fund derivative financial instrument financial instrument derives value price rate underlying item diluted earnings per share diluted income per share employee share ownership plan trusts trusts established group satisfy sharebased employee incentive plans equity shareholders funds shareholders equity finance lease capital lease freehold ownership absolute rights perpetuity group glaxosmithkline plc subsidiary undertakings gsk glaxosmithkline plc subsidiary undertakings hedging reduction risk normally relation foreign currency interest rate movements making offsetting commitments intangible fixed assets assets without physical substance computer software brands licences patents knowhow marketing rights purchased outside parties novartis transaction threepart interconditional transaction novartis ag involving consumer healthcare vaccines oncology businesses completed march ordinary share fully paid ordinary share capital company profit income profit attributable shareholders net income share capital ordinary shares capital stock common stock issued fully paid share option stock option share premium account additional paidup capital paidin surplus distributable shares issue number shares outstanding subsidiary entity gsk exercises control treasury share treasury stock turnover revenue uk corporate governance code required uk listing authority company disclosed annual report applied best practice corporate governance provisions financial reporting councils uk corporate governance code gsk annual report index accountability major restructuring costs accounting principles policies movements equity acquisitions disposals net debt adjustments reconciling profit tax operating new accounting requirements cash flows nominations committee report annual general meeting noncontrolling interests approach tax noncontrolling interests viiv healthcare assets held sale nonexecutive directors fees associates joint ventures notes financial statements audit risk committee report operating profit cash cash equivalents intangible assets ceos statement investments chairmans statement noncurrent assets chairmans governance statement noncurrent liabilities chairmans remuneration report statement operating income commitments provisions consolidated balance sheet behaviour consolidated cash flow statement board consolidated income statement business model consolidated statement changes equity global marketplace consolidated statement comprehensive income integrated approach consumer healthcare people consumer healthcare products competition planet contingent consideration liabilities strategy priorities contingent liabilities pay performance corporate executive team pensions postemployment benefits corporate governance pharmaceuticals corporate responsibility committee report pharmaceutical products competition critical accounting policies intellectual property directors senior management pipeline directors interests shares post balance sheet events directors statement responsibilities presentation financial statements dividends principal group companies donations political organisations principal risks uncertainties political expenditure property plant equipment earnings per share quarterly trend employee costs reconciliation net cash flow movement net debt employee share schemes registrar exchange rates related party transactions executive director remuneration relations shareholders finance expense remuneration governance finance income remuneration policy report financial calendar remuneration report financial instruments related disclosures reporting framework financial position resources research development financial statements glaxosmithkline plc prepared responsible business uk gaap segment information five year record share capital control glossary terms share capital share premium account goodwill share price group companies shareholder information group financial review shareholder services contacts health taxation manage risks tax information shareholders independent auditors report trade payables inventories trade receivables investments associates joint ventures us law regulation investor relations vaccines key accounting judgements estimates viability statement key performance indicators leadership effectiveness legal proceedings gsk annual report gsk glaxosmithkline plc incorporated brand names brand names appearing italics throughout report english public limited company trade marks either owned andor licensed gsk associated companies exception prolia december formed merger owned amgen zofran owned novartis trumenba owned pfizer glaxo wellcome plc smithkline acknowledgements design beecham plc gsk acquired two english friend wwwfriendstudiocom printing companies december part pureprint group iso fsc certified carbon neutral merger arrangements paper annual report printed revive silk recycled paper full fsc certification shares listed london stock exchange pulps used made deinked postconsumer waste elemental chlorine free new york stock exchange manufacturing mill holds iso eu ecolabel certificates environmental management read wwwgskcom download pdfs annual report form f responsible business supplement cautionary statement regarding factors include limited discussed assumptions groups revenue earnings forwardlooking statements principal risks uncertainties pages expectations assume material mergers acquisitions groups reports filed furnished us annual report forwardlooking statements disposals litigation costs share repurchases securities exchange commission sec including made behalf group speak date company change groups shareholdings document written information released oral made based upon knowledge viiv healthcare consumer healthcare also assume statements made public future behalf information available directors date material changes macroeconomic healthcare group may contain forwardlooking statements annual report environment forwardlooking statements give groups current number adjusted measures used report groups expectations assume successful delivery expectations forecasts future events investor performance business measures defined groups integration restructuring plans period identify statements fact relate reconciliation core results material costs investment new product strictly historical current facts use words total results set launches rd factored expectations anticipate estimate expect intend project plan given expectations given constant currency believe words terms similar meaning information document constitute basis assume material change groups connection discussion future operating offer sell invitation buy shares glaxosmithkline effective tax rate financial performance particular include plc invitation inducement engage statements relating future actions prospective products investment activities past performance relied notice regarding limitations product approvals future performance results upon guide director liability english law current anticipated products sales efforts expenses future performance nothing annual report uk companies act safe harbour limits outcome contingencies legal proceedings construed profit forecast liability directors respect statements financial results accordance legal omissions directors report see regulatory obligations including uk listing assumptions related outlook strategic report remuneration rules disclosure transparency rules outlining expectations fiveyear period report english law directors would liable financial conduct authority group undertakes group made certain assumptions company third party one obligation update forwardlooking statements healthcare sector different markets reports contained errors result recklessness whether result new information future events group operates delivery revenues financial knowing misstatement dishonest concealment otherwise reader however consult benefits current portfolio pipeline restructuring material fact would otherwise liable pages additional disclosures group may make programmes inclusive comprise r c loe n aio osa uc c kd tu p il ie om ar gs nrse u e sin r c dw tet au nh tl e oew r mr h e ec ei ov xc c ne p h p tr e r li l acdt ctp ic n eu g ib uole yl nni ds nh w uose ei h ls l r bsa eu en iu ad mr n ato e ca nr tk ec fi ae e ol n e n nc ds st hw ne h e b aot h fref oe tt rg hhh wi oee v ls e ds n dee rtc sh ta r ell h p egf xao h es cse rr lf k uobih n sreee ier vx og p ian td ye n r f uo c ca focu ct es rtp oo otf us rn thep hr et ee h f g rc e na ki rfi rt eoogdc yu eea pphncll reel ai n r sgo die c sv us r ue c mir l un tt set p eh r snae v l nae ep oss rie v tr peo hi eo r f et es os p e mt eo ar e iuv onti r dd e e r l tf na hst esth v f oe ua f ur u rs e e ch n onti er r nge r nlc p ie eet ro g h cem r ts ccs iu oe nr nnr e tp wee r pao dp iat tr hnit n r ya tnt ha n l ar ep cd e w sa c pp eg ao ae r rnr dg es dae p e ns oh c r eo c te h l w sao hit btf ah w l l la tc h bn elu ec ss h si oi inv n uh fe c bra l hec u v jeelo es ca im dv b tn ep e tic r er eec n tco u h e tm p eo r p rh snre w nne forwardlooking statements subject assumptions groups expectation least billion revenues per limitations restrictions provided law inherent risks uncertainties many relate annum cer basis products launched website factors beyond groups control precise last three years includes contributions current estimate group cautions investors number pipeline asset shingrix target expected gsks website wwwgskcom gives additional information important factors including document could met two years earlier group also expects volume group notwithstanding references make cause actual results differ materially expressed demand products annual report gsks website none implied forwardlooking statement increase particularly emerging markets information made available website constitutes part annual report shall deemed incorporated reference hereinhead office registered office glaxosmithkline plc great west road brentford middlesex tw gs united kingdom tel registered number wwwgskcom search us